Targeting Motor Neuron - Immune System Crosstalk to Modulate the Disease Progression in Amyotrophic Lateral Sclerosis Mouse Model by Trolese, Maria Chiara
Open Research Online
The Open University’s repository of research publications
and other research outputs
Targeting Motor Neuron - Immune System Crosstalk to
Modulate the Disease Progression in Amyotrophic
Lateral Sclerosis Mouse Model
Thesis
How to cite:
Trolese, Maria Chiara (2021). Targeting Motor Neuron - Immune System Crosstalk to Modulate the Disease
Progression in Amyotrophic Lateral Sclerosis Mouse Model. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2020 Maria Chiara Trolese
https://creativecommons.org/licenses/by-nc-nd/4.0/
Version: Version of Record
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.21954/ou.ro.0001269f
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright




Targeting motor neuron - immune system 
crosstalk to modulate the disease 
progression in Amyotrophic Lateral 
Sclerosis mouse model 
 
Thesis submitted by Maria Chiara Trolese 
 
 
Istituto di Ricerche Farmacologiche  
“Mario Negri” – IRCCS 
Department of Neuroscience 
Laboratory of Molecular Neurobiology 
 
 
For the degree of Doctor in Philosophy 
Discipline of Life and Biomolecular Science 











ALS is a fatal neurodegenerative disease characterised by remarked heterogeneity, which might 
stem from the multisystemic, non-cell-autonomous and complex nature of the disease.  
The early deterioration of the peripheral compartment has led to ALS being recognised as distal 
axonopathy, whereby muscles and nerves actively contribute to neurodegeneration. However, the 
contribution of the inflammatory response in the CNS starkly contrasts to the periphery, revealing 
its pivotal role at promoting phenomena of protection and/or toxicity. 
We corroborated these observations showing a higher activation of the MCP1 chemokine within 
MNs and peripheral compartment of C57SOD1G93A than 129SvSOD1G93A mice. Therefore, we 
surmised that the higher peripheral degeneration and faster disease progression of 129SvSOD1G93A 
mice stemmed from this defective immune response. 
To decipher the contribution of the peripheral immune response in ALS progression, the 
therapeutic potential of MCP1 was assessed. The chemokine was induced alongside the motor units 
of the two SOD1G93A models through a single intramuscular injection of a scAAV9 vector engineered 
with MCP1 (scAAV9_MCP1). 
The scAAV9_MCP1-mediated boosting of the immune response prevented the degeneration of the 
peripheral compartment whilst the chemokine induction within MNs led to a neuroprotective 
activity, resulting in the amelioration of the clinical phenotype in C57SOD1G93A but not 
129SvSOD1G93A mice.  
This discrepancy pointed the nature and temporal activation of the immune response out as 
discriminating factors to promote the peripheral compartment regeneration and slow-down ALS 
progression. 
The analysis of ALS patients muscles validated our findings, demonstrating a direct correlation 
between the immune cells inflammatory fingerprint and the rate of the disease progression. 
These observations candidate the peripheral compartment as a primary target for the development 





comprehension of the MCP1 role within the motor unit of SOD1G93A mice might provide innovative 
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1.1 AMYOTROPHIC LATERAL SCLEROSIS (ALS) 
Amyotrophic lateral sclerosis (ALS) belongs to a broader group of disorders known as motor neuron 
diseases (MND), which are caused by gradual degeneration and death of motor neurons.  
Motor neurons (MN) are a subclass of neurons present in the central nervous system (CNS) that 
extend from the brain to the spinal cord and muscles throughout the body. Motor neurons initiate 
and provide vital communication links between the brain and the voluntary muscles. 
ALS is the most common MND. The first study of ALS date back to the mid-19th century when, in 
1850, the English scientist Augustus Waller observed the appearance of shrivelled nerve fibres in 
cadavers. However, the first detailed description of ALS was made a few years later by the French 
neurobiologist and clinician Jean-Martin Charcot (Charcot and Joffroy, 1869). Charcot coined the 
name ALS, describing both the typical symptomatology and anatomopathological features of the 
disease. The term “Amyotrophic” refers to the muscle atrophy that characterises the disease; 
whereas “Lateral Sclerosis” describes the hardness of the lateral column of the spinal cord caused 
by the loss of upper motor neurons (UMN), axons that connect the brain with the lower motor 
neurons (LMN), which are replaced by activated glial cells.  
In the 20th century, the baseball legend Lou Gehrig was diagnosed with the disease (1939). Due to 
his popularity in the United States and Canada, ALS is well known as “Lou Gehrig’s disease”. 
Nowadays, ALS or Lou Gehrig’s disease is classified as a rare progressive neurodegenerative disease 
caused by the loss of motor neurons of brain cortex (UMN), brainstem and spinal cord (LMN). The 
MN death causes the loss of the nerve impulse to voluntary muscles, which undergo progressive 
atrophy, eventually leading to the complete paralysis. 
ALS is a poor prognosis disease, in which death usually occurs 3-5 years from the diagnosis due to 
the progressive denervation and dysfunction of respiratory muscles. 
1.1.1 DIAGNOSIS 
ALS is the most common form of MND, which also comprise progressive muscle atrophy (PMA) and 
primary lateral sclerosis (PLS) in which motor neurons loss is restricted to LMN and UMN, 




respectively. ALS is characterised by the typical association of LMN and UMN degeneration, which 
produce the characteristic mixed picture. Due to the absence of a definitive and reliable test, the 
diagnosis of ALS relies predominately on the clinical evaluation, which is based on a history of 
progressive, painless weakness and examination findings of both LMN and UMN dysfunction. 
However, the symptom manifestation varies among patients depending on the subtype of neurons 
primarily affected (LMN or UMN) and the body regions involved. Because of the heterogeneity in 
the clinical manifestation, there are several “ALS-mimic syndromes” (Table 1). To avoid the 
misdiagnosis, a different diagnostic evaluation process, which includes electrophysiological studies 
and neuroimaging and biosamples (blood, cerebrospinal fluid, muscles biopsies) analysis, is applied 
to each patient in base on the first symptoms occurred. 
Region/Involvement UMN suspect findings LMN suspect findings 
Bulbar Brainstem lesion (stroke, multiple 
sclerosis, tumour) 
Brainstem lesion (stroke, multiple sclerosis, 
tumour), neuromuscular junction disorders 
(myasthenia gravis, muscle-specific tyrosine 
kinase myasthenia, bulbospinal muscular 
atrophy 
Cervical Cervical myelopathy Multifocal motor neuropathy, cervical 
radiculopathy 
Lumbosacral Thoracic myelopathy Lumbosacral radiculopathy, hereditary 
spastic paraparesis 
Table 1: Diseases commonly considered in the differential diagnosis of ALS (Modified from Oskarsson et al., 2018). 
Formal criteria for the diagnosis of ALS have been defined by the World Federation of Neurology at 
the meeting in El Escorial (Spain) in 1994 (Brooks 1994). The EEC (El Escorial criteria) illustrate four 
different levels of diagnosis depending on the subtype of MN and the body region (bulbar, cervical, 
thoracic and lumbosacral) affected: certainty, namely definite, probable, possible or suspected. 
In 1998, in Airlie House (Warrenton, VA, US) an experienced group of clinicians revised the EEC 
adding a level of certainty “probably ALS-laboratory supported”, defined after the proper 
application of clinical laboratory protocols and neuroimaging. Besides, the “suspected ALS” level 
was removed (Brooks et al., 2000; Oliveira and Pereira 2009) (Table 2). 
 
 




LEVEL of CERTAINTY CLINICAL MANIFESTATION 
DEFINITE ALS  UMN and LMN signs in the bulbar region and at least two spinal 
regions, 
    or 
 UMN signs in two spinal regions and LMN signs in three spinal 
regions. 
PROBABLE ALS  UMN and LMN signs in at least two regions, with some UMN signs 
rostral to LMN signs 
PROBABLE LABORATORY-
SUPPORTED ALS 
 Clinical evidence of UMN or LMN signs in only one region; 
or 
 UMN signs alone in one region and LMN signs defined by EMG 
criteria in at least two muscles of different root and neve origin in 
two limbs. 
POSSIBLE ALS  UMN and LMN in only one region; 
or 
 UMN signs in two or more regions;  
or 
 LMN signs rostral to UMN signs. 
Table 2: Revised El Escorial criteria (EEC) for the ALS level classification. 
The EEC have been criticised for being overly restrictive in the usage of electrophysiology data and 
for being insensitive to ALS diagnosis based on convention clinical evaluation. Indeed, in ~10% of 
cases, even at the death, the EEC-based diagnosis is categorised as “possible”, and only ~31% of 
patients meet the criteria of “define ALS” at the time of diagnosis (Traynor et al., 2000; de Carvalho 
and Swash 2011). 
In 2006, the Awaji-shima (Japan) criteria simplified the ECC classifying the certainty level of 
diagnosis into one of three categories: clinically definite, probable and possible (Table 3). The Awaji-
criteria, aligning the importance of electrophysiology to the clinical observation, were designed for 
daily clinical practice and early diagnosis; conversely, the EEC seemed to be more useful for 
researchers and clinical trials enrolment (de Carvalho and Swash 2011; Silani et al., 2011). 
REQUISITE FOR 
DIAGNOSIS 
 Presence of evidence of LMN degeneration by clinical, 
electrophysiological or neuropathological examination; 
 Presence of evidence of UMN degeneration by clinical examination; 
 Presence of progressive spread of symptoms or signs within a region or 
to other regions, as determined by history, physical examination or 
electrophysiological tests;  
 Absence of electrophysiological or pathological evidence of other 
disease processes that might explain the signs of LMN and/or UMN 
degeneration; 
 Absence of neuroimaging evidence of other disease processes that might 
demonstrate the observed clinical and electrophysiological signs. 






 Definite ALS: clinical or electrophysiological evidence by the presence of 
LMN as well as UMN signs in the bulbar region and at least two spinal 
regions or the company of LMN or UMN signs in three spinal regions; 
 Probable ALS: clinical or electrophysiological evidence by the presence of 
LMN and UMN signs in at least two regions with some UMN signs 
necessarily rostral to (above) the LMN signs;  
 Possible ALS: clinical or electrophysiological signs of UMN and LMN 
dysfunction in only one region or UMN signs alone in two or more regions 
or LMN rostral to UMN signs. 
Table 3:  ALS criteria according to Arlie House criteria in light of Awaji-shima consensus recommendations (Modified from 
Lenglet and Camdessanché, 2017). 
Although the clinical examination let the ALS diagnosis reasonably straightforward, the main 
challenges remain: i) the considerable time elapses between the appearance of the first symptoms 
and the reaching of the definite diagnosis (Palese et al., 2019); ii) the conspicuous number of false-
negative (26-42%)/-positive (8-10%) (Chiò 2000); iii) the misdiagnosis due to the “ALS-mimic 
syndromes” (Quarracino et al., 2019) and iv) the heterogeneity in symptoms manifestation and 
speed of disease progression (Ticozzi and Silani 2018, Bendotti et al., 2020). 
1.1.2 SYMPTOMATOLOGY 
ALS symptoms are related to the dysfunction and loss of UMN and LMN. The majority (~75%) of 
ALS patients develop a limb-onset, while ~25% of patients exhibit a bulbar-onset, according to the 
body region firstly affected by the disease (extremities versus throat and mouth muscles, 
respectively). Only ~5% of subjects present initial trunk or respiratory involvement, subsequently 
spreading to other body regions (Kiernan et al., 2011).  
The most common symptoms of ALS are fatigue and reduced exercise capability that force patients 
to need assistance in continuum. Nonetheless, the presentation can vary depending on the UMN 
or LMN involvement, which define the symptoms related to the bulbar or limb-onset (Kiernan et 
al., 2011) (Table 4). 
 UMN LMN 
BULBAR ONSET  Spastic dysarthria  Tongue wasting, weakness and 
fasciculation; 
 Flaccid dysarthria; 
 Dysphagia. 




LIMB ONSET  Weakness; 
 Lack of coordination; 
 Rigidity; 
 Spasticity; 
 Increased tendon reflex; 
 Extensor plantar responses. 
 Fasciculation; 
 Upper and lower limb wasting; 
 Weakness 
Table 4: ALS related symptoms depending on the type of onset and motor neuron subtype involvement. 
As discussed above, ALS is characterised by a higher heterogeneity in terms of clinical manifestation 
and speed of the disease progression, confounding factors that complicate the process of diagnosis 
(Talbot 2009). The rate of functional decline, progression and survival might be related to the initial 
clinical manifestation. Nevertheless, studies performed in disease animal models suggest a delay 
between the MN damage and the appearance of symptoms (Kennel et al., 1996).  
The variableness of symptoms decreases as the disease progresses, conforming in muscular wasting 
and paralysis, eventually leading to a bedridden state. As the disease progresses, also respiratory 
muscles are affected impairing the respiratory activity, that constrains patients to mechanic 
ventilation. Respiratory failure is the principal cause of death in ALS patients without tracheostomy 
(Salameh et al., 2015). 
In the second half of the XX century the commonly used instrument for the assessment of the 
disease status and progression in ALS included i) the Norris scale, ii) the Baylor (Appel) scale and iii) 
the Tufts Quantitative Neuromuscular Examination (Cedarbaum and Stambler 1997). However, 
these instruments were not very operational.  
In the same years, the robustness and consistency of the ALS Functional Rating Scale (ALSFRS) was 
demonstrated in multicentre clinical trial ALS CTNF treatment study (Cedarbaum and Stambler 
1997). Developed in 1996 by the World Federation of Neurology (Group ACTSAPI-IS 1996), the 
ALSFRS is an ordinary rating scale consisting of 10 sets of 5 questions scored from 0 to 4, where 4 
is a normal function. These domains comprise 3 bulbar sets (speech, salivation and swallowing), 6 
motor sets (3 upper and 3 lower limbs) and 1 breathing set used to evaluate the status of patients. 
A few years later, the ALSFRS was revised (ALSFRS-R) adding 3 additional respiratory sets, 
addressing dyspnoea, orthopnoea and use of mechanical respiratory aids (Cedarbaum et al., 1999). 




However, measurement of change, in the absence of reliable biological markers, remains an elusive 
clinical exercise.  
Notwithstanding the heterogeneity in symptoms manifestation, ALS is a poor prognosis disease. 
About 50% of patients die within 30 months of the first clinical manifestation, and ~20% of patients 
survive between 5-10 years from the diagnosis (Chiò et al., 2009). Moreover, a simple prognostic 
algorithm based on a multivariate model indicated an association between upper limb or bulbar 
weakness, executive dysfunction and ALSFRS-R slope before first evaluation as negative prognostic 
indicators (Elamin et al., 2015). The biological basis of such differences is not understood. Even in 
families with specific gene mutations, affected members may manifest clinical heterogeneity 
supporting the likelihood that there are gene modifiers and pathways that specifically govern the 
disease manifestation (Camu et al., 1999). 
Besides “pure” motor symptoms, a multifaceted degree of extra-motor involvement (e.g. lexical 
fluency deficit, impaired language and associativity judgement, social cognition disability) has been 
observed in ALS patients that kindled the attention in the overlap between ALS and frontotemporal 
dementia (FTD) (Christidi et al., 2018).  
1.1.3 NEUROPATHOLOGY 
Structural and histological studies performed on post mortem tissues of ALS patients permitted to 
increase the comprehension of this disease. 
Starting from the XIX century, a variety of clinical descriptions of the disease were made. This effort 
culminated in the correlation between the key clinical features of progressive muscle atrophy and 
spasticity and the key neuropathological features described by Charcot, such as the loss of anterior 
horn cells and sclerosis in the lateral columns. 
Subsequent studies contributed to a more in-depth characterisation of ALS neuropathology, 
including i) the observation of the loss of giants cells of Betz (Hammer et al., 1979; Nihei et al., 
1993); ii) the identification of eosinophilic inclusion called “Bunina bodies” (Okamoto 1993); iii) the 
discovery of ubiquitinated cytoplasmic inclusions (Leigh et al., 1988; Lowe et al., 1988) and the 
identification of their main constituents (i.e. TDP-43) (Arai et al., 2006; Neumann et al., 2006), and, 




in the last few years, iii) the association between the ALS and FTD neuropathology (Hudson 1981; 
Kiernan and Hudson 1994). 
Macroscopically, no gross alteration has been found in most brain with ALS, albeit some analyses 
reported atrophy of the precentral gyrus (Qin et al., 2018). Frontal or temporal cortex atrophy was 
found most significant in the brain of patients with overlap ALS-FTD (Mioshi et al., 2013). The spinal 
cord shows atrophy of anterior nerve roots (Chang et al., 2005; Murphy et al., 2007). In addition to 
the grey matter, a reduction of the white matter was observed, particularly in the corticospinal 
tract (Roccatagliata et al., 2009; Zhang et al., 2014b). 
The typical microscopic hallmarks of ALS are the loss of large MN (but not just large neurons) in the 
anterior horn of the spinal cord and lower cranial motor nuclei of the brainstem and Betz cells in 
the V layer of the primary motor cortex (Hammer et al., 1979; Nihei et al., 1993). Furthermore, it 
has been reported clear evidence of reduction of neuron size as well as atrophy and loss of 
myelinated axons (Tandan and Bradley 1985). Other pathological features of ALS include 
vacuolisation, vast empty spaces near neurons, spongiosis and the presence of Bunina bodies 
mostly within MN and occasionally in dendrites (Piao et al., 2006; Tomonaga et al., 1978; Kuroda et 
al., 1999). Unaccountably, some LMN are spared by the disease: Onufrowicz nucleus (located in the 
S2 spinal segment) and the cranial MN, which govern the pelvic floor musculature and the 
extraocular muscles permitting the maintenance of the faecal and urinary continence and the 
ocular movement respectively (Iwata and Hirano 1978; Wijesekera and Leigh 2009). 
ALS is the most common MND. The typical hallmarks of the MN pathology are: 
 Cytoplasmic inclusions_ There are three different subtypes of cytoplasmic inclusions: skin-
like, Lewy-body and hyalin conglomerates inclusions (HCI). The skin-like inclusions are 
specific for ALS, while Lewy-body and HCI are present in other neurodegenerative diseases 
(Jellinger 2008; Leigh et al., 1989). These inclusions are immune-positive for ubiquitin, a 
protein “tag” necessary for the degradation of misfolded or senescent proteins (Bendotti 
et al., 2012), and composed of neurofilaments associated with proteins and organelles and 
the nuclear factor TAR-DNA binding protein 43 (TDP-43) (Neumann et al., 2006). The only 




ubiquitin and TDP43-negative inclusion is the Bunina body, which is composed by 
eosinophilic aggregates (Okamoto et al., 2008). 
 Mitochondrial modifications_ Morphologically, these organelles appear swelled, 
vacuolated and with a dense conglomerate of aggregates. Moreover, alterations have been 
found in respiratory chain enzymes and programmed cell death (Ruffoli et al., 2015; Martin 
2011). 
 Golgi apparatus fragmentation_ Morphologically the organelles appear smaller, 
disconnected and more numerous (fragmented) (Mourelatos et al., 1993; Stieber et al., 
1998). These alterations are accompanied by loss/gain of function in protein sorting, 
processing and transport along the axons. Moreover, the organelles fragmentation allows 
the activation of pro-apoptotic pathways that contributes to MN loss (Haase and Rabouille 
2015). 
 Axonal cytoskeleton dysregulation_ Post mortem studies showed the presence of axonal 
spheroids and perikaryal accumulations/aggregations comprised of the neuronal 
intermediate filament proteins, neurofilaments and peripherin that impairs the axonal 
transport  (Julien 1995; Xiao et al., 2006). In the last decades, the dosage of neurofilaments 
(phosphorylated and the light or heavy chain) in biofluids is a prevalent diagnostic and 
prognostic tool (Poesen and Van Damme 2018; Benatar et al., 2019). 
More recently, several studies performed in patients and disease models have highlighted the 
crucial role of glial cells in the biology of ALS neurodegeneration, showing reactive astrogliosis 
surrounding degenerating MNs (Boillée et al., 2006b; Lasiene and Yamanaka, 2011). Astrocytic 
activation is notable in the grey matter of the ventral horn of the spinal cord, which is accompanied 
by hyaline inclusions and oxidative and nitrative stress markers (Philips and Rothstein 2014). Also, 
microglia activation represents a critical aspect of ALS neuropathology. Indeed, once activated, 
microglia responds to the neuronal distress releasing a plethora of pro-inflammatory factors 
heightening the phlogosis (Philips and Rothstein 2014). Moreover, the degree of microglial 




activation is correlated to the severity of UMN degeneration (Turner et al., 2004; Lasiene and 
Yamanaka 2011). 
However, ALS is a multifactorial and multisystemic disease due to the severe alteration observed in 
multiple tissues and body compartments, including nerves and skeletal muscles (Wijesekera and 
Leigh 2009). These observations led to defining ALS as a “non-cell autonomous” disease (Ilieva et 
al., 2009).  
The damage of peripheral nervous system (PNS) is an early event in ALS pathogenesis, anticipating 
MN degeneration and motor function decline (Dadon-Nachum et al., 2011), and represents a major 
determinant of patients disability (Riva et al., 2016; Gentile et al., 2019). Nowadays, the nerve 
biopsy analysis is a procedure propaedeutic to the diagnosis (Riva et al., 2011). Moreover, 
preclinical studies showed a positive correlation between the extent of PNS damage and the ALS-
related mutation or the speed of disease progression (Nardo et al., 2016b; Tian et al., 2016). 
As proof of the “die-back” phenomenon that characterises ALS pathology (Dadon-Nachum et al., 
2011), also the alteration of skeletal muscles is an early event in the disease. Indeed, muscle 
weakness is the pivotal sign of the disease in both patients and models (particularly mutant SOD1 
mice). Several studies showed that ALS muscles suffer from oxidative stress, mitochondrial 
dysfunction and bioenergetic disturbance. However, the implication of muscles in nourishing the 
degenerative process is still under debate (Loeffler et al., 2016). Furthermore, the knowledge of the 
processes underlying the degeneration/regeneration mechanisms and the myogenic potential of 
ALS muscles is still limited (Jensen et al., 2016). Indeed, studies are still ongoing to clarify the 
different susceptibility of the muscular compartment to the disease (Nijssen et al., 2017; Di Pietro 
et al., 2018; Jensen et al. 2016). 
In the last years, growing attention has been focused on events related to the innate and adaptive 
immune response in ALS determination and progression. Several studies demonstrated that ALS 
patients also show abnormalities in the circulating blood cells (Mantovani et al., 2009; Gustafson et 
al., 2017). In particular, it has been described deregulation in levels or expression profile of dendritic 
cells (Rusconi et al., 2017), monocytes (Zondler et al., 2016; Zhang et al., 2006) and T lymphocytes 




(Katchar et al., 2001; Zhang et al., 2005). These studies showed that these alterations might be the 
mirror of the pathological processes within CNS and put them forward as predictors of disease 
progression (Murdock et al., 2016; Nardo et al., 2011; Rahman et al., 2019; Swindell et al., 2019).   
1.1.4 EPIDEMIOLOGY 
Amyotrophic lateral sclerosis epidemiology has rapidly developed in the last 30 years alongside the 
evolving changes in concepts in the field of clinical ALS and due to the recent proposals of a new 
classification system for motor neuron diseases (Al-Chalabi et al., 2016).  
ALS is considered a rare disease with an incidence (number of new cases per year) between 0.6 and 
3.8 per 100˙000 person-year (p-y). In Europe ALS incidence is higher (ranging from 2.1 to 3.8 per 
100˙000 p-y), in contrast other population-based studies have measured the lowest incidence in 
East and South Asia (0.89 and 0.79 per 100˙000 p-y, respectively) (Longinetti and Fang 2019; 
Logroscino and Piccininni 2019). Speculations for a lower incidence registered in Asia are the 
absence of population-based studies (the first registry in Europe was established in Scotland in 1989 
(Hern et al. 1992)) and the lower prevalence of ALS-associated genes in the Asian population (Kim 
et al., 2016). The origin of the geographic incidence of ALS is a matter of debate, since it is partly 
due to the prevalence of ALS-associated genes and partly to the environmental risk factors. Another 
confounding factor in establishing the incidence of ALS might derive from the delay in the diagnosis. 
Indeed, although the closer surveillance of patients with familial ALS led to early diagnosis, the type 
of onset and the heterogeneous clinical manifestation can postpone it. Patients with bulbar onset 
were reported to be diagnosed earlier compared to them with spinal onset. Moreover, male 
patients were reported to be diagnosed on average sooner than females (Longinetti and Fang 
2019). 
Recent population-based studies reported a prevalence between 4.1 and 8.4 per 100˙000 person 
(Longinetti and Fang 2019). A difference in ALS prevalence by ethnicity has also been recently 
reported. Using the National ALS Registry the prevalence of European- American ALS patients was 
found to be more than double the prevalence of African-American ALS patients (5.4 versus 2.3 per 




100˙000) (Mehta et al., 2018). Furthermore, a male to female ratio between 1 and 2 was reported, 
except for Africa, where this ratio was registered higher than 2.9 (Longinetti and Fang 2019). 
ALS is considered a disease of the adult because the peak of onset is between 51 and 66 years. 
European patients usually have a later age onset compared to Asia and Latin America (Longinetti 
and Fang 2019). 
Despite the predominance of spinal onset (58-82%) in all countries, bulbar onset seems to be 
prevalent in subjects characterised by different traits (females, cognitive impairment, elderly, etc.). 
In addition to the spinal or bulbar onset, recently have been reported other types of onset that 
might alter the incidence of the disease in ALS registers: mixed (spinal and bulbar), thoracic, 
cognitive and respiratory (Longinetti and Fang 2019). 
1.1.5 GENETICS  
ALS is considered a multifactorial disease due to an interplay between environmental and genetic 
factors as disease determinants. The disorder exists in sporadic and familial forms uniformly 
throughout the world, except for a higher familial incidence in Guam island and Kii peninsula of 
Japan (Kuzuhara et al., 2001). The majority of cases (~90%) are sporadic (sALS) with no apparent 
genetic linkage. In comparison, in ~5-10% of the patients, the pathology is familial (fALS) and caused 
by the inheritance of a specific mutation (Ajroud-driss and Siddique 2015). Generally, in adult-onset 
ALS, the disease is inherited as an autosomal dominant (AD) trait. However, rare cases of juvenile 
ALS are commonly associated with autosomal recessive (AR) or X-linked inheritance. Intriguingly, it 
has been reported an AR inheritance of AD genes in specific populations (e.g. FUS in Cape Verde 
and SOD1 in Scandinavia) (Alsultan et al., 2016).  
Several factors may contribute to the missing hereditability in ALS, including the complex nature of 
the disease and the limitations of the technologies used in large association studies. These studies 
are based on short read and high throughput technologies (van Rheenen et al., 2016), which, albeit 
useful in the detection of single-nucleotide polymorphisms (SNP), are not able to identify the 
majority of structural variations of the human genome (e.g. long repeats, repetitions in multiple 
DNA regions, etc..) (Naruse et al., 2019). 




Nonetheless, the clinical phenotype of sALS and fALS patients is usually indistinguishable, even 
though fALS cases exhibit an earlier onset (~46 years) compared to sALS (~56 years) (Camu et al., 
1999). Inexplicably, in sALS a male preponderance was reported (1.5:1) respect to fALS (1:1), 
although this ratio tends to decrease after age 70 (Haverkamp et al., 1995; Gros-Louis et al., 2006; 
Naruse et al., 2019). 
Familial ALS (fALS) 
Each newly discovered gene implicated in the aetiology of ALS provides fundamental insights into 
the pathogenesis of MN degeneration of this disease, as well as facilitating models generation and, 
thus, the preclinical testing of new therapeutic interventions. 
All genes implicated in fALS so far identified and the respective ALS subtype are listed in the table 
below. 
Inheritance Denomination Locus Gene Protein Reference 
Autosomal 
Dominant 
ALS 1 21q22.11 SOD1 Cu/Zn superoxide 
dismutase 1 
(Rosen 1993) 
 ALS 3 18q21 unknown unknown (Hand et al. 
2002) 
 ALS 4 9q34.13 SETX Senataxin (Chen et al. 
2004) 
 ALS 6 16q11.2 FUS/TLS Fused in 
sarcoma/translated in 
liposarcoma 
(Ruddy et al. 
2003; 
Kwiatkowski et 
al. 2009; Vance 
et al. 2009) 
 ALS 7 20p13 unknown unknown (Sapp et al. 
2003) 
 ALS 8 20q13.32 VAPB Vescicle-associated 




 ALS 9 14q11.2 ANG Angiogenin (Greenway et al. 
2004 and 2006; 
van Es et al. 
2011) 




 ALS 10 1p36.22 TARDBP Transactive response 






 ALS 11 6q21 FIG4 Phosphoinositide 5-
phosphatase 
(Chow et al. 
2009) 
 ALS 12 10p13 OPTN Optineurin (Maruyama et 
al. 2010) 
 ALS 13 12q24.12 ATXN2 Ataxin 2 (Elden et al. 
2010) 
 ALS 14 9p13.3 VCP Valosin containing 
protein 
(Johnson et al. 
2010) 
 ALS 17 3p11.2 CHMP2B Charged multivesicular 
body protein 2B 
(Parkinson et al. 
2006) 
 ALS 18 17p13.2 PFN1 Profilin 1 (Wu et al. 2012) 
 ALS 19 2q34 ERBB4 Erb-b2 receptor 
tyrosine kinase 4 
(Takahashi et al. 
2013) 




(Kim et al. 
2013a) 
 ALS 21 5q31.2 MATR3 Matrin 3 (Johnson et al. 
2014) 
 ALS 22 2q35 TUBA4A Tubulin α-4A (Smith et al. 
2014) 
 ALS 23 10q22.3 ANXA11 Annexin A11 (Smith et al. 
2017) 
 - 12q24 DAO D-amino acid oxidase (Mitchell et al. 
2010) 






translocation gene on 
chr18- like 1 
(Teyssou et al. 
2013) 
 ALS- FTD 1 9p21.2 C9ORF72 Chr9 open reanding 
frame 72 
(Renton et al. 
2011; DeJesus-
Hernandez et al. 
2011) 










 ALS- FTD 3 5q35.3 SQSTM1/p62 Sequestosome 1 (Fecto et al. 
2011) 




ALS 1 21q22.11 SOD1 Cu/Zn superoxide 
dismutase 1 
(Al-Chalabi et al. 
1998) 
 ALS 2 2q33.1 KIAA1563 Alsin (Hadano et al. 
2001b; Yang et 
al. 2001) 




Spatacsin (Hentati et al. 
1998; Orlacchio 
et al. 2010) 




al. 2009; Ticozzi 
et al. 2009) 
 ALS 12 10p13 OPTN Optineurin (Goldstein et al. 
2016) 
 ALS 16 9p13.3 SIGMAR1 Σ non-opioid 
intracellular receptor1 




horn cell disease 
with arthrogryposis) 
9q34.11 GLE1 GLE1, RNA export 
mediator 
(Kaneb et al. 
2015) 
X-linked ALS 15 Xp11.21 UBQLN2 Ubiquilin 2 (Deng et al. 
2011) 
Table 5: Classification of inherited forms of ALS (modified from Mathis et al., 2019). 
ALS 1 – Copper/Zinc Superoxide Dismutase 1 (SOD1) 
Mutation of Cu/Zn superoxide dismutase 1 (SOD1) was the first described genetic cause of fALS.  
In 1991 Siddique and colleagues described the linkage of chromosome 21 (where SOD1 is located) 
polymorphisms and ALS (Siddique et al., 1991). Two years later, Rosen and colleagues identified 11 
different mutations of this gene (Rosen 1993).  




SOD1 encodes a 153 amino acid ubiquitously expressed metalloenzyme. The protein binds copper 
and zinc to form an extremely stable homodimer. SOD1 dimers are located in the cytosol and 
intermembrane spaces of mitochondria, providing a vital antioxidant defence mechanism by 
catalysing the production of oxygen and hydrogen peroxide from the superoxide species produced 
during cellular respiration (McCord and Fridovich 1969). 
SOD1 mutations, detected in 23% of fALS and 2-5% of sALS (Andersen 2006), are characterised by 
considerable inter and intra-familial variability. E.g. the G37R and L38V variants are associated to 
an earlier onset and differ from the A4V mutation, which is the most commonly detected and give 
rise to the most aggressive form of the disease characterised by a rapid disease course; conversely, 
other variations (e.g. H46R) display a mild phenotype. This evidence suggests that the SOD1 enzyme 
properties that modulate the timing of symptoms appearance differ from those involved in the rate 
of disease progression (Cudkowicz et al., 1997). Besides, the penetrance is variable and is strictly 
dependant on the genetic variant. Most of the SOD1 mutations are inherited in an AD manner; 
however, the D90A variant shows both a dominant and recessive pedigree (Andersen 2006). 
To date, over 185 disease-associated variations in SOD1 have been discovered, the majority of 
which are missense point mutations (Yamashita and Ando 2015). Given that the SOD1 encodes a 
153 amino acid protein, this number is remarkable, suggesting that the modifications are 
distributed along the gene impacting upon a variety of domains. However, it is not clear whether 
all the identified variants of SOD1 are indeed pathogenic (Felbecker et al., 2010). 
The multiple mutations identified have resulted in challenges in determining the mechanism 
through which each alteration affects the disease phenotype. Considering the ~80% of decreased 
dismutase activity, a loss of enzymatic function was first proposed (Deng et al., 1993; Rosen 1993). 
However, the subsequent studies showed that the dismutase activity did not correlate with the 
disease severity, indicating a gain of toxic function of the mutated SOD1 (Reaume et al., 1996). In 
light of the mutable state of methylation and disulphide bond formation that alter not only the 
catalytic activity but also its conformational stability, many mutually compatible pathogenic 
mechanisms to the mutant SOD1 (mSOD1) have been proposed including oxidative stress, 




excitotoxicity, protein aggregation, neuroinflammation, apoptosis, mitochondrial dysfunction, 
axonal transport deregulation and endoplasmic reticulum stress (Kaur et al., 2016). Intriguingly, it 
has been shown that the mSOD1 can initiate a prion-like seeded aggregation of the wild-type 
protein (Münch and Bertolotti 2011). 
ALS 2 – Alsin 
Alsin gene comprises of 33 exons and encodes to a 184KDa protein consisting of 1˙657 amino acids. 
Predominantly expressed within neurons, Alsin is diffusely distributed, although several dots have 
been found in cytosol and dendrites (Yamanaka et al., 2003; Hadano et al., 2007). The protein is 
composed of multiple motifs homologous to guanine-nucleotide exchange factors (GEF). Indeed, it 
has been shown to function as GEF for Ran, Rho and Rab GTPases (Bischoff 1991). Thanks to this 
property, Alsin is involved in endosome dynamics, cytoskeleton organisation and neuronal 
development (Otomo et al. ,2003; Hadano et al., 2007). Interestingly, through its RhoGEF-Pleckstrin 
domain, Alsin can also specifically binds different variants of the mutant SOD1 (Kanekura et al., 
2004). 
Mutation in the Alsin gene causes a group of overlapping autosomal recessive neurodegenerative 
diseases characterised by a long duration/evolution without any bulbar or respiratory signs: 
infantile onset ascending hereditary spastic paralysis (IAHSP), juvenile primary lateral sclerosis 
(JPLS) and juvenile ALS (ALS 2). All the pathogenic mutations, that have in common the loss of the 
C-terminal VSP9 (GEF) domain, led to the production of a truncated protein, suggesting a loss of 
toxic function mechanism (Hadano et al., 2001a; Yamanaka et al., 2003; Yang et al., 2001). It has 
been hypothesised that alteration of the long and the short variants of Alsin could lead to ALS, while 
mutation affecting only the long isoform could cause milder disease as IAHSP and JPLS (Helal et al., 
2018). Counterintuitively to the proposed loss of function mechanism, knockout mice for Alsin do 
not develop any significant motor deficit. However, they are predisposed to oxidative stress, altered 
vesicles and endosomes trafficking and age-dependent neurological deficit (Cai et al., 2005; 
Chandran et al., 2008). 
 




ALS 4 – Senataxin 
SETX comprises 26 exons and encodes a 302KDa protein of 2˙667 amino acid. Senataxin contains a 
classical C-terminal 7-motif domain characteristic of the superfamily 1 of DNA/RNA helicases. SETX 
exhibit a strong homology to RENT1 and IGHMBP2, genes involved in the RNA processing. 
Interestingly IGHMBP2 mutations are associated with spinal muscular atrophy, a pure LMN disease. 
Homozygous deletions in SETX are linked to ataxia with oculomotor apraxia type 2 (AOA2) and distal 
hereditary motor neuropathy (dHMN), while heterozygous dominant mutations are associated with 
ALS 4 (Bennet et al., 2018b).  
ALS 4 is characterised by early-onset, a plodding progression and the absence of respiratory and 
bulbar signs even in advantage stage (Chen et al., 2004; Chance et al., 1998). Considering the 
different pattern of inheritance of SETX mutations in these diseases, ALS4 is probably caused by a 
gain of toxic function of the mutated Senataxin. 
ALS 5 – Spatacsin 
Mutation in SPG11 represents the most common cause of autosomal recessive hereditary spastic 
paraplegia with thin corpus callosum (Stevanin et al., 2008). However, Orlacchio and colleagues 
identified 12 frameshift or missense mutations in SPG11 in 10 unrelated pedigree of ALS (Orlacchio 
et al., 2010). ALS 5 is characterised by early-onset, a slow progression and distal muscle atrophy 
associated with pyramidal signs. The protein is composed of 4 transmembrane domains, suggesting 
its involvement as a receptor or transporter, even if the exact biological function is still missing. 
Recently, induced pluripotent stem cells (iPS)-derived neuron demonstrated Spatacsin expression 
within cytoskeleton and that SPG11 mutation caused axonal dysfunction (Pérez-Brangulí et al., 
2014). 
ALS 6 – Fused in Sarcoma / Translated in Liposarcoma 
FUS encodes a ubiquitously expressed 526 amino acid protein belonging to the FET family of RNA 
binding protein (RBP). Structurally, presents an N-terminal domain rich in glutamine–glycine–
serine–tyrosine (QGSY), three arginine–glycine–glycine (RGG)-rich domains, an RNA recognition 




(RRM) and a zinc finger motif, as well as a nuclear export signal (NEL) and nuclear localisation signal 
(NLS) that enable nucleocytoplasmic shuttling of the protein (Deng et al., 2014). 
FUS is involved in several aspects of gene expression (transcription, alternative splicing, transport 
and translation) (Ratti and Buratti 2016), DNA repair mechanisms (Mastrocola et al., 2013) and also 
the cellular defence against stress (formation of paraspeckles) (Hennig et al., 2015). 
FUS mutations are detected in 4% of fALS and also in 1% of sALS cases. More than 50 autosomal 
dominant FUS variants have been found in ALS patients. Mostly clustered in the last 18 C-terminal 
residues (NLS), increasing its retention into the cytosol (Vance et al., 2013), others in the RGG 
(prion-like) domain and also in the 3’UTR, that increased the propensity of FUS to aggregate (Shang 
and Huang 2016).  
The debate is still ongoing to clarify the loss or gain of function mechanism causing ALS 6. According 
to the loss of function mechanism, the pathological retainment of the protein within cytosol 
renders FUS unable to exert its nuclear function. However, FUS knockout models did not show ALS-
like phenotype suggesting that loss of FUS is per se not sufficient to cause ALS (Kino et al., 2015). 
Conversely, as confirmation of the toxic gain of function, mouse overexpressing the wild-type FUS 
developed an aggressive MN degeneration and cytoplasmic FUS accumulation (Mitchell et al., 
2013). Discussion is still ongoing concerning whether the toxicity is directly mediated by the FUS 
aggregates or by the retainment of the insoluble FUS within the cytosol. 
ALS 6 patients are characterised by a proximal upper extremities onset, the spreading to the lower 
without a bulbar region involvement. Neuropathologically, patients exhibit an increased 
cytoplasmatic FUS staining, with cytoplasmic and neuritic inclusions that do not colocalise with 
TDP43 (Kwiatkowski et al., 2009). 
ALS 8 – Vesicle associated membrane protein B (VAPB) 
VAPB comprises 6 exons and encodes a 33KDa protein composed of 243 amino acid. VAPB is a 
membrane protein localised in plasma and intracellular vesicle membranes and can associate with 
microtubules. As homodimer (VAMPB) or heterodimer (associated with VAMPA), the complex 
interacts with synaptobrevin 1 and 2 (VAMP1 and VAMP2) regulating the vesicular trafficking (Weir 




et al., 1998). Furthermore, like type 2 integral endoplasmic reticulum (ER) membrane protein, is 
involved in the unfolded protein response and in regulating the ER-mitochondria interaction (Lev 
et al., 2008). 
Linkage analysis of a large Brazilian family put VAPB forward as a causative gene of ALS. In particular, 
the P56S variant has been identified in multiple Brazilian pedigrees suggesting a joint founder 
(Nishimura et al., 2005). The P56S mutant VAPB is characterised by an impaired unfolded protein 
response, altered calcium buffering and disrupted anterograde axonal transport of mitochondria 
(Mórotz et al., 2012a). Several mutations have been discovered during the last years, though not 
all segregated with the disease (Kabashi et al., 2013; van Blitterswijk et al., 2012).  
ALS 8 phenotype is characterised by a slow progression of the disease, LMN symptoms (tremor, 
cramps, fasciculations) without the involvement of UMN (Nishimura et al., 2004). 
ALS 9 – Angiogenin (ANG) 
Angiogenin, a.k.a ribonuclease 5, is a small 123 amino acid protein. Upon the binding to the cognate 
surface receptor, angiogenin is internalised and translocated to the nucleus where stimulates 
several biological pathways, including tRNA (transfer RNA) transcription, ribosome biogenesis, cell 
proliferation, etc. (Moroianu and Riordan 1994). Recent evidence reported a pivotal role of 
angiogenin in the assembly of stress granules. Interestingly, the G-quadruplets structures formed 
by the G4C2 C9ORF72 expansion inhibits this mechanism, thereby establishing a connection 
between these two genes (Ivanov et al., 2014).  
ANG mutations, present in 2% of fALS and 0.8% of sALS patients, lead to inhibition of angiogenin 
secretion and impairment of its numerous functions finally causing MN degeneration (Greenway et 
al., 2006).   
ALS 10 – TAR-DNA binding protein 43 (TDP43) 
TARDBP encodes several protein isoforms, among which TDP43 is the most prevalent.  
TDP43 is a 414 amino acid heterogeneous nuclear ribonucleoprotein (hnRNP) containing a nuclear 
localisation (NLS) and nuclear export signal, which allow shuttling of the protein between the 
nucleus and the cytosol. TDP43 is composed of different domains, two RNA recognition motifs, 




involved in nucleic acid binding, and a C-terminal glycine-rich domain (prion-like domain) which is 
essential for the protein-protein interaction (Ayala et al., 2008; Baralle et al., 2013).  
TDP43 is a regulator of gene expression; therefore it has been shown to play a pivotal role in RNA 
metabolism (transcription, splicing, transport, etc.) (Scotter et al., 2015; Ratti and Buratti 2016). 
Recently, it has been found as a component of stress granules, suggesting its involvement also in 
cell protection from damage (Aulas and Velde 2015). However, the real biological function of TDP43 
is still unknown. 
To date, at least 48 variants in TARDBP have been associated with ALS, the majority of which are 
missense mutations located in the C-terminal of the transcript (Lattante et al., 2013). 
TDP43 is the main component of the characteristic ubiquitinated inclusions observed in patients 
with ALS (97%) and FTD. This evidence establishes TDP43 as the prominent protein signature of ALS, 
not just in the TDP43 mutation carrier patients (Neumann et al., 2006; Schipper et al., 2016). The 
aggregated forms of TDP43 are characterised by abnormal phosphorylation (and/or post-
translational modifications), truncation and mislocalisation in the cytosol. Neurodegeneration is 
probably due to one or all the properties acquired by the mutant TDP43: gain of toxic function, loss 
of function or aberrant function (Alsultan et al., 2016). 
ALS 11 – Phosphoinositide 5-phosphatase (FIG4) 
FIG4, also known as SAC3, regulates PI(3,5)P2 (phosphatidylinositol 3,5-bisphosphate) levels and 
thereby controls retrograde trafficking of endosomal vesicles to Golgi. The mutant proteins showed 
loss of phosphatase activity, mislocalisation, and inability to bind to the PI(3,5)P2 complex.  
Mutations in FIG4 were originally identified in Charcot-Marie-Tooth patients; however, screening 
of ALS patients identified nine variants that possibly led to a FIG4 mislocalisation (Chow et al., 2009).  









ALS 12 – Optineurin (OPTN) 
OPTN gene encodes the coiled-coil containing protein Optineurin of 67KDa. Optineurin is involved 
in the autophagosome transport, through the interaction with ubiquitin and ubiquilin2, in the Golgi 
organisation and the regulation of NF-κB signalling (Bansal et al., 2015).  
OPTN mutation causes an exaggerated activation of NF-κB, altering the neuronal function and 
accelerating the body inclusions formation (Maruyama et al., 2010). 
OPTN variants (exonic deletion and nonsense mutation) were initially identified in Japanese 
consanguineous. Subsequent screening has identified additional heterozygote mutations in fALS 
and sALS cases (Goldstein et al., 2016). 
ALS 13 – Ataxin 2 (ATX2N) 
ATXN2 contains 9 exons, two of which are protein-coding. The CAG repeat in the coding sequence 
is prone to error in DNA replication, and its length can vary widely between individuals. More than 
36 CAG repeats are associated with spinocerebellar ataxia 2. However, a recent meta-analysis has 
identified 25-28 repeats as protective, whilst a significant risk to develop ALS was associated with 
31-33 CAG repeats (Elden et al., 2010; Neuenschwander et al., 2014). 
ATXN2 is an RNA binding protein localised within the endoplasmic reticulum, Golgi and stress 
granules ad it is involved in RNA processing.  
ALS 13 is characterised by spinal onset and shorter survival (Borghero et al., 2015). 
ALS 14 – Valosin containing protein (VCP) 
VCP is an AAA+ ATPase protein involved in various cell activities, including the mediation in the 
degradation of ubiquitinated protein by the proteasome and the targeting of substrates to the 
autophagosome. Therefore, the discovery of VCP mutations highlighted the involvement of 
ubiquitination/protein degradation defects in ALS pathogenesis (Meyer and Weihl 2014). 
Initially, an exome sequencing analysis put VCP variants forward as causative in ALS. Subsequent 
studies identified further four VCP variants providing the evidence of a clear association with fALS 
(Johnson et al., 2010). VCP mutations have also been found in a rare form of Paget Disease (IBMPFD, 
Inclusion Body Myopathy with Paget disease of bone and Frontotemporal Dementia), which is 




characterised by mitochondrial uncoupling and a reduced ATP production, common features of ALS 
16 (Kimonis et al., 2008). 
ALS 15 – Ubiquilin 2 (UBQLN2) 
UBQLN2 encodes for Ubiquilin 2 protein that contains an N-terminal ubiquitin-like domain and a C-
terminal ubiquitin-associated domain. Ubiquilin lays an essential role in the regulation of different 
protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), 
autophagy and the endoplasmic reticulum-associated protein degradation (ERAD) pathway 
(Kleijnen et al., 2000; Xia et al., 2014). 
Mutations in UBQLN2, mostly within the PXX repeat region, have been shown to disrupt the protein 
degradation pathway, causing the mislocalisation of OPTN from endosomal vesicles and also 
impairing the RNA metabolism, through the loss of hnRNP (heterogeneous nuclear 
ribonucleoproteins) binding (Gilpin et al., 2015). These observations highlight how the protein 
turnover and RNA metabolism impairment fulfil a pivotal role in ALS pathogenesis. 
ALS 16 – Sigma-1 Receptor (SIGMAR1) 
SIGMAR1 encodes for the sigma-1 receptor, which is involved in endoplasmic reticulum stress, 
calcium transport within mitochondria and chaperone activity. Mutation of SIGMAR1 causes the 
formation of cytoplasmic aggregations, reduction in ATP production and subsequent decrease in 
proteasome activity (Fukunaga et al., 2015). 
Initially, 3’-UTR variants were observed in FTD-ALS or pure FTD families, suggesting the alteration 
of the RNA metabolism as the leading mechanism (Luty et al., 2010). Subsequent studies identified 
a missense mutation segregating in a large family with autosomal dominant juvenile ALS (Al-Saif et 
al., 2011). However, the contribution of SIGMAR1 mutations in ALS needs further investigations. 
ALS 17 – Charged multivesicular body protein 2B (CHMP2B) 
CHMP2B encodes a component of the heteromeric ESCRT-III complex (Endosomal Sorting Complex 
Required for Transport III) that functions in the recycling or degradation of cell surface receptors. 
CHMP2B is found as a monomer in the cytosol or as an oligomer in ESCRT-III complexes on 
endosomal membranes.  




CHMP2B variants have been identified in both fALS and sALS patients, the majority of which showed 
an LMN phenotype (Cox et al., 2010). 
ALS 18 – Profilin 1 (PFN1) 
PFN1 encodes for an actin-binding protein, that plays an essential role in actin dynamics by 
regulating its polymerisation in response to extracellular stimuli. Moreover, it has been shown a 
profilin 1 co-localisation within stress granules, suggesting a role in cell defence from damage 
(Figley et al., 2014). 
Several PFN1 variants have been found in fALS and sALS patients, with the pE117G mutation 
identified as a risk factor (Wu et al., 2012; Fratta et al., 2014).  
PFN1 mutations destabilise the protein function, although the loss of function/gain of toxic function 
mechanism is yet to be clarified.  
ALS 19 – Erb-b2 receptor tyrosine kinase 4 (ERBB4) 
ERBB4 is one of the four members in the EGFR subfamily of receptor tyrosine kinases. It is 
specifically bound by neuregulins (NRG3 and NRG4) resulting in the autophosphorylation of the C-
terminal.  
ERBB4 was found to localise to interneurons C-boutons which synapse with spinal MNs. 
Interestingly, C-boutons are not present in oculomotor neurons, which are spared from the disease 
(Gallart-Palau et al., 2014).  
ERBB4 mutations, found in both fALS and sALS, decrease the protein activation through the 
inhibition of C-terminal autophosphorylation (Takahashi et al., 2013). 
ALS 20 – Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) 
HNRNPA1 encodes for a member of a family of ubiquitously expressed heterogeneous nuclear 
ribonucleoproteins (hnRNPs). hnRNPA1 is one of the most abundant core proteins of hnRNP 
complexes and plays a crucial role in the regulation of RNA alternative splicing, but also cell 
apoptosis. Interestingly, hnRNP1 interacts with TDP43 and ubiquilin 2 (Gilpin et al., 2015).  




Although histopathological analysis showed intense nuclear staining of hnRNPA1 within MN 
perikaryon, that correlates with nuclear loss of TDP43, a wide screening study of fALS and sALS 
patients suggested that this is an infrequent cause of the disease (Alsultan et al., 2016). 
ALS 21 – Matrin 3 (MATR3) 
MATR3 encodes for a protein with RNA and DNA binding domains that appears to be involved in 
regulating the gene expression (Coelho et al., 2015).  
Exome sequencing studies have identified four MATR3 mutations in fALS and eleven in sALS 
pedigree, that account for less than 1% of ALS  (Johnson et al., 2014; Marangi et al., 2017) 
It has been recently reported that matrin 3 forms complex with other ALS-associated RNA binding 
proteins (RBP) such as FUS and TDP43 (Yamaguchi and Takanashi 2016; Johnson et al., 2014). 
Interestingly, the p.S85C variant increases the interaction whit the RBPs while other mutations 
(pF115C, p.P154S and p.T622A) do not (Johnson et al., 2014). Nevertheless, by contrast to TDP43 
and FUS, the subcellular localisation of the mutant matrin 3 is unaffected. 
Arguably, the different variants hitherto discovered and their intrinsic property of interaction with 
other proteins might be responsible for the heterogeneous phenotype of ALS 21 (Chia et al., 2018). 
ALS 22 – Tubulin-α4A (TUBA4A) 
TUBA4A encodes tubulin-α4A, a protein involved in cytoskeletal structural dynamics.  
Exome sequencing analysis discovered four missense and two nonsense mutations, four of which 
deleterious, that account about 1% of fALS and 0.4% of sALS cases (Smith et al., 2014). 
In vitro studies showed that mutant tubulin-α4A is inefficient at forming αtubulin-βtubulin dimers, 
which are poorly incorporated into microtubules thus reducing the structural stability of 
cytoskeleton, in the interaction with the axonal transport proteins dynein and kinesin, and 
promotes the depositions of ubiquitinated cytoplasmic inclusion (White and Sreedharan 2016; 
Smith et al. 2014). These pieces of evidence highlight the crucial role of cytoskeletal and axonal 
defects in ALS pathogenesis. 
Scant information is available concerning the clinical phenotype of ALS 22. Although patients often 
develop ALS typical features, some display common symptoms of FTD (Smith et al., 2014). 




ALS 23 – Annexin 11 (ANXA11) 
ANXA11 encodes a 56KDa protein member of the annexin family, a group of calcium-dependent 
phospholipid-binding proteins, which are involved in vesicular trafficking between Golgi and ER. 
Annexins have unique N-terminal domains and conserved C-terminal domains, which contain 
calcium-dependent phospholipid-binding sites.  
Physiologically, annexin 11 localised in cytoplasmic vesicle-like structures and foci that are widely 
distributed throughout the somata, dendrites and axons. In vitro studies showed that the mutant 
annexin 11 tends to aggregate, due to the loss of its binding propensity for calcyclin (a protein 
involved in proteostasis), and loses association with the vesicle-like structures. Moreover, as a 
prion-like mechanism, the mutant annexin 11 sequesters the wild-type protein inhibiting its 
biological activity (Smith et al., 2017). 
Mutations in ANXA11 were observed in about 1% fALS and 1.7% sALS patients (Nguyen et al., 2018). 
ALS-FTD 1 – Chromosome 9 open reading frame 72 (C9ORF72) 
Discovered in 2011, the hexanucleotide repeat expansion (G4C2) in the non-coding region of the 
intron 1 of C9ORF72 represents the most common inherited cause of ALS in Europe, but not in Asia 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011; Majounie et al., 2012).  
While healthy controls commonly have <10 G4C2 repeats, ALS patients carrier 400-2˙000 repeats. 
The repeat expansion has been found in 37.6% fALS and 6.3% sALS patients, as well as in up to 
25.1% of FTD cases (Majounie et al., 2012). Accordingly, the clinical phenotype of this ALS subtype 
is strongly associated with FTD. Moreover, it has been reported that ALS-FTD 1 patients exhibit a 
higher incidence of bulbar onset and earlier symptoms manifestation compared to non-C9ORF72 
ALS subjects (Cooper-Knock et al., 2015). 
Recent studies have shown that C9ORF72 has several biological functions. Structural analysis 
revealed a similarity to GDP/GTP exchange factors that regulate Rab proteins and thus the vesicular 
trafficking (Levine et al., 2013), while colocalisation studies candidates C9ORF72 involvement in 
autophagy and endosomal trafficking (Farg et al., 2014).    




Several hypotheses have been proposed to explain how the intronic hexanucleotide expansion may 
cause neurodegeneration: 
 Inhibition of endosomal trafficking and perturbation of endocytosis (leading to autophagy) 
caused by a protein loss of function. However, knock out mice do not develop motor 
neurons degeneration, suggesting that the loss of C9ORF72 function alone is not the 
primary cause of ALS-FTD 1 (Koppers et al., 2015). 
 Formation of RNA foci dependent from the expansion length, in which RNA binding proteins 
are sequestered resulting in the disabling of the RNA processing machinery (Lee et al., 2013; 
Todd and Petrucelli 2016). 
 Production of five different dipeptide repeat (DPR) proteins through RAN (non-AUG) 
translation, which showed a strong propensity to aggregation. Of all (polyGA, polyGP, 
polyGR, polyPA and polyPR), polyGA exhibits the most toxic power through the activation 
of programmed cell death and the dose-dependent cleavage of TDP43, another ALS-
associated protein (Lee et al., 2017). 
 Disruption of the nucleocytoplasmic shuttling at the level of the short isoform (C9-S), 
generally localised at the nuclear membrane. Moreover, it has been demonstrated a 
correlation between the loss of C9-S and the TDP43 mislocalisation (Mihevc et al., 2017). 
 Increased vulnerability to calcium-permeable AMPA receptor-mediated excitotoxicity 
(Selvaraj et al., 2018). 
Finally, in light of the haploinsufficiency characteristic of ALS-FDT 1 patients, the 
neurodegenerative phenomenon might be driven by al least two mechanisms: excitotoxicity 
and impaired clearance of neurotoxic DPR (Shi et al., 2018). Therefore, in ALS-FDT 1, the 
degenerative events are driven by both a loss and a gain of toxic function. 
ALS-FTD 2 – Coiled-coil helix coiled-coil helix domain-containing protein 10 (CHCHD10) 
CHCHD10 encodes 14KDa mitochondrial protein which, together with mitofil, CHCHD3 and 
CHCHD6, forms the multiprotein complex MICOS (mitochondrial contact site and cristae organizing 
system), which is pivotal in the formation and maintenance of cristae structure.  




Twentyone CHCHD10 variants clustered in the exon 2, which encodes an internal hydrophobic 
helical segment important for mitochondrial membrane binding, have been found in a broad range 
of neurodegenerative disorders including ALS and FTD (Bannwarth et al., 2014; Zhang et al., 2015b). 
Analyses performed in fibroblast from subjects with CHCHD10 mutation showed structurally 
abnormal mitochondria and defects in the respiratory chain and mitochondrial genome stability 
(Bannwarth et al., 2014). These alterations are, as the mitochondrial abnormalities, observed in 
mutant TDP43 patients. Physiologically CHCHD10 interacts with TDP43 promoting its nuclear 
retention; however, the mutant CHCHD10 lose this ability augmenting the TDP43 accumulation 
within the cytoplasm (Woo et al., 2017). 
Nevertheless, CHCHD10 mutations appear to be a relatively rare cause of ALS (1%) but might be 
more frequent among FTD patients (10%) (White and Sreedharan 2016). 
ALS-FTD 3 – Sequestosome 1 (SQSTM1/p62) 
SQSTM1 encodes a ubiquitin-binding protein that plays a role in protein degradation via autophagy 
and proteasome. The protein functions as an adaptor, in concert with TNF-receptor associated 
factor 6, to mediate the activation of NF-κB in response to upstream signals. 
Several SQSTM1 variants that led to a loss of protein function have found in fALS and sALS patients 
but also Paget disease (Teyssou et al., 2013; Fecto et al., 2011). 
ALS-FTD 4 – TANK-binding kinase 1 (TBK1) 
TBK1 encodes for a homodimeric multidomain protein containing a kinase domain, a ubiquitin-like 
domain and two coiled-coil domains. 
TBK1 interacts with several proteins and regulates numerous critical cellular processes involved in 
ALS including neuroinflammation, ubiquitin-proteasome systems and autophagy pathways 
engaging other genes ALS-associated (i.e. OPTN, SQSTM1, VCP, and UBQLN2) (Oakes et al., 2017). 
Most mutations localised in the coiled-coil and kinase domains leading to the loss of function of 
TBK1 and resulting in the alteration of the downstream regulatory pathways.  
Patients with mutant TBK1 exhibit haploinsufficiency of the protein (Freischmidt et al., 2015), and 
are characterised by bulbar onset, cognitive impairment. Moreover, TBK1 carrier showed TDP43 




inclusions in the brain and spinal cord, thus listing TBK1-ALS as another “TDP43 proteinopathy” 
(White and Sreedharan 2016). 
TBK1 variants account 1.3% of fALS, 1% of sALS and 4% of ALS-FTD patients (Nguyen et al., 2018). 
Moreover, ALS patients that exhibit FTD signs and TBK1 mutation are negative for C9ORF72 
mutation, candidating TBK1 as an ALS causative gene (Nguyen et al., 2018).  
 
Figure 1: Localisation and role of the targets (proteins) of the main causative genes of fALS (Mathis et al. 2019). 
Altogether the genetic determinants of fALS can also explain more than 20% of sALS.  
These data are represented in Table 6. 
Denomination Gene fALS sALS 
ALS 1 SOD1 20% 2-5% 
ALS 2 ALSIN rare no association 
ALS 3 Unknown (18q21 locus) rare unknown 
ALS 4 SENATAXIN rare rare 
ALS 5 SPATACSIN rare unknown 
ALS 6 FUS/TLS 4% 1% 
ALS 7 Unknown (20p13 locus) rare unknown 
ALS 8 VAPB rare unknown 




ALS 9 ANG 2% rare 
ALS 10 TARDBP 3-6% 1.5% 
ALS 11 FIG4 rare rare 
ALS 12 OPTN 1-4% rare 
ALS 13 ATXN2 rare rare 
ALS 14 VCP 1-2% rare 
ALS 15 UBQLN 1% rare 
ALS 16 SIGMAR1 unknown no association 
ALS 17 CHMP2B 1% rare 
ALS 18 PFN1 2-3% rare 
ALS 19 ERBB4 unknown unknown 
ALS 20 HNRNPA1 rare rare 
ALS 21 MATR3 1% rare 
ALS 22 TUBA4A 1% rare 
ALS 23 ANXA11 1% 2% 
ALS FTD 1 C9ORF72 38% 7-10% 
ALS FTD 2 CHCHD10 1% unknown 
ALS FTD 3 SQSTM1 1% rare 
ALS FTD 4 TBK1 2-3% 1-2% 
Table 6: Common genetic determinants of fALS and sALS. 
Sporadic ALS (sALS) 
The aetiology of ALS remains mostly unknown. However, the epidemiological data hitherto 
collected indicate that genetic factors highly contribute to its pathogenesis. Indeed, genetic 
mutations initially observed in fALS pedigree have also been identified in (apparently) sALS patients, 
as reported in Table 6.  
Nevertheless, the identification of gene variants in sALS cases has met with limited success so far. 
Studies performed to link particular genetic variants to sALS represent a small number of cases, 
reflecting the intricate pattern of inheritance, the high heterogeneity in the clinical manifestation 
and the presence of environmental risk factors in the disease. However, these studies highlighted 
the presence of “susceptibility genes” that, once mutated, might increase the risk to develop the 




disease probably due to the ability of the encoded mutant protein to dysregulate the interaction 
with other ALS-associated pathways. 
The primary discovered gene are listed in the table below. 
Gene Protein Biological function Reference 
DCTN1 Dynactin ER-Golgi transport, lysosome 
and endosome trafficking, 
chromosome movement and 
axonogenesis 
(Münch et al., 2004) 
NEFH, NEFM, 
NEFL 
Neurofilament subunits Axons support (Figlewicz et al. 1994) 
PRPH Peripherin Neurofilament assembly (Gros-Louis et al. 
2004) 




growth and repair 
(Lambrechts et al. 
2003) 
SMN Survival motor neuron RNA processing (Veldink et al. 2005) 
CTNF Ciliary neurotrophic factor Neurotransmitter synthesis, 
neurite outgrowth and 
neuronal trophic factor 
(Giess et al. 2002) 
APOE Apolipoprotein E Lipoprotein metabolism (Moulard et al. 1996) 
APEX DNA repair enzyme 
apurinic/apyrimidinic 
endonuclease 
Gene expression regulation, 
cellular response to stress 
(Kisby et al. 1997) 
HFE Homeostatic iron regulator Cellular response to 
oxidative stress 
(Wang et al. 2004) 
Table 7: Most common sALS “susceptibility genes”. 
In conclusion, increasing the knowledge about the genetic profile that represents a “risk” or 
“protective” factor in ALS will change the way clinical trials are done and how therapy is prescribed 
to patients. The complete characterisation of the genetic profile of patients will allow the correct 
stratification of cohorts and thus increase the success of clinical trials. Finally, raising awareness 
about the genetic profile of patients will be a breakthrough to integrate the genetic screening for 









ALS is a poor prognosis disease without an effective treatment, this due to the several pathogenetic 
mechanisms involved and since the main feature of ALS in the high phenotypic variability (Bendotti 
et al., 2020). 
Recently, two treatments have been recognised and classified as “disease-modifying”. The longest 
available, FDA (Food and Drug Administration) approved in 1995, is the anti-glutamatergic agent 
Riluzole, which prolongs the lifespan of patients of about 3-6 months without affecting the quality 
of life (Miller et al., 2001). 
The other disease-modifying treatment, recently approved by FDA, but not by EMA (European 
Medicines Agency), is Edaravone (Radicut®), an antioxidant agent able to eliminate lipid peroxides 
and hydroxyl radicals (Bhandari et al., 2018).  
A massive number of therapies have been/are being studied on different stages of preclinical and 
clinical practice. They are categorised based on the pathophysiological mechanism and listed 
below. 
Anti-apoptotic  
This group of treatment focuses on mechanisms leading to motor neuron death (e.g. mitochondrial 
impairment, abnormal calcium handling, etc..). In this class are included Dexpramipexole 
(Cudkowicz et al., 2013) with failed outcomes, and more recently Ursodeoxycholic and 
Tauroursodeoxycholic acids, both with moderate positive results (Elia et al. 2016; Min et al. 2012).  
Anti-inflammatory  
Mounting evidence shows that neuroinflammation process associated with reactive glial and 
infiltrating immune cells plays a pivotal role in ALS determination and progression. Forasmuch as 
inflammation has emerged as a critical mechanism in driving the disease, several 
immunomodulatory therapies have been hitherto tested in ALS patients (Wosiski-Kuhn et al., 2019). 
Mentioned among treatments targeting the innate immune system: Celecoxib, cyclooxygenase 2 
(COX2) inhibitor that protects from excitotoxicity blocking the prostaglandins synthesis (Cudkowicz 
et al., 2006); Minocycline, antibiotic that reduces microglial activation and polarises the 




macrophages toward an anti-inflammatory phenotype (Gordon et al., 2007); Glatiramer Acetate 
and RN60, compounds able to tip the balance toward the alternative (Th2, M2) inflammatory 
response (Gordon et al., 2006; Paganoni et al., 2019).  
Conversely, some treatments have been tested to attempt in modulating the adaptive immune 
response, chiefly T lymphocytes. An example is the total lymphoid irradiation (TLI), which, through 
the selective target of lymphoid organs, abolish the circulating lymphocytes. However, this 
treatment did not obtain the expected outcome in ameliorating the disease course of patients but 
rather increased the number of circulating CD8+ cytotoxic T cells (Drachman et al., 1994). Another 
drug able to inhibit the egress of lymphocytes from lymph nodes and recently tested in ALS is 
Fingolimod, which, differently from TLI, do non affect the level of circulating T regulatory cells (Berry 
et al., 2017). 
Efforts were also made to target the link between the innate and adaptive immune system: the 
cytokines. Examples of this class of drugs are Anakinra, a selective interleukin 1 receptor (IL1-R) 
antagonist (Maier et al., 2015), and Tocilizumab, a monoclonal antibody against IL-6 (Mizwicki et 
al., 2012). 
Anti-excitotoxicity 
In ALS, excitotoxicity is derived from an excessive glutamate release combined with alterations in 
post-synaptic glutamatergic receptors and transporters. Directly involved in the inhibition of the 
excitotoxic phenomenon in ALS are, as mentioned before, Riluzole, Ceftriaxone (Cudkowicz et al., 
2014), Memantine (de Carvalho et al., 2010) and Methylcobalamin (Kaji et al., 2019). 
Antioxidant 
Oxidative stress represents one of the most prominent factors playing a pivotal role in ALS 
pathogenesis. Several antioxidant compounds have been tested, including the above mentioned 
Edaravone and Pramipexole (Pattee et al., 2003). 
Anti-aggregation 
The protein aggregation and deposition (in particular TDP43 and mutantSOD1) is a hallmark of ALS; 
indeed, it is considered a proteinopathy. Preclinical evidence candidates as anti-aggregant factors: 




Arimoclomol, an amplifier of heat shock protein-mediated response (Lanka et al., 2009), MIF 
(macrophage migration inhibitory factor), a compound able to inhibit the toxic misfolded SOD1 
aggregates (Shvil et al., 2018) and an acridine derivate [4,5-bis{(N-carboxy methyl 
imidazolium)methyl}acridine] that seems to antagonised the TDP43 aggregation (Afroz et al., 2017). 
Neuroprotection (neurotrophic factors) 
Besides inhibiting the numerous pathological mechanisms underlying neurodegeneration in ALS, 
efforts have been made to identify therapies that could stimulate the repair of damage MN or 
promote the growth of new ones. Recently have been proposed as promising compounds: 7,8-DHF 
(7,8-dihydroxyflavone), an agonist of tyrosine kinase receptor B (TkrB) that mimic the effects of 
BDNF (brain-derived neurotrophic factor) (Korkmaz et al., 2014) and GPNMB (glycoprotein non-
metastatic protein B), which seems to reduce the TDP43-mediated stress (Tanaka et al., 2012). 
Muscle strength 
Although ALS is an MND, the first symptoms appear at the muscular level (Moloney et al., 2014). 
Moreover, the primary cause of death in ALS patients is respiratory failure due to the progressive 
weakening of diaphragm. Therefore, maintain and/or increase the muscle strength and 
functionality might significantly ameliorate the disease progression. 
For this purpose have been proposed: the soluble form of activin IIB receptor, an inhibitor of 
negative regulators of muscle growth (e.g. GDF8 myostatin) (Morrison et al., 2009) and Tirasemtiv, 
a troponin activator (Shefner et al., 2019). 
Cell-based therapy 
Nowadays, stem cells approaches are primarily designed to increase neuroprotection (paracrine 
effect) rather than to replace degenerated neurons. 
Mesenchymal stromal cells (MSC) are primarily being used as an autologous stem cell therapy due 
to their ability to secrete neurotrophic factors and modulate the immune system, as demonstrated 
in several preclinical and clinical studies (Bonafede and Mariotti 2017).  
Another stem cell strategy implies the use of glial-restricted precursors or neural progenitor stem 
cells (Lepore et al., 2011; Edwards 2016). However, the demonstration that only a small amount of 




the injected cells can engraft and differentiate within the injury site suggested that their beneficial 
effect was indirectly and thus mediated by the several factors released. Subsequent studies 
demonstrated that stem cells produce a broad spectrum of extracellular vesicles (EVs) containing 
an enormous amount of factors (cytokines, growth factors, nucleic acids, etc.). This evidence 
indicated that stem cells could exert their beneficial effect through the EVs secretions, which 
promote the wound healing releasing their content within the damaged area (Baglio et al., 2012). 
Thus, EVs (i.e. microvesicles and exosomes) could be used as a novel therapeutic tool, avoiding the 
ethical and immunogenic risks of stem cells (Bonafede and Mariotti 2017). 
Gene therapy 
The progress of medicine brings alternative and innovative approaches for the treatment of so far 
incurable neurodegenerative diseases, including ALS. 
Targeting ALS-associated genes, genetic modifiers or related disease molecules have shown 
promising results (Cappella et al., 2019). Indeed, it has been shown that antisense oligonucleotides 
(ASOs) against SOD1 were able to eliminate the mutant protein without adverse effects (Miller et 
al., 2013). One disadvantage of ASOs is the need for repetitive infusions or the identification of the 
correct dose. The deliver of ASO or short hairpin RNA to knockdown mutant SOD1 through a viral 
vector (e.g. AAV9, adeno-associated virus serotype 9) circumvents this issue (Foust et al., 2013; 
Iannitti et al., 2018). Another approach currently under consideration is the delivery of an AAV9 
expressing a single-chain antibody against misfolded SOD1, which demonstrated its efficacy 
postponing the disease onset and extending survival in ALS mice (Maier et al., 2018). 
Although these studies were focused on SOD1 ALS-related gene, these approaches can potentially 
be applied to others known ALS-causing gene or related disease molecules, thus increasing their 
relevancy also for sALS cases. Indeed, it has been recently reported an amelioration of clinical 
phenotype of ALS mice following the administration of ASOs, an interfering RNA (RNAi) or using a 
CRISPR/Cas9 technique to targeting the G4C2 expansion of C9ORF72 gene (Jiang et al., 2016; 
Martier et al., 2019; Pickles and Petrucelli 2018). 




Moreover, for sALS patients a more general neuroprotective approach was winnowed consisting in 
the delivery of growth factors such as VEGF (vascular endothelial growth factor), IGF1 (insulin-like 
growth factor 1), GCSF/CSF3 (granulocyte-colony stimulating factor/colony-stimulating factor 3) 
(Dodge et al. 2010; Henriques et al. 2011). 
Despite the efforts done in basic research and clinical trials, ALS remains a poor prognosis disease, 
and only two disease-modifying therapies are available to date.  
This failure could have been caused by the use of animal models of ALS. As far as representing a 
useful tool, small rodents do not mimic the heterogeneity of the human disease faithfully and, 
although their genome is closely related to our, animal models do not exhibit precisely the same 
modifications of humans. To overcome this issues, iPS cells (induced pluripotent stem cells) derived 
from ALS patients or control subjects, represent a promising in vitro platform for discovering unique 
“human neuron phenotypes” that may reflect the individual disease and, thus, testing newly-
discovered therapeutic approach (Engle et al., 2018; Morgan et al., 2018). 
Moreover, ALS is considered a multifactorial and multisystemic disease in which MN death 
represents the final event. Therefore, the purpose of drug combinations would appear to be a 
logical approach, even if this strategy remains largely unexplored both in preclinical and clinical 
studies. 
1.2 PATHOGENETIC MECHANISMS 
Despite decades of basic research, causative mechanisms in ALS remain elusive. Studies performed 
in autoptic human samples and animal models suggest that it is likely that multiple pathogenetic 
mechanisms, rather than a single trigger event, actively participate in the determination and 
progression of ALS.  
Moreover, as discussed above, it is known only the 5% of causes of ALS (fALS) while the remaining 
95% (sALS) are still undisclosed. The genetic but also the phenotypic variability represents an 
enormous confounding factor in uncovering and drawing conclusion regarding the pathogenetic 
mechanisms underlying ALS. Nevertheless, since the clinical and pathological profile of fALS and 




sALS patients are indistinguishable, it can be predicted that the evidence obtained from the studies 
performed on animal models of ALS (i.e. fALS) may be acceptable also to sALS patients.  
However, more clarity is needed concerning the timing and extent to which each of the 
pathogenetic mechanisms listed below is involved and actively contribute to ALS development and 
progression. 
 
Figure 2: Proposed pathogenic mechanisms and pathology in ALS (Mejzini et al. 2019). 
1.2.1 MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS 
The term reactive oxygen species (ROS) comprehends hydroxyl radicals (OH-), peroxynitrite   
(ONOO-), superoxide radical anion (O2-), nitric oxide (NO) and hydrogen peroxide (H2O2). Aerobic 
metabolism (mitochondrial respiratory chain) is the primary source of free radicals. Still, they are 
also produced by cytochrome P450 enzymes in the ER or by immune cells as a second messenger 
(Knight 2000). Therefore, at moderate levels, ROS have beneficial effects and are involved in various 
physiological functions, such as immune functions (i.e. defence against pathogens), cellular 
signalling pathways, mitogenic response and redox regulation (Valko et al., 2007).  
Oxidative stress may occur, on one side, when an imbalance between antioxidant capacity and the 
rate of ROS production occurs or, on the other side, when the cell antioxidant capacity is impaired 
due to a deficiency of enzymatic and non-enzymatic antioxidants activity. When antioxidants do 




not neutralise ROS, the latter can seriously damage the integrity of cell homeostasis affecting the 
stability of various biomolecules (Thanan et al., 2014). 
Mounting evidence showed the involvement of oxidative stress in ALS (Barber et al., 2006). Indeed, 
oxidative stress markers have been observed in both patients (Barber and Shaw 2010; Wang et al., 
2019) and disease models  (Cacabelos et al., 2016). However, it is not known yet if oxidative stress 
represents a causative event in ALS degenerative cascade or it is merely a consequence of other 
toxic insults.  
Possible trigger events could be ageing. Indeed, ALS is an adult-onset disease and several pieces of 
evidence reported an increased ROS production during ageing (Liguori et al., 2018). Although ageing 
is unlikely to be the cause of disease, in some patients it could represent a risk factor as the origin 
of an excessive cellular response to toxic stimuli that finally leads to MN degeneration (Barber and 
Shaw 2010). 
Mitochondrial are at the same time the primary source and the main target of ROS, establishing a 
vicious circle (Lin and Beal 2006). The overload of reactive species increases the mutations in 
mitochondrial DNA (mtDNA) altering the production of components of the respiratory complexes, 
this leads to an impairment of mitochondrial detoxifying function finally resulting in further ROS 
production (Genova et al. 2004).  
Therefore, researchers focused on the comprehension of the mitochondria-related pathogenic 
mechanisms in ALS. These studies showed that the mitochondrial functions can be dysregulated by 
the aggregating products of ALS-related genes and/or by the aberrant RNA processing and that 
products cannot be eliminated by cell due to the impaired autophagic mechanism (Carrì et al., 2017; 
Smith et al., 2019).  
SOD1 has been the first ALS-related gene discovered and encodes for the main anti-oxidative 
enzyme of cells. This evidence confirms the involvement of SOD1 protein in ALS pathogenesis, 
suggesting its participation also in the oxidative stress phenomenon. Interestingly, preclinical 
studies demonstrated that ALS pathogenesis might involve not only the decrease/loss of 
antioxidant activity of mutant SOD1 but also the acquirement of a toxic gain of function caused by 




an altered geometry of the active site that allows the entry of reducing substrates (Rakhit and 
Chakrabartty 2006). This alteration results in increased ROS production and a modified interaction 
with mitochondria and other proteins (Cozzolino et al., 2009). Besides, it has been reported that 
mutant SOD1 alters both the structure (vacuolisation) and function of mitochondria (alteration in 
electrons transport and Ca2+ loading, decreased ATP production, apoptosis, impaired axonal 
transport) since the early stage of the disease (Tafuri et al., 2015; Vehviläinen et al., 2014) not only 
within the nervous system but also at the skeletal muscle level (Vielhaber et al., 1999; Ehinger et 
al., 2015). 
Moreover, several shreds of evidence demonstrated that also RNA misregulation occurring in ALS 
augments the oxidative stress within neurons. However, dual views regarding mechanism and 
causation have been proposed. On the one hand, oxidative stress directly causes RNA 
dysregulation, as demonstrated by the cytoplasmatic mislocalisation and increased aggregation of 
RNA binding proteins, such as FUS and TDP43, during oxidative stress (Vance et al., 2013). On the 
other hand, RNA dysregulation is responsible for the oxidative stress and mitochondrial damage, as 
demonstrated by the physiological interaction between FUS and HSP60 within mitochondria (Deng 
et al., 2015) and by the TDP43-mediated regulation of proteins involved in mitochondrial physiology 
(Wang et al., 2013b). 
Additionally, mitophagy (the selective process whereby mitochondria are targeted and degraded 
by the autophagy machinery) is directly involved in oxidative stress and thus in ALS pathogenesis 
(Edens et al., 2016). The most reliable evidence supporting the contribution of impaired mitophagy 
to oxidative stress lies in ALS-related genes. For example, Optineurin fulfils a pivotal role in PINK1-
Parkin-mediated mitophagy (Wong and Holzbaur 2014), VCP lies downstream Parkin (an E3 
ubiquitin ligase) and is recruited to the outer membrane of damaged mitochondria (Kim et al., 
2013b), while TBK1 is activated through a PINK1-Parkin-dependent mechanism to recruit 
autophagy receptors to the depolarised mitochondria (Heo et al., 2015). Thus, once mutated, these 
proteins are no more able to exert their physiological function affecting the mitochondrial activity 
and, thereby, increasing the cellular oxidative stress. The practical role and timing of oxidative stress 




in ALS pathogenesis is still unclear; however, even if it represents a secondary event, it is 
undoubtedly involved in the propagation of cellular damage that culminates with the MN death. 
1.2.2 EXCITOTOXICITY 
Glutamate, the primary excitatory neurotransmitter, is synthesised in the presynaptic terminal, 
stored in the presynaptic vesicles and release into the cleft through a calcium-dependent 
mechanism. Once released in response to depolarization, glutamate binds the receptors localised 
on pre- and post-synaptic domain. Four different families of glutamate receptors have been 
identified in mammals: AMPA, kainate, NMDA and metabotropic receptors. The first three families 
are ionotropic, meaning that when activated they open membrane channels that allow ions (Ca2+) 
to pass through. The metabotropic family is composed by G protein-coupled receptors (GPCR), and 
they exert their effects transducing the signal into the cytoplasm. 
The concentration of glutamate within the synaptic cleft is finely regulated, mostly by the isoform 
2 of the astroglial glutamate transporter (EAAT2/GLT1), to avoid excitotoxicity (i.e. an excessive or 
prolonged stimulation of glutamate receptor that leads to neuron death).  
Thanks to the studies performed in ALS animal models and patients, excitotoxicity has long been 
suspected as a mediator of the disease (Van Damme et al., 2005; Leigh and Meldrum 1996; King et 
al., 2016) since it has been demonstrated an increased susceptibility of MNs to the glutamate 
neurotransmitter (Spencer et al., 1986; Kawahara et al., 2004).  
Have been suggested several direct (over-stimulation) and indirect (over-reaction) mechanisms by 
which the dysregulation of the glutamatergic transmission occurs in ALS (King et al., 2016). The 
direct mechanisms imply that the over-stimulation of MN by the excessive glutamate concentration 
within the cleft might be due to a decrease clearance of the neurotransmitter or due to its increased 
(dysregulated) release. The decrease up-take hypothesis is supported by the observation of a 
reduced function of EAAT2 in ALS patients (Fray et al., 1998) and disease models (Bendotti et al., 
2001); while the dysregulated glutamate release could be driven by the overactivity of the 
presynaptic terminal but also by altered calcium buffering mediated by the “stressed” ER (Nosyreva 
and Kavalali 2010). Conversely, the MN over-reaction might be mediated by an alteration of the 




glutamate regulation exert by GABAergic and glycinergic interneurons (Ince et al., 1993); an 
impaired receptors expression, particularly the NR1 and NR2 NMDA subunits (Virgo and de 
Belleroche 1995; Samarasinghe et al., 1996) and the GluR2 AMPA subunit (Takuma et al., 1999); or 
by the intrinsic excitability (i.e. firing threshold) of motor neurons (Vucic and Kiernan 2006). 
1.2.3 IMPAIRED PROTEOSTASIS 
The accumulation of damaged proteins contributes to several neurodegenerative diseases, and it 
has also emerged as a hallmark in ALS (Soto 2003). Under normal conditions, neurons possess an 
efficient protein quality control machinery which can also be modulated under toxic stress 
(adaptive mechanism) to maintain the proteostasis (i.e. protein homeostasis) (Balch et al., 2008).  
However, it has been reported that neurons are particularly vulnerable to disturbances in 
proteostasis because they are long-lived post-mitotic cells that are not able to dilute out protein 
aggregates during cell divisions (Yue et al., 2009). Moreover, it has been demonstrated that the 
neurons ability to maintain the proteostasis declines during ageing, that might explain why the 
majority of the neurodegenerative diseases occurs in the adulthood (Hipp et al., 2019). 
Proteostasis comprises a network of interconnected quality control processes that include 
(Bendotti et al., 2012; Blokhuis et al., 2013): 
 Chaperones_ assist protein folding and target misfolded proteins to degradation. 
 Ubiquitin proteasome pathway (UPS)_ is the principal mechanism for protein catabolism in 
the cell. Degradation of a protein via this pathway involves two discrete and successive 
steps, tagging or conjugation of the substrate protein by the covalent attachment of 
multiple ubiquitin molecules and the subsequent degradation of the tagged protein by the 
26 S proteasome. 
 ER-associated protein degradation (ERAD)_ designates a cellular pathway that targets 
misfolded proteins from the ER to ubiquitination and subsequent degradation in the cytosol 
by the proteasome. 




 Autophagy-lysosome pathway_ segregate misfolded proteins in a double membrane 
forming an autophagosome. This vesicle is then fused with the lysosome, forming the 
autophagolysosome, where misfolded proteins are degraded. 
 Stress granules_ are cytosolic structures composed of assembled ribonucleoproteins to 
stop protein translation under a variety of cellular stresses. 
 
Figure 3: Contribution to ALS-related gene to proteostasis impairment in the disease (Medinas et al., 2017). 
The most commonly ALS-related genes (SOD1, C9ORF72, TARBDP, FUS) all give rise to proteins that 
are involved in proteostasis machinery and found to aggregate within neurons of ALS patients (Fig. 
3). Moreover, it has been recently reported that the product of mutant genes can change their 
native conformation and seeds in a prion-like mechanism (McAlary et al., 2019). However, 
proteinaceous inclusions are also observed in sALS patients, implying that disturbances in protein 
folding and quality control mechanisms may bring wild-type proteins to misfold and aggregate 
(Bosco et al., 2010; Neumann et al., 2006; Migheli et al., 1990). These pieces of evidence suggest 
that the impairment of the proteostasis quality control can be a common feature of both familial 
and sporadic ALS. 




Protein aggregates have also been found in disease models, particularly within dendrites, 
periaxonal processes of oligodendrocytes and in neurons and astrocytes perikarya (Watanabe et al. 
2001; Stieber et al., 2000). Studies performed showed that these inclusions are composed of several 
proteins, such as SOD1 (Bosco et al., 2010), ubiquitin (Basso et al., 2009), chaperones (Marino et 
al., 2015), TDP43 (Sanelli et al., 2007), Optineurin (Korac et al., 2013), neurofilaments (Beaulieu et 
al., 2000), and many more.  
Interestingly, glial cells and muscles seem mostly spare from the misfolded protein accumulation. 
Recently it has been suggested that these cell types are better equipped in activating chaperones 
and protein degradation system than neurons, resulting in a more efficient response to counteract 
the altered proteostasis (Galbiati et al., 2014; Jansen et al., 2014). 
In conclusion, the accumulation of ubiquitin or ubiquitin-tagged misfolded proteins could affect the 
physiological activity of proteasome machinery, impairing the ordinary protein degradation and 
establishing a vicious circle that increases the protein accumulation, thus resulting in MN 
degeneration and death. However, it is not yet known if the altered proteostasis in ALS is caused 
by an excessive protein accumulation or by an overwhelmed protein clearance.  
1.2.4 AXONAL TRANSPORT DEFECT  
Axonal transport involves the movement and distribution of intracellular cargo such as proteins, 
mRNA, vesicles, lipids and organelles along the axon. Intermediate filaments (IF) represent the 
“binaries” of this transport, which, together with microtubules and microfilaments, compose the 
eukaryotic cells cytoskeleton.  
In the adult neurons, three major IF types are present: neurofilaments, α-internexin and peripherin. 
Thanks to these “binaries” neurons can transport protein synthesised within somata to the 
neuromuscular junction (kinesin-mediate anterograde transport) and substances produced in the 
periphery to the cell body (dynein-dynactin-mediated retrograde transport). 
Neurofilaments (Nfs) are the major IF within neurons and represent the most abundant part of 
large myelinated axons, of which control the calibre. Nfs are composed by the polymerisation of 




the light (Nf-L, 65KDa), the medium (Nf-M, 95KDa) and the heavy (Nf-H, 115KDa) subunits. Nf-L is 
fundamental in filament assembly, while the other two subunits links with other Nfs. 
Axonal transport defects are commonly seen in many neurodegenerative diseases, most of them 
mimicking ALS (Guo t al., 2019). Its involvement as a pathogenetic mechanism in ALS arose from 
the observation of abnormal accumulation of Nfs, mitochondria and lysosome in MN perikarya 
(hyaline conglomerate inclusions) of post mortem tissues (Hirano et al., 1984). Peripherin and Nf 
have also been found in the majority of axonal inclusions (axonal spheroids) of ALS patients (Corbo 
and Hays 1992), particularly in the large calibre axons of α-MNs, which are the more susceptible to 
the disease (Sobue et al., 1981).  
The mechanism driving the formation of Nfs aggregates in ALS is still unclear. Mutation in Nf genes 
have been found in fALS and sALS patients (Figlewicz et al., 1994) and seems to be correlated to 
post-translational protein modification, particularly hyperphosphorylation (Dale and Garcia 2012). 
However, Nf gene mutations are not a common cause of ALS but could represent a risk factor for 
MNs vulnerability (Bonafede and Mariotti 2017).  
Clinical studies suggest that the Nfs aggregation could also be promoted by their altered 
stoichiometry (Zucchi et al., 2018), as confirmed by overexpression/downregulation studies 
performed in disease models (Turner and Talbot 2008). Surprisingly, the overexpression of the Nf-
L and Nf-H was able to slow down the disease in ALS mice, suggesting a protective effect of 
neurofilaments accumulation when occurring within neuron cell body (Kong and Xu 2000). 
Aside from the accumulation, Nfs can also release after neuroaxonal damage and thus can be 
titrated in biofluids (CSF and serum). Nf-L dosage is currently used in clinical practice as a diagnostic 
and informative biomarker since it has been demonstrated its increased level ~12 months 
preceding the manifestation of the first signs of the disease (Benatar et al. 2019; 2018). Further 
studies also showed its predictive value in ALS prognosis (Poesen and Van Damme 2018). 
Nfs are a component of cell cytoskeleton and with that take part in several cellular processes. 
Consequently, an open question concerning their involvement as a cause or consequence of the 
neurodegenerative event in ALS is still debated. For example, it is well known that neurons are 




critically dependent on mitochondria to maintain their function (Schwarz 2013). However, lack of 
mitochondrial adaptors or regulators (e.g. Miro, Milton, Kif5C, etc.) has been likewise connected to 
ALS mutation (Chen et al., 2016; Mórotz et al., 2012b) suggesting that mitochondrial deficit could 
be the causative reason of axonal transport deficit. Similarly, other pathogenic mechanisms such as 
ER stress (Woehlbier et al., 2016), protein aggregation (Oberstadt et al., 2018; Huai and Zhang 
2019), autophagy dysregulation (Lie and Nixon 2019) and DNA damage (Naumann et al., 2018) are 
strictly associated to axonal transport deficit. Nevertheless, further studies are ongoing to clarify 
whether these pathways are localised upstream or downstream to axonal transport defects in ALS. 
1.2.5 NUCLEOCYTOPLASMIC TRANSPORT DEFECTS  
The earliest clue suggesting a nucleocytoplasmic transport defect in ALS arose from a study 
performed in 1995, showing lateral arthrogryposis within the anterior horn of eleven Finnish 
families (Vuopala et al., 1995). Later on, an analysis of a large cohort of patients leads to the 
identification of a rare loss of function mutation in GLE1 (Kaneb et al., 2015), which encodes a 
component of the cytoplasmic face of the nuclear pore complex (NPC) that facilitates the export of 
mRNAs from the nucleus (Nousiainen et al., 2008). This evidence was strengthened by the nuclear 
depletion and cytoplasmic mislocalisation of TDP43 (Winton et al., 2008), FUS (Ling et al., 2013) and 
heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) (Liu et al., 2016), together with the 
observation of a high number of mutations within the nuclear localisation signal of ALS-linked 
proteins. These observations suggested that dysfunction in nucleocytoplasmic transport through 
the NPC might contribute to the disease development and/or progression, either through the loss 
of nuclear functions or gain of toxic cytoplasmic function that increase concentration/residence 
time of these proteins in cytoplasmic assemblies (Kim and Taylor 2017). 
Another link between nucleocytoplasmic transport deficit and ALS has emerged with the discovery 
of the G4C2 expansion of C9ORF72 gene. Recent works demonstrated that several RNA binding 
proteins and NPC components (e.g. Nup205, Nup107) are sequestered within RNA foci and that the 
repeated expansion alters the nuclear-cytoplasmic distribution of TDP43 (Zhang et al., 2015a; Zhang 
et al., 2016). Although these studies did not distinguish between RNA-mediated and DPR-mediated 




toxicity of mutant C9ORF72, Jovičić and colleagues identified eleven altered genes that regulate 
nucleocytoplasmic transport in a model of DPR-mediated toxicity (Jovičić et al., 2015). 
1.2.6 IMPAIRED DNA REPAIR  
Due to its high rate of oxygen consumption and metabolic activity, the CNS is more susceptible to 
DNA damage. Indeed, oxidative stress is the leading cause of DNA damage (i.e. double-strand 
breaks, DSBs) within neurons (Tann et al., 2011). Moreover, the high transcriptional rate also 
increases neurons susceptibility to injury since the genomic stability is fundamental for the 
maintenance of homeostasis (Aguilera and García-Muse 2012; Hill et al., 2016). However, 
differently from other cell types, homologous recombination (HR) is not an available mechanism 
for DNA repair since neurons are long-lived post-mitotic cells. 
The first evidence of the impaired DNA damage response (DDR) in ALS was reported more than 
thirty years ago (Tandan et al., 1987). Concurrently with the discover of ALS-associated genes, 
considerable evidence of an altered DDR in ALS have been collected. 
It has been observed that FUS and TDP43 participate in the DDR. The former physiologically 
colocalises with the histone protein γH2AX and RNA polymerase II (RNA pol II) at sites of damage 
primarily to prevent or repair loop-associated DNA damage (Hill et al., 2016). TDP43, as FUS, 
colocalises with RNA pol II, moreover it binds PAR (the polymer product by PARP1) stabilising the 
DNA replication forks and chromosome remodelling (Rulten et al., 2014). TDP43 is also involved in 
the non-homologous end-joining and base-excision repair mechanism thanks to the interaction 
with the histone deacetylases SIRT1 and HDAC1 (Wang et al., 2013a; Wang and Hegde 2019). All 
these physiological functions are lost by the mutant proteins.  
More recently, it has also been demonstrated a correlation between the G4C2 expansion of 
C9ORF72 and a defective DNA repair, manifested by higher levels of DSBs and impaired DDR 
(Walker et al., 2017). Consistently, high levels of DNA damage markers (p53, GADD45, γH2AX, etc.) 
have been observed in iPS-derived motor neurons of ALS-FTD1 patients (Lopez-Gonzalez et al., 
2016). 




1.2.7 ALTERED RNA METABOLISM 
The interest in the involvement of RNA dysregulation in the pathogenesis of ALS arose from the 
identification of disease-causing variations in RNA-binding protein (RBP) genes: FUS and TARDBP.  
RBPs are involved in several aspects of RNA metabolism including splicing, transcription, transport, 
translation and storage within the stress granules (Dreyfuss et al., 2002). These abilities are mainly 
derived from the prion-like domain of RBPs, a site where the major part of mutations occurs. 
Interestingly, this domain is involved in the stress granules formation thanks to its ability to form 
multiple transient weak interactions with other proteins/RNA. Stress granules are RNA and 
proteins-made complexes formed during cell stress to transiently inhibit translation of non-
essential RNA or pro-apoptotic proteins (Protter and Parker 2016). However, the involvement of 
stress granules formation in ALS pathogenesis is currently under investigation (Fernandes et al., 
2018). 
TDP43 mainly regulates the splicing, stability and transport of ~6˙000 RNA (Buratti and Baralle 2008; 
Polymenidou et al., 2011; Colombrita et al., 2012) which encode for synaptic proteins (GABA 
receptors, AMPA receptor subunit, microtubule-associated proteins, etc.) and proteins implicated 
in ALS and other neurodegenerative diseases (FUS, Ataxin2, etc.) (Butti and Patten 2019). 
Moreover, it has been demonstrated TDP43 involvement in microRNA (miRNA) biogenesis and long 
non-coding RNA (lncRNA) binding (Kawahara and Mieda-Sato 2012; Tollervey et al. 2011). 
Interestingly, TDP43 retains the ability to reduce its owns expression by bind the 3’UTR of its own 
pre-mRNA (Ayala et al., 2011), highlighting the importance of TDP43 in cell homeostasis and thus 
the significance of its deregulation/dysregulation in ALS pathogenesis. 
Similarly to TDP43, FUS binds different transcript of ALS-associated genes (e.g. VCP, OPTN, VAPB) 
(Lagier-Tourenne et al., 2012), modulates the biogenesis of miRNA (Morlando et al., 2012) and 
transcriptional factors (e.g. NF-κB) (Uranishi et al., 2001). As part of hnRNP complex, FUS regulates 
the spicing of ~1˙000 mRNA (Lagier-Tourenne et al., 2012) involved in neurogenesis, cytoskeleton 
organisation, axonal outgrowth and maintenance, potential transmission to skeletal muscles and 
several others important cell functions (Butti and Patten 2019). 




Although SOD1 is not an RBP, pieces of evidence demonstrate its involvement in the regulation of 
the metabolism of VEGF and Nf-L subunit transcripts (Lu et al., 2009; Chen et al., 2014a). 
More recently, it has been observed RNA foci deposition in ALS and FDT patients characterised by 
the G4C2 expansion of C9ORF72, due to both sense and antisense transcription of the altered gene. 
RNA foci sequester several RBPs (e.g. hnRNP3, FUS, TDP43) leading to the dysregulation of the RNA 
metabolism (Lee et al., 2013) and thus affecting multiple cell functions including stress response, 
nuclear transport, synaptic transmission and cell-to-cell signalling. Moreover, also the DPR 
produced by the RAN (non-AUG) translation can modify the splicing patterns of several transcripts 
(Suzuki et al., 2018; Zhang et al., 2015a). 
 
Figure 4: Major ALS-related mutations that disrupt RNA processing through several mechanisms (Butti and Patten 2019). 
1.2.8 NON-CELL AUTONOMOUS MECHANISMS 
Besides the pathogenetic mechanisms hitherto described, several pieces of evidence support the 
involvement of non-cell autonomous processes in ALS development and progression. Thanks to the 
new insights provided by the basic research studies, it has been observed that other cells types, 
besides MNs, such as glial cells and immune cells, actively participate to ALS pathogenesis (Thonhoff 
et al., 2018; Chiot et al., 2019).  
Moreover, it has been demonstrated that ALS is a multisystemic disease in which the first signs 
appears in the peripheral compartment (i.e. muscles and nerves). Indeed, the pathological 




modifications in motor axons and nerve terminals precede the MN degeneration and onset of 
clinical symptoms (Dadon-Nachum et al., 2011). This indication has led to ALS being suggested as a 
distal axonopathy (Fischer et al., 2004), whereby skeletal muscle contributes to a retrograde 
signalling cascade that affects MNs (Moloney et al., 2014; Dupuis et al., 2009). 
The non-cell autonomous pathogenetic mechanisms of ALS are strictly correlated with the current 
study and, therefore, will be discussed more in detail in the next section of this Thesis.  
1.3 NON-CELL AUTONOMOUS MECHANISM IN ALS 
Several pieces of evidence indicate that the neurodegeneration in ALS also occurs due to the 
dysregulated environment surrounding MNs, which drives a cascade of events collectively known 
as “neuroinflammation”. This phenomenon is characterised by the activation of microglia and 
astrocytes, infiltration of peripheral immune cells and elevated release of inflammatory mediators 
in the CNS (Komine and Yamanaka 2015).  
The neuroinflammation in ALS, as in other neurodegenerative diseases, is characterised mainly by 
the innate rather than the adaptive immune response (Prinz and Priller 2017). However, while the 
astrogliosis is the main feature of ALS (Turner et al., 2004) that can be observed even at the pre-
symptomatic stage of the disease in the rodents models (Sanagi et al., 2010), the studies performed 
showed the infiltration also of T lymphocytes and non-resident innate immune cells (mast cells, 
dendritic cells, macrophages) in the CNS of ALS patients and models (Graves et al., 2004; Engelhardt 
et al., 1993; Alexianu et al., 2001). Nevertheless, the role of the infiltrating immune cells and the 
immune-mediated response in the disease pathogenesis remains poorly understood. 
Evidence of the immune and glial cells affecting the fate of MNs comes from the characterisation 
of the mutant SOD1 (mSOD1) transgenic mouse models of ALS. Studies performed in rodents 
demonstrated that the expression of human mSOD1 specifically within MN was not sufficient to 
induce neurodegeneration in mice (Pramatarova et al., 2001; Lino et al., 2002). Intriguingly, it has 
been observed that the expression of mSOD1 at very high levels within MN led to the development 
of the disease very late in the mouse life with a progression rate much slower than mice expressing 
the mSOD1 transgene ubiquitously (Jaarsma et al., 2008). In keeping with this, the specific silencing 




of the human transgene in neurons delayed the disease onset, but cannot alter the disease 
progression of mSOD1 mice (Ralph et al. 2005).  
These findings highlighted the involvement of non-neuronal cells in the pathogenesis of ALS. 
However, it has been observed that the selective mSOD1 expression in non-neuronal cells did not 
lead to the development of the disease but damaged MNs (Yamanaka et al., 2008; Gong et al., 2000; 
Beers et al., 2006), suggesting a pathogenic interaction between neurons and glial cells in ALS. 
Moreover, it has been reported that the astrocyte (Yamanaka et al., 2008) or microglia (Boillée et 
al., 2006b; Beers et al., 2006) specific deletion of mSOD1 significantly slowed down the disease 
progression, without altering the motor onset of ALS mice. Notably, the mSOD1 deletion from 
astrocytes was accompanied by a delay in the activation of microglia cells, suggesting the direct 
pathogenic crosstalk of astroglial cells in the disease (Yamanaka et al., 2008).  
Other non-neuronal cells, such as the oligodendrocytes, contribute to MN damage, although 
through non-inflammatory mechanisms. Indeed, the removal of mSOD1 in oligodendrocyte 
progenitors (NG2+ cells) delayed the disease onset and prolonged the survival of ALS mice (Kang et 
al., 2013). These results suggest that the profound loss of grey matter oligodendrocytes in ALS, and 
the inability to restore their function, accelerate the damage of vulnerable MNs (Kang et al., 2013). 
Besides the resident non-neuronal cells, it has been reported that also the T cells and monocytes 
actively participates to the MN degeneration (Coque et al., 2019; Raoul et al., 2002; Butovsky et al., 
2012). However, the depletion of the entire T lymphocyte population crossbreeding the mSOD1 
mice with RAG2-/- or TCR-/- animals significantly worsened the disease course of the double 
transgenic mice (Chiu et al., 2008; Beers et al., 2008). 
These pieces of evidence suggest that, despite the plethora of intrinsic mechanisms that led 
intracellular injury, MNs do not die alone; glia cells and immune cells are required to mediate the 
progression of the neurodegenerative cascade in ALS. However, the contribution of the immune 
response in ALS determination and progression is still under debate.  
The initial belief regarding the involvement of the non-neuronal cell in ALS was that all the cellular 
players embraced were activated toward a neurotoxic state. This idea was argued following the 




observation that wild-type (WT) glial cells, as well as the transplantation of WT bone marrow, 
extended the survival of mSOD1 mice (Clement et al., 2003; Corti et al., 2004; Ohnishi et al., 2009), 
indicating an intrinsic toxic capability of ALS immune cells. However, the passive transfer of mSOD1 
CD4+ T lymphocytes or CD4+ CD25+ T regulatory (T reg) cells harvested from mSOD1 donor mice 
during the first (i.e. stable) disease phase, but not WT lymphocytes, slowed down the disease in 
double transgenic mSOD1/RAG2−/− mice. Conversely, the transfer of T cells harvested from mSOD1 
in the advanced disease stage did not exert the same beneficial effect (Beers et al., 2011a). These 
studies showed that T reg cells exerted an inductive action on glial cells promoting the polarisation 
toward the anti-inflammatory phenotype and release of trophic factors (Beers et al., 2008; Chiu et 
al., 2008), also highlighting the protective role of the non-neuronal cells in the ALS pathogenic 
cascade. 
Therefore, it has been postulated that the neuroinflammatory event occurring during ALS might 
result in two distinct phases. The first phase, appearing in the initial stage of the disease, is 
characterised by an anti-inflammatory/neuroprotective compensatory response of glia and 
immune cells that release neurotrophic factors as an endeavour to decrease the MN stress. Late in 
the disease, as more neurons are being damaged, a second phase takes place, characterised by a 
cytotoxic response of glia and immune cells (Hooten et al., 2015).  
The first phase is mainly governed by supportive microglia and astrocytes as well as T helper 2 (Th2) 
and T reg lymphocytes. Th2 and T regs cells produce high levels of Interleukin 4 (IL4), thus inducing 
the microglia polarisation toward the neuroprotective M2 phenotype (Chiu et al., 2008). 
Furthermore, neuroprotective T lymphocytes can also influence astroglia behaviour leading to the 
release of anti-inflammatory cytokines (e.g. IL10) and neurotrophic factors (e.g. glial-derived 
neurotrophic factor, GDNF; insulin-like growth factor, IGF1) (Beers et al., 2008). As neuronal 
damage progresses, the response of the neuroprotective T lymphocytes is suppressed, and Th1 cells 
produce high levels of pro-inflammatory cytokines that, together with the activating factors 
released by the injured neurons, activate the pathway mediated by the master control gene nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB). The NF-κB pathway activation fosters 




the microglia M1-cytotoxic phenotype and the astrogliosis (Beers et al., 2008; 2011b). The second 
phase is characterised by the release of several pro-inflammatory factors, such as tumour necrosis 
factor α (TNFα), interferon γ (IFNγ), IL1β, transforming growth factor β (TGFβ) and monocyte 
chemoattractant protein 1 (MCP1) (Endo and Yamanaka 2015; Liao et al., 2012; Sargsyan et al., 
2009), which accelerate the disease course. Indeed, the M1-polarised cells promote proliferation 
and function of Th1/Th17 lymphocytes, which release inflammatory factor, thus establishing a 
vicious circle that results in the propagation of the inflammation and therefore in the disease 
progression (Hooten et al., 2015).  
This evidence highlights a tight neuro-immune dialogue during the neuroinflammatory 
phenomenon of ALS and that the net effect of this crosstalk critically depends on the context of the 
interaction. Indeed, the evidence collected shown that T lymphocytes can polarise the microglia 
toward the M2-neuroprotective or M1-neurotoxic phenotype depending on the T cells subtype and 
the cytokine milieu (Appel et al.,  2010). Moreover, all cytokines-producing cell types release factors 
that can influence the activation state and the protective/toxic activity of the other neighbouring 
cells (Boillée et al., 2006a; 2006b).  
The evidence collected suggests that injured MNs initiate the inflammatory response, which is 
propagated by the glia and immune cells. However, the exact mechanism is still unknown. Arguably 
the mSOD1 released by neurons activates astroglia through the toll-like receptor (TLR)-mediated 
response (Zhao et al., 2010). Once activated astroglia release inflammatory factors fostering the 
recruitment of the immune cells. Intriguingly, it has been demonstrated that mSOD1 can activate 
microglia to the M1-proinflammatory state but also promote the release of trophic factors thus 
inducing a neuroprotective phenotype (Philips and Robberecht 2011; Meissner et al.,  2010; Van 
Damme et al., 2008; Philips et al., 2010). Accordingly, the characterisation of the transcriptional 
profile of microglia isolated from mSOD1 mice at different stages of the disease reported the 
expression of both pro- and anti-inflammatory genes at the same time (Chiu et al., 2013). These 
observations suggested that a highly complex mechanism occurs in ALS, in which the M1 or M2 
polarization of microglia is not a mutually exclusive state. The balance between harmful and 




protective phenotypes of microglia is actively influenced by both intrinsic and extrinsic factors, 
released by damaged MNs, astrocytes and infiltrating immune cells. Similarly, it has been reported 
that astrocytes isolated from pre-symptomatic mSOD1 mice downregulated the peroxisome 
proliferator-activated receptor 1 alpha (PCG1α), indicating an earlier impairment in the ROS 
detoxifying activity, and are already enriched in genes linked to toxic or apoptotic effects such as 
CXC-motif chemokine 10 (CXCL10) and insulin-like growth factor binding protein 7 (IGFBP7) (Sun et 
al., 2015).  
Therefore, the preclinical evidence obtained through the characterisation of mSOD1 mice indicates 
that the mutant transgene expression by neuronal and non-neuronal cells is fundamental for the 
ALS determination and progression. In particular, the mSOD1 expression by MNs is pivotal in 
determining the timing of the disease onset and early progression. In contrast, its expression within 
resident or infiltrating non-neuronal cells can actively influence the disease severity and 
progression (Lyon et al., 2019). 
Moreover, ALS is defined as a multisystemic disease in which structural, physiological and metabolic 
alteration in different cells types may act synergistically to sustain and exacerbate its course. 
However, the contribution of the peripheral compartment in the ALS pathogenic cascade was 
underestimated so far. Indeed, although mSOD1 is also expressed within ALS patients muscle, its 
relative contribution to the muscular damage and disease progression has been debated. A 
pioneering work showed that the silencing of the muscular mSOD1 was not sufficient to rescue the 
motor ability in SOD1G93A mice (Miller et al., 2006). Conversely, more recently, it has been reported 
that the specific expression of mSOD1 within skeletal muscle was sufficient to induce severe muscle 
damage (Wong and Martin 2010; Dobrowolny et al., 2008). Although the effect on astroglia 
activation and neurodegeneration was controversial, this evidence challenges the accepted dogma 
that MN degeneration, caused by the mSOD1 expression, is the primary cause of muscle atrophy in 
the disease. 
These observations derived from the characterisation of mSOD1 mice, which mirrors an exiguous 
percentage of ALS cases. Therefore, the development of others disease models, such and FUS, 




TDP43 or C9orf72 mice, offers a precious opportunity to test the contribution of the inflammatory 
phenomenon to the non-cell autonomous degeneration of MN in ALS.  
In most of these models clear signs of astrogliosis were readily reproduced, confirming the 
involvement of astrocytes and microglia in the ALS course (Alrafiah 2018). However, data collected 
so far are still controversial. If, on the one hand, the expression of the TDP43M337V variant by 
astrocytes led to neurodegeneration and muscle denervation in a rat model of ALS (Tong et al., 
2013), on the other, the delayed activation coupled with a gradual increase of the mutant 
TDP43A315T expression in the CNS of mature mice resulted in progressive functional deficits with 
neuron and muscle loss but the absence of a glial response, indicating that astrocytes are not 
involved in the TDP43-mediated toxicity (Chan et al., 2020). Similarly, in vitro experiments reported 
that the TDP43 knock-out or the expression of the mutant protein in astrocytes was not sufficient 
to induce degeneration in co-cultured MNs (Serio et al., 2013; Haidet-Phillips et al., 2013). However, 
although the expression of the human TDP43 gene with a defective nuclear localisation signal 
(hTDP43ΔNLS) affected MNs viability, minimal microglial activation was observed. Intriguingly, 
when the hTDP43ΔNLS was suppressed, the microglia proliferation significantly increased to clear 
the TDP43 aggregates, resulting in functional recovery (Spiller et al., 2018). 
Conversely, the specific motoneuronal expression of the mutant FUS was sufficient to drive 
neurodegeneration, thereby pointing to a cell-autonomous mechanism (Sharma et al., 2016; Scekic-
Zahirovic et al., 2016). However, it has been suggested that the motor symptoms could be caused 
by the concerted action of the mutant FUS in MNs and other cell types, including oligodendrocytes 
(Scekic-Zahirovic et al., 2017). According to the involvement of non-neuronal cell in the FUS-
mediated toxicity, it has been recently reported that the overexpression of the mutant or WT 
protein within astrocytes significantly affected their reactivity and drove their properties toward 
pro-inflammatory and neurotoxic functions (Ajmone-Cat et al., 2019; Kia et al., 2018).  
Contradictory observations have been obtained regarding the involvement of glial cells in the 
c9orf72 ALS models, since the astrogliosis is not a common pathological feature of the 
hexanucleotide repeat expansion (c9-HRE) or knock-out mice (Koppers et al., 2015; Peters et al., 




2015; Jiang et al., 2016). However, recent studies suggest that astrocytes from c9-HRE carriers with 
ALS can mediate neurotoxicity. Indeed, it has been shown that the partial replacement of the 
culture medium of murine embryonic stem cell-derived MNs co-cultured with fibroblast-derived 
astrocytes from c9-ALS patients with conditioned medium of control astrocyte did not prevent cell 
death (Meyer et al., 2014). This observation suggests the involvement of a gain-of-toxic-function 
mechanism (possibly impairing neuronal autophagy) rather than insufficient trophic support by the 
c9-HRE astrocytes in driving neuronal death (Meyer et al., 2014). Accordingly, the conditioned 
media of c9-HRE astrocytes was sufficient to dramatically decreased the viability of induced 
pluripotent stem cell (iPSC)-derived MNs of C9-ALS patients or control subjects (Madill et al., 2017). 
Furthermore, it has been observed that the DRP length or type and/or additional concomitant 
factors (e.g. TDP43 phosphorylation) significantly affect the microglial activation in c9-ALS models 
(Schludi et al., 2017; Zhang et al. 2016; 2018b).  
Although a more in-depth characterisation of these ALS models is needed, these observations did 
not rule out the central and dual role of the inflammatory response in the early compared with late 
stage of the disease. Moreover, the scant knowledge acquired on these disease models did not 
allow comprehending the role of the non-resident immune cells in governing the ALS pathogenic 
cascade. 
Notably, besides the ALS-associated gene model, mouse strains vary in their immune response 
(McCombe and Henderson 2011). Moreover, it has been reported that non-specific inflammation 
(i.e. chronic LPS administration) worsens the disease course in ALS rodents (Nguyen 2004), 
indicating that the immune system can exacerbate the disease in the murine models independently 
from the primary toxic insult (i.e. mSOD1). Therefore, the observation obtained from mSOD1 mice 
and other ALS models cannot necessarily be generalised to patients since human ALS suffers have 
different immune system capability, which could be responsible for the high phenotypic 
heterogeneity (Ticozzi and Silani 2018; Bendotti et al., 2020). Indeed, a recent study of gene 
expression showed that ALS patients could be divided into two subgroups: patients with higher 
expression of IL6R and myeloid lineage-specific genes, and patients with higher expression of IL23a 




and lymphoid-specific genes (Swindell et al., 2019). Although an immunological component to ALS 
pathophysiology has also been recognised (Malaspina et al.,  2015) and prior studies have identified 
alterations in immune cell abundance and activity in ALS patients (Murdock et al., 2017), recent 
pieces of evidence suggest a different contribution of the inflammation in the PNS compared with 
the CNS (Dibaj et al., 2011; Thonhoff, Simpson, and Appel 2018). These observations elicited a 
fervent debate concerning the role of the inflammatory response in the peripheral compartment 
of ALS. Indeed, recent evidence suggested that the inflammatory phenomenon and the related 
infiltration of immune cells could aid in the response of the peripheral axon to degeneration (Kano 
et al. 2012; Dibaj et al. 2011; Schreiber et al. 2019; Nardo et al., 2016b).  
The knowledge so far acquired demonstrated a pivotal role of non-neuronal resident or infiltrating 
immune cells in ALS. However, their temporal (early or late in the disease) or spatial (CNS versus 
peripheral compartment) contribution in the disease determination and progression is still unclear. 
1.3.1 INNATE IMMUNITY  
Innate immunity is an antigen-independent response used by the host to defend itself from an 
intruding pathogen immediately. The mechanisms of defence triggered by innate immunity are not 
specific, and it does not have any immunologic memory.  
The innate system relies on pattern recognition receptors (PRRs) to respond to pathogens, which 
are recognised thanks to the presence of pathogen-associated molecular patterns (PAMPS). The 
essential function of innate immunity is to recruit immune cells to the site of infection/damage and 
to trigger inflammation through the production of cytokines and chemokines (Murphy and Weaver 
2016).  
In the CNS, the presence of the blood brain barrier (BBB) and the blood spinal cord barrier (BSCB) 
allows the maintenance of the homeostasis, regulating fluctuations in electrolytes, and the passage 
of hormones and metabolites making it an immunologically privileged area, with limited capacity 
to recruit immune cells from the circulation (Pachter et al., 2003; Engelhardt and Coisne 2011). 
Moreover, the CNS displays low immune surveillance and the absence of specialised antigen-
presenting cells, which further limit the local immune responses. Despite this “immunologically 




privileged status”, T lymphocytes and monocytes can be trafficked into the CNS parenchyma to 
instrument a specific inflammatory reaction upon tissue damage (Brown and Al-Chalabi 2017; Chiu 
et al. 2009; Engelhardt et al. 1993). 
1.3.1.1 MICROGLIA  
In the CNS, microglia are the primary myeloid cell type (Lyck et al., 2009) and are responsible for 
pivotal functions, such as development, immune surveillance and tissue homeostasis (Kreutzberg 
1996; Matcovitch-Natan et al. 2016; Stevens and Schafer 2018).  
Microglia are primarily considered as the CNS resident immune cell, which has been classically 
described to exist in two states: resting and activated (Cherry et al., 2014). However, two-photon 
imaging of healthy adult brains showed that the so-called “resting” microglia is a highly dynamic 
population (Nimmerjahn 2005) which actively screen their microenvironment with motile 
processes, exerting a crucial role in maintaining homeostasis secreting factors that allow the close 
communication with astrocytes and neurons (Luo and Chen 2012). Although during the steady-state 
these cells constantly surveying the environment, upon injury microglia migrate toward the 
damaged area and produce cytokines and trophic factors to mitigate the damage (Kreutzberg 
1996). Through phagocytosis, microglia remove pathogens and debris, as well as regulate the 
synaptic pruning during the development or disease (Hong et al., 2016). As a stereotyped response 
to injury, microglia change their morphology and upregulate ionised calcium-binding adapter 
molecule 1 (Iba1) and CD11b, and gain the expression of molecules associated with antigen 
presentation, such as major histocompatibility complex (MHC), CD80, and CD86 which are absent 
in naïve microglia. Microglia finally lose their ramified morphology and surveillance mode and 
convert to amoeboid-like, functional cells (Kettenmann et al., 2011). 
Microglia possess specific tools to react to the changes occurring within the parenchyma properly. 
They express toll-like receptors (TLR) and pattern recognition receptors (PPR), such as CX3CR1 
(fractalkine receptor), CD200 receptor (CD200R) and triggering receptor expressed on myeloid cell 
2 (TREM2). Membrane-bound fractalkine is pivotal to maintain microglia in the homeostatic non-




activated state (Cardona et al., 2006), while TREM2 is necessary not only for pathogen recognition 
but also for the internalisation of misfolded protein (Hsieh et al., 2009).  
Some genes expressed by microglia have been suspected as causative or modifiers of ALS. Increased 
expression of Trem2 transcript was observed in pre-symptomatic SOD1G93A mice, and the p.R47H 
variant represents a risk factor for sporadic ALS (Cady et al., 2014). Moreover, microglia are the only 
cells within the CNS expressing CX3CR1, making this pathway fundamental for MN-microglia 
crosstalk (Harrison et al., 1998). Indeed, the deletion of CX3CR1 in SOD1G93A mice is associated with 
faster disease progression and increased MN loss (Liu et al., 2019a). Similarly, specific variants in 
the cx3cr1 gene are associated with a faster ALS progression in patients, although they do not 
represent a risk factor (Calvo et al., 2018). 
It has been reported that injured MNs and astrocytes release misfolded proteins (e.g. mSOD1) 
which activate microglia through CD14, TLR2, TLR4 and scavenger receptor-dependent pathways 
(Roberts et al., 2013; Zhao et al., 2013). Moreover, dying and degenerating neurons release ATP, 
which interacts with the ionotropic P2X and metabotropic P2Y purinergic receptors activating 
microglia (Volonté et al., 2016). This observation was confirmed in ALS patients and SOD1G93A mice 
through positron emission tomography (PET) imaging, which demonstrated a widespread activation 
of microglia since the early stage of the disease (Turner et al., 2004; Gargiulo et al., 2016). 
Interestingly, these studies reported a significant correlation between the extent of microglia 
activation and the severity in the symptoms manifestation (Turner et al., 2004). Notably, it has been 
reported that mice homozygously expressing high levels of mSOD1 specifically within MNs 
presented a strong microgliosis, confirming that microglia activation is strictly governed by signals 
released from damaged neurons (Jaarsma et al., 2008). Therefore, as the disease progresses, 
microglia cells acquire a cytotoxic phenotype and play a deleterious role in promoting 
neurodegeneration, thus governing the speed of the ALS progression. 
Once activated microglia display a very distinct and different phenotype, which can be protective 
or toxic to MNs depending on the stage and rate of the disease progression. Once activated, 




microglia cells can be divided into “classically” activated M1 microglia and “alternatively” activated 
M2 microglia.  
M1 microglia are cytotoxic due to the release of reactive oxygen species (ROS) and pro-
inflammatory factors (e.g. IL1β, TNFα, etc.). The role of cytotoxic microglia in ALS has been so far 
investigated. In vitro studies demonstrated that mSOD1 microglia were more reactive compared to 
wild-type cells to the pro-inflammatory LPS stimulus, resulting in the release of a plethora of 
neurotoxic factors thus increasing motor neurons death (Xiao et al., 2007). Accordingly, it has been 
reported that TLR4 antagonists efficiently protected MNs from LPS-induced lethality in spinal cord 
cultures, inhibiting IL1β production by stimulated microglia (De Paola et al. 2016). Using transgenic 
models of ALS, it has been shown that the replacing of the mSOD1 with the wild-type microglia 
significantly protected MNs and increased the survival of mice (Beers et al., 2006). Similarly, the 
removing of mSOD1 from microglia through a Cre-LoxP approach delayed the disease progression 
of ALS models (Wang et al. 2009; Boillée et al.,2006a). 
Conversely, M2-polarised microglia produce high levels of neurotrophic (BDNF, IGF1) and anti-
inflammatory (IL4, IL10) factors promoting tissue repair, extracellular matrix reconstruction and 
neuron survival (Zhao et al., 2013). Accordingly, the CNS delivery of IL4 in SOD1G93A mice resulted 
in a general amelioration of clinical outcomes during the early phase of the disease through the 
induction of M2 gene expression by microglia. However, such approach did not revert the 
neurodegenerative processes occurring in the late and fast progressing phase of the disease, 
confirming the concerted action of MNs and non-neuronal cells in ALS progression (Rossi et al. 
2018). 
It has been demonstrated a dual phenotypic and functional characterisation of microglia over ALS 
progression. During the early stage of the disease, microglia exhibit an anti-inflammatory 
phenotype characterised by the upregulation of CD206 and chitinase-like protein 3 (Chil3/Ym1). 
The M2-polarised microglia react to the initial injury releasing neuroprotective factor to promote 
repair and regeneration (Appel, Beers, and Henkel 2010). As the disease progresses, the “danger 
signals” released from damaged neurons induce microglia to release ROS and inflammatory factors 




promoting their phenotypic switch toward the M1 polarisation. Accordingly, an in vitro paradigm 
showed that early-stage M2 microglia enhanced the survival of co-cultured MNs whilst late-stage 
M1 microglia was cytotoxic (Liao et al. 2012).  
However, the M1/M2 polarisation is a more complex continuum, and microglial reactivity is 
multifactorial and injury-specific (Ransohoff 2016). Indeed, the coexistence of the two opposite 
phenotypes, more than the transition from M2 to M1 phenotype, during ALS progression has been 
recently suggested. The analysis of the transcriptome of mSOD1 microglia evidenced that the 
activation of genes involved in anti-inflammatory pathways (Igf1, Progranulin and Trem2) coexists 
with the upregulation of genes related to potentially neurotoxic factors (Matrix metalloproteinase-
12, il1β, tnfα) (Chiu et al. 2013). Accordingly, it has been reported a parallel increase of the inducible 
nitric oxide synthase (iNOS; M1 marker) and arginase 1 (Arg1; M2 marker) in microglia of mSOD1 
mice (Lewis et al., 2014). 
As discussed above, the knowledge so far acquired suggests that, although MNs represent the site 
of onset, ALS is a non-cell autonomous disease in which the glial response significantly contributes 
to governing its progression. Therefore, targeting the microglia has been the focus of 
neuroprotective strategies. Pioneer studies performed showed that the administration of 
minocycline, a tetracycline antibiotic that prevents microglial activation, in pre-symptomatic 
mSOD1 mice attenuated microglial activation and ameliorated the disease progression (Kriz et al., 
2002). However, its administration after the disease onset failed to exert a beneficial effect, even 
increasing the microgliosis (Keller et al., 2011). Interestingly, it has been reported that minocycline 
specifically attenuated the M1 phenotype, without influencing the expression of M2 markers 
(Kobayashi et al., 2013). However, the genetic deletion of pro-inflammatory cytokines did not 
ameliorate the disease course of ALS mice (Gowing et al., 2006). These pieces of evidence suggest 
the inefficiency of the specific targeting of pro-inflammatory factors, highlighting the importance 
of M1/M2 balance to attempt to modulate ALS progression. 
Moreover, it has been shown that the deletion of the cystine/glutamate-antiporter xCT/Slc7a11 
(xCT), a critical glial transporter system involved in the excessive glutamate release from M1 




microglia, early in the disease of  mSOD1 mice increased the expression of IL1β and concurrently 
reduced the M2 marker Ym1, thus resulting in anticipation of the motor impairment. Conversely, 
the absence of xCT in the advance stage increased Ym1 and Arg1 expression, which possibly 
sustained the delay of disease progression (Mesci et al., 2015).  
This evidence confirms microglia as an attractive candidate to interfere with the progressive 
neurodegeneration occurring in ALS. However, the evidence hitherto collected suggested that, 
although the modulation of microglia polarisation may still be an effective strategy to counteract 
the neurodegeneration, the interception of other pathogenic mechanisms is necessary to obtain a 
significant effect on ALS course (Frakes et al. 2017; Geloso et al. 2017). 
 
Figure 5: M1/M2 microglia polarisation during ALS. During the disease progression activated microglia represent a 
continuum between the neuroprotective M2 phenotype, which promotes tissue repair and supports neuron survival by 
releasing neuroprotective factors, versus the toxic M1, which produces cytokines increasing inflammation and further 









In the CNS, astrocytes represent the most abundant cell population. A single astrocyte can enwrap 
more than one million synapses and have one process with end-feet surrounding a blood vessel. 
This particular arrangement places astrocytes in a very suitable position to provide structural, 
metabolic and trophic support to neurons (Burda and Sofroniew 2014). Moreover, astrocytes are a 
reservoir of glycogen (Calì et al., 2019) and, thanks to the control of ionic and osmotic homeostasis, 
they are key players in the global and regional management of brain blood flow in response to 
neuronal activity (Koehler et al., 2009). 
During neurodegeneration, astrocytes undergo morphological and functional modifications and 
respond to various stimuli, e.g. inflammatory factors produced by microglia cells (Liddelow et al., 
2017). Activated astrocytes are hypertrophic, proliferate and release of pro- and anti-inflammatory 
cytokines and growth factors, together with components of extracellular matrix (Zamanian et al., 
2012). The astrocyte activation is fundamental to limit the spread of the lesion and hamper the 
ongoing inflammation by preventing the infiltration of activated immune cells (Faulkner 2004). 
However, the resulting modification of the extracellular matrix due to the formation of the glial scar 
contributes to the inhibition of axonal regeneration and growth  (Zamanian et al., 2012). 
In ALS patients astrogliosis occurs more diffusely than microgliosis, and it is detectable in the spinal 
cord as well as in the grey and subcortical white matter (Nagy et al., 1994; Schiffer et al., 1996). In 
mSOD1 mice, reactive astrocytes appear concomitantly with a decreased number of MNs (Schiffer 
et al., 1996). Studies performed in ALS rodent models showed that activated astrocytes are 
hypertrophic and express markers that are typical for astrogliosis as well as features of immature 
astrocytes, such as glial fibrillary acidic protein (GFAP) (Lepore et al., 2008), connexin 43 (Cx43) 
(Almad et al., 2016) and the α2 subunit of Na+/K+ ATPase (Gallardo et al., 2014). The latter directly 
interacts with astrocytic glutamate transporters affecting the buffering activity of EAAT1 and 
EAAT2, thus altering the electrochemical gradient (Illarionava et al., 2014).  
Glutamate buffering is one physiological feature of the astrocyte, fundamental to protect neurons 
from excitotoxicity-mediated cell death. Although it has been reported that, during the 




development, the expression of EAAT2 in glia-restricted progenitors is higher in SOD1G93A mice, as 
the disease progresses transgenic mice lose the majority of glutamate transporters (Lepore et al., 
2008; Haidet-Phillips et al., 2015). Moreover, it has been shown that EAAT2 sumoylated fragments 
produced by caspase 3 activity accumulate within the cell nucleus causing morphological changes 
and dysregulating the astrocyte gene expression programme (Gibb et al., 2007), particularly those 
related to mitochondrial functions and cellular respiration (Foran et al., 2011). As a consequence, 
damaged mitochondria lose the ability to buffer intracellular Ca2+ and its cytosolic concentration 
increases, together with the concentration of ROS, NOX2 (gp91PHOX) and iNOS (Agarwal et al., 2017). 
Consistently, the overexpression of Nrf2, a transcription factor for antioxidant genes, specifically 
within astrocytes conferred neuroprotection in mSOD1 mice (Vargas et al., 2008). This evidence 
suggests that activated astrocytes fail to support and protect MNs in ALS (Liddelow et al., 2017).  
Astrocytosis is not the first event in the ALS pathogenic cascade (Schiffer et al., 1996). Nevertheless, 
astrocytes actively participate in the MN degeneration in a non-cell autonomous mechanism. In 
vitro and in vivo studies have shown that astrocytes expressing mSOD1 exert a cytotoxic effect to 
both wild-type and mSOD1 MNs (Di Giorgio et al., 2008; Nagai et al., 2007). Accordingly, the 
selective silencing of the mutant SOD1 or the transplantation of healthy astrocytes reduced MN 
death ameliorating the disease progression in mSOD1 mice (Lepore et al. 2008; Haidet-Phillips et 
al. 2011; Wang et al., 2011). Conversely, the transplantation of astrocytes expressing mSOD1 in 
wild-type rats induces focal MN degeneration (Papadeas et al., 2011). Intriguingly, it has been 
recently shown that both MNs and non-neuronal cells degenerate following the transplantation of 
spinal neural progenitors derived from sporadic ALS patients in the spinal cord of severe combined 
immunodeficient (SCID) mice, also affecting their locomotor ability (Qian et al. 2017). This process 
is mediated by astrocyte-specific soluble factors which, besides affecting the functioning of other 
cell types (e.g. microglia) and regulating their immunological responses, directly mediate the MN 
degeneration (Alami et al., 2018). Indeed, ALS astrocytes release several cytotoxic factors (IL6, 
CXCL1, CXCL10, TNFα, IFNγ, Sonic hedgehog and its responsive gene, etc.) (Bruijn et al., 1997; Diaz-
Amarilla et al., 2011; Huang et al., 2014; Kia et al., 2018). Among them, the astrocytes-derived 




TGFβ1 is a negative regulator of the neuroprotective anti-inflammatory response activated by 
microglia and T lymphocytes in the early stage of the disease (Endo and Yamanaka 2015). 
Understanding the involvement of astrocytes in the neurodegenerative phenomenon and their 
interaction with neuronal and non-neuronal cells provides a conceptual framework that highlights 
the potential of this cell subtype as the focus of therapeutic effort. Indeed, the crucial role of 
astrocytes in ALS suggests that therapies aimed at modulating astrocytes biology may contribute to 
the development of integral therapeutic approaches to halt the disease progression (Pehar et al. 
2018). 
 
Figure 6: Pathological changes of astrocytes during ALS (Filipi et al. 2020). 
 
1.3.1.3 MONOCYTES / MACROPHAGES 
Monocytes constitute one component of the “mononuclear phagocyte system” (MPS), which they 
share with macrophages and conventional dendritic cells (cDCs) (Guilliams et al. 2014).  
Monocytes develop in the adult bone marrow from a dividing common myeloid progenitor (CMP) 
shared with erythrocytes, cDCs, platelets and granulocytes. Following their generation, monocytes 
are released into the blood circulation where make up ~4% of peripheral leucocytes in mice and 
~10% in humans.   




Classically, monocytes were considered as a bridge linking the bone marrow-precursors with 
terminally differentiated macrophages and cDCs in tissues (van Furth and Cohn 1968). However, it 
has now become clear that in most tissues the majority of resident macrophages have an embryonic 
origin (Ginhoux and Guilliams 2016). These tissue-resident macrophages (e.g. microglia in the CNS) 
arise from a precursor in the yolk sac and then from foetal liver monocytes, which migrate to 
different organs (Sorokin et al., 1992). Once in the tissue, the population of these tissue-specific 
macrophages is maintained by self-renewal (Sieweke and Allen 2013).  
In mammals, circulating monocytes can be classified in two types: the “patrolling monocytes”, 
which have endothelial supporting functions (Auffray et al., 2007), and the “infiltrating monocytes”, 
which possess the capability to transmigrate across the endothelium and enter in the tissue in 
response to appropriate signals (chemotactic gradient) (Jakubzick et al., 2013).  
In humans, discrete populations of monocytes were first identified by morphology and differential 
expression of CD14 and CD16 (Passlick et al., 1989). The combination of these clusters of 
differentiation on HLA-DR+ cells enabled the classification of three main subsets: CD14+ CD16- cells, 
also known as “classical pro-inflammatory monocytes”, that constitute the 80-90% of the human 
monocytes pool with the remaining 10-20% shared by CD14+ CD16+ intermediate cells and CD14low 
CD16+ “non-classical monocyte”. In mice, monocytes expressing high levels of the lymphocyte 
antigen 6 complex (Ly6chi monocytes) have pro-inflammatory functions and show high levels of C-
C chemokine receptor 2 (CCR2) and low levels of CX3C chemokine receptor 1 (CX3CR1) (Ly6chigh 
CX3CR1int CCR2+) (Geissmannet al., 2003). The Ly6chi monocytes transport antigens to the lymph 
node and accumulate at sites of inflammation, where they can differentiate into macrophages or 
dendritic cells depending on the local cytokine environment (Crane et al., 2014; Patsalos et al., 
2017; Jakubzick et al., 2013). Ly6clow monocytes survey the vasculature (patrolling monocytes) and 
are involved with tissue repair. These alternative monocytes express high levels of CX3CR1 and low 
levels of CCR2 (CX3CR1hiCCR2low) (Geissmann et al., 2003; Jakubzick et al., 2013). Gene expression 
analysis correlated the Ly6chigh and Ly6clow murine monocytes with the “classical” CD14+ CD16- and 
“non-classical” CD14low CD16+ human cells, respectively. 




Several factors are involved in the regulation of monocytes development and differentiation. 
Studies in mice deficient in the colony-stimulating factor 1 receptor (MCSF/CD115) or CCR2 showed 
a reduced number of circulating monocytes and their retainment within the bone marrow (Tsou et 
al., 2007; Dai et al., 2002), indicating these factors as pivotal in monocyte mobilisation. Moreover, 
it has been reported that, once released in the blood under healthy homeostasis, Ly6chigh monocytes 
remain in the circulation or repopulate a proportion of tissue-resident macrophages in several 
organs (e.g. heart, dermis, lung) (Epelman et al., 2014; Tamoutounour et al., 2012; Jakubzick et al., 
2013). An exception is the CNS, where the combination of the high self-renewal potential of the 
tissue-resident macrophages (i.e. microglia cells) with the restricted access because of the presence 
of the BBB limits their infiltration (Ajami et al., 2007; Mildner et al., 2007).  
The homeostatic process of monocyte infiltration is maintained over time and requires significant 
gene modifications to allow the adaptation of monocyte-derived macrophages to the local tissue 
environment through the acquirement of a transcriptomic signature similar to whose of the 
resident macrophages of embryonic origin (Lavin et al. 2014; T’Jonck et al., 2018). Conversely, 
monocytes-derived macrophages that infiltrate during phlogosis show distinct gene signature and 
might respond differently to inflammation compared to embryo-derived resident macrophages 
(Bennett et al., 2018; Cronk et al., 2018). Moreover, they often fail to self-maintain for prolonged 
periods. Indeed, a low-grade tonic inflammation is required for the continuous monocytes 
recruitment suggesting a fine regulation of the mobilisation of the immune cells upon injury 
(Guilliams, Mildner, and Yona 2018). Notably, even though they can adopt a tissue-resident 
macrophage signature, Ly6Chigh monocytes can also act as a local reservoir maintaining their 
monocyte-like state, avoiding the complete differentiation towards macrophages (Swirski et al., 
2009).  
An alternative maturation route of the infiltrating Ly6chigh monocytes is the transition into Ly6clow 
monocytes. Non-classical monocytes exhibit an increased lifespan (~2 weeks) compared with their 
Ly6chigh counterpart ensuring the constant cell numbers even under pathological conditions, when 
the majority of classical monocytes are recruited to peripheral inflammatory lesions or when their 




functional transition into non-classical monocytes is blocked (e.g. chronic phlogosis) (Guilliams et 
al., 2018). Although several factors have been shown to modulate the classical to non-classical 
monocytes transition (e.g. delta-like 1, C/EBPβ, NR4A1, and KLF2) (Mildner et al., 2017; Hanna et 
al., 2011; Gamrekelashvili et al., 2016), the exact mechanism is still unknown. Indeed, although this 
evidence suggests that Ly6chigh and Ly6clow monocytes are biologically interconnected, this does not 
exclude that some cells in the non-classical monocyte pool might develop without passing through 
a classical monocyte stage (Carlin et al., 2013). 
In conclusion, the leading characteristic that differentiates monocytes from others MPS members 
is their aptitude to be rapidly mobilised towards inflamed body compartment, where they exhibit 
a proinflammatory or resolving capability shaped by micro-environmental and spatial cues 
(Guilliams et al., 2018). However, in pathological conditions, the distinction between tissue-resident 
and recruited macrophages has not yet possible (Italiani and Boraschi 2014). 
 
Figure 7: In many tissues, the tissue-resident macrophage population is derived from the yolk sac and foetal liver during 
development but is complemented by inflammatory monocytes recruited from the bone marrow after injury. The recruited 
and resident macrophages undergo marked phenotypic and functional changes in response to DAMPs, PAMPs, growth 
factors, cytokines, and other mediators released in the local tissue microenvironment. The dominant phenotypic variants 
depicted here regulate inflammation, tissue repair, regeneration, and resolution. Macrophages produce a variety of 
factors that stimulate the proliferation, differentiation, and activation of fibroblasts, epithelial cells, endothelial cells, and 
stem and progenitor cells that facilitate tissue repair. During the later stages of the repair process, they assume a 
regulatory pro-resolving phenotype that ensures that the tissue-damaging inflammatory response is suppressed and 
normal tissue architecture is restored. If the process is not controlled effectively, persistent inflammation and/or 
maladaptive repair processes can lead to tissue-destructive fibrosis. In some cases, the recruited monocytes seed the 
tissues and adopt a resident macrophage phenotype (Modified from Wynn & Vannella, 2016). 




Traditionally, macrophages can assume both the M1 (pro-inflammatory) or M2 (anti-inflammatory) 
phenotype. Macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) are the primary cytokines that stimulate the macrophage M2 or M1 
polarization, respectively (Hamilton 2008). Monocytes stimulated by GM-CSF participate in the 
antigen presentation and produce pro-inflammatory factors, such as IL12, IL23, IL1β and TNFα, 
amplifying the ongoing inflammation through the release also of chemoattractant factors. 
Moreover, the M1-polarised monocyte-derived macrophages express high levels of iNOS, thus 
generating NO, which can tag cellular debris for removal by phagocytosis or contribute to cytolysis 
of neighbouring cells (Hibbs et al., 1988). Moreover, the M1-polarised macrophages promote the 
Th1 response sustaining the establishment of a pro-inflammatory milieu (Martinez et al., 2008). In 
contrast, M-CSF-induced cells are more involved in scavenging and release anti-inflammatory 
cytokine (e.g.IL10, Ym1) that deactivate M1 cells supporting Th2 effector functions (Fleetwood et 
al., 2007; Martinez et al., 2008). Besides, the M2 macrophage-derived TGFβ can also induce 
arginase 1 expression (Arg 1) (Mills et al., 2000), an enzyme involved in arginine metabolism from 
which derive polyamines that can stimulate fibroblast proliferation and increase proline synthesis, 
thus leading to increased connective tissue production and tissue healing (Modolell et al., 1995). 
These pieces of evidence indicate that monocytes and macrophages are versatile and plastic cells, 
whose function and phenotype are regulated by signals deriving from the local milieu. Although 
following tissue alteration pro-inflammatory M1 monocytes are recruited into the damaged area 
and mature to (pro-inflammatory) macrophages, this categorisation is somewhat prejudicial since 
these cells actively contribute to the resolution of the inflammatory response and help to restore 
the tissue homeostasis. Similarly to microglia cells (Chiu et al., 2013; Lewis et al., 2014), the ly6Chigh 
are generally considered pro-inflammatory (M1) monocytes while the ly6Clow cells are the anti-
inflammatory (M2) counterpart. Nevertheless, in real ongoing inflammation, infiltrating monocytes 
are highly heterogeneous and express mixed batches of M1/M2-associated genes as they go 
through the various maturation stages (Kratofil et al., 2017; Dal-Secco et al., 2015; Sica and 
Mantovani 2012). 




The involvement of monocyte in the CNS pathology during ALS is still under debate. Assessment of 
circulating monocytes in ALS patients has been performed to gain insight into potential 
inflammatory or immune system activation in the disease. These studies showed a functional 
alteration of peripheral monocytes in ALS patients (Zhang et al., 2005; Nardo et al., 2011; Zondler 
et al., 2016), indicating their skewing toward a pro-inflammatory state (Zhao et al., 2017a).  
Speculations about the mechanisms behind the monocytic dysregulation in ALS are altered bone 
marrow egression, different transdifferentiation between monocyte subtypes, or differential 
changes in tissue infiltration that results in an altered composition of the haematogenous 
monocytes (Zondler et al., 2016). Interestingly, it has been found a direct correlation between the 
levels of circulating CD14+CD16- pro-inflammatory monocyte and the functional rating score in ALS 
(Murdock et al., 2016). Accordingly, it has been observed that once isolated and in vitro stimulated, 
ALS monocytes exhibit an increased ability to be activated to toxic M1 macrophages compared with 
immune cells derived from healthy subjects (Du et al., 2020). Besides, circulating CD14+ monocytes 
are decreased in the blood of ALS patients at the early stage of the disease, indicating a potential 
mobilisation toward the CNS (Mantovani et al., 2009) and inflamed/damaged tissues.  
It has been postulated that microglia release the pro-inflammatory chemokine monocyte 
chemoattractant protein 1 (MCP1) (Butovsky et al., 2012), which is elevated in the CSF of ALS 
patients (Nagata et al., 2007), to promote the recruitment of CCR2+ proinflammatory monocytes 
(Mildner et al., 2009), possibly aggravating the MN degeneration. Properly, preclinical studies 
demonstrated that blocking the monocytes infiltration in the CNS resulted in the amelioration of 
the disease course of mSOD1 mice (Butovsky et al., 2012). However, it has been recently reported 
that the presence of peripheral myeloid cells in the spinal cord protected MNs from degeneration 
indicating that, differently from other neurodegenerative diseases (Gao et al., 2015), the monocyte 
infiltration in ALS might not be mediated by CD95 ligand (FasL) (Zondler et al., 2016). This evidence 
suggests that the role of monocytes in ALS may be highly dependent on the context of a specific 
neurodegenerative condition, but also on different time frames during the disease progression 
(Zondler et al., 2016). However, whether peripheral monocytes display an increased CNS invasion 




in mSOD1 mice is still a matter of debate. Indeed several preclinical studies reported undetectable 
levels of monocytes-derived macrophages in the spinal cord of ALS mice (Ajami et al., 2007; Chiu et 
al., 2009, Chiot et al., 2020) or found them confined to the perivascular spaces of the blood brain 
barrier (Lewis et al., 2009). This evidence was confirmed through an in-depth RNA sequencing 
analysis of the myeloid population of the spinal cord of ALS mice revealing that only a negligible 
population of infiltrating myeloid cells was recruited during the disease progression (Chiu et al., 
2013). Moreover, it has been shown that the choroid plexus of mSOD1 is not enabled to support 
leucocytes trafficking during the disease progression and requires to be activated (e.g. 
immunisation with myelin-derived peptide) to sustain the accumulation of immune cells (Kunis et 
al., 2015).  
CNS invasion might not be necessary or at least not be the only mechanism of action mediating the 
impact of peripheral monocytes on the ALS course. Pre-clinical evidence recently described the 
involvement of monocyte-derived macrophages at the peripheral level (i.e. nerves and muscles). 
Studies performed in ALS mice showed that peripheral macrophages are detectable alongside 
degenerating nerve fibres since the pre-symptomatic stage of the disease and continue to increase 
until the terminal phase of the disease (Chiu et al., 2009; Graber et al., 2010; Lincecum et al., 2010; 
Dal Canto and Gurney 1994; Kano et al., 2012). Similarly, immune cells infiltration has been 
reported within the skeletal muscles of ALS rodent models (Wang et al., 2017; Trias et al., 2018; 
Chiu et al., 2009; Vallarola et al., 2018; Chiot et al., 2020). Accordingly, the release of 
chemoattractant factors (e.g. MCP1) and complement deposition were detected in the sciatic nerve 
and skeletal muscle of ALS mice concomitant with macrophages infiltration, indicating putative 
signalling through which immune cells are recruited within degenerating tissues (Chiu et al., 2009; 
Nardo et al., 2016b; Wang et al., 2017; Kano et al., 2012). However, it remains to be determined 
whether infiltrated macrophages are protective supporting tissues regeneration or serve only to 
remove cellular debris and amplify the ongoing inflammation.  
Notably, the robust macrophages activation recorded within the nerves of SOD1G93A mice was not 
correlated with the expression of inflammatory cytokines (Chiu et al., 2009) suggesting that the 




peripheral nerve inflammation does not initiate the degenerative phenomenon but represents a 
response to the denervation of muscles in ALS mice (Kano et al., 2012). Moreover, the observation 
of macrophages infiltration in the phrenic nerve concomitantly with minimal cervical MNs damage 
suggested a possible protective role of their phagocytic activity during nerve degeneration (Kano et 
al., 2012). Noteworthy, we have recently demonstrated that macrophages recruitment along motor 
axons and within the skeletal muscles correlates with a slower disease progression in mSOD1 mice 
(Nardo et al., 2016b; Vallarola et al., 2018). Intriguingly, in line with the putative protective role of 
infiltrated macrophages, it has been recently reported an association of PNS inflammation and 
longer disease duration in ALS patients (Schreiber et al., 2019). 
1.3.2 ADAPTIVE IMMUNITY  
The adaptive immune response has a longer duration, involves a complex orchestration of cellular 
and molecular responses, and is generated to a specific pathogen or antigen with a presence that 
may not have been resolved by the innate inflammatory response. 
The main functions of the adaptive immune response are: 
• Discrimination between self and non-self antigens; 
• Generation of pathogen-specific effector pathways; 
• Development of immunologic memory. 
Cells associated with the adaptive immune response include tissue macrophages (e.g. microglia in 
the CNS) that can serve as antigen‐presenting cells, B cells that mature into antibody‐producing 
cells, and T cells with subsets that are critical to cellular immunity. The orchestrated immune 
response may further contribute to inflammation that can then enhance additional immune system 
involvement. 
1.3.2.1 LYMPHOCYTES 
In human, lymphocytes constitute ~20-40% of the total number of white blood cells. They are found 
in the circulation and are also concentrated in lymphoid organs and tissues (e.g. spleen, tonsils and 
lymph nodes) where the initial immune response is likely to occur. B and T lymphocytes develop 




from hematopoietic stem cells (HSCs) that originate from bone marrow. HSCs then differentiate 
into multipotent progenitors (MPPs) which retain the potential to give rise to both myeloid and 
lymphoid lineage. The process of differentiation then proceeds to a common lymphoid progenitor 
(CLP), which can only differentiate into T, B or Natural Killer (NK) cells. Some lymphocytes migrate 
to the thymus, where they mature into T cells, others remain in the bone marrow, where they 
develop into B cells. 
1.3.2.1.1 T LYMPHOCYTES 
The maturation of T cells occurs in the thymus, where the CPL engraft. The cells arrived in the 
thymus are called double negative as they express neither the CD4 nor CD8 co-receptor. In the 
thymus these immature cells undergo three steps of selection: i) the T cell receptor beta (TCRβ)-
selection, consisting in numerous rearrangements critical to creating a functional TCRβ chain to 
recognise antigens; ii) the positive selection, where the self-antigens are presented and iii) the 
negative selection, fundamental for the self-tolerance.  
T cells are grouped in different subsets based on their function: 
 CD4+ T helper (Th) cells (Th1, Th2, Th17); 
 CD4+ T regulatory cells (T reg); 
 CD8+ cytotoxic T cells; 
 Memory T cells. 
Although the investigations on the involvement of inflammation in ALS pathogenic cascade have 
mostly focused on microglia and innate immunity, several studies reported T cells infiltration in post 
mortem material from ALS patients (Troost et al., 1990; Engelhardt et al., 1993).  
Contradictory results were instead obtained from the characterisation of the circulating T cells 
population in ALS patients. Some studies reported an increased level of circulating CD4+ T cells 
(Gustafson et al., 2017; Mantovani et al., 2009); conversely, others have found reduced numbers 
of T lymphocytes in the blood of ALS patients (Chen et al., 2014b). Similarly, CD8+ cytotoxic T 
lymphocytes were found reduced (Mantovani et al., 2009), increased (Gustafson et al., 2017), or 
unchanged (Chen et al., 2014b) in ALS patients compared with healthy controls. These contradictory 




results suggest that the different level of circulating T cells recorded in the different cohorts 
examined might be related to the variation in the immune responsiveness of individuals (McCombe 
et al., 2020). 
In mSOD1 mice, CD4+ T cells were observed in the lumbar spinal cord at the early phase of the 
disease, while both CD4+ and CD8+ populations were present at the end stage of the disease (Beers 
et al., 2008; Henkel et al., 2006; Chiu et al., 2008). Like microglia/macrophages phenotype, CD4+ T 
cells are classified in two simplified classes: those that are neuroprotective (Th2 and T regulatory 
lymphocytes), and those that are pro-inflammatory/neurotoxic (Th1 and Th17 lymphocytes).  
The role of T cells in ALS has been unravelled through the years. Several studies proposed a 
protective role of CD4+ T helper lymphocytes. Indeed, it has been demonstrated that the 
crossbreeding of mSOD1 mice with mice lacking functional T cells (RAG2-/- mice) or depleted for 
CD4+ cells worsened the disease progression increasing the production of pro-inflammatory 
cytokines (Beers et al., 2008). Similar results were obtained by the breeding of mSOD1 mice onto a 
TCRβ deficient background (Chiu et al., 2008). The protective role of CD4+ T lymphocytes was 
further supported by the evidence that the reconstitution of the bone marrow or the passive 
transfer of ex vivo activated CD4+ T cells improves neurological function and survival of ALS mice 
(Beers et al., 2008; Banerjee et al., 2008). Notably, it has been reported that the passive transfer of 
the T cell population enriched in T regulatory cells compared with whole CD4+ T cell subset 
translated in a greater amelioration of the disease course in ALS mice, indicating a neuroprotective 
role of T reg lymphocytes (Beers et al., 2011a).  
In-depth analysis in ALS models showed that the role (neuroprotective or neurotoxic) of CD4+ T cells 
is strictly dependant from their interaction with microglia cells. In the early stage of the disease, 
Treg and Th2 cells predominate and release anti-inflammatory factors (e.g. IL4, IL10, TGFβ), which 
promote the M2 polarisation of microglia (Beers et al., 2011b; Zhao et al., 2004). In turn, M2 
polarised microglia sustain and promote T reg and Th2 proliferation. In a synergic mechanism, the 
anti-inflammatory factors released by M2 microglia and Th2 and T reg lymphocytes inhibit the toxic 
function of Th1 cells (Beers et al., 2011b). As the disease progresses, a transformation occurs from 




the supportive T reg/M2 response to the toxic Th1/M1 response. Following the release of 
inflammatory factors by the Th1 cells, microglia acquire a cytotoxic phenotype and, in a vicious 
circle, release toxic factors that foster the activity of Th1 lymphocytes. The toxic factors released by 
Th1 lymphocytes and M1 polarised astroglia (TNFα, IFNγ, IL6, IL1β) also induce the dysfunction of 
T reg cells allowing the progression and worsening of the disease symptoms (Zhao et al., 2013). 
According to the progressive T reg lymphocytes dysfunction, it has been found that the 
transplantation of T reg cells harvested from mSOD1 rodents at the stable phase, but not at the 
symptomatic stage of the disease, was sufficient to improve the clinical outcome of recipient double 
transgenic RAG2-/-/SOD1G93A mice (Beers et al., 2011a). 
Similar observations have been made in ALS patients. Indeed, a dysfunctional activity of T reg cells 
of ALS patients compared with healthy subjects (Beers et al., 2017), and an inverse correlation 
between circulating T reg cells level and the disease progression rate and severity have been 
reported (Beers et al., 2011a; Henkel et al., 2013; Sheean et al., 2018). This evidence suggests that 
both the reduced number and the impaired immunosuppressive function of T reg cells could 
influence ALS progression. Moreover, the protective role of T reg cells has been recently confirmed 
observing that their expansion by the peripheral injection of IL2 monoclonal antibody complexes 
reduced microglia activation, protected MNs and increased the life expectancy of mSOD1 mice 
(Sheean et al., 2018). Accordingly, the MIROCALS phase II clinical trial assessing the therapeutic 
potential of IL2 is currently ongoing (ClinicalTrial.gov NCT03039673). 
 
Figure 8: CD4+ T cells tip the balance between glial neurotrophism and neurotoxicity. Circulating CD4+ T cells (specifically 
T reg and Th2 cells) via yet-to-be-identified mechanisms promote microglial and astrocyte production of trophic factors 
and anti-inflammatory cytokines. Depletion of CD4+ T cells in mSOD1 mice via different genetic approaches switches them 
to an activated proinflammatory phenotype with neurotoxic properties (Modified from Iyer et al. 2018). 




Among the neurotoxic lymphocytes, also Th17 cells seem involved in ALS pathogenic cascade, 
although evidence regarding their involvement in the disease is narrow. Studies reported higher 
expression of Th17-related cytokines (i.e. IL17 and IL23) in biofluids and spinal cord of ALS patients 
(Saresella et al., 2013; Rentzos et al., 2010; Jin et al., 2020); however, little information was 
obtained in ALS models. Preclinical evidence showed a higher level and increased activation of Th17 
cells upon facial nerve injury in mSOD1 compared to wild type mice, suggesting that the specific 
antigens released by damaged MNs primed the Th17 cells and promoted their recruitment into the 
CNS, where sustain the inflammation and neurodegeneration (Liu et al., 2017b; Ni et al., 2016). 
Despite part of the innate immunity, Natural killer (NK) T lymphocytes are another T cell population 
involved in ALS. NK cells are pivotal in regulating the immune response since they release a plethora 
of pro- and anti-inflammatory factors, such as IL2, IL3, IL4, TNFα, IFNγ. NKT cells were found 
increased in peripheral blood of ALS patients and spinal cord, liver and spleen of mSOD1 mice 
(Rentzos et al., 2012; Finkelstein et al., 2011; Garofalo et al., 2020). Moreover, it has been reported 
that the treatment with an analogue of α-galactosylceramide, a compound that induced hypo-
responsiveness of NK T cells, or the depletion of NK T subpopulation ameliorate the disease course 
and the histopathological features in ALS mice (Finkelstein et al. 2011; Garofalo et al. 2020). 
However, further investigations are needed to clarify the involvement of NK T lymphocytes in ALS. 
In the last years, several studies have focused on CD8+ T population of lymphocytes. Although 
preliminary evidence reported a delayed presence of CD8+ T cells in the CNS of ALS mice (Beers et 
al., 2008), newly evidence described the infiltration of cytotoxic T lymphocytes as an early event in 
the disease (Nardo et al., 2018; Coque et al., 2019). CD8+ T lymphocytes have been classically 
considered detrimental for MNs due to their antigen-specific effector cells capability. Indeed, CD8+ 
T cells express the Fas ligand (FasL/CD95) (Peter et al., 2007), and it has been reported an increased 
susceptibility of MNs to Fas-mediated death (Raoul et al., 2002).  
The role of CD8+ T cells in ALS has been exploited through different experimental paradigms, such 
as crossbreeding mSOD1 mice with animals depleted (CD8a knock-out) (Coque et al., 2019) or 
defective (knock-out for the β2microglobulin subunit of MHCI) for CD8+ T cells (Nardo et al., 2018) 




or by the injection of anti-CD8a antibody (Komine et al., 2018).  Results are controversial since CD8a-
/-/SOD1G93A animals, or ALS mice injected with anti-CD8a antibody did not modify their survival 
while the β2microglobulin-/-/SOD1G93A mice showed and anticipation of the disease onset with 
prolonged survival.  
Despite these discrepancies, CNS infiltrating CD8+ T cells release a high level of IFNγ compared to 
the wild-type circulating cytotoxic lymphocytes. This pro-inflammatory cytokine might contribute 
to the neurodegeneration promoting the somatic expression of MHCI by dying MNs (Coque et al., 
2019). However, it is still unclear whether the elimination of damaged MNs is part of the cell death 
process or if dying neurons express autoantigens that trigger their removal through T cytotoxic 
lymphocytes. Accordingly, the production of IFNγ was reduced, and spinal MNs loss was delayed, 
in double transgenic β2microglobulin-/-/SOD1G93A mice. Nevertheless, the lack of CD8+ T cells 
severely affected the structure and function of peripheral motor axons anticipating the motor 
impairment in double transgenic β2microglobulin-/-/SOD1G93A mice (Nardo et al., 2018). This 
evidence suggests a pivotal role of CD8+ T cells in the immune-mediated axonal regenerative 
process occurring in the PNS. Suitably, we found a reduced infiltration of cytotoxic T cells within the 
sciatic nerve of the SOD1G93A mice characterised by faster disease progression (Nardo et al., 2016b). 
These findings highlighted the complexity of ALS, in which the multifaceted activity of immune cells 
is affected by the disease progression and the environment with which they interact.  
1.3.2.1.2 B LYMPHOCYTES 
The maturation of HSC into B cells required various gene expression patterns and immunoglobulin 
heavy and light chain gene loci arrangements (Pelanda and Torres 2012). To ensure a proper 
development within the bone marrow, B cells undergo two types of selection: a positive selection, 
which occurs through antigen-independent signalling, and a negative selection, which occurs 
through the binding of self-antigen (LeBien and Tedder 2008). The achievement of the complete 
maturation takes place in the secondary lymphoid organs (e.g. spleen), where B cells became 
activated by binding the antigen via BCR (B cell receptor) (Yuseff et al., 2013). 




The evidence concerning the involvement of B lymphocytes in ALS pathogenesis is narrow. 
Although no B cells infiltration has been observed in the spinal cord of human ALS (Troost et al., 
1990; Engelhardt et al., 1993), increased concentrations of specific antibodies suggest an expansion 
of specific B‐cell populations in patients. Indeed it has been reported increased immunoglobulin 
concentrations in peripheral blood of ALS patients compared with healthy subjects (Provinciali et 
al., 1988). Although with discordant results, some studies reported the presence of antibodies to 
ganglioside GM1 (Pestronk et al., 1989; Niebroj-Dobosz et al., 2009), calcium channel subunits 
(Smith et al., 1992), Fas (Sengun and Appel 2003) and lipoprotein‐related protein 4 (Tzartos et al., 
2014) in the sera of ALS patients. However, these autoantibodies have also been detected in others 
neurodegenerative disease and are not indicative for the specific MN degeneration (van den Berg 
et al., 1992; Bekircan-Kurt 2015; Shen et al., 2013). Therefore, the functional role of these 
autoantibodies in ALS is still speculative. However, they might be a driving factor in the disease 
progression of a limited population of ALS patients even if they do not contribute to the majority 
of cases (Lyon et al., 2019).  
The contribution of B lymphocytes in ALS has also been addressed in the disease models, in which 
no B cells infiltration was recorded in the spinal cord (Chiu et al., 2008) albeit the production of 
autoantibodies has been confirmed. However, the B cells of mSOD1 mice did not exhibit an 
activated phenotype or increased responsiveness to pro-inflammatory stimulus compared with the 
wild type counterpart (Naor et al., 2009). Moreover, it has been demonstrated that the B cells 
depletion in SOD1G93A mice did not affect the disease course, suggesting their minor if not negligible 
contribution in the disease (Naor et al., 2009). Therefore, given the correlation with the severity of 
disease course, it is conceivable that autoantibody production is a secondary immunological 
consequence of neuronal death that may accelerate the neurodegenerative cascade (Niebroj-
Dobosz et al., 2006). Although speculative, a better understanding of the role of autoantibodies and 
their ability to escape immune tolerance may pave the way for the development of disease-specific 
immunological signatures to be used for disease monitoring and to rate treatment response 
(Malaspina et al., 2015). 




1.3.3 CYTOKINES  
Cytokines are important signalling molecules synthesised by immune cells in peripheral tissues and 
blood, and by glial cells or non-resident immune cells in the CNS. One characteristic feature of 
cytokines is the functional redundancy and pleiotropism. Numerous cell types respond to cytokines, 
thereby regulating both homeostatic and pathological functions (Dinarello 2007).  
It is well established that cytokines are mediators of both innate and adaptive immunity, therefore 
are involved in virtually every facet of immunity and inflammation, including antigen presentation, 
bone marrow differentiation, cellular recruitment and activation, and adhesion molecule 
expression (Borish and Steinke 2003). Once released, cytokines target the cells expressing the 
cognate receptors, which typically results in the recruitment of other immune cells and secretion 
of more cytokines.  
In physiological condition, cytokines are expressed in low concentration in the CNS. However, in 
response to immune challenge, both cytokines and immune cells can pass through the BBB. Besides, 
non-neuronal cells (e.g. microglia, astrocytes) secrete cytokines on the brain side of the BBB 
inducing the neuroinflammatory phenomenon (Hanisch 2002). 
The term cytokine encompasses a broad range of molecules which can be classified in chemokines, 
interferons, interleukins, lymphokines, tumour necrosis factor but generally not hormones or 
growth factors (despite some terminological overlap, e.g. TGFβ).  
An extensive literature has been devoted to these molecules and their role in neurodegenerative 
diseases. Here, we will focus on the chemokine subclass of cytokines, in particular on the Monocyte 
Chemoattractant Protein 1 (MCP1), a.k.a C-C motif Chemokine Ligand 2 (CCL2). 
1.3.3.1 CHEMOKINE  
Chemokines – chemotactic cytokines – are the largest family of cytokines in humans. Their name 
derives from “-kinos,” which is Greek for “movement”. Indeed, chemokines play a vital role in cell 
migration through venules from the blood into tissue and viceversa, and in the induction of cell 
movement in response to a chemical (chemotactic) gradient by a process known as chemotaxis 
(Baggiolini 1998).  




Inducible chemokine expression is generally modulated by pro-inflammatory stimuli to promote 
the chemotaxis of macrophages, neutrophils, and other lymphocytes to sites of injury, infection or 
phlogosis. However, chemokines are also involved in leucocyte degranulation (Mackay 2001), 
hematopoiesis (Youn et al., 2000), and angiogenesis (Belperio et al., 2000). Accordingly, they can 
be grouped in: inflammatory chemokines, that control leucocytes recruitment into the 
inflamed/damaged tissue, and homeostatic chemokines, that fulfil housekeeping functions (Zlotnik 
and Yoshie 2000). 
Chemokines are small proteins of approximately 80 amino acids in size that are classified into main 
subfamilies based on the sequential positioning of the first two of four highly conserved cysteine 
residues: CXC (α subfamily), CC (β subfamily) and CX3C (δ subfamily) (Zlotnik and Yoshie 2000). In 
the largest α and β subfamilies the first two cysteines are adjacent (CC motif) or separated by one 
amino acid residue (CXC motif) respectively. In contrast, in the δ subfamily chemokines have three 
amino acids between the first two cysteine residues (CX3C motif) (Zlotnik and Yoshie 2000). The 
CXC chemokines can be further divided into two subgroups, ‘ELR’ and ‘non-ELR,’ based on the 
presence/absence of the Glu-Leu-Arg motif before the first cysteine. An exception is represented 
by the γ subfamily, in which only one N-terminal cysteine residue is present (XC motif) (Kelner et 
al., 1994). 
Even though the sequence identity between chemokines varies from about 20% to 90%, their 
sequences overall are highly conserved. Moreover, chemokines acquire substantially the same fold. 
These structures consist of a flexible N-terminus and N-terminal loop, followed by a three-stranded 
antiparallel β-sheet onto which is folded a C-terminal α-helix. The highly conserved cysteine 
residues interact to form disulphide bridges that are crucial at maintaining the structural integrity 
of the protein, which is a prerequisite for chemokine binding to their respective receptors 
(Campbell 2003; Miller and Mayo 2017).  





Figure 9: Schematic representation of the three dimensional chemokine structure (Rajagopalan and Rajarathnam 2006). 
Chemokines exert their function by interacting with two classes of receptors: conventional 
chemokine receptors (cCKRs) and atypical chemokine receptors (aCKRs). Chemokine‐bound cCKRs 
typically transduce signals through pertussis toxin‐sensitive Gαi G‐proteins, β‐arrestins and JAK-
STAT pathways, ultimately leading to cell migration, adhesion and/or a variety of other biological 
responses (Bachelerie et al., 2014; Kehrl 2006). Chemokines are thought to initially tether to their 
cognate cCKR via the extracellular loops and N-terminus of the receptor. Once a chemokine is 
tethered to a cCKR, its unstructured N-terminus enters the heptahelical bundle of the receptor to 
induce a conformational change that is translated into intracellular signals (Kufareva et al., 2015). 
This classical two‐site model of chemokine-receptor interaction is probably oversimplistic. Indeed, 
recent studies suggested that the two supposedly independent ligand‐binding sites can be 
physically and allosterically linked and that additional interactions between chemokine and 
receptor are likely to be involved in ensuring full receptor activation (Kleist et al., 2016).  
Atypical chemokine receptors are structurally related to cCKRs but do not couple to many, if any, 
of the signal transduction pathways activated by the conventional receptors. This may be in part 
due to the absence, or modification, of appropriate signalling motifs on the intracellular surface of 
aCKRs, such as the canonical DRY (Asp–Arg–Tyr) motif (Nibbs and Graham 2013). aCKRs structurally 
resemble cCKRs but cannot directly initiate migratory responses. Instead, they scavenge, sequester 
or transport chemokines to control cCKR-driven responses, and can also regulate co-expressed 
cCKRs (Nibbs and Graham 2013). However, chemokine scavenging is not restricted to aCKRs; 




indeed, the activation of cCKR is accompanied by the internalisation of chemokine-cCKR complexes 
(Volpe et al., 2012).  
1.3.3.1.1 MONOCYTE CHEMOATTRACTANT PROTEIN 1 (MCP1 / CCL2)  
Monocyte chemoattractant protein 1 (MCP1), a.k.a. C-C Motif chemokine Ligand 2 (CCL2), is a 
member of the β chemokine subfamily. This family encompasses several small, secreted, 
chemotactic cytokines, named after their best-known function of attracting cells (Baggiolini 1998). 
MCP1 is the first discovered human CC chemokine. Located on chromosome 17 (chr.17, q11.2), 
human MCP1 is composed of 76 amino acids and is 13kDa in size (Van Coillie et al., 1999). MCP1 
belongs to a family consisting of other three members: MCP2/CCL8, MCP3/CCL7 and MCP4/CCL13. 
In mouse, four proteins have been identified (MCP1, MCP2, MCP3 and MCP5/CCL12) that share 
substantial amino acid identity to the human’s chemokines. However, the cross-species 
assignments of orthologs among these genes are not entirely clear. The murine MCP1, MCP2 and 
MCP3 are orthologs of the human MCP1, MCP2 and MCP3 proteins. However, no mouse ortholog 
has been described for human MCP4 and, viceversa, no ortholog in the human genome was found 
for the murine MCP5 (Van Coillie et al., 1999). 
Human MCP1 is produced as a precursor molecule containing a hydrophobic N-terminal signal 
sequence of 23 amino acids. After cleavage of the signal peptide portion, a mature protein of 74-
76 amino acids is secreted. Different molecular mass forms of MCP1 have been purified. Still, these 
seem to be caused by post-translational modifications (e.g. O-glycosylation) (Jiang et al., 1990), 
which have been shown to slightly reducing its chemotactic potency (Proost et al., 1998).  
Mutation studies identified the regions 10-13 and 34-35 as critical for the biological activity of MCP1 
(Beall et al., 1996). Deletion of residues at the N-terminus, which is crucial for the receptor 
recognition and signalling, resulted in the loss of chemokine activity. Conversely, the modification 
of the C-terminus does not affect the chemotactic capability of MCP1 (Proost et al., 1998). However, 
some of these mutant forms of MCP1 act as chemokine antagonists (Gong and Clark-Lewis 1995). 
MCP1 is expressed by a variety of cells, such as endothelial cells, smooth muscle cells, fibroblasts, 
epithelial cells,  astroglia, T cells (Cushing et al., 1990; Strieter et al., 1989; Standiford et al., 1991; 




Barna et al., 1994; Hayashi et al., 1995; Owen et al., 2007). However, myeloid cells (i.e. 
monocytes/macrophages) are the primary source of the chemokine (Rollins 1997).  
MCP1 expression is inducible, triggered upon exposure to inflammatory stimuli, such as LPS, 
interleukins (IL1, IL4, IL6), TNFα, TGFβ, IFNγ, platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF), M-CSF and GM-CSF (Van Coillieet al., 1999; Kumar and Boss 2000; 
Luther and Cyster 2001; Choi et al., 2017; Yoshimura 2018). MCP1 is usually released to exert a 
potent chemotactic activity by binding the C-C chemokine receptor type 2 (CCR2), which is 
expressed by several cell subsets, among these monocytes (Han et al., 1998), macrophages 
(Gendelman et al., 2009), B and T lymphocytes (Carr et al., 1994; Frade et al., 1997; Allavena et al., 
1994), dendritic cells (Zhu et al., 2000), neutrophils (Johnston et al., 1999), but also by endothelial 
cells (Weber et al., 1999) and smooth muscle cells (Hayes et al., 1998). CCR2 is a cCKR (seven 
transmembrane G protein coupled receptor, GPCR) which can also be activated by non-selective 
ligands including MCP3 and MCP4 (Gouwy et al., 2004; Wain et al., 2002). However, among these 
ligands, MCP1 is the most potent inducer of the signal transduction pathways leading to monocytes 
transmigration (Sozzani et al., 1994). 
MCP1-CCR2 binding activates several intracellular cascades mediated by numerous interactors, 
such as JAK2/STAT3, MAP kinases, phosphatidylinositol 3-kinases (PI3K), which are involved in cells 
migration (Wainnet al., 2002; Mellado et al., 1998; Kuang et al., 1996), and phospholipase C, which 
promotes calcium release (Kuang et al., 1996). Two alternatively spliced forms of CCR2 have been 
discovered (CCR2A and CCR2B) which differ only in their C-terminal tails (Charo and Taubman 2004) 
and possibly, in the downstream signalling (Sanders et al. 2000).  
Besides, MCP1 can bind two atypical chemokine receptors (no GPCR), aCKR1 and aCKR2, which 
show broad specificity for inflammatory chemokines. aCKR1 is expressed by red blood cells and 
blood vessels endothelial cells (but not leucocytes) and participates at regulating the chemokine 
abundance (scavenging activity) and transcytosis (Nibbs and Graham 2013). Lymphatic endothelial 
cells and mouse-innate like B cells are the unique cells expressing aCKR2 (Nibbs et al., 2001; Hansell 
et al., 2011).  




Notably, CCR2 is considered the key regulator of Ly6chigh monocytes infiltration within inflamed 
tissues and mobilisation from the bone marrow (BM) under steady-state condition (Tsou et al., 
2007). However, the BM mobilisation of monocytes is also governed by aCKR2, which is further 
involved in controlling their abundance in the circulation (Savino et al., 2012).  
 
Figure 10: (a) Schematic diagram of the CCR2 protein: it consists of four extracellular domains, seven transmembrane 
domains, and four intracellular domains. The DRY (Asp–Arg–Tyr) motif, which is important for G‐protein‐mediated signal 
transduction, is located in the juxtamembrane region of the second intracellular loop. G‐protein binding sites are also 
located on the second and third intracellular loops. G‐Protein receptor kinase (GRK) binds to the third intracellular loop 
and phosphorylates the GRK targets on the C‐tail to initiate internalisation of the CCR2 receptor after ligand binding. (b) 
Schema of MCP1/CCL2 and receptor binding. MCP1 consists of a short N‐terminal region and an extended N‐loop region, 
followed by three β‐strands and an α‐helix. High‐affinity binding of each ligand occurs between the N‐loop of the 
chemokine and the N‐terminal of the receptor, followed by interactions between the body of MCP1 and the extracellular 
loops of CCR2. The N‐terminal segment of MCP1 binds within the receptor and initiates intracellular signalling (inset) 
(Yamasaki et al. 2012). 
Intriguingly, MCP1 is not merely a guidance cue during immune cells extravasation toward the site 
of phlogosis as it also controls the monocyte adhesion to vascular endothelium promoting the 
expression of two members of the β2 family of integrins, CD11b and CD11c (Vaddi and Newton 
1994; Jiang et al., 1992). Moreover, it has been proposed the involvement of MCP1 in the 
macrophage polarization and subsequent cytokines release. However, the comprehension of the 
biological function of the chemokine remains elusive. Numerous evidence showed that the direct 
in vitro stimulation with the chemokine favoured the M1 polarization of macrophages promoting 
the release of pro-inflammatory factors (TNFα, IL1β, IL6) (Wang et al., 2014b; Sodhi and Biswas 
2002). Coherently, MCP1-null mice displayed an M2 phenotype characterised by the increased 
expression of TGFβ and Arginase 1 (Nio et al., 2012). In contrast, it has been reported that the 




stimulation of human myeloid cells with MCP1 led to an increase of CD14+/CD206+ cells (i.e. M2 
macrophages) (Roca et al., 2009) and that CCR2-null mice exhibited a reduced number of M2 
polarised peritoneal macrophages compared to controls (Sierra-Filardi et al., 2014).  
These pieces of evidence showed that the effect of MCP1 might be dependent on the intrinsic 
activation and polarisation state of the monocytes at the time of stimulation, suggesting that the 
MCP1-mediated polarisation fingerprint may be strictly dependant from the inflammatory context. 
Role of MCP1 in the Central Nervous System 
The role of the MCP1/CCR2 axis in the CNS is still controversial.  
Increased expression of MCP1 is usually associated with the neuroinflammatory phenomenon 
(Conductier et al., 2010; Sawyer et al., 2014; Semple et al., 2010b). Accordingly, MCP1 upregulation 
has been identified in several neurodegenerative/neuroinflammatory disorders such as ALS (Wilms 
et al., 2003; Baron et al., 2005; Nagata et al., 2007), Parkinson disease (Reale et al., 2009),  
Alzheimer disease (Ishizuka et al., 1997) and in their respective rodent models (Janelsins et al., 
2005; Kalkonde et al., 2007; Henkel et al., 2006). 
Typically, MCP1 is secreted by activated astrocytes to attract microglia cells to the site of neuronal 
injury, where they phagocyte the pathogens and cellular debris (Ransohoff et al., 1993; Hurwitz et 
al., 1995; Glabinski et al., 1996). Moreover, it has been reported that also microglia, neurons and 
endothelial cells are a source of MCP1 during pathological conditions (Berman et al., 1996; 
Thibeault et al., 2001; Howe et al., 2017). Notably, the CNS-recruited monocytes trough MCP1 
chemotactic guidance are in turn a source of the chemokine, implying the presence of autocrine 
regulation that perpetuates cells recruitment and activation during phlogosis (Calvo et al., 1996; 
Gunn et al., 1997; Gourmala et al., 1997).  
Intriguingly, it has been observed that the brain microvasculature endothelial cells respond to 
MCP1 enhancing the permeability of the BBB via RhoA signalling and cytoskeleton reorganization 
(Stamatovic 2003; 2005). These effects were attenuated in MCP1-treated animals that had 
previously been depleted of peripheral macrophages, indicating a direct impact of this chemokine 
on the endothelial cells of the BBB and an indirect effect involving leucocytes recruitment and 




subsequent changes in the BBB permeability (Stamatovic et al., 2006; Song and Pachter 2004). 
According to the neurotoxic role of MCP1/CCR2 axis, the depletion of chemokine or its receptor 
reduced the inflammatory phenomenon in several rodent models of neuroinflammatory diseases 
(Zhang et al., 2018a; Varvel et al., 2016; Dimitrijevic et al., 2007). Specularly, the chemokine 
overexpression exacerbated the pathological features (Chen et al., 2003; Joly-Amado et al., 2020; 
Yamamoto et al., 2005).  
However, considerable evidence reported the physiological expression of the chemokine in 
microglia cells, astrocytes and neurons (Goazigo et al., 2013; Banisadr et al., 2005). Besides, a 
distinct pattern of MCP1 and CCR2 expression had been identified at different embryonic stages, 
implying a role for this pathway during brain development (Meng et al., 1999; Rezaie et al., 2002). 
Neural progenitors cells are attracted in an MCP1-mediated manner to the site of injury, where 
promote regeneration (Belmadani et al., 2006). Moreover, the genetic ablation of CCR2 or MCP1 in 
a mouse model of Alzheimer disease enhanced the accumulation of Amyloid β (Aβ) and accelerated 
the cognitive decline in a manner that correlated with the gene dosage (El Khoury et al., 2007; 
Kiyota et al., 2013) suggesting an initial protective role of the chemokine in stimulating the 
phagocytic activity of microglia cells.  
Interestingly, it has been reported that the in vitro stimulation of microglia with MCP1 did not 
induce morphological changes nor the release of neurotoxic factors, suggesting that other stimuli 
might be necessary to drive the modifications that led to the acquirement of toxic function when 
the chemokine levels are elevated (Hinojosa et al., 2011). Moreover, it has been observed that the 
in vitro stimulation of the astrocytic CCR2 enhanced their survival, through the activation of NFκB 
and Akt signalling pathways, promoted the release of neurotrophic factors, and reduced the 
production of neurotoxic molecules even after a pro-inflammatory stimulus (Quinones et al., 2008; 
Kalehua et al., 2004; Semple et al., 2010a). Besides, it has been proven that the MCP1 released from 
astrocyte exerted a neuroprotective role in several in vitro neurotoxic paradigms such as excessive 
glutamate exposure (i.e. excitotoxicity), oxygen-glucose deprivation (Rosito et al., 2012) or methyl 
mercury administration (Godefroy et al., 2012). The chemokine release by astrocytes is pivotal for 




the maintenance of the homeostasis within the CNS. Indeed, it has been recently reported that 
astrocytes derived from a mouse model of Spinal Muscle Atrophy (SMA) showed a decreased 
production of MCP1 that translated in reduced support and axonal elongation of SMA or wild type 
isolated MNs. Notably, this deficit could be restored through the exogenous administration of the 
chemokine (Martin et al., 2017).  
Notably, the axonal outgrowth seems directly regulated by neuronal MCP1 as demonstrated by the 
reduced motility and axonal elongation observed in the NSC34 motor neuron-like cells expressing 
a splicing variant of Survival Motor Neuron protein (axonal SMN) upon chemokine knocking-down 
in vitro (Locatelli et al., 2012). Intriguingly, the therapeutic action of the mesenchymal stem cells in 
rodent models of spinal cord injury (SCI) is strictly mediated by the release of MCP1. Indeed, it has 
been reported that the chemokine exerts a neuroprotective effect by fostering the polarisation of 
the recruited macrophages towards the M2 pro-healing phenotype, reducing the neurons 
susceptibility to the excitotoxic phenomenon and also directly promoting the neurite arborisation 
(Papa et al., 2018; Matsubara et al., 2015). Corroborative evidence demonstrated that the 
preconditioning peripheral nerve injury in the SCI animal model increased the production of MCP1 
by neurons promoting the dorsal root ganglia outgrowth through the direct M2 polarisation of the 
recruited macrophages (Kwon et al., 2015). Coherently, the overexpression of the chemokine 
through the intrathecal injection of an AAV5_MCP1 engineered viral vector led to the increased of 
the neurite outgrowth (Niemi et al., 2016). 
 
Figure 11: The roles of CCL2(MCP1)/CCR2 axis during neuroinflammation. MCP1 induces the recruitment of macrophages, 
production of cytokines, and direct alteration of the expression of endothelial cell tight-junction proteins to increase blood-
brain barrier permeability, which contributes to inflammation, potentially exacerbating neuronal loss. MCP1-mediated 




macrophage accumulation may also be beneficial, as these phagocytic cells remove myelin debris, which otherwise inhibits 
regeneration. Furthermore, MCP1 is chemotactic for neural precursor cells and thus, may influence repair after injury by 
enhancing neurogenesis. (Semple et al., 2010b). 
In the ALS context, MCP1 is classically associated with the neuroinflammatory phenomenon. 
Indeed, high levels of the chemokine have been found in serum and particularly in the CSF of ALS 
patients (Wilms 2003; Simpson et al., 2004; Henkel et al., 2004; Baron et al., 2005; Tanaka et al., 
2006). Notably, it has also been reported a direct correlation between the MCP1 levels in the CSF 
and the severity or the speed of the disease progression in patients (Tanaka et al., 2006). However, 
this evidence was disproved by more recent clinical examinations (Martínez et al., 2020). 
Nevertheless, the elevated concentration of the chemokine in the CSF surmises an intrathecal 
production rather than a CNS diffusion from blood circulation. Indeed, MCP1 immunoreactivity was 
detected within the microvasculature, astroglia cells, MNs and infiltrating macrophages in the 
lumbar spinal cord of ALS patients (Henkel et al., 2004; Baron et al., 2005). 
Although ALS mice are more amenable to study specific pathways, the involvement of MCP1-CCR2 
axis in the disease is far to be elucidated. It has been recently reported that the antibody-mediated 
neutralisation of the chemokine reduced the immune cells infiltration in the CNS and ameliorated 
the disease course in mSOD1 mice (Garofalo et al., 2020). Moreover, similarly to patients, it has 
been shown a gradual upregulation of MCP1 transcript in the spinal cord of mSOD1 mice as the 
disease progresses, and the increased expression of the chemokine by activated microglia and MNs 
of ALS mice compared with wild type animals (Henkel et al., 2006). Notably, this study reported an 
upregulation of the chemokine already in 15 days old mSOD1 mice, i.e. before the microglia cells 
activation and the massive production of pro-inflammatory cytokines underlying the establishment 
of the neuroinflammatory event. As suggested in a mouse model of Alzheimer disease (Kiyota et 
al., 2013), this evidence might imply a protective action on this signalling in the early disease stage 
that might evolve in neurotoxic during the ALS progression (Henkel et al., 2006). Indeed, it has been 
reported that, at the disease onset, microglia strongly upregulate MCP1 and others chemokines 
fostering the recruitment of monocytes within the CNS (Butovsky et al., 2012). Moreover, an in vitro 




study showed that mSOD1 microglia cells exhibit pro-inflammatory fingerprints which include the 
increased secretion of MCP1 upon LPS stimulus (Sargsyan et al., 2009).  
Even more controversial is the evidence concerning the CCR2 expression in the CNS of ALS mice. 
The initial difficulty stands in the characterisation of the cellular subtype expressing the chemokine 
receptor. Constitutive CCR2 expression has been reported in neurons, astrocytes and microvascular 
endothelial cells of wild type mice (Banisadr et al. ,2002; Ge et al., 2008). However, this evidence 
was not corroborated by the characterisation of transgenic mice in which the receptor sequence 
was substituted by the red fluorescent reporter gene (CCR2-RFP mice), in which a specific CCR2 
expression was recorded in the leucocytic population (e.g. monocytes/macrophages and T cells) 
(Saederup et al., 2010). A further explorative study in ALS mice identified the receptor exclusively 
on the membrane of activated astrocytes (Kawaguchi-Niida et al., 2013). Conversely, it has been 
recently reported the CCR2 expression by microglia, neurons and infiltrating monocytes, but not 
astrocytes, of mSOD1 mice (Komiya et al., 2020).  
Given the opposite results and the poor aptitude of mSOD1 at recruiting CCR2+ immune cells in the 
CNS (Chiu et al., 2009; Kunis et al., 2015), we still lack a definitive picture illustrating both the 
expression pattern and the role of MCP1-CCR2 axis in the CNS pathology of ALS. 
Role of MCP1 in the Peripheral Nervous System 
CNS axons do not spontaneously regenerate after injury in adult mammals. In contrast, PNS axons 
readily regenerate, allowing the recovery of function after peripheral nerve damage. Therefore, 
understanding factors underlying the PNS regeneration or its inhibition is essential for developing 
therapies for individuals with axonopathies, including ALS (Moloney et al., 2014). 
After damage, peripheral axons degenerate and regrow following a process termed “Wallerian 
degeneration”, so named in honour of the clinician Augustus Volney Waller who described it in 
1850. Notably, the typical ovoidal structures of the Wallerian degeneration have been observed 
within the degenerating motor axons of ALS patients and models (Tian et al., 2016).  
Successful axon regeneration relies on a robust regenerative response of injured axons and the 
coordinate contribution of non-neuronal cells, including immune cells (Gaudet et al., 2011). Indeed, 




considerable evidence reported that innate (monocytes/macrophages, neutrophils) and adaptive 
immune cells (T lymphocytes) are massively involved in PNS degeneration and regeneration 
(Gaudet et al., 2011; Benowitz and Popovich 2011; Chen et al., 2015b; Bombeiro et al., 2016). The 
immune response is fundamental to turn the peripheral nerve tissue into an environment 
permissive to regeneration by removing inhibitory signals (e.g. myelin and cellular debris) and by 
upregulating neurotrophic features. The characteristics of an efficient immune response are the 
rapid onset and conclusion, and the fine and orchestrated interplay between the involved 
interactors (resident or infiltrating cells) and the molecules that they release (Rotshenker 2011). 
Upon nerve damage, several cytokines involved in inflammation, immune response and chemotaxis 
are upregulated, including IL1β, TNFα, IFNγ, RANTES (CCL5), MIP1α (CCL3) and MCP1 (CCL2) (Perrin 
et al., 2005; Taskinen and Roytta 2000; Kleinschnitz et al., 2005). Experimental evidence 
demonstrated that almost all the resident (Schwann cells, endoneurial macrophages) or infiltrating 
(monocytes-derived macrophages, T lymphocytes) cells involved in response to nerve degeneration 
are a source of cytokines, among these MCP1. Intriguingly, also the degenerated motor axons 
increased the expression of MCP1 to mediate the interaction with the infiltrating macrophages 
(Kwon et al., 2015). These pieces of evidence highlight the relevance of this signalling pathway in 
the PNS degeneration and regeneration mechanisms (Stratton et al., 2020; Tofaris et al., 2002).  
Schwann cells (SCs) are the first line response upon peripheral nerve damage and are the primary 
mediators in triggering many of the events in Wallerian degeneration (Jessen et al., 2015). In the 
absence of the physical contact to the axon, and following the stimulation by the Toll-like Receptor 
ligands released by the damaged axons, SCs de-differentiate to an immature non-myelinating 
(ensheathing) phenotype (Gaudet et al., 2011). De-differentiated SCs upregulate MAC2 protein to 
acquire a phagocytic phenotype (Reichert et al., 1994) fundamental to remove the myelin debris 
that contains molecules, such as MAG (myelin-associated glycoprotein) and OMgp 
(oligodendrocyte-myelin glycoprotein), that inhibit the axonal regrowth (Huang et al., 2005). Once 
de-differentiated, SCs downregulate miR-327 allowing the release MCP1 (Zhao et al., 2017b) to 
recruit hematogenous monocytes within the injury site (Taskinen and Roytta 2000; Tofaris et al., 




2002; Subang and Richardson 2001), a process also favoured by the breakdown of the blood nerve 
barrier (BNB). Together, the endoneurial activated macrophages release cytokines and chemokine, 
such as LIF, TNFα and MCP1 to amplify the recruitment of monocytes from circulation (Mueller et 
al., 2003) and VEGF to alter the permeability of the BNB microvessels (Shimizu et al., 2011). 
This evidence demonstrates the pivotal role of macrophages and the signalling pathway that govern 
their infiltration upon nerve damage. Indeed, in the later stage of the peripheral nerve 
degeneration, monocytes-derived macrophages are the major cells contributing to remove myelin 
and axonal debris and thus to create a favourable milieu to attempt to regenerate (Barrette et al., 
2008; Chen et al., 2015b).  
The pivotal role of MCP1-CCR2 axis and macrophages recruitment in peripheral nerve response to 
injury has been demonstrated through several experimental approaches. Indeed, the impairment 
of the regenerative capacity of the injured nerve during ageing is strictly related to the 
downregulated expression of MCP1 by macrophages of old mice but not to their migratory activity 
compared to macrophages derived from young animals (Stratton et al., 2020). Moreover, studies 
performed in the mice lesioned sciatic nerve showed that the in situ administration of MCP1-
neutralizing antibody suppresses the macrophage-mediated response and significantly impairs the 
myelin clearance within the damaged nerve (Perrin et al., 2005). Similarly, the administration of 
antibodies to CCR2 decreased the circulating monocytes level also impeding their infiltration in the 
injured sciatic nerve, thus hampering the nerve regeneration  (Lindborg et al., 2017). Corroborating 
evidence showed that mice genetically depleted for the chemokine or its receptor exhibited a 
reduced macrophages accumulation in the distal sciatic nerve and dorsal root ganglia (DRG) after 
nerve injury (Niemi et al., 2013; Siebert et al., 2000; Lindborg et al., 2017). Similarly, the depletion 
of monocytes/macrophages through the administration of macrophages deactivators, such as 
minocycline or clodronate liposome (Keilhoff et al., 2007; Chen et al. 2015b), or by using CD11b 
conditional knock out mice (CD11b-TKmt-30 mice) (Barrette et al., 2008), decreased the recruitment 
of these immune cells in the distal stump of the nerve severely affecting the axonal regeneration 
and the locomotor function of injured animals. Notably, the injection of MCP1 within the DRG 




increased macrophages recruitment and, differently from other chemokines (i.e. CX3CL1 and CCL3), 
promoted the neurite outgrowth instructing the infiltrating macrophages toward the M2 anti-
inflammatory phenotype (Kwon et al., 2015). This observation suggested that the participation of 
the MCP1-recruited macrophages in the axonal regeneration is not limited to their phagocytic 
activity toward the cellular debris but are actively involved in the releasing of trophic factors. 
Indeed, it has been demonstrated that upon injury both M1 and M2-polarised macrophages are 
recruited (Tomlinson et al., 2018) and that the ratio of pro-healing to pro-inflammatory population, 
rather than the extent of macrophage presence within the damaged nerve, regulates the 
regenerative outcomes (Mokarram et al., 2012). However, the exact mechanisms governing 
macrophage polarization in peripheral nerve injury models are still poorly understood (Zhang et al. 
2019). Pro-healing macrophages release some trophic factors, such as VEGF, that is essential for 
the formation of new blood vessels and Schwann cells guidance (Cattin et al., 2015). Accordingly, 
the angiogenesis mediated by macrophages in the acellular nerve allograft promotes the efficient 
SCs and T cells repopulation finally leading to nerve regeneration and functional recovery (Pan et 
al., 2020). Moreover, macrophages directly govern the mature or immature status of SCs, thus 
promoting or inhibiting the remyelination upon injury (Stratton et al., 2018). 
Although ALS is considered a distal axonopathy (Moloney et al., 2014), the PNS degeneration and 
regeneration and the stream of these mechanisms have been so far underestimated. Indeed, the 
macrophages and immune response involvement in the early pathology of the peripheral 
compartment has not been investigated in ALS. However, studies in SOD1G93A mice showed the 
presence of peripheral macrophages along degenerating nerve fibres in the ventral root, sciatic 
nerve and intramuscular axons (Chiu et al., 2009). Accordingly, upregulation of MCP1 and CD68 
transcripts were recorded in the sciatic nerve of mSOD1 mice suggesting that peripheral nerve 
inflammation is probably not the cause of the degeneration, but rather a response to the damage 
(Kano et al., 2012; Deng et al., 2018). Moreover, although it has been reported the BNB leakage in 
mSOD1 mice, the recruitment of macrophages is reduced compared to non-transgenic littermates 
upon a nerve crush. This observation suggests that a deficit/inhibition of the immune response may 




occur in ALS mice that might be responsible for the impaired nerve regeneration following an injury 
(Deng et al., 2018).  
Although MCP1 preferentially recruits monocytes (Rollins 1997), CCR2 is also expressed by 
activated T lymphocytes (Bonecchi et al., 1998; Luther and Cyster 2001). Notably, it has been 
demonstrated that the inflammatory factors released by adaptive immune cells potentiate the 
phagocytic activity of macrophages, indicating a pivotal role of T lymphocytes in the regenerative 
mechanisms upon a nerve injury (Bombeiro et al., 2016). Accordingly, it has been recently observed 
a reduced innate and adaptive immune cells infiltration within the sciatic nerve of fast progressing 
SOD1G93A mice that correlated with reduced expression of MCP1 along motor axons compared with 
slow progressing ALS mice (Nardo et al., 2016b). Suitably, the absence of cytotoxic T lymphocytes 
in double transgenic SOD1G93A/β2microglobulin-/- animals severely affected the peripheral axon 
structure resulting in anticipation of the motor deficit (Nardo et al., 2018). 
The recent characterization of the PNS of ALS patients corroborated the preclinical evidence. 
Indeed, it has been reported a direct correlation between the PNS inflammation and longer disease 
duration (Schreiber et al., 2019). Moreover, the gene expression profile of motor nerves of ALS 
patients revealed the downregulation of CCR2, suggesting that a defective immune cells infiltration 
at the site of degeneration may be implicated in ALS pathology (Riva et al., 2016).  
Role of MCP1 in the skeletal muscle 
Skeletal muscle is one of the most abundant tissues in the human body. It accounts for ~45% of the 
total body mass and is necessary for generating forces for movement.  
Progressive muscle loss can result from mechanical traumas, metabolic disorders, inherited genetic 
diseases (e.g. ALS, Duchenne muscular dystrophy, Charcot-Marie-Tooth disease) (Pansarasa et al., 
2014; Shin et al., 2013; Jani-Acsadi et al., 2015) or can also be a consequence of peripheral nerve 
injuries, chronic kidney disease, diabetes, and heart failure (Kalyani et al., 2014). 
Up to a certain threshold (~20%), skeletal muscle has the capability of regenerating the lost tissue 
thanks to its high adaptability and healing potential (Tedesco et al. ,2010). Beyond this threshold, 
the remaining muscular tissue is unable to regenerate its function fully. This loss of skeletal muscle 




with lasting functional impairment, defined as “volumetric muscle loss” (Grogan and Hsu 2011), can 
substantially impact the quality of life of patients by significantly reducing the functionality of the 
locomotion system. 
Several stages compose the process of muscle regeneration upon injury: i) necrosis of the injured 
muscle cell; ii) activation, proliferation and differentiation of muscle stem cells (satellite cells); iii) 
maturation of the newly formed muscle fibres and, finally, iv) the remodelling of muscle fibres. 
Acute inflammation and immune cells play critical roles in almost all stages of muscle regeneration 
(Yang and Hu 2018).  
Previous studies have suggested that chemokines are important actors in the regeneration of the 
skeletal muscle (Nicholas et al., 2015; Warren et al., 2005; 2004). Indeed, increased expression 
levels of several chemokine ligands and their cognate receptors have been found in muscle biopsies 
of patients and animal models of muscular dystrophy or inflammatory myopathies (Confalonieri et 
al., 2000; De Paepe and De Bleecker 2013; Porter et al., 2003). Among the cytokines upregulated 
upon a muscle injury (e.g. TNF family, interleukins, interferons, α and β chemokines), MCP1 seems 
pivotal in triggering the regenerative process of skeletal muscle (Lu et al., 2011a). Indeed it has been 
reported that myogenic precursor cells (a.k.a. satellite cells), injured muscle fibres, epimysium and 
perimysium resident macrophages and recruited monocytes are source of MCP1 (Chazaud et al., 
2003; Brigitte et al., 2010; Lu et al., 2011a). Notably, it has been observed a significant upregulation 
of MCP1 transcript 4-8 hours following muscle crush in mice, preceding chemokine expression and 
the resulting infiltration of macrophages in the injured muscle (Nicholas et al., 2015). This evidence 
highlights the pivotal role of MCP1 in orchestrating the immune-mediated response upon muscle 
injury. 
Several preclinical studies showed that following muscle injury (acute trauma, toxins 
administration, exercise or diseases, etc.) the damaged tissue initiates a stereotypical inflammatory 
response in which the number of intramuscular leucocytes rapidly increase (Yang and Hu 2018; 
Chazaud 2020; Tidball 2017; Rigamonti et al., 2014; Pizza 2008). Resident macrophages are pivotal 
in sensing the damage occurred and, once activated, secrete chemokines, such as neutrophil 




chemoattractant CXC chemokine ligand 1 (CXCL1) and MCP1, to promote the recruitment of 
neutrophils and monocytes respectively (Tidball 2005; Brigitte et al., 2010). Within hours, 
neutrophils invade damaged muscle and reach maximum numbers at approximately 12-24 hours 
post-injury, after which they rapidly return to near-normal numbers (Pizza 2008). Neutrophils 
stimulate host defence through the phagocytosis of cellular debris and releasing ROS and proteases 
(Tidball 2011). Besides, neutrophils also sustain and amplify the inflammatory process releasing 
cytokines, such as MIP1α and MCP1, thus attracting circulating monocytes within the damaged 
tissue (Scapini et al., 2000). Intriguingly, muscle resident T lymphocytes exert unexpected, essential 
roles at initiating the cascade of events leading to wound healing. Indeed, it has been reported that 
CD8α deficiency led to a reduction in the release of MCP1, that translates in the impairment of 
macrophages recruitment and thus muscle regeneration upon cardiotoxin muscular injection in 
mice (Zhang et al., 2014a). 
The high chemotactic MCP1 gradient established within the damaged muscle promotes the massive 
recruitment of Ly6chigh monocytes, which extravasate and enter in a muscular environment that is 
enriched with pro-inflammatory cytokines, such as IFNγ and TNFα (Warren et al., 2002; Collins and 
Grounds 2001; Cheng et al., 2008). Therefore, monocytes-derived macrophages are initially 
polarised toward the M1 phenotype and secrete pro-inflammatory and chemotactic factors (e.g. 
IFNγ, IL1β, TNFα and MCP1) and ROS to facilitate the removal of cellular debris and the recruitment 
of immune cells to the damaged area, therefore amplifying the ongoing inflammatory response 
(Dort et al., 2019; Tidball et al., 2014; Villalta et al., 2009). Preclinical studies showed that M1 
polarised macrophages reach peak number 24-48 hours after the acute injury, after that they switch 
toward the pro-healing anti-inflammatory M2 phenotype (Arnold et al. ,2007; Varga et al., 2016). 
M2 polarised macrophages are actively involved in promoting the resolution of the inflammatory 
process by releasing a wide array of anti-inflammatory factors (IL4, IL13, Arginase 1), pro-resolving 
lipids (15Δ-PGJ2) and trophic factors (IGF1) (Dort et al., 2019; Arnold et al., 2007; Chazaud 2020).  
However, as previously discussed, the M1/M2 signature represents an oversimplification of the 
inflammatory milieu within the degenerating/regenerating muscles. Although a mixture of M1 and 




M2 polarized macrophages have been observed following a muscle injury (Heredia et al., 2013; 
Wang et al., 2018;), their phenotypic switch and temporal and spatial recruitment represent a 
critical step to accomplish the proper muscle regeneration. Indeed, it has been reported that 
macrophages interact with satellite cells to regulate myogenesis (Chazaud et al., 2009; Madaro et 
al., 2019). The soluble factors released by pro-inflammatory macrophages stimulate myogenic 
precursor cells proliferation, while anti-inflammatory cytokines from M2 macrophages promote 
their differentiation (Arnold et al., 2007; Tidball et al., 2014; Varga et al., 2016). Similarly, the 
macrophage skewing also regulates the balance between muscle fibrosis and tissue remodelling, 
directly inhibiting (M1 macrophages) or promoting (M2 macrophages) fibroadipogenic progenitors 
expansion (Lemos et al., 2015). 
According to the classic kinetic of immune cells infiltration, T lymphocytes are the last cells entering 
in the damaged muscle peaking around 3-5 days post-injury (Fu et al., 2015; Tidball 2017). Although 
the presence of T cells was initially identified as a pathologic phenomenon of muscle damage 
(Orimo et al., 1991; McLennan 1996), the loss or gain of CD8+ or CD4+ T lymphocytes affected and 
rescued muscle regeneration capacity, respectively (Fu et al., 2015; Zhang et al. 2014a). Similarly, 
the loss of T reg cells, whom infiltration coincides and sustains the phenotypic M1->M2 transition 
of macrophages, impaired muscle repair and regeneration upon damage (Burzyn et al., 2013; 
Castiglioni et al., 2015; Kuswanto et al., 2016). 
Altogether these observations indicate that muscle regeneration is a collection of highly 
synchronised processes involving several cellular, molecular and signalling responses in which the 
coordinate effort of inflammation and regeneration is fundamental for the achievement of an 
efficient repair program following an injury (Bentzinger et al., 2013). Particularly, the intramuscular 
inflammatory signalling plays a critical role in mediating the regenerative response of the injured 
muscle and must be finely regulated. This because the inflammatory cytokine expression is capable 
of promoting both muscle growth and muscle loss (Muñoz-Cánoves et al., 2013; Howard et al., 
2020).  




In vivo studies in CD11b-diphtheria toxin receptor (CD11b-DTR) transgenic mice (Wang et al., 2014a; 
Arnold et al., 2007) or following the administration of clodronate liposome or Etoposide (Liu et al., 
2017b; Xiao, Liu and Chen 2016; Bryer et al., 2008; Dumont and Frenette 2010) have unequivocally 
demonstrated that the depletion of macrophages severely impairs skeletal muscle regeneration. 
Accordingly, the role of MCP1-CCR2 axis has been extensively investigated.  
Several studies identified MCP1-CCR2 signalling pathway as the primary entry route of the Ly6chigh 
monocytes into the injured muscle (Saclier et al., 2013a; 2013b; Shireman et al., 2007; Lu et al., 
2011a). Suitably, studies performed in MCP1 deficient mice showed a reduced macrophages 
recruitment that translated to a poor muscle regeneration (Shireman et al., 2007; Lu et al., 2011a; 
Martinez et al., 2010). Intriguingly, intravenously injected MCP1-deficient bone marrow monocytes 
could not enter in wild-type injured muscle despite the chemotactic gradient established within the 
damaged tissue upon barium chloride injection (Lu et al., 2011a). This evidence suggests that MCP1 
expressed by circulating monocytes may exert an autocrine function fundamental for their 
transmigration toward the damaged site and that chemokine expression by bone marrow-derived 
cells and injured muscle is required for proper muscle regeneration (Lu et al., 2011a). The same 
results have been obtained in CCR2 knock-out mice, in which the impaired egression of monocytes 
from the bone marrow resulted in poor muscle regeneration (Contreras-Shannon et al., 2007; 
Ochoa et al., 2007; Lu et al., 2011b; Sun et al., 2009; Warren et al., 2005). The deficient macrophages 
recruitment in CCR2 knockout mice led to the increase of pro-inflammatory (TNFα, MIP1β, MCP1, 
MCP3, MCP5), pro-angiogenic (KC-GRO, IL3 and GM-CSF) and pro-hematopoietic (SCF and SDF1) 
cytokines release depicting a scenario similar to the so-called “inflammaging”, condition well known 
to impair the tissue regeneration (Melton et al., 2016). This dysregulation was rebalanced by wild 
type bone marrow-derived cells, which restored the physiological inflammation in CCR2 deficient 
mice, and partially in MCP1 depleted animals, re-establishing the inflammatory response within the 
injured muscle (Sun et al., 2009; Lu et al., 2011a; Melton et al., 2016). Notably, the regenerative 
impairment recorded in MCP1 deficient mice was not severe as observed in CCR2 depleted mice, 




suggesting a compensatory action of other chemokines (e.g. CCL5) in the absence of the CCR2 
specific ligand (Martinez et al., 2010; Lu et al., 2011a).  
Besides MCP1-CCR2 axis, other chemokines signalling pathways participate in the muscular 
response to damage. Indeed, preclinical studies have shown that the depletion of CXCL16 (Zhang 
et al., 2009) or the fractalkine receptor (CX3CR1) (Zhao et al., 2016) severely impaired the muscle 
regeneration reducing the macrophages recruitment and their phagocytic capability respectively. 
Conversely, the administration of CXCL12 in rat crushed muscles activated and mobilised the 
CD34+/CXCR4+ precursor cells residing in the bone marrow or blood circulation, thus improving the 
muscle regeneration (Brzoska et al., 2012). Noteworthy, these studies reported a direct action of 
the chemokines, including MCP1 (Warren et al., 2005), on the muscular progenitor cells.  
This evidence highlighted the pivotal role of chemokine in muscle degeneration and regeneration 
upon an acute injury, suggesting a dual mechanism of action. On one hand, through the 
establishment of a chemotactic gradient within the injured tissue, chemokine recruit leucocytes 
which, in turn, release cytokines (e.g. TNFα) and trophic growth factors (e.g. IGF1) that promote 
the activation and commitment of satellite cells (Tidball, Dorshkind, and Wehling-Henricks 2014). 
On the other hand, chemokines directly interact with the myogenic precursor cells influencing their 
response following an injury (Warren et al., 2005; Zhang et al., 2009; Brzoska et al., 2012). 
The involvement of MCP1 signalling in the degenerating muscle has not been investigated in ALS. 
However, it has been reported a progressive increase of the chemokine transcript in the skeletal 
muscle of SOD1G93A mice at the later stage of the disease (Manzano et al., 2011). Nevertheless, the 
contribution of immune cells, particularly macrophages, in the degenerative or regenerative 
mechanism of the skeletal muscle during the disease course has attracted considerable attention 
in the last years. Indeed, T cells and macrophages infiltrate, and a significant increase of CD68 and 
CD45 transcripts have been observed in skeletal muscle biopsies of ALS patients compared with 
healthy subjects (Jensen et al., 2016). This evidence confirmed the previous observations, indicating 
a close association between the infiltration of the immune and the extent of muscle fibres 
destruction in ALS (Troost et al., 1992). Similarly, it has been reported a progressive upregulation 




of CD11b and CD68 markers and macrophages infiltration in the skeletal muscle of rodent models 
of the disease (Chiu et al., 2009; Van Dyke et al., 2016; Wang et al., 2017; Trias et al., 2017). 
Intriguingly, the studies performed in SOD1G93A mice demonstrated that the more severely affected 
muscles, such as tibialis anterior, showed greater macrophages infiltration compared with the 
diaphragm (Chiu et al., 2009). However, the role of macrophages in ALS degenerating muscle is still 
unclear. Some preclinical studies demonstrated that the reduction of the macrophages recruitment 
was sufficient to preserve the neuromuscular junctions from denervation and thus ameliorate the 
motor deficit in ALS models (Van Dyke et al., 2016; Trias et al., 2017; Wang et al., 2017). Conversely, 
it has been reported that the reduced macrophages infiltration in the hind limb skeletal muscles 
was associated with an earlier onset and a more aggressive disease course in SOD1G93A mice 
(Vallarola et al., 2018). Noteworthy, it has been suggested that ALS macrophages possess a 
dysregulated capability, as demonstrated by the promoted skeletal muscle regeneration observed 
in mSOD1 mice following whole wild type bone marrow transplantation (Corti et al., 2004). 
These pieces of evidence highlighted the complexity and pleiotropy of the immune response, 
depicting it as a real-time example of an evolving system. Mainly, in the ALS field, the observations 
hitherto collected paint a picture of a rising systemic immune response as the disease progresses. 
However, whether the immune changes are causative and therefore represent an attractive 
therapeutic target, or whether they are a secondary downstream effect of the dysfunctions 
occurred in the CNS is still debated. Furthermore, the recent evidence suggested a dual role of the 
immune response in the CNS compared with the peripheral compartment (Chiu et al., 2009; Dibaj 
et al., 2011) making the comprehension of the immune mechanism involved in ALS even more 
challenging.  
  



























OVERALL OBJECTIVES and SPECIFIC AIMS 
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease characterised by a higher 
heterogeneity in term of clinical manifestation and speed of disease progression (Ticozzi and Silani 
2018; Bendotti et al., 2020). Arguably, such heterogeneity stems from the different mechanisms 
involved in its pathogenesis. Indeed, the knowledge so far acquired through the study of ALS mouse 
models showed that multiple mechanisms contribute to motor neuron (MN) injury (Mejzini et al., 
2019). Moreover, it has become clear that ALS is a non-cell autonomous disease with other cell 
types within the central nervous system (CNS) actively contributing to the disease including 
microglia, astrocytes and immune cells (Chiot et al., 2019; Thonhoff, Simpson, and Appel 2018). 
However, the impressive amount of knowledge acquired did not yield the expected outcomes in 
term of therapeutic benefit. Several bodies of evidence demonstrated that the preservation of MNs 
is per se not sufficient to tangibly counteract the disease (Rouaux et al., 2007; Gould et al., 2006). 
Accordingly, it has been observed that skeletal muscle atrophy and axonal degeneration are early 
events in the disease pathogenic cascade, anticipating MN loss and symptoms manifestation (Clark 
et al., 2016; Azzouz et al., 1997). In agreement with this observation, ALS has been recently 
described as a distal axonopathy whereby skeletal muscles actively contributes to a retrograde 
signalling cascade that culminates with MN death (Moloney et al., 2014; Dadon-Nachum at al., 
2011). 
Mounting experimental evidence highlights the different contribution of the inflammatory 
response in the CNS compared with the periphery (i.e. nerves and muscles) (Dibaj et al., 2011; Chiu 
et al., 2009). Indeed, while the aberrant glial cells activation, T cells infiltration and the resulting 
release of pro-inflammatory factors drive neurodegeneration, the successful axon and muscle 
regeneration depends on the coordinated efforts of immune cells which, besides removing cellular 
debris, release factors that support wound healing (Deng et al. ,2018; Gaudet et al., 2011; Sass et 
al., 2018; Van Dyke et al., 2016).  
It is, therefore, possible to postulate that the immune response can actively influence the 
progression of the disease, promoting phenomena of neuroprotection and/or neurotoxicity (Lyon 




et al., 2019; Wosiski-Kuhn et al., 2019). To shed light on the nature and temporal development of 
immune response in central and peripheral compartments affected by the disease could be a useful 
tool to discover new biomarkers and identify targets for the development of precise therapeutic 
strategies aimed to slow down ALS progression. 
The assumption of a pivotal role of the peripheral immune response in governing the speed of the 
disease progression has been recently validated in our laboratory following the characterisation of 
two mouse strains (C57 and 129Sv) carrying the same copies of human mutant SOD1 transgene 
(SOD1G93A) but exhibiting remarkable differences in term of disease onset, progression and overall 
survival (Marino et al., 2015; Nardo et al., 2016a). Our studies revealed that, despite the two ALS 
models exhibiting the same extent of MNs loss during the disease progression (Marino et al., 2015), 
the fast progressing mice (129Sv SOD1G93A) showed earlier muscle denervation that correlates with 
a reduced macrophages infiltration within the peripheral compartment compared with the slow 
progressing ALS mice (C57 SOD1G93A) (Nardo et al., 2016b; Vallarola et al., 2018). Further analyses 
showed a strong downregulation of one of the most potent chemotactic agent for haematogenous 
monocytes, such as Monocyte Chemoattractant Protein 1 (MCP1), a.k.a C-C Motif Chemokine 
Ligand 2 (CCL2), in fast progressing compared with slow progressing ALS mice at both central and 
peripheral level (Nardo et al., 2013, 2016b). 
The evidence hitherto collected suggests that the immune system might be pivotal in delaying 
muscular denervation and triggering the regeneration of the neuromuscular system, thus 
regulating the speed of disease progression of the two ALS models. At the same time, MCP1 seems 
to fulfil a critical role in these processes. Indeed, the involvement of MCP1-mediated pathway in 
nerve and muscle regeneration has been recently suggested  (Niemi et al., 2016; Shireman et al., 
2007) along with its engagement also as a neuroprotective factor (Locatelli et al., 2012; Papa et al., 
2018). 
To verify the heftiness of these observations and to clarify whether a proinflammatory chemokine 
might exert a protective role in ALS, this project will aim to characterise the effect of the early 




induction of MCP1 on the clinical outcomes and histopathological/biomolecular features of fast and 
slow progressing ALS mice.  
SPECIFIC AIMS 
To induce the chemokine an innovative approach is chosen consisting in the single injection of a 
self-complementary Adeno-Associated Virus serotype 9 (scAAV9) engineered with the sequence 
encoding for the murine MCP1 gene (scAAV9_MCP1).  
The characterisation of the effect of scAAV9_MCP1 injection will be achieved through the following 
steps: 
 In the first section of this Thesis, the assessment of the monocytes/macrophages recruitment 
and their inflammatory fingerprint within the skeletal muscles of fast and slow progressing 
ALS patients will be performed to corroborate the relevance of the preliminary preclinical 
observations. 
 The second section of this project will be devoted to the characterisation of the best route 
of administration of the scAAV9 to target the entire motor unit (i.e. MN soma, axons and 
skeletal muscle) in ALS mice. A comparison between the intracerebroventricular (i.c.v) and 
intramuscular (i.m.) administration of the scAAV9 engineered with the Green Fluorescent 
Protein (GFP) reporter gene sequence will be tested to reach the target avoiding the 
secondary side effects following the systemic induction of a pro-inflammatory chemokine. 
 The third section of the project will aim to understand whether an early (pre-symptomatic 
disease stage) induction of MCP1 might ameliorate the motor ability and symptoms 
progression of fast and slow progressing ALS mice. An in-depth characterisation of the effect 
of chemokine induction on the lower motor units will be performed in the two SOD1G93A 
models focusing at the symptomatic stage of the disease. 
 In the last section, we will examine the early regenerative mechanisms activated by slow 
progressing C57 SOD1G93A mice six weeks after the MCP1 induction. We will also analyse 
whether the preservation of the upper motor units is pivotal in slowing down the disease 
progression of ALS mice. 


























3.1 MURINE MODELS 
In this study, female transgenic SOD1G93A mice on C57BL/6J (C57G93A) and 129S2/Sv (129SvG93A) 
genetic background, and their corresponding non-transgenic (Ntg) littermates were used. Both 
SOD1G93A mouse strains were maintained on the homogenous background for more than 15 
generations.  
Mice were housed 4/5 per standard cages in specific pathogen-free and controlled environmental 
condition (temperature: 21±1°C; relative humidity: 60% and 12 hours of light). All the experimental 
procedures were conducted in conformity with institutional guidelines that comply with national 
(D.L. n.26, G.U. 4 March 2014) and international guidelines and laws (EEC Council Directive 86/609, 
OJ L 358, 1, 12 December 1987, Guide for the Care and Use of Laboratory Animals, U.S. National 
Research Council, 1996). All the experimental procedures were reviewed and approved by the 
intramural ethical committee and the Italian Ministry of Health. 
3.1.1 SOD1G93A ALS MOUSE MODELS 
The ALS animal models used in the experiments are transgenic mice expressing ~20 copies of the 
gene encoding for the human Superoxide Dismutase 1 (SOD1) enzyme with the point mutation 
Glycine to Alanine in position 93 (SOD1G93A). All the lines are hemizygous for the transgene (Gurney 
et al., 1994), so SOD1G93A male mice were repeatedly backcrossed with non-transgenic (Ntg) female 
mice.  
The animals used in the experiments are on two different homogeneous genetic backgrounds: 
 C57BL/6J-SOD1G93A (C57 SOD1G93A) are derived from B6.Cg-Tg(SOD1*G93A)1Gur/J (Jackson 
Laboratories) and crossed with non-transgenic C57BL/6J female mice. 
 129S2/SvHsd-SOD1G93A (129Sv SOD1G93A) have been generated in the laboratory by 
repeated backcross of C57 SOD1G93A males with 129Sv Ntg female mice, obtaining 
transgenic mice on the homogeneous 129Sv genetic background. 
 
 




3.1.2 MICE GENOTYPING 
Genotyping was performed on tail biopsies collected from mice at weaning age (~21 days), to 
identify transgenic (SOD1G93A) and non-transgenic (Ntg) animals. Samples were wholly digested by 
overnight incubation at 55°C in Direct- PCR Lysis Buffer (Viagen Biotech, Los Angeles, California, 
USA) containing 0.1 μg/μl of Proteinase K (Promega). The following day, after the inactivation of 
the Proteinase K at 85°C for 30 minutes, the Polymerase Chain Reaction (PCR) was performed using 
the Life Express Cycler TC-96/G/H(b)A (Bioer Technology Co. Ltd, Hangzhou, Zhejiang, China). 50 ng 
of extracted DNA for each animal was used as a substrate for qualitative PCR in a mix containing 1X 
PCR Buffer, Go-Taq DNA Polymerase (0.25U), deoxyNTPs (250μM each), specific forward (5’->3’, 
CATCAGCCCTAATCCATCTGA) and reverse (5’->3’, CGCGACTAACAATCAAAGTGA) primers (0.5μM 
each) in a final volume of 10 μl. All reagents were purchased by Promega, except for primers that 
were synthesised by Invitrogen.  
Sequences, annealing temperatures and PCR programme for hSOD1 primers are reported in the 
table below. 
PCR programme:   




94°C for 45 seconds 
58°C for 45 seconds 
72°C for 60 seconds 
 
   x 30 times 
Final elongation step 72°C for 10 minutes 
Table 8: PCR assay programme for the detection of the human SOD1 (hSOD1) transgene. 
Amplicons were resolved in 1% agarose gel containing GelRed Nucleic Acid Gel Stain (Biotium) 
1:30000 in Tris-Acetate-EDTA (40mM Tris, 0.35% vol/vol acid acetic, 1 mM EDTA) and visualised 
under UV using ChemiDoc XRS system (BioRad). 
3.2. CLINICAL DISEASE PROGRESSION IN SOD1G93A MICE 
3.2.1 BEHAVIOURAL ANALYSIS 
The onset and the progression of the disease have been monitored through behavioural analysis as 
previously described (Pizzasegola et al., 2009). Briefly, mice were trained per two weeks to perform 




the Paw Grip Endurance (PaGE) test starting at the pre-symptomatic disease stage (i.e. 6 weeks of 
age). After the two weeks of training, body weight was recorded, and mice were tested for the 
motor performance twice a week by a blinded operator.  
3.2.1.1 BODY WEIGHT MONITORING 
The weight of mice was measured before every behavioural test session. The weight loss was 
calculated by subtracting the maximum weight value from each registered weight. 
3.2.1.2 PAW GRIP ENDURANCE TEST 
The grip strength test is a simple non-invasive method designed to evaluate mouse muscle force in 
vivo, by taking advantage of the animal tendency to grasp a horizontal metal bar or a grid with its 
paws. Mice were placed on a horizontal metallic grid, which was then gently inverted. The latency 
to fall of each mouse was recorded. The test was considered passed if the mouse was able to cling 
to the grid for 90 seconds. In case of failure, the measurement was repeated three times, and the 
best performance of the session was considered for the statistical analysis.  
The test has been performed on C57SOD1G93A mouse model and the latency was evaluated. 
Concerning 129svSOD1G93A mouse model, the performance obtained in the grip strength test was 
assessed through a score, which is calculated as indicated by Lauranzano et al. (2015): 











Briefly, the Ttot is the time spent hanging before falling from the grid, n is the number of events in 
which both the hind limbs (i) or the fore/hind limb paw (j) were detached from the grid, the Tdouble 
i is the number of seconds the i-th event lasted, the Tsingle j is the number of seconds the j-th event 
lasted. The paw detachment was considered significant above 3 seconds. 
3.2.2 DETERMINATION OF THE PATHOLOGICAL STAGE 
The clinical onset was determined by the inability of the mouse to reach the maximum score at the 
PaGE test in two consecutive sessions of the behavioural analysis. The time occurred before the 
disease onset was considered as the pre-symptomatic stage of the disease. 




3.3 MICE TREATMENT 
Fast and slow progressing mice were treated through the injection of a self-complementary adeno-
associated virus serotype 9 (scAAV9) engineered with the enhanced green fluorescent protein 
(eGFP) or MCP1 murine gene under cytomegalovirus (CMV) promoter. An empty vector was used 
as control. 
3.3.1 scAAV9 VECTOR ENGINEERING 
The scAAV9 engineered with the eGFP or MCP1 gene sequence and the empty vector (control) were 
produced by Virovek (Hayward, CA, USA) following the steps below: 
 
Figure 12: Description of AAV production by Virovek (www.virovek.com/company/aav-production-technology). 
The scAAV9 vector was chosen considering the great tropism of the serotype 9 toward skeletal 
muscles. Moreover, it has been demonstrated the capability of the scAAV9 in mediating a 
widespread gene delivery from muscles to the spinal cord (Benkhelifa-Ziyyat et al., 2013).   
3.3.2 TREATMENT WITH THE ENGINEERED scAAV9  
Intra-cerebro-ventricular (i.c.v.) injection of scAAV9 
The i.c.v. injection of scAAV9_eGFP was performed in P1 (postnatal day 1) mice as previously 
described (Glascock et al., 2011; Gholizadeh et al., 2013). Briefly, mice underwent a single bilateral 
i.c.v. injection of 4.48x1012 vg/μL of scAAV9_eGFP opportunely diluted in 0.1% w/v trypan blue in 
sterile phosphate buffered saline (PBS) (2µl/ventricle). Cryo-anesthetised P1 mice were placed on 
a fibre-optic light to illuminate the midline and transverse sutures, which were used as a guide for 
the identification of neonates cerebral ventricle, and injected with a sterilised glass micropipette 
attached to a 3mL Hamilton syringe (Hamilton, Reno, NV) through a polyethene catheter. The 
sterile glass micropipette was inserted 2mm deep, perpendicular to the skull surface, at a location 




approximately 0.25mm lateral to the sagittal suture and 0.50–0.75mm rostral to the neonatal 
coronary suture and left in place for 30 seconds after discontinuation of plunger movement to 
prevent backflow. After the surgical procedure, mice were placed under an infra-red lamp to 
restore the physiological body temperature and brought back into the cage with the dam once the 
normal movement and general responsiveness were reinstated. 
Intramuscular (i.m.) injection of scAAV9 
In general, the AAV vector is considered less immunogenic in rodents. However, the immune 
response against the AAV vector and transgene product is the main obstacle spotted in large 
animals and humans (Qiao et al., 2011). To avoid the establishment of an illicit immune response, 
for the i.m. treatment, the viral vector dose was maintained in the range from 5x108 to 5x1010 
vg/site, as recommended by Gruntman et al. (2013).  
Adult mice underwent a single bilateral i.m. injection of 2,18x1010 vg/μL of the engineered (eGFP or 
MCP1 gene) scAAV9 or the empty vector as control. The injection has been performed on both hind 
limb (Tibialis Anterior, TA; Gastrocnemius Caput Medialis, GCM; Gluteus Maximus, GM) and 
forelimb (Triceps Brachii, TB) muscles following the protocol previously described by Gruntman et 
al. (2013) to allow the targeting of both cervical and lumbar motor neurons (Tosolini et al., 2013; 
Mohan et al., 2014). Briefly, mice were anaesthetised with isoflurane inhalation, fur was shaved, 
and the limbs were taped in position to visualise the target muscles. A 30-gauge needle was inserted 
into the muscle mid-belly, to facilitate the targeting of neuro-muscular junction (Tosolini et al., 
2013; Mohan et al., 2014), and 10μL of the engineered or empty vector opportunely diluted in 
sterile PBS was injected in each muscle. The syringe needle was left in place for 30 seconds after 
discontinuation of plunger movement to prevent backflow. 
After the surgical procedure, mice were placed under an infrared lamp to restore the physiological 
body temperature and brought back into their cages once the normal movement and general 
responsiveness were reinstated. To allow the full recovery from the anaesthesia, animals were 
tested in the behavioural analysis two days after the i.m. injection. 
 




3.4 HUMAN SAMPLES 
The skeletal muscle biopsies were selected from the Telethon Neuromuscular Bank of Tissues and 
DNA samples and kindly provided by Dr Pegoraro and Dr Soraù (University of Padua). 
Biopsies were collected from n=20 ALS patients with spinal onset. The categorisation in fast and 
slow progressing patients was performed according to the calculated progression rate (ΔFS) as 
previously indicated by Kimura et al. (2006). 
𝛥𝐹𝑆 =
48 − ALSFRS˗R at "time of diagnosis"
duration from onset to diagnosis (month)
 
After the collection, bioptic samples were frozen into the liquid phase of cooled isopentane for no 
more than 45 seconds and finally stored at -80°C until use. 
ID Gender ALS 
type 









9957 M sALS Jan 
2010 
Nov 2015 37 LVL  Mar 2015 0.16 
10275 M sALS Jan 
2014 
Feb 2017 42 LVL  Dec 2016 0.16 
9837 M fALS Apr 
2013 
Mar 2014 46 LVL  July 2014 0.18 
10008 M ALS Jan 
2013 
Sept 2015 43 LVL  July 2015 0.18 
10064 F sALS Feb 
2013 
Oct 2015 42 LVL  Oct 2015 0.19 
10429 M sALS Jan 
2014 
Feb 2018 38 LVL  Dec 2017 0.20 
9785 M sALS Apr 
2013 
June 2014 45 LVL  Apr 2014 0.21 
9992 M ALS Dec 
2012 
Jan 2016 36 LVL  May 2015 0.24 
10039 M sALS Sept 
2014 
Aug 2015 43 LVL  Aug 2015 0.45 
10430 F sALS May 
2017 
May 2018 40 LVL  Jan 2018 0.67 




9887 M fALS Feb 
2014 
Dec 2014 41 LVL  Oct 2014 0.70 
9899 F sALS Mar 
2014 
Jan 2015 41 LVL  Nov 2014 0.70 
10347 M ALS Oct 
2016 
Apr 2017 43 LVL  May 2017 0.83 
10425 F sALS Mar 
2017 
Nov 2017 41 LVL  Dec 2017 0.88 
9926 M sALS Jan 
2012 
Nov 2014 17 LVL  Feb 2015 0.91 
10337 M sALS July 
2016 
Oct 2017 34 LVL May 2017 0.93 
10518 M sALS Jan 
2018 
Oct 2018 38 LVL Sept 2018 1.11 
9984 M sALS Jan 
2014 
May 2015 27 LVL May 2015 1.31 
10358 M ALS Sept 
2017 
Dec 2017 44 LVL June 2017 1.33 
9865 F sALS Mar 
2013 
Nov 2014 33 RQF Sept 2014 1.88 
Table 9: List and features of ALS patients whose muscles have been analysed in this study (LVL, left vastus lateralis muscle; 
RQF, right quadriceps femoris muscle). 
3.5 HISTOLOGICAL ANALYSIS 
3.5.1 TISSUE COLLECTION 
Mice were anaesthetised with a mix of ketamine (1.75 mg/Kg) and medetomidine (1 mg/Kg) and 
transcardially perfused with 50 ml of 0.1M PBS pH 7.4. Following the blood removal, the skeletal 
muscles (TA, GCM, GM and TB) were dissected out and immediately frozen in cooled isopentane. 
At the same time, the vertebral column was post-fixed overnight in a solution of 4% 
paraformaldehyde in 0.1M PBS. The following day the vertebrae were removed, and the spinal cord 
was transferred to 30% sucrose solution in 0.1M PBS and conserved at 4°C for at least two O/N 
(overnights). Before the use, the spinal cord was divided in the cervical, thoracic and lumbar 
segments, which were individually embedded in Tissue-Tek OCT compound (Sakura, 




Zoeterwounde, The Netherlands), and finally frozen in cooled n-pentane. All tissues collected were 
stored at -80°C until required. 
Sections 30μm thick were obtained by cutting the spinal cord in the coronal plane on a cryostat at 
-20°C (CM1950, Leica Biosystems). The L2-L5 lumbar and C2-C7 cervical level of the spinal cord were 
chosen for the experiments. Serial longitudinal (20 μm) or coronal (12 μm) cryosections of the TA 
and TB muscles were collected on poly‐lysine objective slides (VWR International). 
3.5.2 INDIRECT IMMUNOFLUORESCENCE 
Free-floating sections of spinal cord or glass adhered sections of the TA and TB muscles were 
treated for 1h with a blocking solution composed of NGS and Triton X-100/Tween20 at the 
appropriate concentration in 0.01M PBS. Subsequently, the sections were incubated overnight at 
4°C with the primary antibody diluted in PBS containing NGS and Triton X-100. Then, after three 
washes in PBS, samples were treated for 1h with the appropriate secondary antibody conjugated 
to fluorochromes with various wavelengths (Alexa Fluor 488, 594 or 647; Molecular Probes, 
Invitrogen), diluted 1:500 in PBS added with NGS. The following markers represent an exception: 
DAPI (4′,6-diamidino-2-phenylindole), Neurotrace (recognise the Nissl substance present in the 
neurons perikaryon) and Wheat Germ Agglutinin (WGA) lectin, since they are directly conjugated 
with the fluorophore. After three washes, sections were mounted on slides and cover-slipped with 
Fluorsave (Calbiochem, Nottingham, UK). Controls sections were incubated without the primary 
antibody. The antibodies used in this study are listed below. 
Antibody Host species Dilution Supplier 
Choline Acetyltransferase (ChAT) goat 1:200 Merck Millipore 
Glial Fibrillary Acidic Protein (GFAP) mouse 1:2˙500 Merck Millipore 
Green fluorescent protein (GFP) chicken 1:750 Merck Millipore 
Macrosialin (CD68) rat 1:200 Biorad 
Myogenic determination gene (MyoD) rabbit 1:100 DSHB 
Neurofilament heavy polypeptide (NF200) rabbit 1:1˙000 Abcam 
Neutrophil Elastase rabbit 1:300 Abcam 
Paired box 7 (Pax7) mouse 1:400 DSHB 
Table 10: List of the antibodies used for the immunohistochemistry analysis. 




3.5.3 SUCCINATE DEHYDROGENASE (SDH) STAINING 
For the muscle fibre composition, serial transverse cryosections (10 μm) from the mid-belly region 
of the TA muscle were air‐dried and then incubated at 37°C for 30′ in phosphate buffer (0.2M, pH 
7.6) containing 13.5mg/mL Na‐succinate (Sigma‐Aldrich, St. Louis, MO, USA) and 0.5mg/mL of nitro 
blue tetrazolium (Sigma‐Aldrich, 0.29mg/mL of buffer solution). Sections were finally fixed with 4% 
paraformaldehyde, dehydrated in a graded series of ethanol (70%, 90% and 100%) for 5′ each and 
dipped in xylene. Finally, the objective slide was cover-slipped with DPX mounting medium (Sigma 
Aldrich).  
3.5.4 IMAGE ANALYSIS 
For motor neurons count analysis, a total of 12 serial ChAT-stained sections were analysed with an 
IX81 microscope equipped with a confocal scan unit FV500 with three laser lines: Argon-Krypton 
(488 nm), Helium-Neon red (646 nm), and Helium-Neon green (532 nm) and a UV diode (Olympus, 
Tokyo, Japan) using a 10× objective. The neuron areas were analysed with Fiji software (Image J, U. 
S. National Institutes of Health, Bethesda, Maryland, USA). Only neuronal somas with an area ≥ 400 
μm2 were considered for quantitative analysis of MN numbers (Friese et al., 2009).  
Fluorescence-labelled sections images (3/5 per animal) of the TA and TB muscle were analysed with 
an Olympus virtual slide system VS110 (Olympus, Center Valley, USA) and acquired at 20x 
magnification. 
The images of SDH stained muscles were acquired with a CCD colour camera (Color View III; Soft 
Imaging System, GmbH), using AnaliSYS software (Soft Imaging Systems, GmbH, ver. 3.2) at 20x 
magnification. 
For cells counting analyses (macrophages density, satellite cells and centralised myonuclei) and the 
SDH staining, a systematic random sampling procedure was applied as previously described (Nardo 
et al. 2018; Geuna et al. 2001). Briefly, a grid of equivalent sampling fields was outlined on the 
muscle slice profile. To ensure that every part of the slice had an equal chance of being sampled, a 
bidimensional stereological sampling procedure was applied analysing equivalent fields placed at a 




fixed distance from each other on the tissue slice, using the "Grid" function in Fiji (Image J, U. S. 
National Institutes of Health, Bethesda, Maryland, USA). 
The same approach was used to evaluate the neutrophil elastase staining by calculating with Fiji 
software the percentage of covered area (Area fraction %) per field for each section in the analysis. 
3.6 WESTERN BLOTTING 
3.6.1 TISSUE COLLECTION 
Mice were anaesthetised with a mix of ketamine (1.75mg/Kg) and medetomidine (1mg/Kg) and 
transcardially perfused with 50ml of 0.1M PBS pH7.4. Following the blood removal, the skeletal 
muscles (TA, GCM, GM and TB) were dissected out and immediately frozen in cooled isopentane. 
The spinal cord was fluxed from the vertebral column employing sterile physiological solution (0.9% 
NaCl) and dissected in the three main segments (i.e. cervical, thoracic and lumbar). Spinal cord 
segments and nerve were immediately frozen on dry ice. All tissues collected were stored at -80°C 
until required. 
3.6.2 PROTEIN EXTRACTION AND QUANTIFICATION 
First, 40µm thickness sections of frozen muscles were obtained with a cryostat (Leica Biosystems, 
Wetzlar, Germany). Spinal cord segments or muscle cryosections were homogenised in boiling in 
0.1% sodium dodecyl sulfate (SDS) in distilled water solution with Teflon potter. Then, samples were 
boiled at 100°C for 5 minutes to facilitate the action of SDS, sonicated three times per 10 seconds 
and boiled at 100°C for 5 minutes to completely homogenise the tissue. Finally, the suspension was 
centrifuged at 1200g for 10 minutes and the supernatant collected.  
 Sciatic nerves were ground in the recovery vial in the presence of liquid nitrogen to obtain a fine 
powder. Immediately after grinding, the nerve powder was homogenised with Teflon potter in ice-
cold homogenisation buffer (20mM Tris-HCl pH 7.4, 2% Triton X-100, 150mM NaCl, 1mM EDTA, 
5mM MgCl2, 10% anhydrous glycerol, protease and phosphates inhibitor cocktail, Roche). Then 
samples were sonicated three times per 10 seconds and centrifuged at 1200g for 10 minutes at 4°C. 
Finally, the supernatant was collected and stored at -80°C unit use. 




Protein extracts were quantified using the PierceTM BCA Protein assay kit (Thermo Fisher Scientific, 
Waltham, MA, USA) with bovine serum albumin (BSA) as standard. The absorbance of the solution 
was read at 562nm wavelength using the Infinite®200 multimode reader (Tecan). A simple linear 
regression analysis of the BSA curve was performed to which the absorbance of samples was 
interpolated to estimate the protein concentration of samples. 
3.6.3 MONO-DIMENSIONAL SDS-POLY-ACRYLAMIDE GEL ELECTROPHORESIS (SDS-
PAGE) 
Prior to electrophoresis, samples were boiled in SDS sample buffer (6% SDS, 0.1M DTT, 20% 
glycerol, 0.125M Tris/HCl pH6.8, 0.025% blue bromophenol) at 95°C for 5 minutes. Equal amounts 
of total proteins (20-30μg) were separated on Tris-glycine polyacrylamide gels and electroblotted 
onto a polyvinylidene difluoride (PVDF) membrane using a BioRad mini-transfer system (BioRad 
Laboratories, Hercules, CA, USA). 
To quantify the total protein electroblotted, membranes were briefly immersed in Ponceau S 
solution (Merck Life Science) and rinsed in water. Membranes were then placed between plastic 
sheets, scanned on Epson Perfection 1260 scanner, and the densitometry analysis was performed 
with Image Lab 6.1 software (BioRad). 
For the immunoblotting protocol, membranes were incubated in blocking buffer composed of 5% 
BSA dissolved in 0.1% Tween20 in Tris-buffered saline pH 7.4 (TBS-T) solution for 1h and then 
probed over-night at 4°C with the primary antibody diluted in 3% BSA in TBS-T. After three washes 
of 5 min in TBS-T, membranes were incubated with the opportunely diluted HRP-conjugated 
secondary antibody (Santa Cruz) for 1h at room temperature (RT) and finally washed three times 
per 5 min in TBS-T. Immunoreactivity was visualised with Luminata Forte Western HRP substrate 
(Millipore, Billerica, MA, USA) at ChemiDoc XRS (Biorad).  
The optical density of the blots was measured with Image Lab 6.1 software (BioRad) and normalised 
to the total amount of protein loaded stained with Ponceau S solution (Thacker et al. 2016) unless 
otherwise specified. Results were expressed as the percentage in respect of the non-transgenic 
littermates. 




The antibodies used in this study are listed below.  
Antibody  Host species Dilution Supplier 
Arginase 1 (Arg1) rabbit 1:1˙000 Abcam 
Beta importin (β importin) rabbit 1:5˙000 Merck Millipore 
Glial Fibrillary Acidic Protein (GFAP) mouse 1:30˙000 Merck Millipore 
Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) 
mouse 1:10˙000 Merck Millipore 
Green fluorescent protein (GFP) chicken 1:5˙000 Merck Millipore 
Heme binding subunit of NADPH oxidase (gp91PHOX) mouse 1:1˙000 BD 
inducible Nitric Oxide Synthase (iNOS) rabbit 1:1˙000 Invitrogen 
Ionised calcium-binding adapter molecule 1 (Iba1) rabbit 1:1˙000 Fujifilm Wako 
Macrosialin (CD68) rat 1:300 Biorad 
Mannose receptor (CD206) rabbit 1:500 Abcam 
Musclin goat 1:300 R&D Biosystems 
Myelin Basic Protein (MBP) rat 1:1˙000 Biorad 
Myogenic determination gene (MyoD) rabbit 1:5˙000 DSHB 
Myogenic factor 4 (MyoG) mouse 1:130 DSHB 
Neural Cell Adhesion Molecule (NCAM) rabbit 1:1˙000 Merck Millipore 
Neurofilament heavy polypeptide (NF200) rabbit 1:4˙000 Abcam 
p75 neurotrophin receptor (p75NTR) goat 1:1˙000 Santa Cruz 
Paired box 7 (Pax7) mouse 1:1˙000 DSHB 
Sirtuin 1 (SIRT1) mouse 1:750 Sigma Aldrich 
Table 11: List of the antibodies used for the western blotting analysis. 
3.7 REAL-TIME PCR (RT-PCR)  
3.7.1 TISSUE COLLECTION 
Murine tissues were collected ad described in paragraph 4.6.1.  
Human and muscle cryosections were collected in TRIzolTM (Invitrogen) and stored at -80°C until 
use. 
3.7.2 RNA EXTRACTION AND cDNA SYNTHESIS 
The total RNA from spinal cord, nerves and muscles was extracted using the TRIzolTM method 
(Invitrogen), purified with Ambion PureLink RNA columns (Thermo Fisher Scientific) according to 
the manufacturer's recommendation, and suspended in RNAse-free water. Extracted RNA was 




quantified with NanodropTM Spectrophotometers (Thermo Fisher Scientific). Prior to the retro-
transcription, RNA samples were treated with DNase I (Invitrogen) to avoid genomic DNA 
contamination, and the reverse transcription was done with the High Capacity cDNA Reverse 
Transcription Kit (Invitrogen).  
The quality of the cDNA obtained was tested with a qualitative PCR using primers for the murine 
Superoxide Dismutase 2 (SOD2) gene (forward: TGCACTGAAGTTCAATGGTGG; reverse: 
TAGAGCAGGCAGCAATCTGT) or the human Peptidylprolyl Isomerase A (PPIA) gene (forward: 
GTCTCCTTCGAGCTGTTTGC; reverse: AGCCAAATCCTTTCTCTCCAG). 
3.7.3 GENE EXPRESSION ANALYSIS 
For Real-time PCR, the TaqManTM Gene expression assay (Thermo Fisher Scientific) was employed 
following the manufacturer's instructions, on cDNA specimens in triplicate, using SensiFAST Probe 
Hi-ROX Kit (Aurogene) and 1X mix containing the specific probes (Thermo Fisher Scientific). 
The TaqManTM probes used in this study are listed below. 
Probe  ID 
Acetylcholine Receptor gamma subunit (AChRγ) Mm00437419_m1 
Beta-actin (β actin) Mm02619580_g1 
CD4 Mm00442754_m1 
CD8a Mm01182107_g1 
Forkhead box P3 (FOXP3) Mm00475162_m1 
Insulin-like Growth Factor 1 (IGF1) Mm00439560_m1 
Interleukin 1 beta (IL1β) Mm00434228_m1 
Interleukin 4 (IL4) Mm00445259_m1 
Macrosialin (CD68) Mm03047343_m1 
Monocyte Chemoattractant Protein 1 (MCP1) Mm00441242_m1 
Tumour Necrosis Factor alpha (TNFα) Mm00443258_m1 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Hs02786624_g1 
Monocyte Chemoattractant Protein 1 (MCP1) Hs00234140_m1 
Table 12: List of the TaqManTM probes used for the Real-Time PCR assay. 
Relative quantification was calculated from the ratio between the cycle number at which the signal 
crossed a threshold set (Ct) within the logarithmic phase of the given gene and that of the reference 
β-actin/GAPDH gene.  




Mean values of the triplicate results for each animal were used as individual data for the Livak 
statistical analysis (2-ΔΔCt). Conversely, the mean values of the triplicate resulted from the 
assessment of the human bioptic samples were analysed by variation of the Livak Method (i.e. 
2Ct(reference gene)-Ct(target gene)) due to the absence of the "calibrator" (i.e. healthy control subjects) as 
described in the "Real-Time PCR Application Guide" (Biorad). 
3.8 STATISTICAL ANALYSIS 
All the statistical analyses were performed using Prism 7 for Windows (GraphPad Software Inc.). 
Values are reported as mean ± SEM.  
Parameters (body weight and locomotor ability) used to evaluate disease progression in SOD1G93A 
mice were analysed by repeated-measures ANOVA followed by Sidak’s post hoc test. Symptoms 
onset was analysed by Log-rank Mantel-Cox test and Kaplan-Meier plots were generated.  
Satellite cells dynamic was analysed by two-way ANOVA followed by Tukey's Multiple Comparison 
Test.  
Previous D’Agostino & Pearson omnibus normality test, mean values ± standard deviation were 
used for statistical analysis by Student's t-test for two groups or by One-way ANOVA followed by 
Tukey's multiple comparison test for more than two groups.  
The non-parametric Spearman rank correlation was used to the bivariate analysis of the human 
samples. 
For all analyses, a p-value < 0.05 was considered statistically significant. The asterisk * indicates the 
comparison with the non transgenic littermates, while the dot ° indicates the comparison between 
scAAV9_MCP1 treated mice and the control group (i.e. empty vector). 
 


















Evaluation of the contribution of the immune response 
in the skeletal muscles of fast and slow progressing 
ALS patients 




4.1 BACKGROUND and AIM 
The skeletal muscle represents the first body compartment in which the ALS-related dysfunction 
appears. Indeed, progressive weakness and atrophy of skeletal muscles is the cardinal feature of 
the disease. 
Although the muscle involvement in nourishing the degenerative phenomenon of ALS is still elusive, 
there is compelling evidence suggesting that it might fulfil a critical role in the disease (Loeffler et 
al., 2016). Indeed, preclinical and in vitro studies demonstrated that the specific expression of the 
mSOD1 within the skeletal muscle led to limb weakness, NMJ abnormalities, axon degeneration 
and glial cells activation, suggesting a direct role of muscles in ALS pathophysiology (Dobrowolny et 
al., 2008; Maimon et al., 2018; Wong and Martin 2010). Moreover, molecular signalling that 
regulates muscle reinnervation, regeneration (i.e. myogenic programme) and metabolism have 
found dysregulated in ALS patients (Elf et al., 2014; Di Pietro et al., 2018; Jensen et al., 2016; 
Pansarasa et al., 2014) and models (Scaricamazza et al., 2020; Pansarasa et al., 2014; Dobrowolny 
et al., 2018; Palamiuc et al., 2015; Manzano et al., 2013). 
The knowledge recently acquired highlighted the pivotal role of the immune cell-mediated 
inflammation (Tidball and Villalta 2010; Tidball 2017; Howard et al., 2020; Pizza 2008; Sass et al., 
2018), mainly driven by macrophages (Chazaud 2020), in the mechanisms underlying the muscular 
healing upon an injury. Therefore, the role fulfilled by the peripheral immune response in ALS 
muscle pathology is only starting to emerge.  
We recently reported the reduced macrophages infiltration in the hind limb skeletal muscle of fast 
progressing compared with slow progressing SOD1G93A mice (Vallarola et al., 2018), highlighting the 
importance of the peripheral immune response in driving the speed of the disease progression. 
Therefore, the first section of this Thesis aimed to verify the heftiness of our preliminary 
observations through the characterisation of the extent in the activation of the peripheral immune 
response and the eventual inflammatory milieu established in skeletal muscle biopsies derived from 
fast and slow progressing sporadic ALS patients. Indeed, a detailed understanding of the muscle 




pathology in ALS might lead to the identification of novel prognostic/therapeutic targets useful in 
clinical practice. 
4.2 EXPERIMENTAL DESIGN 
Muscles biopsies of the right quadriceps femoris or left vastus lateralis muscle from n=10 fast 
progressing (ΔFS>0.68) and n=10 slow progressing (ΔFS<0.68) age and sex-matched sporadic ALS 
patients, kindly provided by Dr Sorarù and Dr Pegoraro (Università degli Studi di Padova), have been 
analysed through a biochemical (western blotting) and gene expression approach (qRT-PCR). A 
more detailed list of the human samples analysed with the relative specifications is available in 
section 3.4 of material and methods. 
4.3 CHARACTERISATION OF THE IMMUNE CELLS INFILTRATE AND ITS 
INFLAMMATORY FINGERPRINT IN THE SKELETAL MUSCLES OF ALS PATIENTS  
To assess a striking correlation between the ΔFS and the skeletal muscle preservation, we started 
our characterisation analysing the expression of musclin, a myokine produced by glycolytic muscle 
fibres (Banzet et al., 2007). Studies in musclin deficient mice described this protein as an exercise-
responsive factor promoting mitochondrial biogenesis and exercise endurance (Subbotina et al., 
2015). Moreover, the induction of musclin was effective in reducing the muscle wasting in C26-
bearing mice, a model of cancer cachexia (Re Cecconi et al., 2019).  
Our analysis showed an inverse relationship between the expression level of musclin and the speed 
of the disease progression (Fig. 13A), suggesting the preservation of the fibres from the metabolic 
switch (fast to slow) (Telerman-Toppet and Coërs 1978) and reduced atrophy of the skeletal muscle 
in slow progressing compared with fast progressing ALS patients. 
We next evaluated the extent of MCP1 activation within the human biopsies. Our analysis did not 
show any significant correlation between the chemokine transcription and the ΔFS score (Fig. 13B). 
Accordingly, the monocytes recruitment was unchanged in the two cohorts of patients, as 
demonstrated by the analysis of the monocytic Iba1 marker (Fig. 13C). Nevertheless, in line with 
our preclinical observation (Vallarola et al., 2018), we recorded an increased infiltration of activated 
macrophages in the skeletal muscle of slow progressing ALS patients as demonstrated by the 




inverse correlation between the expression level of the CD68 phagocytic marker and the ΔFS score 
(Fig. 13D).  
 
Figure 13: Bivariate analysis to measure the strength of association between the muscular expression of Musclin (A), MCP1 
(B), Iba1 (C), CD68 (D), CD206 (E) and iNOS (F) and the ΔFS score of ALS patients. Data were analysed by non-parametric 
Spearman rank correlation. 
Preclinical evidence showed that the phenotypic macrophage switching (M1->M2) is a fundamental 
step to trigger and achieve the tissue regeneration upon an injury (Arnold et al., 2007; Patsalos et 
al., 2017). Therefore, we characterised the macrophages inflammatory fingerprint in the skeletal 
muscles of fast and slow progressing ALS patients analysing the expression of the mannose receptor 
(CD206) and the inducible nitric oxide synthase (iNOS), as markers of the M2 and M1 macrophage 
polarisation, respectively (Novak and Koh 2013). The data obtained revealed an inverse relationship 
between the expression of the M2 marker CD206 and the speed of the disease progression (Fig. 
13E). Specularly, the expression of the M1 marker iNOS positively correlated with the faster disease 
progression of human ALS (Fig. 13F).  
4.4 DISCUSSION 
ALS is a neuromuscular disease. Indeed, the most common symptoms that appear in both familial 
and sporadic patients are muscle weakness, twitching, and cramping, which eventually can lead to 




the impairment of muscles function (Wijesekera and Leigh 2009). However, the contribution of 
skeletal muscle in nourishing the degenerative phenomenon of ALS is still elusive.  
Recent evidence highlighted the pivotal role of leucocytes, particularly macrophages, in governing 
and promoting the regenerative response of the skeletal muscle upon acute injury (Tidball 2017; 
Howard et al., 2020; Chazaud 2020). However, the contribution of the peripheral immune response 
has been so far underestimated in ALS, although immune cells infiltration has been reported within 
the skeletal muscle of both ALS patients and disease models (Jensen et al., 2016; Chiu et al., 2009). 
For the first time, here we reported an inverse correlation between the speed of the disease 
progression and the extent of CD68+ activated macrophages within the skeletal muscles of ALS 
patients, suggesting the protective role of these immune cells even during the chronic damage 
occurring in ALS. Nevertheless, we did not find any difference between the two cohorts of patients 
in the expression of MCP1 chemokine, indicating that the extent of haematogenous monocyte 
recruitment was unchanged between fast and slow progressing ALS patients.  
Noteworthy, our analysis sustains the preclinical evidence describing the phenotypic transition 
(M1->M2) of macrophages as a fundamental step to promote the muscle healing upon an acute 
injury (Arnold et al., 2007; Patsalos et al., 2017). Indeed, the CD206 anti-inflammatory marker was 
highly expressed in the skeletal muscle of slow progressing ALS patients. In contrast, the infiltrated 
macrophages of fast progressing patients exhibited a proinflammatory fingerprint as demonstrated 
by the higher expression of iNOS. Accordingly, the activation of the musclin myokine was higher in 
the slow progressing ALS patients, indicating a preservation of the skeletal muscle compared with 
fast progressing patients. 
Although preliminary, this evidence shed light on the importance of the peripheral immune 
response in counteracting the progressive degeneration occurring within ALS skeletal muscles. 
Moreover, given the accessibility in the collection of the muscular bioptic samples, even 
longitudinally in the disease course, the analysis of the immune muscle profile might be useful as a 
clinical adjunct in the prognostic evaluation of ALS patients.



















Selection of the best route of administration of the 
scAAV9_GFP vector to target the motor unit in ALS mice 
 
 




5.1 BACKGROUND and AIM 
Therapeutic gene delivery to the CNS is a significant challenge for the treatment of 
neurodegenerative diseases (Joshi et al., 2017). Accordingly, the first step of this project was to 
select the best route of administration of the viral vector to obtain an efficient and accurate 
induction of MCP1 chemokine in ALS mice. Indeed, our preliminary evidence demonstrated that 
the MN of ALS mice expresses immune molecules (among which MCP1) and that their upregulation 
is more prominent in the animal model characterised by the slower disease progression (i.e. C57 
SOD1G93A) (Nardo et al. 2013). Moreover, according to the previous evidence demonstrating the 
importance of the MCP1/CCR2 axis in promoting the macrophages recruitment and thus the nerve 
regeneration upon injury (Siebert et al., 2000; Zigmond and Echevarria 2019), we recorded a 
significant expression of the chemokine alongside the motor axons of the slow progressing 
compared with fast progressing SOD1G93A mice (Nardo et al., 2016b). This evidence depicts the 
pivotal role of the central and peripheral immune response, particularly that mediated by the MCP1 
chemokine, in regulating the speed of the disease progression of ALS mice.  
Among the viral vectors available, we selected the self-complementary Adeno-Associated Virus 
(scAAV) which we believe is superior to other recombinant AAV for several properties including i) 
no need to convert a single-stranded genome in a double-stranded prior to expression, ii) stability, 
iii) efficient nuclear transport and iv) high gene expression (McCarty 2008). Notably, scAAV is the 
transfer vehicle with the most potential use in therapies of neuromuscular disorders with non-
existent treatment options because of its safety profile and efficiency at transducing a wide range 
of cell types (Chtarto et al., 2013; Deverman et al., 2018). Among serotypes, we selected the scAAV9 
because of its higher transduction efficiency in neurons through different routes of delivery (Li and 
Snider 2018; Dayton et al., 2012). 
Based on recent evidence concerning the use of the AAV-mediated gene therapy in 
neurodegenerative diseases (Benkhelifa-Ziyyat et al., 2013; Duque et al., 2009; Foust et al., 2013; 
Perez et al., 2020), we tested the most commonly used routes of administration: a CNS-direct 




delivery, i.e. intracerebroventricular (i.c.v.) injection, and systemic delivery, i.e. intramuscular (i.m.) 
injection.  
5.2 EXPERIMENTAL DESIGN 
To test the i.c.v. and i.m. routes of administration, the two strains of SOD1G93A mice were treated 
with the vector opportunely engineered with the enhanced Green Fluorescent Protein reporter 
gene sequence (scAAV9_GFP) (purchased by Virovek Inc., as described in section 3.3.1) under CMV 
(cytomegalovirus) promoter to analyse the transduction efficiency and the distribution within the 
mouse body compartments.  
For the evaluation of the transduction efficiency following the CNS-direct administration, ALS mice 
(n=6 per group) underwent i.c.v. injection of 4.48x1012vg/μL scAAV9_GFP at postnatal day 1 (P1) 
(Glascock et al., 2011; Gholizadeh et al., 2013) and the histological and molecular analyses of tissues 
were performed six weeks after the treatment.  
Conversely, to increase its translatability to the clinical practice, the i.m. injection was tested in 
adult SOD1G93A mice (n=6 per group) before the symptom onset. Mice underwent a single bilateral 
i.m. injection of a lower dose of scAAV9_GFP (2.18x1010vg/μL) to reduce the immunogenicity 
deriving from the systemic administration (Gruntman et al., 2013). The scAAV9_GFP was injected 
in both hindlimb (Gastrocnemius Caput Medialis, GCM; Tibialis Anterior, TA and Gluteus Maximus, 
GM) and forelimb (Triceps Brachii, TB) muscles to target most segments of the spinal cord and 
relative MNs (Tosolini et al., 2013; Mohan et al., 2014). Mice were treated at 10 weeks of age and 
the analyses were performed three weeks later. 





Figure 14: Experimental schedule of i.c.v. and i.m. injection of scAAV9_GFP in fast and slow progressing SOD1G93A mice. 
5.3 ANALYSIS OF GFP EXPRESSION ALONGSIDE THE MOTOR UNIT OF FAST 
AND SLOW PROGRESSING ALS MICE 
5.3.1 ANALYSIS OF GFP EXPRESSION IN THE CENTRAL AND PERIPHERAL NERVOUS 
SYSTEM  
To verify whether both routes of administration of scAAV9_GFP were able to transduce MN 
efficiently, the expression levels and the cellular distribution of the reporter gene were analysed in 
the CNS of ALS mice. According to previous evidence (Dirren et al. 2014; Benkhelifa-Ziyyat et al. 
2013), both routes of administration tested were able to reach the CNS as demonstrated by the 
strong GFP expression recorded in the spinal cord of treated mice compared with the control group 
(untreated mice) (Fig. 15A-D, Fig. 16A-D’). However, the histological analysis performed showed 
that the i.m. injection of scAAV9_GFP specifically transduced the MN soma, as confirmed by the 
absent colocalisation between the reporter gene and astroglial markers (Fig. 16C-D’). Conversely, 
the CNS-direct delivery led to the transduction of both MNs and glial cells (Fig. 15D). 





Figure 15: Analysis of Green Fluorescent Protein (GFP) expression in the CNS and PNS of fast and slow progressing ALS 
mice following i.c.v. injection of scAAV9_GFP. (A, B, E, F) Representative immunoblot analysis of GFP in the spinal cord (A, 
B), sciatic (E) and radial (F) nerve of treated (GFP) and untreated (UT) mice (C+T, cervical and thoracic spinal cord; L, 
lumbar spinal cord; SN, sciatic nerve; RN, radial nerve; GFP). (C, D, G) Immunohistochemistry analysis of GFP expression in 
the spinal cord and sciatic nerve of ALS mice. Following i.c.v. treatment, GFP colocalised with motor neurons (NT, 
neurotrace) (C), microglia (CD68) (D) and motor axon (NF200, neurofilament) (G) Scale bar=20µm.  
ALS is a multisystemic disease and it has been recently defined as distal axonopathy (Moloney et 
al., 2014). Accordingly, recent evidence illustrated the importance of the PNS immune response in 
the disease progression of ALS patients (Schreiber et al., 2019). Moreover, we have recently 
demonstrated that the ability at activating the MCP1 pathway and recruiting immune cells within 
damaged nerves significantly influenced the speed of the disease progression in the SOD1G93A model 
(Nardo et al., 2016b).  
Therefore, we analysed the ability of the two delivery systems to target the motor axons. The 
western blot and immunohistological analysis showed a strong GFP expression within the sciatic 
and radial nerves of treated mice compared with the control group following both i.c.v (Fig. 15E-G) 
and i.m. (Fig. 16E-G) administration of scAAV9_GFP, confirming the ability of the viral vector to 
move along motor axons anterogradely (i.c.v injection) or retrogradely (i.m. injection), respectively 
(Castle et al., 2016).  





Figure 16: Analysis of the Green Fluorescent Protein (GFP) expression in the CNS and PNS of fast and slow progressing ALS 
mice following i.m injection of scAAV9_GFP. (A, B, E, F) Representative immunoblot analysis of GFP in the spinal cord (A, 
B), sciatic (E) and radial (F) nerve of treated (GFP) and untreated (UT) mice (C+T, cervical and thoracic spinal cord; L, 
lumbar spinal cord; SN, sciatic nerve; RN, radial nerve). (C-D’, G) Immunohistochemistry analysis of GFP expression in the 
spinal cord and sciatic nerve of ALS mice. Following i.m treatment, GFP is specifically expressed by motor neurons and 
motor axons (NF200, neurofilament) (G), but not astrocytes (GFAP) (C, C’) and microglia (CD68) (D, D’). C’, D’ and G Scale 
bar= 50µm; C and D scale bar= 100µm. 
5.3.2 ANALYSIS OF GFP EXPRESSION IN THE PERIPHERAL ORGANS OF ALS MICE 
Muscle weakness is considered the cardinal sign of ALS that appears before MN death. A debate 
still exists as to whether denervation originates from the neuron or the muscle (Dadon-Nachum et 
al., 2011; Dobrowolny et al., 2008) and regarding the involvement of muscle remodelling as an actor 
in ALS progression (Jensen et al., 2016). Moreover, MCP1 chemokine seems to be pivotal in 
regulating the regeneration of skeletal muscle (Shireman et al., 2007). Thus, verifying the capability 
of the two scAAV9 administration routes herein tested to target the skeletal muscles represents 
also a fundamental goal for the overall aim of this project.   
As previously reported (Riaz et al., 2015), we confirmed the ability of the i.m. injection of 
scAAV9_GFP to transduce the muscle fibres significantly (Fig. 17C-F). Conversely, following i.c.v 




injection we did not record any GFP signal in the TA and TB muscles, indicating the inability of the 
viral vector at transducing muscle fibres once injected in the CNS (Fig. 17A, B, E, F). 
 
Figure 17: Analysis of the Green Fluorescent Protein (GFP) expression in the Tibialis anterior (TA) and Triceps Brachii (TB) 
muscle of fast and slow progressing ALS mice following the i.c.v and i.m injection of scAAV9_GFP (GFP, scAAV9_GFP 
treated; UT, untreated). Representative immunoblot and confocal micrographs of the GFP expression in the TA and TB 
muscle following i.c.v (A, B, E, F) or i.m. (C, D, E, F) injection of the scAAV9_GFP. Scale bar= 100µm. 
Recent evidence reported that scAAV9 exhibits a specific tropism toward neurons, muscle, liver and 
lung (Castle et al., 2016). To avoid the manifestation of secondary side effects following the 
induction of a proinflammatory chemokine in whole mouse body, we analysed the GFP expression 
in the liver and lung. As shown in Figure 18, we did not record any GFP signal within lung either 
following i.c.v or i.m. injection of the scAAV9_GFP (Fig. 18B, C). Conversely, according to previous 
evidence (Dirren et al., 2014), the scAAV9 exhibited a great tropism toward the liver (Fig. 18A, D). 
Notably, our analysis revealed higher GFP expression in the liver following i.c.v compared with i.m. 
administration (Fig. 18E). 





Figure 18: Representative immunoblot analysis of the Green Fluorescent Protein (GFP) expression in the liver and lung of 
fast and slow progressing ALS mice following the i.c.v (A, B) and i.m (C, D) injection of scAAV9_GFP (GFP, scAAV9_GFP 
treated; UT, untreated). (E) The densitometric analysis revealed a higher expression of the reporter gene in the liver of i.c.v 
treated compared with i.m. treated mice (n=6 per group). 
5.4 DISCUSSION 
The targeting of CNS is the major challenge for the application of gene therapy to 
neurodegenerative diseases (Joshi et al., 2017; Walthers and Seidlits 2015).  
Here, two innovative gene delivery protocols have been tested with the aim to target the entire 
motor unit in SOD1G93A mice. 
The data collected from the analysis of the GFP expression showed that, although the i.c.v. injection 
of scAAV9_GFP efficiently transduced the nervous system, the use of a promoter non-specific for 
the MNs (i.e. CMV promoter) led to the targeting also of glial cells, which are one of the primary 
sources of neurotoxic pro-inflammatory factors (including MCP1) in the CNS (Sargsyan et al., 2009). 
Conversely, the i.m. administration of scAAV9_GFP led to the specific transduction of MN perikarya 
and axons, avoiding the targeting of astroglia.  
Notably, the CNS-direct administration of scAAV9_GFP was not able to transduce skeletal muscles. 
This deficit represents a black mark of this administration route compared with the i.m. injection 
since increasing evidence candidate the skeletal muscles as an emerging target for therapeutic 
interventions in ALS (Di Pietro et al., 2017; Loeffler et al., 2016; Shefner 2009; Musarò et al., 2019). 
Moreover, it has been reported the involvement of MCP1 and other inflammatory factors in 
triggering the muscle regeneration (Shireman et al., 2007; Martinez et al., 2010; Zhang et al., 
2014a), candidating the targeting of skeletal muscles as a fundamental goal of this project. 




Furthermore, the i.m. injection showed the lower intrinsic tropism of scAAV9 towards liver 
compared to the i.c.v administration (Castle et al., 2016), warding off the establishment of 
secondary side effects due to the undesired targeting. 
Finally, the i.m. injection of scAAV has proven effective in the adult mouse, thus increasing the 
translational potential of this experimental protocol to the clinical practice. 
In conclusion, the data herein collected designated the i.m. delivery as the optimal protocol to our 
purpose. Accordingly, the i.m. route of administration will be used for the induction of MCP1 
chemokine in both fast and slow progressing ALS mice. The effects derived from the treatment will 
be described in the next sections of this Thesis. 
 

















Evaluation of the effect of the i.m. injection of 
scAAV9_MCP1 on the disease progression and muscle 
impairment of fast and slow progressing ALS mice 
 




6.1 BACKGROUND and AIM 
MCP1 is considered one of the most potent inflammatory chemokine able to drive and exacerbate 
the phlogosis in several tissues (Gu et al., 1999). Although inflammation has so far considered a 
prejudicial process in the alteration of tissue homeostasis, it seems to be pivotal in wound healing 
and regeneration (Eming et al., 2017). 
In keeping with this, our previous data showed a higher MCP1 expression in slow progressing 
compared with fast progressing SOD1G93A ALS mice (Nardo et al. 2013; 2016b). Moreover, recent 
evidence reported a beneficial involvement of this inflammatory molecule within the main body 
compartments affected by ALS: MN (Locatelli et al., 2012; Conductier et al., 2010; Kwon et al., 
2015), axon (Deng et al., 2015; Liu et al., 2019b) and skeletal muscle (Shireman et al., 2007; Martinez 
et al., 2010; Lu et al., 2011a). 
Therefore, this project aimed to analyse whether the specific induction of MCP1 early in the disease 
is able to modify the disease progression and the pathological and molecular features in ALS mice. 
Particularly, in light of the higher MCP1 expression recorded in the MN soma and axons of slow 
progressing (C57 SOD1G93A) compared with fast progressing (129Sv SOD1G93A) ALS mice (Nardo et 
al. 2013; 2016b), this project aimed to investigate whether the sustained expression of the 
chemokine is sufficient to ameliorate the clinical outcome in C57 SOD1G93A mice and if the 
chemokine induction in the animal model characterised by the faint activation of this immune axis 
(i.e. 129Sv SOD1G93A) is effective to slow down the disease progression tangibly. 
6.2 EXPERIMENTAL DESIGN 
To induce the chemokine, a scAAV9 vector properly engineered with the murine sequence encoding 
for the MCP1 gene (scAAV9_MCP1) under the CMV promoter was purchased by Virovek Inc. (as 
described in section 3.3.1). 
The same protocol used for the i.m. injection of scAAV9_GFP (paragraph 5.2) was applied to induce 
MCP1 in the two ALS models. Fast (n=12) and slow (n=10) progressing ALS mice underwent a single 
bilateral i.m. injection of 2.18x1010vg/μL scAAV9_MCP1 in both hindlimb (TA, GCM and GM) and 




forelimb (TB) muscles (10μL per muscle) at 8 weeks of age (pre-symptomatic stage of the disease). 
An empty vector was used as control.  
To evaluate the effect of MCP1 induction on the disease onset and progression, behavioural tests 
were performed starting from 8 weeks until the symptomatic stage of the disease (i.e. 17weeks, 
fast progressing 129Sv SOD1G93A mice; 20weeks, slow progressing C57 SOD1G93A mice). 
 
Figure 19: Experimental schedule of i.m. injection of scAAV9_MCP1 in fast and slow progressing SOD1G93A mice. 
6.3 ANALYSIS OF THE EFFECT OF MCP1 INDUCTION ON THE MOTOR 
IMPAIRMENT AND DISEASE PROGRESSION OF FAST AND SLOW 
PROGRESSING ALS MICE 
Aimed to assess whether MCP1 induction could have any effect on the determination of the disease 
onset and progression, the muscle force impairment and the weight loss were monitored twice a 
week in ALS mice starting from 8 weeks of age until their respective symptomatic stage of the 
disease. 
In both ALS models, the MCP1 induction did not exert any significant effect in terms of body weight 
loss compared to the control group (Fig. 20A, B), suggesting that neither the i.m. injection of scAAV9 
nor the induction of a pro-inflammatory chemokine within motor unit causes any macroscopic 
adverse effect in SOD1G93A mice.  
Surprisingly, the behavioural analysis showed a different effect of the treatment on the motor 
ability of the two ALS strains. Although the treatment did not modify the disease onset of fast 




progressing mice (Empty 14.3±1.6 weeks, MCP1 13.5±1.4 weeks; p=0.3455) (Fig. 20C), we recorded 
a worsening of the motor performance in the scAAV9_MCP1 treated mice compared with the 
control group in the later stage of the disease (Fig. 20B).  
 
Figure 20: Behavioural analysis of fast progressing (A-C) and slow progressing mice (D-F) treated i.m. with scAAV9_MCP1 
compared with the control group (empty vector) (n=12/group, 129Sv SOD1G93A mice; n=10/group, C57 SOD1G93A mice). 
The i.m. injection of scAAV9_MCP1 did not affect the body weight in both strains of ALS mice (A, D). The scAAV9_MCP1 
injection increased the muscle force impairment in the fast progressing mice (B), while improved the motor performance 
of the slow progressing mice (E). Data are reported as mean±SEM for each time point. °p< 0.05 EMPTY Vs MCP1 by 
repeated-measures ANOVA with Sidak’s post-analysis. The scAAV9_MCP1 injection did not modify the onset of the disease 
in fast progressing mice (C), while postponed the appearance of the muscle force deficit in slow progressing mice (F). Data 
are expressed as mean±SEM by Mantel-Cox Log Rank Test. 
Conversely, in slow progressing mice, the chemokine induction significantly slowed down the 
disease course. Indeed, in the scAAV9_MCP1 treated mice, we recorded an amelioration of the 
motor ability since the early phase of the disease (Fig. 20E), and this resulted in the postponement 
of the motor symptom onset of ~2weeks compared with the control group (Empty 16±2.5 weeks, 




MCP1 18.6±1.2 weeks; p=0.0088) (Fig. 20F). Notably, the induction of a pro-inflammatory 
chemokine did not basally affect animals' motor performance, as demonstrated by the ability of 
both strains of non-transgenic scAAV9_MCP1 treated mice to pass the behavioural test throughout 
the analysis (Fig. 20B, E). 
6.4 VALIDATION OF MCP1 INDUCTION IN THE SKELETAL MUSCLES OF FAST 
AND SLOW PROGRESSING ALS MICE  
To assess whether the different clinical outcome observed in the two ALS mice following the 
treatment was directly associated to the induction of MCP1 and not the result of an intrinsic 
variability of each mouse strain to the scAAV9 vector (He et al., 2019), the transcription level of the 
chemokine was evaluated in TA and TB muscles. As expected, MCP1 transcript was significantly 
upregulated within the skeletal muscles of both strains of SOD1G93A treated mice compared with 
their respective control groups, albeit to a lower extent in the forelimb compared with hindlimb 
muscles (Fig. 21). 
 
Figure 21: Real-Time PCR analysis of MCP1 transcript in the tibialis anterior (TA) and triceps brachii (TB) muscle of 129Sv 
SOD1G93A (A, B) and C57 SOD1G93A mice (C, D) compared with their respective non-transgenic (Ntg) littermates. Following 
scAAV9_MCP1 injection, the chemokine transcript resulted dramatically upregulated in treated mice compared with the 
control groups (Fold change vs Ntg TA muscle_129Sv SOD1G93A: 65.08±12.4 Empty, 757.1±208.5 MCP1; C57 SOD1G93A: 
2.97±0.2 Empty, 542.1±82.5 MCP1. Fold change vs Ntg TB muscle_129Sv SOD1G93A: 1.50±0.2 Empty, 42.31±9.7 MCP1; C57 
SOD1G93A: 1.87±0.4 Empty, 16.13±1.0 MCP1). Data are normalised to β-actin and expressed as mean±SEM (n=4 per 
experimental group). **p<0.01, ****p<0.0001 Ntg vs MCP1; °°p<0.01, °°°°P<0.0001 EMPTY vs MCP1 by ANOVA with 
Tukey’s post-analysis. 




6.5 ANALYSIS OF DENERVATION ATROPHY OF THE SKELETAL MUSCLES OF 
FAST AND SLOW PROGRESSING ALS MICE 
Aimed to characterise the different effect recorded in the motor performance of the two SOD1G93A 
models following MCP1 induction, we started our investigation from the skeletal muscles. In fact, 
besides being the injection site of scAAV9_MCP1, the impairment of skeletal muscles is an early 
event in the disease pathology (Loeffler et al., 2016; Campanari et al., 2016) pivotal in determining 
the motor ability and thus the overall survival of ALS mice. Therefore, the characterisation of the 
muscle atrophy and denervation could provide useful information about the different effect 
observed in fast and slow progressing SOD1G93A mice following MCP1 induction. 
Among the injected muscles of the hind limbs, we focused our attention on the TA muscle 
considering the higher percentage of fast-fatigable muscle fibres than the GCM (Lionikas et al., 
2005). Indeed, skeletal muscles of ALS patients and models show a progressive and irreversible 
metabolic switch from fast-glycolytic to slow-oxidative muscle fibres composition (Dobrowolny et 
al., 2018; Telerman-Toppet and Coërs 1978; Palamiuc et al., 2015). Therefore, the analysis of the 
TA muscle would have been more informative regarding the changes that occurred during the 
disease progression. In parallel, the attention was focused on the injected forelimbs TB muscle. 
The analysis of muscles weight did not show any difference in the TA muscle wasting between 
treated mice and control group in both strains of ALS mice (129Sv SOD1G93A: 27.5±4.1% Empty, 
35.6±5.1% MCP1; C57 SOD1G93A: 50.7±4.5% Empty, 52.7±4.7% MCP1) (Fig. 22A, B). Conversely, the 
forepaw muscle appeared protected in the C57 SOD1G93A (45.8±4.6% Empty, 33.4±3.2% MCP1) but 
not 129Sv SOD1G93A mice following the chemokine induction (22.2±4.8% Empty, 30.9±4.9% MCP1) 
(Fig. 22C, D). 





Figure 22: Analysis of the wasting of the tibialis anterior (TA) and triceps brachii (TB) muscles in 129Sv SOD1G93A (A, C) and 
C57SOD1G93A (B, D) mice. Data are expressed as mean±SEM (n=12 per group, 129sv SOD1G93A; n=10 per group, C57 
SOD1G93A) by unpaired t-test. 
Previous experiments have shown an alteration in the synthesis of the acetylcholine receptor 
(AChR) subunits during the denervation of the neuromuscular junction (NMJ), characterised by the 
replacement of the adult epsilon subunit (AChRε) with the foetal gamma subunit (AChRγ) (Rimer et 
al., 1997; Dobrowolny et al., 2011). Therefore, we analysed the transcription level of AChRγ in the 
TA and TB muscles of symptomatic ALS mice upon MCP1 induction as an index of NMJ denervation. 
The analysis revealed that the transcription level of AChRγ was significantly reduced by the 
scAAV9_MCP1 injection in the TA muscle of fast progressing mice (Fig. 23A). In contrast, no 
difference was recorded between treated and control C57 SOD1G93A mice within the hind limb 
muscle (Fig. 23B). Conversely, upon MCP1 induction, the forepaw muscle of 129Sv SOD1G93A mice 
was significantly denervated, whereas marked protection of the TB muscle NMJs was recorded in 
C57 SOD1G93A mice compared with their respective controls (Fig. 23C, D). 





Figure 23: Real-time PCR analysis of the gamma subunit of the acetylcholine receptor (AChRγ) in the tibialis anterior (TA) 
and triceps brachii (TB) muscles of 129Sv SOD1G93A (A, C) and C57 SOD1G93A mice (B, D). Data are normalised to βactin and 
expressed as mean±SEM (n=4 per experimental group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or 
MCP1; °° p<0.01, °°° p<0.001, °°°° p<0.0001 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
To better characterise the NMJ degenerative phenomenon in the two ALS strains upon MCP1 
induction, we next analysed the expression of the Neural Cell Adhesion Molecule (NCAM), a 
glycoprotein involved in neuron-muscle adhesion which is accumulated by denervated or paralysed 
skeletal muscle (Covault and Sanes 1985; Hegedus et al., 2007).  
The immunoblot analysis did not show any significant difference in the NCAM expression in the TA 
and TB muscles between the treated and control group in both strains of ALS mice (Fig. 24). 
However, upon MCP1 induction, the two strains of ALS mice showed an opposite trend in the NCAM 
expression, suggesting a different effect of the treatment in the muscular compartment of the two 
SOD1G93A models. Accordingly, the evaluation of the NMJ degenerative phenomenon assessing, the 
overlap between the pre-synaptic (stained with synaptic vesicle protein 2 and neurofilament) and 
post-synaptic (stained with fluorescent α-bungarotoxin) domain of the AChR (Sleigh et al. 2014) 
confirmed the immunoblot analysis (data not show). 





Figure 24: Representative immunoblot images of the Neural Cell Adhesion Molecule (NCAM) in the tibialis anterior (TA) 
and triceps brachii (TB) muscle extracts of 129Sv SOD1G93A (A) and C57 SOD1G93A mice (D). Densitometric analysis indicated 
a significant expression of NCAM in the TA muscle of both fast (B) and slow progressing (E) ALS mice compared with their 
respective Ntg littermates. No difference in the NCAM expression was recorded in the TB muscle of 129Sv strain (C). 
Conversely, NCAM resulted significantly expressed in the TB muscle of scAAV9(empty) but not scAAV9_MCP1 -treated C57 
SOD1G93A mice compared with the Ntg littermates (F). Data are expressed as mean±SEM (n=4 per experimental group). 
*p<0.05; ***p<0.001 Ntg Vs EMPTY or MCP1 by ANOVA with Tukey’s post-analysis. 
6.6 DISCUSSION 
MCP1 is a chemokine with a well know proinflammatory activity. However, recent evidence 
demonstrated its involvement in wound healing and regenerative processes (Deshmane et al., 
2009). This protective effect comes mainly from its chemoattractant capability toward 
macrophages (Oishi and Manabe 2018; Papa et al., 2018; Spiller and Koh 2017). Nevertheless, 
several pieces of evidence depicted a pleiotropic neuroprotective role of MCP1 when expressed by 
neuronal cells (Locatelli et al., 2012; Papa et al., 2018; Matsubara et al., 2015; Kwon et al., 2015).  
We have recently observed that MCP1 was less activated in 129Sv SOD1G93A mice at both central 
and peripheral level compared with C57 SOD1G93A mice, and this correlated with a faster and more 
aggressive disease progression (Nardo et al. 2013; 2016b). 
Base on this evidence, we tested the effect of early induction of MCP1 on the disease progression 
of fast and slow progressing ALS models. Unexpectedly, the treatment differently influenced the 
clinical phenotype of the two strains of ALS mice. In the C57 SOD1G93A mice, the MCP1 induction 
ameliorated the disease progression postponing the appearance of the muscle strength deficit. 




Conversely, in the fast progressing mice, the chemokine induction did not have any effect on the 
motor onset but led to a worsening of the clinical phenotype in the late phase of the disease. 
Intriguingly, although the chemokine transcription level was higher in the TB muscle of the fast 
progressing compared with the slow progressing mice upon the scAAV9_MCP1 injection (fold 
change 129Sv SOD1G93A: 42.3±9.7; fold change C57 SOD1G93A: 16.1±1.0), the forepaw muscle was 
protected from the denervation atrophy in the C57 but not in 129Sv SOD1G93A mice. 
Counterintuitively to the behavioural data and muscle wasting, the AChRγ transcript analysis 
suggested a reduced NMJs denervation in the TA muscle of 129Sv but not C57 SOD1G93A mice upon 
MCP1 induction. Nevertheless, the histological and western blot analyses did not reveal any 
difference in terms of NMJs denervation in the two experimental groups either of fast or slow 
progressing ALS mice. The opposite result recorded between the gene expression and 
histological/western blot analysis might derive from a background-related difference in the 
turnover of the AChR subunits during the disease progression of two ALS models (Rudolf et al., 
2013; 2014). However, further assessment will be necessary to clarify this discrepancy. Intriguingly, 
preliminary data obtained in our laboratory showed lower transcription of the adult AChRε and 
reduced response to the acetylcholine neurotransmitter of the TA muscle NMJs of fast progressing 
compared with slow progressing ALS mice, which could partly explain the opposite effect recorded 
in the skeletal muscles analysis of the two ALS strains upon MCP1 induction. However, the 
investigation of the AChR subunits rearrangement between the two SOD1G93A models is part of 
another project of our laboratory; therefore, it has not been further examined in this context. 
Altogether, these data suggest that the effect (beneficial or detrimental) deriving from the MCP1 
induction is strictly dependant from the genetic background of the SOD1G93A models. Understanding 
which factors are implicated in such controversial results might pave the way to identify potential 
biomarkers useful to drive a specific therapy in ALS patients.  
Besides, the feeble effect of the chemokine on the NMJs innervation despite its significant 
upregulation in the TA muscle of both murine strains (fold change 129Sv SOD1G93A: 757.1±208.5; 
fold change C57 SOD1G93A: 542.1±82.5) might be due to the temporal and regional involvement of 




hindlimbs compared to forelimbs in the pathoprogression of SOD1G93A mice (Beers et al., 2011b; 
Capitanio et al., 2012; Clark et al., 2016; Nardo et al., 2018). Indeed, it is well known that the mSOD1 
murine model is characterised by ascending paralysis, which mainly affects hindlimbs and, 
afterwards, the forelimbs (Gurney et al., 1994; Bruijn et al., 1997). Accordingly, it is possible that 
the differential biomolecular effect resulting from the chemokine induction in the hind paws 
muscles of the two ALS strains was no more detectable at the symptomatic stage. To confirm this 
hypothesis, in the next section of this Thesis, we deeper investigated the mechanism of action 
resulting from the scAAV9_MCP1 injection in the lower motor units of ALS mice. 
 

















Mechanism of action of MCP1 induction in fast and 
slow progressing ALS mice: 
 focus on the lower motor units 
 




7.1 BACKGROUND and AIM 
Recent observations have demonstrated the pivotal effect of MCP1-mediated phlogosis in wound 
healing and regenerative processes (Eming et al., 2017). Furthermore, it has been shown the 
beneficial involvement of this inflammatory chemokine within the main body compartments 
affected by ALS: MN (Locatelli et al., 2012; Conductier et al., 2010), motor axon (Deng et al., 2015; 
Liu et al., 2019b) and skeletal muscle (Shireman et al., 2007; Martinez et al., 2010; Lu et al., 2011a). 
Given the capability of the experimental protocol herein used at transducing the entire motor unit 
of ALS mice, as demonstrated by the specific transduction of skeletal muscles, nerves and MN soma 
following the single i.m. injection of scAAV9_GFP (Chapter V), this part of the project aimed at 
analysing the effect of MCP1 induction in the lower motor units of fast and slow progressing ALS 
mice, which are the first affected by the disease (Clark et al., 2016; Beers et al., 2011b; Capitanio et 
al., 2012; Nardo et al., 2018). 
7.2 EXPERIMENTAL DESIGN 
An extensive histological and biochemical/molecular analysis was done at TA muscle, sciatic nerve 
and lumbar spinal cord level to characterise the indirect (mediated by the recruitment of the 
immune cells) and direct (pleiotropic) effect of MCP1 induction on the clinical outcome of fast and 
slow progressing ALS mice. 
7.3 FOCUS ON THE TIBIALIS ANTERIOR MUSCLE 
Muscles are the first compartment affected by the disease in both patients and ALS models 
(Pansarasa et al., 2014). In light of the pivotal role of the immune response in muscle regeneration 
(Peake et al., 2017) and thus in governing the speed of disease progression of SOD1G93A mice (Nardo 
et al., 2016b; Vallarola et al., 2018), the first step of this project was the characterisation of the 
biomolecular alterations occurred in the TA muscles of the two ALS models following the induction 
of MCP1 chemokine. 
 




7.3.1 ANALYSIS OF THE INFILTRATION OF IMMUNE CELLS FOLLOWING MCP1 
INDUCTION  
The acute pro-inflammatory signalling and immune cell infiltration are the initial phase of muscle 
response to injury, in which the recruitment of the inflammatory cells appears to be critical for 
successful regeneration (Kharraz et al., 2013). Among the infiltrated inflammatory cells, monocytes 
and macrophages are pivotal in this process (Summan et al., 2006; Chazaud 2020). 
Multiple evidence correlates the protective effect of the MCP1-mediated inflammation to its 
chemoattractant activity toward immune cells (Oishi and Manabe 2018; Spiller and Koh 2017), 
particularly on monocytes/macrophages. The temporal and spatial recruitment of macrophages 
represents a critical step to the muscle response to injury. Indeed, it has been demonstrated that 
the inhibition of the accumulation of monocytes/macrophages within injured muscles strongly 
impairs the regenerative response (Summan et al., 2006; Lu et al., 2011a). 
Accordingly, we started our investigation from the analysis of the extent of macrophages infiltration 
in the TA muscle of fast and slow progressing mice following scAAV9_MCP1 i.m. injection. 
 
Figure 25: (A, C) Confocal micrographs of longitudinal sections of tibialis anterior muscle of 129Sv SOD1G93A (A) and C57 
SOD1G93A mice (C) stained with the phagocytic marker CD68 and DAPI (nucleus). Imaging analysis revealed a significant 
increase of macrophages recruitment in fast progressing (B) but not in slow progressing (D) ALS mice following 
scAAV9_MCP1 injection. Data are expressed as mean±SEM (n=4 per experimental group). **p<0.01, ****p<0.0001 Ntg 
vs EMPTY or MCP1; °°p<0.01 EMPTY vs MCP1 by ANOVA with Tukey’s post-analysis. Scale bar= 100µm. 
 




Suitably to the significant upregulation of the chemokine (Fig. 21A, C), the analysis of the cells 
immunopositive for the CD68 phagocytic marker showed higher recruitment of macrophages 
within the TA muscle of fast progressing mice following MCP1 induction compared to controls (Fig. 
25A, B). Conversely, in the TA muscle of C57 SOD1G93A mice treated with the scAAV9(empty) we 
recorded significant recruitment of CD68+ macrophages compared to the non-transgenic 
littermates, immune responsivity that was not modified by the MCP1 induction (Fig. 25C, D). 
Although MCP1 preferentially recruit monocytes (Rollins 1997), CCR2 is also expressed on activated 
T lymphocytes (Bonecchi et al., 1998; Luther and Cyster 2001), which actively participates in the 
regenerative mechanisms of skeletal muscles (Yang and Hu 2018;  Zhang et al., 2014a; Deyhle and 
Hyldahl 2018). Therefore, we analysed the effect of MCP1 induction also on the recruitment of T 
cells within the TA muscle of the two ALS models. 
As with macrophages, CD4+ and CD8+ T cells showed a heightened infiltration in the TA muscle of 
scAAV9_MCP1-treated 129Sv SOD1G93A mice, and this occurred along with the increased levels of 
FoxP3 transcript, a marker of T regulatory (Treg) cells (Fig. 26A-C). Conversely, MCP1 induction did 
not modify the ability of slow progressing mice in also recruiting the T lymphocytes within the hind 
paw muscle (Fig. 26D-F).  
 
Figure 26: Real-Time PCR analysis of CD4, CD8 and Foxp3 transcripts in the tibialis anterior muscle of 129Sv SOD1G93A (A-
C) and C57 SOD1G93A mice (D-F) compared with their respective non-transgenic (Ntg) littermates. The scAAV9_MCP1 
injection increased the recruitment of T lymphocytes in fast progressing but not in slow progressing ALS mice. Data are 
normalised to β-actin and expressed as mean±SEM (n=4 per experimental group). **p<0.01, ***p<0.001, ****p<0.0001 
Ntg vs EMPTY or MCP1; °°°p<0.001, °°°°P<0.0001 EMPTY vs MCP1 by ANOVA with Tukey’s post-analysis. 




7.3.2 CHARACTERISATION OF THE MUSCULAR INFLAMMATORY MILIEU 
FOLLOWING MCP1 INDUCTION  
A large amount of evidence reported that the inflammation is pivotal at regulating the regenerative 
mechanisms of the skeletal muscle. Indeed, it participates to the activation of the prompt tissue 
response to damage, governing the concerted interaction of the numerous actors (e.g. resident and 
infiltrating immune cells, satellite cells) involved in this process (Yang and Hu 2018; Tidball 2017).  
However, the inflammatory milieu must be finely regulated as it represents a limiting step for the 
achievement of muscle regeneration and thus to return to tissue homeostasis (Howard et al., 2020; 
Musarò 2014; Urso 2013). Indeed, while the acute inflammation bridges from the muscle necrosis 
to the preparation of a strong response to injury (Rigamonti et al., 2013), its resolution is necessary 
to wound healing (Mann et al., 2011; Howard et al., 2020). To accomplish this regenerative 
mechanism within muscles, immune cells, particularly macrophages (Saclier et al., 2013b), must 
switch from the M1 (pro-inflammatory) to the M2 (anti-inflammatory) phenotype to establish a 
permissive milieu for wound healing (Rigamonti et al., 2014; Tidball et al., 2014; Arnold et al., 2007; 
Kharraz et al., 2013; Wang et al., 2014a). 
Therefore, we analysed the inflammatory milieu within the TA muscle of fast and slow progressing 
SOD1G93A mice following MCP1 induction to correlate its polarisation (M1 or M2) to the 
responsiveness of tissues to ALS damage.  
The data collected showed that the TA muscle of fast progressing treated mice was polarised 
toward a pro-inflammatory milieu, as demonstrated by the increased transcription of Tumour 
Necrosis Factor-alpha (TNFα) cytokine and the expression of gp91PHOX (heme-binding subunit of the 
NADPH oxidase) compared to the control group (Fig. 267-C). Conversely, upon MCP1 induction, in 
the TA muscle of C57 SOD1G93A treated mice we recorded a reduced expression of gp91PHOX and a 
trend in the downregulation of TNFα transcript compared with the scAAV9(empty) treated mice 
(Fig. 27D-F). 





Figure 27: Real-Time PCR analysis of TNFα transcript in the tibialis anterior muscle of 129Sv SOD1G93A (A) and C57 SOD1G93A 
mice (D) compared with their respective non-transgenic (Ntg) littermates. The scAAV9_MCP1 injection increased the 
transcription of TNFα in fast progressing but not slow progressing ALS mice. Data are normalised to β-actin and expressed 
as mean±SEM (n=4 per experimental group). Representative immunoblot images of gp91PHOX in the tibialis anterior muscle 
extract of 129Sv SOD1G93A (B) and C57 SOD1G93A mice (E) compared with their respective Ntg littermates. Densitometric 
analysis indicated that, following scAAV9_MCP1 injection, gp91PHOXexpression is increased in fast progressing (C) while it 
was reduced in slow progressing mice (F) compared with the control group. Data are expressed as mean±SEM (n=4 per 
experimental group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or MCP1; °p<0.05, °°p<0.01 EMPTY 
Vs MCP1 by ANOVA with Tukey’s post-analysis. 
However, we did not observe any significant difference in the expression of the anti-inflammatory 
marker Arginase 1 in the TA muscle of both fast and slow progressing treated mice compared with 
their respective control group of scAAV9(empty) treated animals (Fig. 28A, B, D, E). 
Recent evidence highlighted the involvement of the Insulin-like Growth Factor 1 (IGF1) in 
orchestrating muscle regeneration through the modulation of the macrophages switching from the 
M1 toward the M2 phenotype (Tonkin et al., 2015; Mourkioti and Rosenthal 2005; Lu et al., 2011b). 
Therefore, we analysed the effect of the treatment on the transcriptional level of IGF1 in both ALS 
strains. Surprisingly, a significant downregulation of IGF1 transcript was recorded in both SOD1G93A 
models upon scAAV9_MCP1 injection (Fig. 28C, F). 





Figure 28: Representative immunoblot images of Arginase 1 in the tibialis anterior muscle extract of 129Sv SOD1G93A (A) 
and C57 SOD1G93A mice (D) compared with their respective non-transgenic (Ntg) littermates. The densitometric analysis 
did not show any significant variation in the Arginase 1 expression in both strain of ALS mice upon scAAV9_MCP1 injection 
(B, E). Data are expressed as mean±SEM (n=4 per experimental group). Real-time PCR analysis of Insulin-like growth factor 
1 (IGF1) transcript in the tibialis anterior muscle of 129Sv SOD1G93A (C) and C57 SOD1G93A mice (F). Following scAAV9_MCP1 
injection, IGF1 transcript was significantly downregulated compared to the scAAV9(empty) treated animals in both strains 
of ALS mice. Data are normalised to β-actin and expressed as mean±SEM (n=4 per experimental group). *p<0.05 Ntg Vs 
EMPTY or MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
7.3.3 CHARACTERISATION OF THE EFFECT OF RECRUITED IMMUNE CELLS AND 
THEIR INFLAMMATORY PHENOTYPE ON THE SATELLITE CELL-MEDIATED RESPONSE 
FOLLOWING MCP1 INDUCTION 
Numerous evidence showed that myeloid lineage cells regulate the muscle wound healing through 
two inductive mechanisms: a mechanism that led to the establishment of a permissive milieu for 
regeneration (“permissive mechanism”) and an “instructive mechanism” that acts directly on 
myogenic progenitor cells (MPCs) (a.k.a. satellite cells) (Arnold et al., 2007; Cantini et al., 1994; 
Saclier et al., 2013b; Tidball 2017; Madaro et al., 2019; Dort et al., 2019; Ceafalan et al., 2018). The 
phagocytic M1 macrophages promote the activation and proliferation of satellite cells, while the 
final commitment to myocytes is supported by the M2 polarised macrophages (Kharraz et al., 2013; 
Oishi and Manabe 2018; Tidball et al., 2014; Tidball 2017). 
Besides macrophages, the adaptive immune response is pivotal in muscle regeneration. Indeed, 
considerable evidence showed that T lymphocytes are instrumental in the repair/regeneration 
process following severe muscle damage in mice (Castiglioni et al., 2015; Madaro and Bouché 2014; 




Deyhle and Hyldahl 2018). However, the role of T lymphocytes at influencing satellite cells response 
and/or modulating the inflammation occurring within damage site (i.e. the immunosuppressive 
activity of T reg cells) has yet to be elucidated (Deyhle and Hyldahl 2018).  
Given the close relationship between immune cells recruitment and MPCs activation, we evaluated 
the extent of the satellite cell-mediated response analysing the expression of two critical myogenic 
transcription factors: Paired box protein 7 (Pax7), the hallmark of satellite cells stemness (Mauro 
1961), and Myogenin (MyoG), a marker of early commitment and differentiation (Cornelison and 
Wold 1997).  
 
Figure 29: Representative immunoblot images of Pax7 and Myogening (MyoG) in the tibialis anterior muscle extracts of 
129Sv SOD1G93A (A) and C57 SOD1G93A mice (D) compared with their respective non-transgenic (Ntg) littermates. The 
densitometric analysis did not show any significant variation in the expression of the satellite cells transcriptional factors 
in both strains of ALS mice. Data are expressed as mean±SEM (n=4 per experimental group). *p<0.05, **p<0.01 Ntg Vs 
EMPTY or MCP1 by ANOVA with Tukey’s post-analysis. 
Although in the TA muscle of the fast progressing scAAV9(empty) treated mice the expression level 
of both Pax7 and MyoG was significantly increased compared to the non-transgenic littermates, the 
satellite cell-mediated response was not modified by the MCP1 induction (Fig. 29A-C). Similarly, 
MyoG, but not Pax7, was significantly increased in the hind paw muscle of scAAV9(empty) treated 
mice compared with the non-transgenic littermates; however, the chemokine induction did not 
affect the extent of the MPCs activation also in the slow progressing mice (Fig. 29D-F). This evidence 
suggests that, at the symptomatic stage of the disease, the recruitment and fingerprint of immune 




cells within hindlimb skeletal muscles is pointless to the regenerative response of myofibers in ALS 
mice. 
7.4 FOCUS ON THE SCIATIC NERVE 
Growing evidence suggests that distal axonal degeneration begins very early in the ALS course, long 
before symptom onset and MN death (Clark et al., 2016; Fischer and Glass 2007; Fischer et al., 
2004). Indeed the Wallerian degeneration, a well-orchestrated morphologic and biochemical 
changes which involve the activation of Schwann cells (SCs) and immune cells, is a pathological 
feature recorded in both ALS models and patients (Deng et al., 2018; Gentile et al., 2019; Tian et 
al., 2016; Clark et al., 2016). 
We have previously demonstrated that the extent of immune responses in the peripheral axons is 
pivotal in governing the speed of the disease progression of SOD1G93A mice (Nardo et al., 2016b). 
Particularly, recruited immune cells (e.g. macrophages, T cells) cooperate to remove cellular debris 
creating a favourable milieu for axon repair and regeneration (Gaudet et al., 2011; Jessen and 
Mirsky 2016; Ydens et al., 2013). 
Based on the retrograde transduction of the engineered scAAV9 following the i.m. injection 
(Chapter V), the following step of this project was the analysis of the sciatic nerve of the two ALS 
models following MCP1 induction, paying specific attention to the immune-mediated response in 
axonal regeneration.  
7.4.1 VALIDATION OF MCP1 INDUCTION AND IMMUNE CELLS INFILTRATION  
The recruitment of immune cells is a fundamental step to achieve a successful axonal regeneration 
(Barrette et al., 2008; Liu et al., 2019b; Moalem et al., 1999; Hu and McLachlan 2002). Moreover, it 
has been demonstrated a pivotal role of the MCP1-mediated pathway in facilitating the recovery 
after an axonal injury (Zigmond and Echevarria 2019).  
Accordingly, we first verified the chemokine induction and the resulting immune cells infiltration 
within the sciatic nerve of the two ALS models following scAAV9_MCP1 i.m. injection. 




Consistently with previous evidence (Deng et al., 2018), MCP1 and CD68 transcripts resulted 
upregulated in both strains of scAAV9(empty) treated mice compared with their respective non-
transgenic littermates (Fig. 30A, B, D, E). However, our analysis revealed increased recruitment of 
cytotoxic T lymphocytes in the sciatic nerve of slow progressing but not fast progressing 
scAAV9(empty) treated mice, as demonstrated by the different modulation of the CD8 transcript 
(Fig. 30C, F). Intriguingly, in the 129Sv SOD1G93A mice the scAAV9_MCP1 i.m. injection increased the 
transcription level of the chemokine (Fig. 30A), promoting the infiltration of CD8+ T cells without 
affecting the extent of macrophage recruitment within the sciatic nerve (Fig. 30B, C). Conversely, 
in the slow progressing mice, the treatment did not induce a further increase in the MCP1 
transcription (Fig. 30D). Noteworthy, the infiltration of macrophages, but not T cells, was 
significantly reduced in the sciatic nerve of C57 SOD1G93A treated mice compared with the control 
group (Fig. 30E, F). 
 
Figure 30: Real-Time PCR analysis of MCP1, CD68 and CD8 transcripts in the sciatic nerve of 129Sv SOD1G93A (A-C) and C57 
SOD1G93A mice (D-F) compared with their respective non-transgenic (Ntg) littermates. The scAAV9_MCP1 injection 
increased the transcription of MCP1 (A) and CD8 (C), but not CD68 (B) in the fast progressing mice compared with the 
scAAV9(empty) control. In the slow progressing mice, the treatment did not modify the transcription levels of MCP1 (D) 
and CD8 (F), while it downregulated the CD68 mRNA (E) compared with the scAAV9(empty) control. Data are normalised 
to β-actin and expressed as mean±SEM (n=3 per group 129Sv; n=4 per group, C57). *p<0.05, **p<0.01, ****p<0.0001 Ntg 
Vs EMPTY or MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
It has been demonstrated that, besides damaged motor axons (Perrin et al., 2005), also injured 
dedifferentiated (non-myelinating) Schwann cells release proinflammatory cytokines, including 
MCP1 (Ydens et al., 2013), and can acquire a macrophagic phenotype following a nerve injury 




(Reichert et al., 1994; Nardo et al., 2016b). Consistently we cannot exclude that the difference in 
the transcription levels of MCP1 and CD68 recorded in the two SOD1G93A strains following the 
scAAAV9_MCP1 i.m. injection could derive from a different SCs-mediated response at the 
symptomatic stage of the disease.  
7.4.2 ANALYSIS OF THE INFLAMMATORY MILIEU  
The studies performed illustrated the relevance of a fine-tuned spatiotemporal expression of 
cytokines/chemokines in the context of peripheral nerve regeneration (Chen et al., 2015b; Dubový 
et al., 2013; Büttner et al., 2018). Therefore, we characterised the inflammatory milieu within the 
sciatic nerve of the two ALS strains following scAAV9_MCP1 injection.  
The MCP1-mediated immune cells infiltration triggered the inflammation in the nerve of fast 
progressing mice, as demonstrated by the upregulation of TNFα (Fig. 31A). Specularly, the reduced 
immune cells infiltration observed in C57 SOD1G93A mice following MCP1 induction, translated in a 
significant downregulation of TNFα compared with the scAAV9(empty) treated mice (Fig. 31B). 
 
Figure 31: Real-Time PCR analysis of TNFα transcript in the sciatic nerve of 129Sv SOD1G93A (A) and C57 SOD1G93A mice (B) 
compared with their respective non-transgenic (Ntg) littermates. The scAAV9_MCP1 injection upregulated the TNFα 
transcript in fast progressing mice compared with the Ntg littermates. Conversely, the treatment significantly reduced the 
transcription of TNFα in slow progressing mice compared with the scAAV9(empty) treated mice. Data are normalised to 
β-actin and expressed as mean±SEM (n=3 per group 129Sv; n=4 per group, C57). *p<0.05, **p<0.01 Ntg Vs EMPTY or 
MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
7.4.3 ANALYSIS OF NERVES AND SCHWANN CELL-MEDIATED RESPONSE  
The axonal deterioration is an early event in the pathology of SOD1G93A mice (Clark et al., 2016) that 
occurs prior than the degeneration of myelin and Schwann cells (Deng et al., 2018). Notably, it has 
been reported the MCP1 is pivotal at sustaining the PNS regeneration after injury (Zigmond and 
Echevarria 2019; Niemi et al., 2016).  




Therefore, we investigated the effect of the early induction of MCP1 on the maintenance of motor 
axon structure and function. The expression of neurofilament (NF200), the main constituent of the 
axonal cytoskeleton (Lee and Shea 2014), and β-importin, a karyopherin involved in transducing 
damage signals from the axons of injured neurons back to the cell body (Hanz et al., 2003), were 
analysed in the sciatic nerve of the two strains of SOD1G93A mice. 
The immunoblot analysis showed that MCP1 induction did not modify the retrograde injury 
signalling in both strains of ALS models, as demonstrated by the unchanged expression level of β-
importin compared with the respective scAAV9(empty) treated animals (Fig. 32A-D). Notably, the 
chemokine induction led to full maintenance of the structural integrity of motor axons in slow 
progressing mice, given the unchanged expression of NF200 in scAAV9_MCP1 treated mice 
compared with non-transgenic littermates (Fig. 32G, H). Conversely, in fast progressing mice, which 
are characterised by a higher impairment of sciatic nerve compared with C57 SOD1G93A mice (Nardo 
et al., 2016b), the early induction of MCP1 was not sufficient to significantly protect the axonal 
structure from ALS degeneration (Fig. 32E, F). 
 
Figure 32: Representative immunoblot images of β-importin and neurofilament (NF200) in the sciatic nerve extracts of 
129Sv SOD1G93A (A, E) and C57 SOD1G93A mice (C, G) compared with their respective non-transgenic (Ntg) littermates. The 
densitometric analysis did not show any significant variation in the expression of β-importin in both strains of ALS mice 
following the treatment (B, D). The scAAV9_MCP1 injection significantly preserved the cytoarchitecture of motor axons is 
slow progressing (H), but not fast progressing mice (F). Data are expressed as mean±SEM (n=4 per experimental group). 
*p<0.05, **p<0.01 Ntg Vs EMPTY or MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 




Following an acute nerve injury, the Schwann cells associated to the damaged axons 
dedifferentiate, proliferate and, in concerted action with infiltrated immune cells, clear the 
apoptotic debris paving the way for a permissive milieu for regeneration (Gaudet et al., 2011; Jessen 
and Mirsky 2019). Indeed, it has been demonstrated that the first response of SCs to damage 
consists in the reversing of their molecular expression toward a progenitor-like state activating 
genes usually found on immature cells, such as p75NTR (Jessen and Mirsky 2008). However, it has 
been recently reported that ALS mice failed at activating p75NTR after damage (Deng et al., 2018), 
suggesting a severe impairment in the activation of the SCs-mediated response and remyelination 
upon an injury (Tomita et al., 2007; Song et al., 2006). According to the preservation of the 
cytoarchitecture of the nerve, p75NTR was upregulated in slow progressing but not fast progressing 
mice following MCP1 induction (Fig. 33A-D). Suitably, our analysis showed that C57 SOD1G93A 
treated mice had unchanged myelin basic protein (MBP) levels compared to non-transgenic 
littermates, while fast progressing mice showed a remarked downregulation both in the presence 
and absence of MCP1 induction (Fig. 33E-H).  
 
Figure 33: Representative immunoblot images of p75NTR and Myelin Basic Protein (MBP) in the sciatic nerve extracts of 
129Sv SOD1G93A (A, E) and C57 SOD1G93A mice (C, G) compared with their respective non-transgenic (Ntg) littermates. The 
scAAV9_MCP1 injection in fast progressing mice did non modify the expression of p75NTR (B) and MBP (F) compared with 
the scAAV9(empty) treated mice. Conversely, the densitometric analysis indicated a significant increase in the expression 
of p75NTR (D) and MBP (H) in slow progressing treated mice compared with the control group (empty vector). Data are 
expressed as mean±SEM (n=4 per experimental group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or 
MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
 




7.5 FOCUS ON THE LUMBAR SPINAL CORD 
The analysis of GFP distribution showed that the scAAV9 spreads retrogradely from the injected 
skeletal muscle alongside the motor unit of ALS mice, finally transducing the motor neuron soma 
(Chapter V). 
Although the physiologic or pathologic role of MCP1 in the CNS is well known (Conductier et al., 
2010; Madrigal and Caso 2014; Semple et al., 2010b), the evidence relating to its neuroprotective 
capability are narrowed. Most investigations have correlated the beneficial effect of the chemokine 
to its ability at modulating the blood-brain-barrier permeability (Dzenko et al., 2005) and the 
polarisation of the recruited macrophages (Matsubara et al., 2015). However, it has been 
demonstrated that hematogenous monocytes do not infiltrate the CNS of SOD1G93A mice (Chiu et 
al. 2009; 2013; Kunis et al., 2015; Chiot et al., 2020). 
We previously showed a significant upregulation of MCP1 in laser captured MNs from slow 
progressing compared to fast progressing ALS mice (Nardo et al., 2013), and recent studies 
demonstrated the beneficial and direct effect of MCP1 on neuron somata and motor axons 
(Locatelli et al., 2012; Papa et al., 2018). These data hinted at a pleiotropic and neuronal-specific 
MCP1 effect in the CNS. Therefore, we analysed whether the specific induction of MCP1 within MN 
soma was able to protect neurons from degeneration and exert a modulatory influence on the 
inflammatory milieu within the lumbar spinal cord.  
7.5.1 VALIDATION OF MCP1 INDUCTION AND ANALYSIS OF ITS EFFECT ON LUMBAR 
MOTOR NEURONS SURVIVAL  
We first verified the chemokine induction in the lumbar tract of the spinal cord of the two ALS 
models following scAAV9_MCP1 i.m. injection.  
As previously reported (Henkel et al., 2006), at the symptomatic stage of the disease, MCP1 was 
significantly upregulated in the spinal cord of SOD1G93A mice compared with the non-transgenic 
littermates. However, the scAAV9_MCP1 injection did not increase the chemokine transcription 
either in fast progressing or in slow progressing ALS mice compared to the scAAV9(empty) treated 
animals (Fig. 34A, B). This result suggests that in a full-blown stage of the disease, the strong 




expression of MCP1 by mSOD1 microglia (Sargsyan et al., 2009; Butovsky et al., 2012) might overlap 
and mask the neuronal scAAV9-mediated overexpression of the chemokine. 
 
Figure 34: Real-Time PCR analysis of MCP1 transcript in the lumbar spinal cord of 129Sv SOD1G93A (A) and C57 SOD1G93A 
mice (B) compared with their respective non-transgenic (Ntg) littermates. The scAAV9_MCP1 injection did not modify the 
chemokine transcription level in the CNS of both strains of ALS mice. Data are normalised to β-actin and expressed as 
mean±SEM (n=4 per group). Confocal micrographs of coronal sections of the lumbar spinal cord of 129Sv (C) and C57 mice 
(D) stained with Choline Acetyltransferase (ChAT). Scale bar= 50µm. The scAAV9_MCP1 injection reduced the motor 
neuron loss in slow progressing (F) but not in fast progressing mice (E) compared with the scAAV9(empty) treated mice. 
Data are expressed as mean±SEM (n=4 per group). **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or MCP1; °p<0.05 
EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis.  




Nevertheless, the analysis of the α-MNs (Area > 400μm2), which are the main target of the disease 
(Conradi and Ronnevi 1993; Lalancette-Hebert et al., 2016), showed that the treatment significantly 
reduced the neurodegenerative phenomenon in the slow progressing SOD1G93A mice (MN nr: 
2.16±0.22, EMPTY; 3.36±0.04, MCP1) (Fig. 34D, F). Conversely, the scAAV9_MCP1 injection was 
ineffective to counteract the MNs loss in the lumbar spinal cord of fast progressing ALS mice (MN 
nr: 2.09±0.23, EMPTY; 2.70±0.30, MCP1) (Fig. 34C, E).  
7.5.2 ANALYSIS OF GLIA CELLS ACTIVATION AND INFLAMMATORY MILIEU 
FOLLOWING MCP1 INDUCTION  
Neuroinflammation is pivotal in ALS pathogenesis, actively contributing to the disease progression 
(Zhao et al., 2013). Indeed, ALS is considered a non-cell autonomous disease, in which other cell 
types besides MNs are fervently involved in the pathogenic cascade (Chiot et al., 2019; Thonhoff et 
al., 2018). In this context, the detrimental contribution of reactive astroglia to the disease was by 
now established (Boillée et al., 2006a; Ilieva et al., 2009; Valori 2013). To gain further insights on 
the effect of the MCP1 induction in the CNS of SOD1G93A mice, we analysed the degree of activation 
of astrocytes (GFAP) and the proliferation of microglial cells (Iba1) in the lumbar spinal cord. 
 
Figure 35: Representative immunoblot images of glial fibrillary acidic protein (GFAP) and ionised calcium-binding adapter 
molecule 1 (Iba1) in the spinal cord extracts of 129Sv SOD1G93A (A) and C57 SOD1G93A mice (B) compared with their 
respective non-transgenic (Ntg) littermates. The scAAV9_MCP1 injection attenuated the astrogliosis in both fast (C, E) and 
slow (D, F) progressing ALS mice compared with the control group (empty). Data are expressed as mean±SEM (n=4 per 
experimental group). Real-time PCR analysis of CD68 transcript in the lumbar spinal cord of 129Sv SOD1G93A (G) and C57 
SOD1G93A mice (H) compared with their respective non-transgenic (Ntg) littermates. The scAAV9_MCP1 injection did not 




modify the phagocytic activity of microglia in both strains of ALS mice. Data are normalised to β-actin and expressed as 
mean±SEM (n=4 per experimental group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or MCP1 by 
ANOVA with Tukey’s post-analysis. 
As shown in Figure 35, GFAP was less expressed in the lumbar spinal cord of both ALS models 
following MCP1 induction. However, the treatment was able neither to prevent nor to significantly 
decrease the astrocytosis compared with the scAAV9(empty) treated mice (Fig. 35A, D). Likewise, 
the proliferation of microglia was reduced in the slow progressing mice upon MCP1 induction, 
although not significantly compared with the scAAV9(empty) treated group (Fig. 35F). In the fast 
progressing mice, we recorded a higher expression of Iba1 in both experimental groups of SOD1G93A 
mice compared with the non-transgenic littermates, albeit lower upon MCP1 induction (Fig. 35E). 
Despite these differences, no variations were found in the phagocytic activity of microglia of both 
ALS models, as assessed by the analysis of the CD68 transcript (Fig. 35G, H).  
 
Figure 36: Representative immunoblot images of Arginase1 and gp91PHOX spinal cord extracts of 129Sv SOD1G93A (A, C) 
and C57 SOD1G93A mice (F, H) compared with their respective non-transgenic (Ntg) littermates. The densitometric analysis 
did not show any modification in the Arginase1 expression (B, G), while gp91PHOX is slightly reduced in both strains of ALS 
mice upon scAAV9_MCP1 injection (D, I). Data are expressed as mean±SEM (n=4 per experimental group). Real-time PCR 
analysis of interleukin 1β transcript in the lumbar spinal cord of 129Sv SOD1G93A (E) and C57 SOD1G93A mice (J) compared 
with their respective non-transgenic (Ntg) littermates. Data are normalised to β-actin and expressed as mean±SEM (n=4 
per experimental group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or MCP1; °p<0.05 EMPTY Vs MCP1 
by ANOVA with Tukey’s post-analysis. 
The activated state of microglia is an oversimplification of the range of the polarisation states 
(M1/M2) and its activity (toxic/protective) on MNs (Geloso et al., 2017). However, microglia 
fingerprint is highly dependant from the neighbouring inflammatory environment (Hanisch 2002). 




Therefore, we characterised the inflammatory milieu within the lumbar spinal cord of the two ALS 
models.  
Notwithstanding the expression of the anti-inflammatory marker Arginase 1 in SOD1G93A mice was 
not influenced by the treatment (Fig. 36A, B, F, G), we recorded reduced oxidative stress upon 
MCP1 induction. Indeed, the immunoblot analysis showed a strong expression of gp91PHOX in both 
strains of scAAV9(empty) treated mice compared with the respective non-transgenic littermates. 
However, following the chemokine induction, ALS mice showed a reduction trend in the gp91PHOX 
expression compared with the control groups (Fig. 36C, D, H, I).  
Besides, following MCP1 induction, we found a significant downregulation of the IL1β 
proinflammatory cytokine in the spinal cord of C57 but not 129Sv SOD1G93A mice (Fig. 36E, J).  
7.6 DISCUSSION 
Although the primary hallmark is the MN death, ALS is a non-cell autonomous disorder with other 
cell types actively contributing to the disease including microglia, astrocytes and immune cells 
(Chiot et al., 2019; Thonhoff et al., 2018). Moreover, ALS encompasses distant biological systems 
(muscle, nerves, spinal cord, brain), and makes it even more challenging to identify a proper 
therapeutic target (Silani et al., 2017).  
Mounting evidence highlighted the different contribution of the inflammatory response in the CNS 
compared with the periphery (i.e. nerves and muscles) in ALS (Dibaj et al., 2011; Chiu et al., 2009). 
Indeed, the aberrant glial cells activation, T cells infiltration and the resulting release of pro-
inflammatory factors drive the neurodegenerative phenomenon (Chiot et al., 2019; Thonhoff et al., 
2018). Conversely, the successful axonal and muscle regeneration depends on the coordinated 
efforts of immune cells that, besides removing cellular debris, release factors that support the 
wound healing (Deng et al., 2018; Van Dyke et al., 2016; Gaudet et al., 2011; Sass et al., 2018). 
However, the contribution of the immune response to ALS progression is still elusive (McCombe 
and Henderson 2011; Iyer et al., 2018).  
MCP1 is usually released to exert a potent chemotactic activity by binding the C-C chemokine 
receptor type 2 (CCR2) on target cells, such as macrophages, microglia and T cells. The MCP1-CCR2 




pathway leads to pathological microgliosis and inflammation in chronic disorders (Semple et al., 
2010b), including ALS (Henkel et al., 2006; Martínez et al., 2020). Nonetheless, considerable 
evidence depicted MCP1 as a neuroprotective factor involved in modulating the blood-brain-barrier 
permeability (Dzenko et al., 2005) and promoting neurogenesis (Chintawar et al., 2009; Liu et al., 
2007) and axonal elongation and outgrowth (Locatelli et al., 2012; Papa et al., 2018).  
The chemotactic activity of MCP1 toward leucocytes (monocytes and T lymphocytes) is crucial in 
triggering wound healing and regenerative processes (Ridiandries et al., 2018). Indeed, 
macrophages and T cells infiltration within the damaged area is a critical step for nerves (Liu et al., 
2019b; Chen et al., 2015b; Zigmond and Echevarria 2019) and muscles (Shireman et al., 2007; 
Martinez et al., 2010; Dort et al., 2019; Zhang et al., 2014a; Deyhle and Hyldahl 2018; Yang and Hu 
2018) regeneration, which are the first body compartments affected by ALS (Moloney et al., 2014).  
In the present study, we showed that the early induction of MCP1 in the motor units of fast and 
slow progressing SOD1G93A mice induced opposite clinical outcomes, which are related to the strain-
specific differences at activating the immune response and thus promoting the tissue reaction to 
damage. 
At the symptomatic stage, the intramuscular injection of scAAV9_MCP1 exacerbates 
inflammation in 129Sv SOD1G93A mice, while it is ineffective in counteracting the skeletal muscle 
degeneration in C57 SOD1G93A mice 
MCP1 has a pivotal role in the recruitment and modulation of immune cells thus governing the 
wound healing of skeletal muscle (Contreras-Shannon et al., 2007; Shireman et al., 2007; Lu et al., 
2011). 
Here, we reported that MCP1 transcript level is equally and remarkably increased in the skeletal 
muscles of both ALS models also several weeks after the single scAAV9_MCP1 i.m. injection. 
Nevertheless, this resulted in a differential response of the skeletal muscles of the fast compared 
with the slow progressing ALS mice to the treatment. 129Sv SOD1G93A mice showed a heightened 
infiltration of macrophages and T lymphocytes in the TA muscles, while C57 SOD1G93A are refractory 
to further increase immune cell recruitment, despite the significant increase of MCP1 levels. 




Intriguingly, the increased immune cells infiltration in 129Sv SOD1G93A mice exacerbated the muscle 
force impairment. Conversely, the C57 SOD1G93A mice showed an amelioration of the motor 
performance compared to controls. This result suggests that triggering the immune cell infiltration 
in the skeletal muscles late in the disease is detrimental in mSOD1 mice. 
We have previously demonstrated that 129Sv SOD1G93A mice are less prone than C57 SOD1G93A mice 
at activating an effective peripheral immune response through macrophage and T cells recruitment 
in the PNS and skeletal muscles (Vallarola et al., 2018; Nardo et al., 2016b). Here, we confirmed this 
evidence showing that, at the symptomatic stage, scAAV9(empty) and scAAV9_MCP1 treated C57 
SOD1G93A mice exhibit a similar extent in immune cells infiltration. Conversely, an exogenous 
boosting of MCP1 is necessary to promote the leucocytes infiltration in the skeletal muscle of 129Sv 
SOD1G93A mice, suggesting a strain-related modulation of the inflammatory response following an 
injury.  
The reduced ability at recruiting inflammatory cells has been already reported in 129Sv compared 
with C57 genetic background (White et al., 2002; Hoover-Plow et al., 2008). Furthermore, 129Sv 
mice have an intrinsic propensity in exacerbating the proinflammatory status following the injection 
of the lipopolysaccharides (LPS) endotoxin (Piirsalu et al., 2020). This evidence suggests a 
dysregulated immune system in 129Sv mice that led to an impairment in the effective management 
of the immune response once activated. 
The sustained inflammation impairs the skeletal muscle regeneration inasmuch the establishment 
of a permissive environment is necessary to guarantee and achieve functional results (Yang and Hu 
2018; Howard et al., 2020; Musarò 2014). Our data showed that the immune cells infiltrated in the 
TA muscle of the fast progressing ALS mice exhibited a pro-inflammatory fingerprint and failed to 
switch towards the M2 phenotype, as assessed by the reduced transcription of IGF1, which is 
pivotal in macrophage polarisation and inflammation resolution upon muscle injury (Tonkin et al., 
2015; Tidball and Welc 2015; Pelosi et al., 2007). In parallel, the increased infiltration of T reg cells 
in 129Sv SOD1G93A mice upon MCP1 induction might be an attempt to decrease the established 
phlogosis through the interaction with the innate immune cells (Li et al., 2018; Schiaffino et al., 




2017). However, it has been demonstrated that the phenotypic abilities of T reg cells to suppress 
inflammation is reduced in mSOD1 mice at the advanced disease stage (Beers et al., 2011a), which 
might explain the remarked expression of TNFα and gp91PHOX recorded in the TA muscle of 129Sv 
SOD1G93A treated mice despite the higher FoxP3 transcription compared with the control group. 
Unlike the fast progressing mice, the scAAV9_MCP1 injection did not affect the extent of the 
immune cells recruitment in the skeletal muscle of C57 SOD1G93A mice. However, TNFα, gp91PHOX 
and IGF1 were downregulated in the scAAV9_MCP1 treated mice compared with controls, 
indicating the mitigation of inflammation thanks to the phenotypic switch of macrophages from the 
M1 to the M2 fingerprint. Noteworthy, this effect was not associated with the immunomodulatory 
intervention of the T reg cells, suggesting a better capability of C57 SOD1G93A mice in governing a 
functional immune response.   
The downregulated transcription of IGF1 recorded in both ALS models may also suggest a failure in 
the proliferation or differentiation of the satellite cells at the symptomatic stage of the disease 
(Manzano et al., 2011; 2013). Indeed, IGF1 is a potent myogenic factor (Tonkin et al., 2015; 
Dobrowolny et al., 2005), and its downregulation might correlate with the substantial impairment 
and damage of the hindlimbs of SOD1G93A mice at the advanced stage of the disease. 
In conclusion, the MCP1-enhanced immune cells recruitment profoundly altered the muscular 
environment and the muscle strength of fast progressing mice, suggesting a detrimental role of the 
immune activation and inflammation in these mice possibly due to the impairment of the 129Sv 
strain in coordinating a functional and protective immune response (Piirsalu et al., 2020; White et 
al., 2002; Hoover-Plow et al., 2008). Conversely, the data on C57 SOD1G93A mice suggested that, 
once the disease progresses to the advanced stage, the immune-mediated response, fostered by 
MCP1, is worthless. Nevertheless, given that the MCP1 induction resulted in the postponement of 
the motor impairment in the slow progressing ALS mice, it is conceivable that a protective immune 
response might have occurred earlier in the disease. Indeed, immune cell infiltration and skeletal 
muscle impairment are early events in the pathogenic cascade of ALS (Pansarasa et al., 2014). 




Therefore, only the last glimpse of the protective effect mediated by the MCP1 induction was 
detectable in the hid paws of C57 SOD1G93A mice at the symptomatic disease stage.  
The intramuscular injection of scAAV9_MCP1 preserves motor axons of C57 SOD1G93A mice but not 
129Sv SOD1G93A mice 
As muscles, axons are affected early in the ALS pathogenic cascade (Clark et al. 2016; Gentile et al. 
2019).  
We previously showed that the peripheral immune cell response during the first disease stages has 
a beneficial role in promoting Schwann cells proliferation and axonal regeneration. Conversely, at 
the disease onset, the fast progressing ALS mice failed to activate a consistent peripheral immune 
response in the sciatic nerves, and this resulted in earlier denervation of skeletal muscles (Nardo et 
al., 2016b). Nevertheless, here we show that, at the symptomatic stage of the disease, the 129Sv 
SOD1G93A mice are able to activate the MCP1-mediated axis as well as recruit macrophages and T 
lymphocytes within the sciatic nerve. However, this tardive activation translates in a delayed 
immune response to injury, which, as demonstrated in aged mice (Büttner et al., 2018),  proves to 
be ineffective in promoting axonal regeneration, remyelination and the maintenance of the nerve 
cytoarchitecture. Moreover, the further enhancement of the chemokine through the injection of 
scAAV9_MCP1 did not improve this process but instead promoted the recruitment of immune cells 
(CD8+ T lymphocytes) with an inflammatory phenotype, which, as demonstrated in the 
Experimental Autoimmune Neuritis model (Ydens et al., 2013), hampers the regeneration. This 
evidence suggests a detrimental role of a dysregulated immune response and inflammation in the 
PNS of ALS mice. 
Conversely, the slow progressing mice had an earlier and robust peripheral immune response since 
the disease onset, and this resulted in the preservation of myelin sheets and motor axon 
neurofilaments compared with fast progressing mice (Nardo et al., 2016b). Nevertheless, the 
scenario at the symptomatic stage of the disease depicted an intense inflammation which, as 
observed in 129Sv SOD1G93A treated mice and old injured mice (Büttner et al., 2018), is ineffective 
to counteract the PNS degeneration as confirmed by the significant impairment of the locomotor 




ability at 20 weeks. However, we can surmise that the scAAV9-mediated MCP1 induction in the 
sciatic nerves of C57 SOD1G93A mice since the early stage of the disease has further enhanced the 
response to stress boosting the recruitment of immune cells in the first stage of the disease, as 
demonstrated by their switching toward a pro-regenerative anti-inflammatory phenotype. Thus, 
although at the symptomatic stage chemokine levels are similar in the sciatic nerves of 
scAAV9_MCP1 and scAAV9(empty) treated mice, the early MCP1 boosting reduced the tissue 
phlogosis and maintained the axon-cytoarchitecture and myelin wrapping around motor axons of 
slow progressing mice. 
The intramuscular injection of the scAAV9_MCP1 exerts a protective effect in the CNS of 
SOD1G93Amice 
Several pieces of evidence depicted MCP1 as a neuroprotective factor in the CNS (Dzenko et al., 
2005; Chintawar et al., 2009; Liu et al., 2007; Locatelli et al., 2012; Papa et al., 2018; Matsubara et 
al., 2015). Most of them correlated the beneficial effect of the chemokine to its ability in modulating 
the blood-brain-barrier permeability (Dzenko et al., 2005) and positively influencing the 
polarisation of infiltrated macrophages (Matsubara et al., 2015; Kwon et al., 2015). However, 
limited evidence demonstrated the direct beneficial effect of MCP1 in neuron perikarya and axons 
(Locatelli et al., 2012; Papa et al., 2018).  
The analysis performed showed that the treatment was able to attenuate the activation of the glia 
cells reducing the oxidative stress within the spinal cord of ALS models. Notably, the neuronal 
induction of MCP1 delayed the lumbar MN loss in C57 SOD1G93A mice by reducing inflammation. 
Conversely, this effect was absent in 129Sv SOD1G93A mice, suggesting that glial cells of fast 
progressing ALS mice are more refractory to the modulative capability of neuronal MCP1. Further 
analysis will be necessary to assess the influence of MCP1 on non-neuronal neighbourhoods within 
the spinal cord of ALS mice. 
In conclusion, the data collected indicate that the clinical response of SOD1G93A mice to the 
induction of MCP1 within the neuromuscular system may be beneficial, detrimental or ineffective 
depending on the mouse genetic background, its immune-related capability and the time of 




intervention. This evidence may explain the failure of the immune-modulatory/-suppressive 
treatments so far tested in clinical trials in which the cohorts were composed by patients genetically 
heterogeneous and in the full-blown stage of the disease (Wosiski-Kuhn et al., 2019; McCombe and 
Henderson 2011).   
The data herein collected also reveal that the immune response and inflammation play a dual 
opposite role in governing the speed of ALS progression depending on the extent of the 
neuromuscular system damage. Thus, we hypothesise that at the onset of symptoms, when the 
damage is limited, the activation of immune response is pivotal to prevent further damage and 
sustain the effective regeneration of axons and skeletal muscles. On the contrary, at the later stage 
of the disease, this phenomenon should be restrained to avoid the detrimental effect of the 
inflammatory milieu, which accelerates the speed of ALS progression as demonstrated in 129Sv 
SOD1G93A mice. To further strengthen this hypothesis, in the next chapter of this Thesis the 
mechanisms through which the induction of MCP1 significantly delays the motor deficit in slow 
progressing ALS mice will be examined at the early stage of the disease. 
 

















Analysis of the effect of MCP1 induction in slow 
progressing ALS mice at earlier time point:  
look back at 14 weeks 
 




8.1 BACKGROUND and AIM 
The degeneration of the peripheral compartment is an early event in ALS pathogenic cascade that 
occurs before the clinical manifestation of the disease (Clark et al., 2016; Azzouz et al., 1997; Fischer 
et al., 2004). However, the evidence describing the involvement of the immune response in 
governing the degeneration/regeneration or the stream of these mechanisms in the peripheral 
compartment during ALS progression is narrow. Besides, current knowledge on acutely damaged 
nerves and muscles indicates that immune cell recruitment is as an early event occurring a few 
hours after injury (Gaudet et al., 2011; Yang and Hu 2018). This evidence makes hard to define 
parallelism with the chronic and progressive degeneration occurring in ALS. 
Suitably to the pivotal role of a functional and temporally appropriate immune response in 
promoting the wound healing following an injury, the data herein obtained in fast and slow 
progressing ALS mice at the symptomatic stage showed that the dysregulated response of SOD1G93A 
mice is worthless to counteract the degeneration of the peripheral compartment. Indeed, we 
recorded a full-blown alteration of the TA muscle and sciatic nerve in both ALS strains at the 
advanced stage of the disease.  
Besides, we observed that the induction of MCP1 exacerbated the (background-related) impaired 
immune response in the fast progressing ALS mice, worsening the clinical phenotype. Conversely, 
the scAAV9_MCP1 injection in C57 SOD1G93A mice improved the motor ability since the early stage 
of the disease, postponing the disease onset. Therefore, we hypothesise that the data collected at 
the symptomatic phase of the disease could represent the last glimpse of the protective effect of 
the induction of MCP1 in slow progressing ALS mice. Hence, the next section of this thesis seeks to 
address the early regenerative mechanisms underlying MCP1 induction activated by slow 
progressing mice within the peripheral compartment. Moreover, we investigated the ability of the 
specific overexpression of MCP1 within MNs at modulating the neuroinflammatory phenomenon 
in ALS mice. 
 
 




8.2 EXPERIMENTAL DESIGN 
Using the experimental protocol described in section 6.2, C57 SOD1G93A mice (n=8) underwent a 
single bilateral i.m. injection of 2.18x1010vg/μL scAAV9_MCP1 in both hindlimbs (TA, GCM and GM) 
and forelimbs (TB) muscles (10μL per muscle) at 8 weeks of age. An empty vector was used for the 
treatment of the control group (n=8). 
Mice were sacrificed six weeks after the i.m. injection (i.e. ~2 weeks after the virus reaches its 
maximum transduction efficiency (Benkhelifa-Ziyyat et al., 2013)) to analyse the effect of the MCP1 
induction when the skeletal muscle of ALS mice exhibits the first signs of the disease. Therefore, an 
extensive histological and biochemical/molecular analysis was performed at the TA muscle, sciatic 
nerve and lumbar spinal cord level in 14 weeks old mice. 
 
Figure 37: Experimental schedule of i.m. injection of scAAV9_MCP1 slow progressing SOD1G93A mice. 
8.3 ANALYSIS OF THE EARLY EFFECT OF MCP1 INDUCTION IN THE TIBIALIS 
ANTERIOR MUSCLE 
8.3.1 ANALYSIS OF THE DENERVATION ATROPHY OF THE TIBIALIS ANTERIOR 
MUSCLE  
According to the early involvement of the muscular compartment in ALS mice (Kalmar et al., 2012; 
Azzouz et al., 1997; Hegedus et al., 2007; Clark et al., 2016), at 14 weeks, the TA muscle of ALS mice 
is significantly affected by the disease. Indeed, as shown in Figure 38, our analysis recorded a 
reduction of 38.8±2.6% of the muscle mass and a significant upregulation of AChRγ transcript and 
NCAM protein in the scAAV9(empty) treated mice compared with non-transgenic littermates. 
Notably, following the scAAV9_MCP1 injection, the TA muscle of C57 SOD1G93A mice was less 




atrophied compared with the scAAV9(empty) treated mice (25.9±2.3% of muscle mass lost 
compared with the non-transgenic mice) and did not upregulate NCAM suggesting the reduced 
denervation of the neuromuscular junction (NMJ) (Fig. 38A, C, D). Accordingly, the AChRγ transcript 
was significantly downregulated in treated mice compared with the control group (Fig. 38B). 
 
Figure 38: (A) The analysis of the tibialis anterior (TA) muscle wasting revealed a significant reduction of the muscle 
atrophy in scAAV9_MCP1 treated mice compared with the control group. Data are expressed as mean±SEM (n=8 per 
experimental group). °°p<0.01 by unpaired t-test. (B) Real-time PCR analysis of the gamma subunit of the acetylcholine 
receptor (AChRγ) showed a significant upregulation of AChRγ transcript in scAAV9(empty) but not in scAAV9_MCP1 
treated mice compared with the non-transgenic (Ntg) littermates. Data are normalised to βactin and expressed as 
mean±SEM (n=4 per experimental group). (C) Representative immunoblot analysis of the Neural Cell Adhesion Molecule 
(NCAM) in the TA muscle. (D) The densitometric analysis revealed a significant accumulation of NCAM in the TA muscle of 
scAAV9(empty) treated mice but not in the scAAV9_MCP1 treated mice compared with the non-transgenic (Ntg) 
littermates. Data and expressed as mean±SEM (n=4 per experimental group). *p<0.05, **p<0.01, ***p<0.001 Ntg Vs 
EMPTY or MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
Intriguingly, it has been reported that muscle wasting occurs with differential sensitivity between 
selective skeletal muscle fibre subtypes. Indeed, it has been reported that the fast-fatigable 
glycolytic muscle fibres are more susceptible to the atrophic phenomenon compared with the slow 
oxidative fibres (Wang and Pessin 2013). Notably, a metabolic dysregulation of skeletal muscle, 
characterised by the progressive loss of fast-twitch glycolytic fibres and a compensatory increase 
of slow-twitch oxidative fibres as the results of the mitochondrial deficit and oxidative stress, occurs 
in ALS patients and models (Telerman-Toppet and Coërs 1978; Palamiuc et al., 2015; Peggion et al., 




2017; Dobrowolny et al., 2018). Therefore, we analysed the expression of the succinate 
dehydrogenase (SDH) enzyme, a component of the mitochondrial respiratory chain complex II, as 
an index of the oxidative capacity of the TA muscle (Old and Johnson 1989; Martin et al., 1985). 
According to previous evidence (Palamiuc et al., 2015; Dobrowolny et al., 2018; Scaricamazza et al., 
2020), the SDH staining showed a significant increase in the percentage of oxidative fibres in the 
ALS mice (Empty: 87.3±1.5%; MCP1: 74.8±1.9%) compared with the non-transgenic littermates 
(52.9±0.2%). Nevertheless, the scAAV9_MCP1 injection significantly reduced the SDH-positive 
oxidative fibres in the TA muscle of SOD1G93A mice, thus preventing the metabolic degeneration 
occurring during ALS progression (Fig. 39A, B). 
These beneficial effects seem to be strictly dependant from the chemokine induction, as 
demonstrated by the increased transcription level of MCP1 recorded in the TA muscle of treated 
mice compared with the control groups (Fig. 39C). 
 
Figure 39: (A) Confocal micrographs of coronal sections of the tibialis anterior (TA) muscle stained for the Succinic 
Dehydrogenase (SDH) enzyme to identify oxidative muscle fibres. (B) Imaging analysis revealed an increased percentage 
of oxidative fibres in the TA muscle of ALS mice, albeit significantly lower upon MCP1 induction. Data are expressed as 
mean±SEM (n=3 Ntg; n=4 SOD1G93A mice). Scale bar= 50µm. (C) Real-time PCR analysis of MCP1 transcript revealed a 
significant upregulation of the chemokine in treated mice compared with the control groups. Data are normalised to βactin 
and expressed as mean±SEM (n=4 per experimental group). ****p<0.0001 Ntg Vs EMPTY or MCP1; °°p<0.01, °°°°p<0.0001 
EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
 
 




8.3.2 CHARACTERISATION OF THE RECRUITMENT OF THE IMMUNE CELLS AND THE 
INFLAMMATORY MILIEU IN THE TIBIALIS ANTERIOR MUSCLE 
Several shreds of evidence have highlighted the pivotal role of MCP1 in driving the skeletal muscle 
regeneration thanks to its chemoattractant activity toward CCR2-expressing cells (Shireman et al., 
2007; Contreras-Shannon et al., 2007; Lu et al., 2011b; Martinez et al., 2010; Oishi and Manabe 
2018).  
Interestingly, the kinetic of leucocytes accumulation within the injured skeletal muscle resembles 
the classical response to infection. The damage-associated molecular patterns (DAMPs) and 
cytokines released by necrotic cells attract neutrophils, which remove the fibre debris (Dumont et 
al., 2008) and foster the recruitment of macrophages and T lymphocytes (Yang and Hu 2018; 
Butterfield et al., 2006; Oishi and Manabe 2018; Rigamonti et al., 2013; Pizza 2008; Tidball 2017).  
At 14weeks, the damaged muscle of SOD1G93A mice recruited neutrophils, as demonstrated by the 
massive expression of the proteolytic elastase enzyme (chymotrypsin-like serine-proteinase) 
(Okada 2017; Arecco et al., 2016) compared with the non-transgenic animals. Conversely, the 
induction of MCP1 early in the disease anticipated the physiological immune response within the 
skeletal muscles of ALS mice. Indeed, neutrophils were no longer present within the TA muscle of 
treated mice (Fig. 40B, D). In contrast, upon MCP1 induction, we recorded a remarked infiltration 
of phagocytic CD68+ macrophage and T lymphocytes compared with the scAAV9(empty) treated 
mice (Fig. 40A, C). 
Moreover, although the treatment did not significantly modify the extent of CD8+ and CD4+ T 
lymphocytes infiltration, the increased recruitment of the immunoregulatory T reg cells, which are 
pivotal in promoting skeletal muscle regeneration (Castiglioni et al., 2015; Schiaffino et al., 2017), 
was recorded compared with the scAAV9(empty) treated mice (Fig. 40E-G). 





Figure 40: (A, B) Confocal micrographs of longitudinal sections of tibialis anterior (TA) muscle stained with the CD68 
phagocytic marker (A) or Elastase enzyme (B) and DAPI (nucleus). Imaging analysis revealed increased recruitment of 
macrophages (C) and a reduced presence of neutrophils (D) in the TA muscle of treated mice compared with the control 
group. Data are expressed as mean±SEM (n=4 per experimental group). A, scale bar= 100µm; B, Scale bar= 50µm. (E, G) 
Real-time PCR analysis of CD8α receptor, CD4α receptor and Foxp3 transcripts in the TA muscle of ALS mice and non-
transgenic (Ntg) littermates. The scAAV9_MCP1 injection increased the infiltration of T lymphocytes in the TA muscle of 
ALS mice compared with the control groups. Data are normalised to βactin and expressed as mean±SEM (n=4 per 
experimental group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or MCP1; °°p<0.01, °°°°p<0.0001 
EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
The ability of the infiltrated immune cells in governing the response of the skeletal muscle to injury 
is strictly dependent to their M1/M2 polarisation (Arnold et al., 2007; Kharraz et al., 2013; Tidball 




2017; Tidball et al., 2014; Saclier et al., 2013b; Patsalos et al., 2017). Therefore, we analysed the 
inflammatory milieu of the TA muscle of SOD1G93A mice at 14 weeks of age.  
In line with the first phase of the immune response to damage (Yang and Hu 2018), we recorded a 
strong upregulation of the inflammatory marker TNFα in the TA muscle of scAAV9(empty) treated 
mice compared with the non-transgenic animals (Fig. 41A). Conversely, the leucocytes infiltrated in 
the hind paw muscle of scAAV9_MCP1 treated mice have already shifted toward the anti-
inflammatory phenotype. Indeed, the transcription of TNFα was downregulated in favour of the 
increased expression of the M2 pro-regenerative marker Arginase 1 compared to the 
scAAV9(empty) treated mice (Fig. 41A, C, D). 
 
Figure 41: (A, B) Real-time PCR analysis of tumour necrosis factor alpha (TNFα) and insulin-like growth factor 1 (IGF1) 
transcripts in the tibialis anterior (TA) muscle of ALS mice and non-transgenic (Ntg) littermates. The gene expression 
analysis showed significant downregulation of TNFα and IGF1 in the TA muscle of treated mice compared with the control 
group. Data are normalised to βactin and expressed as mean±SEM (n=4 per experimental group). (C-D) The immunoblot 
analysis revealed an increased expression of Arginase 1 (Arg1) and Sirtuin 1 (SIRT1) in the TA muscle of treated mice 
compared with the control group. Data are expressed as mean±SEM (n=4 per experimental group). *p<0.05, 
****p<0.0001 Ntg Vs EMPTY or MCP1; °p<0.05, °°p<0.01, °°°p<0.001 EMPTY Vs MCP1 by ANOVA with Tukey’s post-
analysis. 
Coherently, IGF1 transcript resulted significantly downregulated in the hind paw muscle of treated 
mice compared with the control group (Fig. 41B), suggesting the complete switch of the infiltrated 
macrophages toward the anti-inflammatory phenotype (Tonkin et al., 2015). To verify this evidence, 
we analysed the expression of the NAD+-dependent Sirtuin 1 (Sirt1) deacetylase, enzyme promoting 
both the myogenic activity of satellite cells (Cerletti et al., 2012; Rathbone et al., 2009) and the 




macrophage shift toward the M2 phenotype by inhibiting NFκB signalling (Tonkin et al., 2012; Schug 
et al., 2010). Consistently, we found that Sirt1 was significantly expressed within the TA muscle of 
treated mice compared with controls (Fig. 41E, F). 
8.3.3 CHARACTERISATION OF THE SATELLITE CELL-MEDIATED RESPONSE IN THE 
TIBIALIS ANTERIOR MUSCLE 
Numerous evidence suggest the both the innate and the adaptive immune response actively 
influence the skeletal muscle regeneration directly governing the response of satellite cells in both 
acute and chronic injury (Deyhle and Hyldahl 2018; Madaro et al., 2019; Tidball and Villalta 2010). 
Therefore, we analysed the expression of two critical myogenic transcription factors: Pax7, the 
hallmark of satellite cells stemness (Mauro 1961), and Myogenin (MyoG), a marker of early 
commitment and differentiation (Cornelison and Wold 1997) in the TA muscle of 14 weeks-old 
mice.  
 
Figure 42: (A-C) Immunoblot analysis of satellite cells transcriptional factors Pax7 (A), MyoG (B) and MyoD (C) in the tibialis 
anterior (TA) muscle of ALS mice and non-transgenic (Ntg) littermates. The densitometric analysis indicated an increased 
expression of these markers in treated mice compared with the control group. Data are expressed as mean±SEM (n=4 per 
experimental group). *p<0.05, **p<0.01, ****p<0.0001 Ntg Vs EMPTY or MCP1; °p<0.05, °°p<0.01 EMPTY Vs MCP1 by 
ANOVA with Tukey’s post-analysis. (D) Confocal micrographs of coronal sections of TA muscle stained with Pax7 (red), 
MyoD (green) and DAPI (blue). Scale bar= 20µm. (E) Imaging analysis indicated a higher percentage of differentiating 
(MyoD+/Pax7-) satellite cells in the TA muscle of treated mice compared with the control group Data are expressed as 
mean±SEM (n=4 per experimental group). *p<0.05, **p<0.01, Ntg Vs EMPTY or MCP1; °°p<0.01 EMPTY Vs MCP1 by Two-
way ANOVA with Tukey’s post-analysis. 




As shown in Figure 42, MyoG, but not Pax7, was significantly activated in the TA muscle of treated 
mice compared with the control group, suggesting that the early MCP1-mediated immune response 
promoted the myofiber shift towards the differentiation programme (Fig. 42A, B). 
Moreover, the treatment strongly enhanced the activation of the myoblast determination protein 
1 (MyoD) transcription factor in the TA muscle of ALS mice compared with the control groups (Fig. 
42C), which is critical at defining the fate of the activated satellite cells. MyoD downregulation 
guarantees the preservation of the satellite cells pool, whereas its upregulation coincides to the 
ceasing in the Pax7 expression promoting the final commitment to myoblast (Relaix and Zammit 
2012; Forcina et al., 2019). Accordingly, our data suggest an enhancement of the myogenic activity 
in the TA muscle of scAAV9_MCP1-treated mice since the early stage of the disease. In keeping with 
this, the histological evaluation of the satellite cells dynamic in the hindlimb muscle of SOD1G93A 
mice showed a reduction of quiescent (Pax7+/MyoD-) satellite cells and a significant increase in their 
differentiation (Pax7-/MyoD+) upon MCP1 induction (Fig. 42D, E). 
Several shreds of evidence describe that, in resting muscles, the myonuclei are positioned at the 
periphery of the muscle fibres, to protect them from the force of contraction, and are distributed 
to maximise the distance to each other and to guarantee the transcription and translation 
machinery necessary to sustain the entire myofiber (Bruusgaard et al., 2003; Folker and Baylies 
2013). However, during the regenerative process, muscle fibres undergo a series of architectural 
changes among which the positioning of the nucleus at their centre (Folker and Baylies 2013). 
According to the increased myogenic activity observed upon MCP1 induction, the histological 
analysis performed showed an increased density of muscle fibres characterised by the central 
location of the nucleus in the TA muscle of treated mice compared with the control groups (Fig. 43). 
 





Figure 43: (A) Confocal micrographs of coronal sections of the tibialis anterior (TA) muscle stained with Laminin 
(extracellular matrix) and DAPI (nucleus). Scale bar= 50µm. Regenerating muscle fibres display centrally located myonuclei 
(white arrow). (B) Imaging analysis indicated an increased density of muscle fibres characterised by the central location 
of the myonucleus in treated mice compared to the control groups. Data are expressed as mean±SEM (n=4 per 
experimental group). **p<0.01 Ntg Vs MCP1; °p<0.05 EMPTY Vs MCP1 by Two-way ANOVA with Tukey’s post-analysis. 
8.4 ANALYSIS OF THE EARLY EFFECT OF MCP1 INDUCTION IN THE SCIATIC 
NERVE 
8.4.1 VALIDATION OF MCP1 INDUCTION, IMMUNE CELLS INFILTRATION AND 
SCHWANN CELL-MEDIATED RESPONSE 
At the disease onset, the C57 SOD1G93A mice strongly activated the MCP1-mediated pathway to 
recruit macrophages and T lymphocytes within degenerating motor axons (Nardo et al., 2016b). 
However, here, we did not record any difference in the transcription of the CD68 phagocytic marker 
between the two groups of ALS mice, although MCP1 was significantly upregulated six weeks after 
the scAAV9_MCP1 injection (Fig. 44A, B). Besides, the gene expression analysis of the CD8 cytotoxic 
T cell marker and the pro-inflammatory cytokine TNFα showed that the sciatic nerve of ALS mice 
did not exhibit any sign of inflammation compared with the non-transgenic littermates at the 
presymptomatic stage of the disease even upon MCP1 induction (Fig. 44C, D).  
These data suggest that the extent of impairment of the sciatic nerves of SOD1G93A mice at 14 weeks 
(i.e. ~2 weeks before the onset of motor symptoms) is not sufficient to promote the recruitment of 
haematogenous immune cells, which instead showed a considerable influence late in the disease 
(Nardo et al., 2016b). 
 





Figure 44: (A, D) Real-time PCR analysis of MCP1 (A), the CD68 phagocytic marker (B), CD8α receptor (C) and tumour 
necrosis factor alpha (TNFα) (D) transcripts in the sciatic nerve of ALS mice and non-transgenic (Ntg) littermates. Although 
MCP1 mRNA was significantly upregulated in treated mice compared with the control groups (A), no difference in the 
transcription of CD68 was recorded between the two groups of ALS mice (B). Moreover, no variation in the transcriptional 
levels of CD8α receptor (C) and TNFα (D) was recorded in the three experimental groups. Data are normalised to βactin 
and expressed as mean±SEM (n=4 per experimental group). (E, F) The immunoblot analysis revealed a higher expression 
of p75NTR in the sciatic nerve of treated mice compared with the control groups. Data are expressed as mean±SEM (n=4 
per experimental group). *p<0.05 Ntg Vs EMPTY or MCP1 by ANOVA with Tukey’s post-analysis. 
The Schwann cells (SCs) are the first line response following a peripheral injury that precede and 
promote the infiltration of haematogenous immune cells through the release of chemoattractant 
factors, including MCP1 (Gaudet et al., 2011; Jessen and Mirsky 2019).  
We found an increased expression of p75NTR in the sciatic nerves of scAAV9_MCP1 treated mice 
compared to the control groups (Fig. 44E, F), indicating an early de-differentiation of SCs toward an 
immature non-myelinating phenotype, which is prodromal to their proliferation/regeneration 
(Jessen and Mirsky 2008). This evidence suggests that in the scAAV9_MCP1 treated mice the SCs 
are better equipped to respond to injury compared with the control group (Deng et al., 2018).  




8.5 ANALYSIS OF THE EARLY EFFECT OF MCP1 INDUCTION IN THE LUMBAR 
SPINAL CORD 
8.5.1 ANALYSIS OF THE MOTOR NEURON SURVIVAL AND GLIA CELLS ACTIVATION 
IN THE LUMBAR SPINAL CORD  
We previously showed that the intramuscular injection of scAAV9 specifically transduces the MN 
perikaryon (Chapter V). Therefore, we first examine the MCP1 transcript in the lumbar spinal cord. 
 
Figure 45: (A) Confocal micrographs of coronal sections of the lumbar spinal cord of ALS mice and non-transgenic (Ntg) 
littermates stained with Choline Acetyltransferase (ChAT). Scale bar= 50µm. Data are expressed as mean±SEM (n=3 per 
group). (B) The scAAV9_MCP1 injection reduced the motor neuron loss treated mice compared with the control group. (C) 
The real-time PCR analysis of MCP1 transcript in the lumbar spinal cord showed a significant upregulation of the 
chemokine in the lumbar spinal cord of treated mice compared with the control group. Data are normalised to βactin and 
expressed as mean±SEM (n=4 per group).  (D, E) The immunoblot analysis of the glial fibrillary acidic protein (GFAP) and 
ionised calcium-binding adapter molecule 1 (Iba1) in lumbar spinal cord extracts did not show any significant difference 
in the three experimental groups. Data are expressed as mean±SEM. **p<0.01, ****p<0.0001 Ntg Vs EMPTY or MCP1; 
°p<0.05, °°p<0.01 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
The gene expression analysis showed a greater upregulation of the chemokine in the CNS of treated 
mice compared with the control group (Fig. 45C). Moreover, our findings revealed that the MCP1 




induction exerted a beneficial effect in the lumbar spinal cord, where MNs resulted significantly 
protected compared to the control group (Fig. 54A, B). This result is in line with the pleiotropic 
neuroprotective role of the chemokine observed in the neurologic context (Papa et al., 2018; 
Locatelli et al., 2012). 
We previously found that glial cells were not significantly activated in C57 SOD1G93A mice compared 
with non-transgenic littermates at the presymptomatic stage of the disease (Marino et al., 2015). 
Here, we confirmed this evidence observing that the induction of a pro-inflammatory chemokine 
within MN did not increase the gliosis within the lumbar spinal cord of ALS mice, as demonstrated 
by the unvaried expression of GFAP and Iba1 among the selected experimental groups at 14 weeks 
(Fig. 45D, E). 
8.5.2 ANALYSIS OF THE INFLAMMATORY MILIEU IN THE LUMBAR SPINAL CORD 
The data collected at the symptomatic stage of the disease showed that the specific MCP1 induction 
within MNs was able to modulate the neuroinflammatory phenomenon in ALS mice (section 7.5). 
Therefore, we investigated whether the immunomodulatory activity of the chemokine was already 
detectable a few weeks upon the scAAV9_MCP1 injection. 
We found that the MCP1 induction within MNs was able to shift the glial fingerprint towards the 
M2 anti-inflammatory phenotype, as demonstrated by the upregulation of Arginase 1 and IL4 
compared with the scAAV9(empty) treated mice (Fig. 46A, B). Moreover, our analysis revealed an 
attenuation in the expression of the pro-oxidative and inflammatory marker gp91PHOX upon MCP1 
induction (Fig. 456). In line with the moderate activation of glial cells during this stage (Marino et 
al., 2015), no difference was observed in the transcription level of the IL1β chemokine between the 
three experimental groups (Fig. 46D).   





Figure 46: (A, C) The immunoblot analysis showed a significant upregulation of Arginase 1 (A) and reduced expression of 
the NADPH oxidase subunit (gp91PHOX) (C) in the lumbar spinal cord of treated mice compared with the control group. Data 
are expressed as mean±SEM (n=4 Ntg; n=5 SOD1G93A EMPTY or MCP1).  (B, D) Real-time analysis of interleukin 4 (IL4) and 
interleukin 1 beta (IL1β) transcripts in the lumbar spinal cord of ALS mice and non-transgenic (Ntg) littermates. The gene 
expression analysis showed a significant upregulation of IL4 (B), but not IL1β (C) in treated mice compared with the control 
group. Data are normalised to βactin and expressed as mean±SEM (n=4 per group). **p<0.01, Ntg Vs EMPTY or MCP1; 
°p<0.05, °°p<0.01 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 
8.6 DISCUSSION 
ALS is considered a non-cell autonomous disease, in which other (resident or infiltrating) cell types 
besides MNs actively participate to the disease progression (Ilieva et al., 2009; Boillée et al., 2006a). 
Indeed, immune cells infiltration has been reported in both central and peripheral compartment of 
ALS patients and models (Chiu et al., 2009; Schreiber et al., 2019; Engelhardt et al., 1993; Henkel et 
al., 2004; Appel et al., 2010). Notably, axonal degeneration, destruction of nerve terminals and 
muscle atrophy are early events in the disease pathogenic cascade, anticipating the MN 
degeneration and the onset of motor symptoms (Clark et al., 2016; Azzouz et al., 1997; Fischer et 
al., 2004). This evidence has led to ALS being recognised as a distal axonopathy, whereby skeletal 
muscle contributes to a retrograde signalling cascade that affects MNs (Moloney et al., 2014; 
Dadon-Nachum et al., 2011). 
The role of inflammatory mechanisms in influencing the degeneration/regeneration of the 
peripheral compartment is still partially known in comparison with the understanding of 
inflammation involving glial and immune cells in the CNS.  However, studies in rodent models of 




the disease recently reported that successful axon and muscle regeneration depends on the 
coordinated efforts of immune cells which, besides removing the cellular debris, led the 
establishment of a permissive milieu to wound healing (Deng et al., 2018; Van Dyke et al., 2016; 
Nardo et al., 2016b). This evidence suggested a protective role of the immune response in the 
peripheral compartment of ALS. 
The intramuscular injection of the scAAV9_MCP1 prevents the degeneration of the skeletal 
muscles of SOD1G93A mice at the early stage of the disease anticipating the peripheral immune 
response  
The analysis performed at the 14 weeks (i.e. ~2 weeks before the overt muscle strength 
impairment) showed that C57 SOD1G93A mice, in concomitance with the loss of ~40% of the TA 
muscle mass, launched the inflammatory immune response activating the resident macrophages 
and recruiting neutrophils from circulation. As indicated by the fine kinetic governing the infiltration 
of the immune cells within the injured muscle (Yang and Hu 2018; Tidball 2017; Oishi and Manabe 
2018), the chemotactic gradient (MCP1, CXCL2, GM-CSF, etc..) established within the injured 
muscle recruits neutrophils (Peterson and Pizza 2009; Shireman et al., 2007), which are the first 
non-resident cells entering within the damage site to amplify the inflammation and promote the 
recruitment of haematogenous macrophages (Teixeira et al., 2003; Tidball 1995). This evidence 
indicated that, in comparison to the extent of damage occurred in the TA muscle at 14 weeks, the 
pro-regenerative immune response of ALS mice is delayed and therefore inadequate to counteract 
the progressive denervation atrophy of the hind limb muscles. Conversely, the early induction of 
MCP1 anticipated the recruitment of the immune cells and this translated in remarkable 
preservation of the skeletal muscles of ALS mice, as demonstrated by the reduced denervation 
atrophy and metabolic dysregulation recorded in the TA muscle of treated mice compared with the 
control group. Indeed, the data collected showed that a “second wave” of immune cell infiltration, 
in which neutrophils give way to macrophages and T lymphocytes (Yang and Hu 2018; Tidball 2017; 
Oishi and Manabe 2018), characterised the TA muscle of treated mice six weeks after the 
scAAV9_MCP1 injection. Notably, our analysis revealed an increased infiltration of T reg cells, which 




repress the inflammation sustaining the switch of M1 phagocytic macrophages towards the M2 
myogenic pro-regenerative phenotype (Schiaffino et al., 2017; Villalta et al., 2014). Accordingly, 
TNFα and IGF1 were downregulated whereas Sirt1 was increased upon MCP1 induction, indicating 
that the phenotypic switch of macrophages has already occurred in the TA muscle of 14 weeks old 
treated mice (Tonkin et al., 2015; 2012).  
Noteworthy, Sirt1 also sustains the myogenic activity (Rathbone et al., 2009; Tonkin et al., 2012), 
which is increased in the TA muscle of treated mice by virtue of the inductive action of the T reg 
cells and M2 macrophages on myogenic progenitor cells (Castiglioni et al., 2015; Tidball et al., 2014; 
Tidball 2017; Arnold et al., 2007), thus translating in the muscle regeneration. 
Therefore, the data collected showed that the early induction of MCP1 anticipated the immune-
mediated regeneration of the skeletal muscle of ALS mice, resulting in their preservation from the 
denervation atrophy. 
The intramuscular injection of the scAAV9_MCP1 in SOD1G93A mice did not modify the nerve 
response to damage at the presymptomatic stage of the disease 
The analysis of the sciatic nerve of ALS mice did not show any notable difference following the 
MCP1 induction. Although the treatment increased the expression of p75NTR, suggesting a better 
ability of treated mice to respond to the nerve damage (Deng et al., 2018), it did not modify the 
extent of the immune response. Indeed, differently from the scenario visible at the disease onset 
(Nardo et al., 2016b), we did not observe cytotoxic T cells infiltration either any sign of inflammation 
in both groups of ALS mice. These data suggest that at 14 weeks (i.e. ~2 weeks before the 
appearance of the motor dysfunction) the peripheral nerves of ALS mice are not damaged enough 
to require either the activation of the immune-mediated response or its enhancement through the 
MCP1 induction. 
Our data are in line with the dying-back degeneration theory of the neuromuscular system in ALS 
(Dadon-Nachum et al., 2011; Clark et al., 2016) surmising that the skeletal muscle is the first 
compartment affected by the disease (Loeffler et al., 2016; Clark et al., 2016). Indeed, we showed 
that, during the early stages of the disease, a significant and beneficial immune response occurred 




exclusively in the hind limb muscles of SOD1G93A mice. Accordingly, it has been suggested that the 
peripheral nerve inflammation does not initiate the degenerative phenomenon in ALS but 
represents a response to the skeletal muscle degeneration (Kano et al., 2012). 
The intramuscular injection of the scAAV9_MCP1 exerts a protective effect in the CNS of SOD1G93A 
mice at the presymptomatic stage of the disease 
Several pieces of evidence depicted MCP1 as a neurotoxic factor in ALS, inasmuch produced by 
activated microglia (Sargsyan et al., 2009; Henkel et al., 2006). However, we previously reported an 
increased expression of the chemokine in the MNs perikaryon of slow progressing compared with 
fast progressing SOD1G93A mice, suggesting an intrinsic protective role of MCP1 in the CNS of ALS 
mice (Nardo et al., 2013).  
Corroborative evidence demonstrated that MCP1 exerts a neuroprotective effect in rodent models 
of spinal cord injury directly acting on MN and also by promoting the polarisation of the recruited 
macrophages toward the M2-phenotype (Papa et al., 2018; Matsubara et al., 2015; Kwon et al., 
2015; Niemi et al., 2016). Although haematogenous monocytes do not infiltrate the CNS of SOD1G93A 
mice (Chiu et al., 2009; Kunis et al., 2015; Chiot et al., 2020), we showed that boosting MCP1 
specifically within MNs promoted the M2 fingerprint in resident microglia, which resulted in the 
reduction of the neuroinflammatory phenomenon and thus in MNs preservation. 
In conclusion, the data collected at the presymptomatic stage of the disease showed that the early 
induction of MCP1 alongside the motor unit of ALS mice could exert a dual protective effect. In the 
periphery, through its “classic” chemotactic activity toward leucocytes, MCP1 induction anticipated 
the physiologic immune response in the skeletal muscle of ALS mice, thus promoting the tissue 
regeneration and the preservation of the muscle strength. In the CNS, the MCP1 induction 
counteracted the neuroinflammatory phenomenon and protected MNs from degeneration through 
an immune-unrelated pleiotropic activity. 

















Evaluation of the effect of scAAV9_MCP1 i.m. injection 
in slow progressing ALS mice:  
the involvement of forelimb motor units 
 




9.1 BACKGROUND and AIM 
Ever since its development, mSOD1 transgenic mouse has been the most widely used animal model 
of ALS. Indeed, it faithfully recapitulates many of the pathological features of the disease (Philips 
and Rothstein 2015).  
However, differently from ALS patients, mSOD1 mice first develop hindlimb tremors, then 
progressive hindlimb weakness with rapidly deteriorating gait, eventually culminating in the 
paralysis of one or both hindlimbs (Gurney 1997; Gurney et al. 1994; Bruijn et al., 1997; Bendotti 
and Carrì 2004). Forelimbs function remains comparatively spared throughout the disease 
progression, indicating a distinct susceptibility of the upper motor unit in mSOD1 mice (Bruijn et 
al., 1997; Nardo et al., 2018; Schäfer and Hermans 2011). Accordingly, considerable evidence 
highlighted fundamental differences in the hindlimbs compared with forelimbs motor units 
response to the disease (Beers et al., 2011b; Capitanio et al., 2012; Clark et al., 2016). However, the 
comprehension of the mechanisms underlying the ascending paralysis characterising the mSOD1 
mice is still unclear. 
These observations highlighted the importance of the forelimbs contribution in the disease 
progression of ALS mice, particularly in the advanced stage of the disease. Accordingly, we have 
recently demonstrated that the preservation of the upper motor units functions actively influenced 
the disease duration and the overall survival of SOD1G93A mice (Nardo et al., 2018).  
The behavioural analysis herein performed showed that the scAAV9_MCP1 injection in both 
hindlimbs and forelimbs muscles ameliorated the motor ability of C57 SOD1G93A mice until the 
symptomatic stage, suggesting a protective effect also within the upper motor units. Moreover, in 
light of tardive involvement of the forepaws in the disease course, the analysis of the upper motor 
units might be helpful to shed light on the precocious alterations and the pro-regenerative response 
activated by SOD1G93A mice within the neuromuscular compartment. Accordingly, the next section 
of this Thesis aimed to characterise the effect of the MCP1 induction alongside the upper motor 
unit of C57 SOD1G93A mice. 
 




9.2 EXPERIMENTAL DESIGN 
An extensive histological and biochemical/molecular analysis was performed at the Triceps Brachii 
(TB) muscle and cervical spinal cord level of scAAV9_MCP1 treated mice and relative controls 
(empty vector) at both the presymptomatic (14 weeks) and the clear symptomatic (20 weeks) stage 
of the disease. 
9.3 ANALYSIS OF THE EFFECT OF MCP1 INDUCTION IN THE TRICEPS BRACHII 
MUSCLE  
9.3.1 ANALYSIS OF THE DENERVATION ATROPHY OF THE TRICEPS BRACHII MUSCLE 
AT THE PRESYMPTOMATIC AND SYMPTOMATIC STAGE OF THE DISEASE 
The clinic impairment of the forepaws appears late in the disease of SOD1G93A mice (Schäfer and 
Hermans 2011). However, likewise the hindlimbs, alterations in the forepaws could be detectable 
before the observation of evident motor impairment (Clark et al., 2016). Therefore, we first 
characterised the degeneration of the TB muscle in both treated and control C57 SOD1G93A mice at 
the presymptomatic and symptomatic stage of the disease.  
 
Figure 47: (A, B) The analysis of the triceps brachii (TB) muscle wasting revealed a significant reduction of the muscle 
atrophy in scAAV9_MCP1 treated mice compared with the control group at both presymptomatic (14wks) and 
symptomatic (20wks) stage of the disease. Data are expressed as mean±SEM (14wks: n=8 per experimental group; 20wks: 
n=10 per experimental group). °p<0.05, °°°p<0.001 by unpaired t-test. 
The recording of the muscle weight showed that at 14 weeks the TB muscle of ALS mice lost the 
19.3±2.6% of its mass compared with the non-transgenic littermates (Fig. 47A), which increased at 
the 46.8±4.1% at 20 weeks (Fig. 47B). Notably, at both time points, the induction of MCP1 
significantly preserved the TB muscle of ALS mice from the atrophic phenomenon reducing the 




muscle mass loss compared with the non-transgenic littermates at the 2.5±1.9% and 31.3±2.6% 
respectively (Fig. 47). 
Suitably, our analysis showed that, at 14 weeks, the AChRγ transcript is significantly upregulated in 
the TB muscle of ALS mice, indicating the alteration of the NMJs before the appearance of any 
clinical sign of motor impairment. However, in the treated mice, we recorded a slightly increased 
of the AChRγ transcript, suggesting an MCP1-mediated protective effect on the forelimb muscles 
even starting from the presymptomatic stage of the disease (Fig. 48A). Nevertheless, we did not 
record any significant difference in the expression of the Neural Cell Adhesion Molecule (NCAM) in 
the two experimental groups of SOD1G93A mice (Fig. 48C). Intriguingly, the beneficial effect of the 
MPC1 induction was more evident in the late stage of the disease, where we recorded a significant 
downregulation of AChRγ transcript and NCAM expression compared with the scAAV9(empty) 
treated mice (Fig. 48B, D).  
 
Figure 48: (A, B) Real-time PCR analysis of acetylcholine receptor gamma-subunit (AChRγ) transcript in the triceps brachii 
(TB) muscle at the presymptomatic (A) and symptomatic (B) stage of the disease. Data are normalised to βactin and 
expressed as mean±SEM (n=4 per experimental group). (C, D) Immunoblot analysis of the Neural Cell Adhesion Molecule 
(NCAM) in the TB muscle at 14 weeks (C) and 20 weeks (D). Data are expressed as mean±SEM (n=4 per experimental 
group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or MCP1; °p<0.05, °°°p<0.001 EMPTY Vs MCP1 by 
ANOVA with Tukey’s post-analysis. 




9.3.2 ANALYSIS OF THE RECRUITMENT OF THE IMMUNE CELLS AND 
INFLAMMATORY MILIEU AT THE PRESYMPTOMATIC AND SYMPTOMATIC STAGE 
OF THE DISEASE  
We next analysed the extent of MCP1 induction in the TB muscle six weeks and twelve weeks after 
the scAAV9_MCP1 i.m. injection. The gene expression analysis showed that MCP1 resulted 
significantly upregulated in the treated mice compared with the control group with the same extent 
at both the considered time points (Fig. 49A, B).  
 
Figure 49: (A, B) Real-time PCR analysis of MCP1 transcript in the triceps brachii (TB) muscle at the presymptomatic (A) 
and symptomatic (B) disease stage. Data are normalised to βactin and expressed as mean±SEM (n=4 per group). (C, D) 
Confocal micrographs of longitudinal sections of the TB muscle stained with the CD68 phagocytic marker and DAPI 




(nucleus). Scale bar= 100µm. (E, F) Imaging analysis revealed increased recruitment of macrophages in the TB muscle of 
treated mice compared with the control group at both time points. Data are expressed as mean±SEM (14wks: n=4 per 
group; 20wks: n=6 per group). ****p<0.0001 Ntg Vs MCP1; °°°p<0.001 EMPTY Vs MCP1 by ANOVA with Tukey’s post-
analysis.  
Suitably, macrophages recruitment was significantly increased in the TB muscle of treated mice 
compared with the control group at both time points (Fig. 49C-F). Nevertheless, at 14 weeks, the 
MCP1 induction fostered the infiltration of cytotoxic CD8+ T cells (but not CD4+ cells and FoxP3+ T 
reg cells) (Fig. 50A-C); whereas, at 20 weeks, the scAAV9_MCP1 treated mice showed a trend in the 
reduction of lymphocytes recruitment (Fig. 50D-F). On the contrary, scAAV9(empty) treated mice 
did not recruit lymphocytes at the presymptomatic stage of the disease (Fig. 50A-C). In contrast, a 
significant infiltration of T cells and immunomodulatory lymphocytes was recorded in the mSOD1 
mice at the symptomatic stage, arguably to counteract the denervation atrophy occurred and 
promote the skeletal muscle regeneration (Fig. 50D-F).  
 
Figure 50: Real-time PCR analysis of CD8α receptor, CD4α receptor and Foxp3 transcripts in the triceps brachii (TB) muscle 
of ALS mice and non-transgenic (Ntg) littermates at the presymptomatic (A-C) and symptomatic (D-F) stage of the disease. 
Data are normalised to βactin and expressed as mean±SEM (n=4 per experimental group).  *p<0.05 Ntg Vs EMPTY or 
MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis.  
Based on this evidence, we next analysed the M1/M2 polarisation of the immune cells recruited 
within the forepaw muscle of ALS mice following MCP1 induction. At 14 weeks, TNFα was 
significantly upregulated in the TB muscle of treated mice compared with controls while no 
difference in the expression of Arginase 1 was found between the two groups of ALS mice (Fig. 51A, 
E), suggesting a massive infiltration of M1 polarised leukocytes six weeks after the scAAV9_MCP1 




injection. Notably, our analysis revealed a significant increase in the transcription level of IGF1 (Fig. 
51C), indicating the switching of the infiltrated M1 cells toward the anti-inflammatory phenotype 
(Tonkin et al., 2015). Accordingly, at the symptomatic stage of the disease, TNFα was 
downregulated whereas Arginase 1 was increased in the treated mice compared with the control 
group (Fig. 51B, F), suggesting the establishment of an anti-inflammatory milieu twelve weeks after 
the scAAV9_MCP1 injection. Suitably, we did not record any difference in the transcription of IGF1 
among the experimental groups at the symptomatic disease stage (Fig. 51D). 
 
Figure 51: (A-D) Real-time PCR analysis of tumour necrosis factor alpha (TNFα) and insulin-like growth factor 1 (IGF1) 
transcripts in the triceps brachii (TB) muscle of ALS mice and non-transgenic (Ntg) littermates at the presymptomatic (14 
weeks)  and symptomatic (20 weeks) stage of the disease. The gene expression analysis revealed a significant upregulation 
of TNFα and IGF1 transcripts in the treated mice compared with the control group at the presymptomatic stage of the 
disease (A, C). Conversely, an opposite trend was observed at the symptomatic stage of the disease (B, D). Data are 
normalised to βactin and expressed as mean±SEM (n=4 per experimental group). (E, F) Immunoblot analysis performed in 
the TB muscle extract showed a significant expression of Arginase 1 (Arg1) in treated mice compared with the control 
group at the symptomatic (F) but not at the presymptomatic (E) stage of the disease. Data are expressed as mean±SEM 
(n=4 per experimental group). *p<0.05, **p<0.01, ***p<0.001 Ntg Vs MCP1; °p<0.05, °°°p<0.001 EMPTY Vs MCP1 by 
ANOVA with Tukey’s post-analysis.  
9.3.3 CHARACTERISATION OF THE SATELLITE CELL-MEDIATED RESPONSE AT THE 
PRESYMPTOMATIC AND SYMPTOMATIC STAGE OF THE DISEASE  
It has been reported that the inflammatory polarisation of the infiltrating immune cells actively 
influences the fate of the myogenic progenitor cells (MPCs, a.k.a. satellite cells) (Tidball 2017; Yang 
and Hu 2018). Therefore, we analysed the effect of the MCP1-mediated immune cells infiltration 
on the activity of the satellite cells in the TB muscle of ALS mice at both 14 weeks and 20 weeks. 




The immunohistological analysis of transverse TB muscle sections showed that the treatment did 
not modify the quiescent status of the MPCs at the presymptomatic stage of the disease (Fig. 52A, 
B). Conversely, at 20 weeks, the full switch of the recruited leucocytes toward the anti-
inflammatory phenotype promoted the TB regeneration in treated mice, as demonstrated by the 
increased percentage of differentiating Pax7-/MyoD+ satellite cells compared with the control group 
(Empty: 10.5±3.6%; MCP1: 19.5±2.3%) (Fig. 52A, C). 
 
Figure 52: (A) Confocal micrographs of coronal sections of triceps brachii muscle of ALS mice and non-transgenic (Ntg) 
littermates stained with Pax7 (red), MyoD (green) and DAPI (blue). Imaging analysis did not show any difference in the 
myogenic program of satellite cells between the three experimental groups at 14weeks (B). Conversely, increased 
differentiation of satellite cells was recorded in treated mice compared with the control group at 20 weeks (C). Scale bar= 
20µm. Data are expressed as mean±SEM (n=4 per experimental group). °p<0.05 EMPTY Vs MCP1 by Two-way ANOVA with 
Tukey post-analysis. 
9.4 ANALYSIS OF THE EFFECT OF MCP1 INDUCTION IN THE CERVICAL SPINAL 
CORD  
9.4.1 CHARACTERISATION OF THE EFFECT OF MCP1 INDUCTION ON THE CERVICAL 
MOTOR NEURON SURVIVAL 
The progressive increase of MCP1 within the CNS is classically known as detrimental in promoting 
the neuroinflammation (Bose and Cho 2013; Conductier et al., 2010). Nevertheless, robust 
experimental evidence indicates that the chemokine also possesses pleiotropic non-immune 




beneficial properties (Semple et al., 2010b; Papa et al., 2018; Locatelli et al., 2012; Chintawar et al., 
2009).  
 
Figure 53: (A, B) Real-time PCR analysis of MCP1 transcript in the cervical spinal cord of ALS mice and non-transgenic (Ntg) 
littermates at the presymptomatic (A) and symptomatic (B) stage of the disease.  The gene expression analysis revealed a 
significant upregulation of the chemokine in treated mice compared with the control group at the 14 weeks but not at 20 
weeks. Data are normalised to βactin and expressed as mean±SEM (14 weeks: n=3 Ntg, n=4 SOD1G93A Empty or MCP1; 20 
weeks n=4 per group). (C, D) Confocal micrographs of coronal sections of the cervical spinal cord of ALS mice and non-
transgenic (Ntg) littermates stained with choline acetyltransferase (ChAT) at the presymptomatic (C) and symptomatic 
stage of the disease (D). Cervical motor neuron count (MN Area > 400μm2) at 14 weeks (E) and 20 weeks (F). Scale bar= 
50µm. Data are expressed as mean±SEM (14 weeks: n=3 per experimental group; 20 weeks: n=4 per experimental group). 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Ntg Vs EMPTY or MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s 
post-analysis.  




The data collected showed that the specific induction of MCP1 in the lower motor unit of C57 
SOD1G93A mice significantly reduced the lumbar MNs loss at both time points considered in this 
study (Figs. 34F and 45B). Therefore, we verified the extent of chemokine induction in the cervical 
segment of the spinal cord at both the presymptomatic and symptomatic stage of the disease and 
whether the induction of MCP1 was efficient to protect the cervical MNs from degeneration. The 
gene expression analysis showed a significant upregulation of the MCP1 transcript in the cervical 
segment of the spinal cord of treated mice compared with the control groups at the pre-
symptomatic stage of the disease (Fig. 53A). However, no difference was recorded between the 
two groups of ALS mice at the symptomatic disease stage (Fig. 53B).  
Suitably, the histological analysis performed at 14 weeks showed a trend in the reduction of the 
MN death following MCP1 induction, although not significant compared with the scAAV9(empty) 
treated mice (MN nr Empty: 6.36±0.14, MN nr MCP1: 8.06±0.51) (Fig. 53C, E). However, this 
protective trend was lost with the disease progression as we did not record any significant 
difference in the neurodegenerative phenomenon between the two groups of ALS mice at the 
symptomatic stage of the disease (MN nr Empty: 3.25±0.27, MN nr MCP1: 4.29±0.40) (Fig. 53D, F). 
9.4.2 ANALYSIS OF THE GLIA CELLS ACTIVATION AND THE INFLAMMATORY MILIEU 
IN THE CERVICAL SPINAL CORD 
The cervical and lumbar segment of the spinal cord of ALS mice showed a different modulation of 
the inflammation during the disease progression (Beers et al. 2011b).  We found that the induction 
of MCP1 within the lower motor units of C57 SOD1G93A mice was efficient in modulating the 
neuroinflammatory phenomenon within the lumbar spinal cord at both presymptomatic and 
symptomatic disease stage (Figs. 35, 36, 45, 46). Therefore, we assessed the extent of the glial cells 
activation and the resulting inflammation in the cervical spinal cord of ALS mice upon MCP1 
induction. 





Figure 54: (A, D) Immunoblot analysis of glial fibrillary acidic protein (GFAP) and ionised calcium-binding adapter molecule 
1 (Iba1) performed in cervical spinal cord extracts from ALS mice and non-transgenic (Ntg) littermates at the pre-
symptomatic (A, B) and symptomatic (C, D) stage of the disease. The densitometric analysis did not show any difference 
in the expression of GFAP and Iba1 between the three experimental groups at 14 weeks (A, B). Conversely, a reduced 
astrocytosis (C) but not microglia proliferation (D) was observed in treated mice compared with the control group at 20 
weeks. Data are expressed as mean±SEM (n=3 Ntg; n=5 SOD1G93A Empty or MCP1). *p<0.05 Ntg Vs EMPTY or MCP1 by 
ANOVA with Tukey’s post-analysis.  
The data collected showed that the scAAV9_MCP1 injection modified neither the astrocytes 
activation nor the microglia proliferation in the cervical spinal cord at 14 weeks (Fig. 54A, B). 
Conversely, at the symptomatic stage of the disease, we recorded a reduced astrocytosis upon 
MCP1 induction (Fig. 54C). However, no difference was observed in the extent of microglia 
proliferation between the two groups of ALS mice (Fig. 54D). 
Moreover, in line with the trend in the cervical MN protection observed at the pre-symptomatic 
stage of the disease, Arginase 1 was significantly upregulated in treated mice compared with the 
control group at 14 weeks but not at 20 weeks (Fig 55A, E). However, upon MCP1 induction, the 
transcription level of IL4 resulted upregulated at both time points, although not significantly 
compared with the scAAV9(empty) treated mice (Fig. 55B, F). Nevertheless, no difference in the 




expression of the inflammatory markers gp91PHOX and IL1β was observed between the two groups 
of ALS mice at both time points (Fig. 55C, D, G, H). 
 
Figure 55: Representative immunoblot images of arginase 1 (Arg1) and the NADPH oxidase subunit (gp91PHOX) in cervical 
spinal cord extracts from ALS mice and non-transgenic (Ntg) littermates at the pre-symptomatic (A, C) and symptomatic 
(E, G) stage of the disease. The densitometric analysis showed an increased expression of Arg1 in treated mice compared 
with the control group at 14weeks (A) but not at 20 weeks (E). However, the MCP1 induction did not modify the gp91PHOX 
expression at both time points (C, G). Data are expressed as mean±SEM (14wks: n=3 Ntg; n=4 SOD1G93A Empty or MCP1; 
20wks: n=3 Ntg, n=5 SOD1G93A Empty or MCP1). Real-time PCR analysis of Interleukin 4 (IL4) and Interleukin 1β (IL1β) 
transcripts in the cervical spinal cord of ALS mice and Ntg littermates at the pre-symptomatic (B, D) and symptomatic (F, 
H) stage of the disease. The gene expression analysis revealed a significant upregulation of IL4 in following MCP1 induction 
compared with the Ntg littermates, but not scAAV9(empty) treated mice at both time points (B, F). However, no difference 
in the IL1β transcription was recorded between the two groups of ALS mice at both 14 (D) and 20 weeks (H). Data are 
normalised to βactin and expressed as mean±SEM. (14wks: n=3 Ntg; n=4 SOD1G93A Empty or MCP1; 20wks: n=4 per group). 
*p<0.05, **p<0.01 Ntg Vs EMPTY or MCP1; °p<0.05 EMPTY Vs MCP1 by ANOVA with Tukey’s post-analysis. 





The characterisation of mSOD1 rodent model reported that mice first developed hindlimb tremors, 
then progressive hindlimb weakness with rapidly deteriorating gates, which eventually culminated 
in paralysis of one or both hindlimbs (Gurney et al., 1994; Bendotti and Carrì 2004). Forelimb 
weakness occurred later if at all in disease (Bruijn et al., 1997; Schäfer and Hermans 2011), 
suggesting a different susceptibility of the upper motor units in the SOD1G93A ALS murine model.  
Despite the ascending paralysis is a well-recognised clinical feature of mSOD1 mice, few studies 
have been aimed at the analysis of the temporal and regional pattern of degeneration of the upper 
compared with the lower motor units in ALS mice (Capitanio et al., 2012; Beers et al., 2011b; Clark 
et al., 2016; Nardo et al., 2018). Therefore, the mechanisms underlying the delayed degeneration 
of the forelimb motor units in mSOD1 mice are still unknown. 
The intramuscular injection of the scAAV9_MCP1 prevents the degeneration of the forelimb 
skeletal muscles of SOD1G93A mice anticipating the peripheral immune response  
In line with previous evidence (Clark et al., 2016), our results showed that that the degeneration of 
the forepaw skeletal muscles is an early event in ALS pathogenic cascade, which already occurs 
even several weeks before the appearance of motor symptoms in SOD1G93A mice. Indeed, at 14 
weeks, the TB muscle of ALS mice was significantly atrophied and denervated compared with the 
non-transgenic littermates. Nevertheless, during this stage, ALS mice did not recruit immune cells 
as a mechanism to hamper the degenerative cascade occurring within the skeletal muscles 
(Ceafalan et al., 2018; Yang and Hu 2018). However, the recent literature described an inductive 
mechanism of the M1 or M2-polarised immune cells on the muscular progenitor cells, promoting 
their proliferation and differentiation respectively to accomplish the muscle regeneration (Yang and 
Hu 2018; Tidball 2017).  
Here, we confirm this evidence showing that the anticipation of the inflammatory response through 
the MCP1-mediated immune cells recruitment protected the TB muscle of SOD1G93A mice from the 
denervation atrophy since the early stage of the disease. Notably, the significant upregulation of 
IGF1 recorded at 14 weeks suggested that the scAAV9_MCP1 injection also anticipated the switch 




of the infiltrated leucocytes toward the anti-inflammatory phenotype (Tonkin et al., 2015). 
Accordingly, at the symptomatic stage of the disease, the reduced inflammation in the TB muscle 
of treated mice compared with the control group was recorded. Specifically, the establishment of 
the anti-inflammatory milieu within the forepaw muscle of treated mice promoted the 
differentiation of the satellite cells, thus resulting in the preservation of the tissues from the 
denervation atrophy.  
The intramuscular injection of the scAAV9_MCP1 exerts a protective effect in the cervical spinal 
cord of SOD1G93A mice at the early stage of the disease 
MCP1 is a well-known pro-inflammatory neurotoxic factor produced by activated microglia 
(Sargsyan et al., 2009; Henkel et al., 2006; Conductier et al., 2010). However, recent evidence 
suggested a pleiotropic protective role of MCP1 within the CNS unrelated to its chemotactic 
function (Madrigal and Caso 2014; Papa et al., 2018; Locatelli et al., 2012). 
Accordingly, the data herein collected showed that the specific induction of MCP1 within the MN 
soma partially preserve cervical MNs from degeneration at 14 weeks, increasing the expression of 
anti-inflammatory factors thus prolonging the so-called stable phase of the disease in mSOD1 mice 
(Henkel et al., 2009; Beers et al., 2011a). Although small in size, the neuroprotective worthiness of 
MCP1 was detectable early in the disease, when, as demonstrated by the negligible MN loss and 
glial cells activation, the cervical spinal cord segment of SOD1G93A mice is almost spare from the 
degenerative phenomenon (Beers et al., 2011b).  
Conversely, at 20 weeks, we did not record any significant increase in the chemokine transcription 
within the cervical spinal cord of treated mice compared with the control group. This might derive 
from the progressive MCP1 production by activated microglia cells of mSOD1 mice (Sargsyan et al., 
2009; Butovsky et al., 2012), as previously observed in the lumbar segment of the spinal cord of 
SOD1G93A mice (Fig. 33B). However, the neuroprotective effect mediated by MCP1 was not 
maintained until the symptomatic stage of the disease. Nevertheless, we recorded an increased 
transcription of the anti-inflammatory IL4 cytokine in the CNS of treated mice compared with the 




control group, which might be responsible for the reduced activation of astrocytes upon MCP1 
induction (Brodie et al., 1998; Hu et al., 1995). 
In conclusion, the data collected showed that the early induction of MCP1 alongside the upper 
motor units anticipated the physiologic immune response within the TB muscle of ALS mice, 
delaying the denervation atrophy. Furthermore, thanks to its pleiotropic neuroprotective activity, 
the chemokine induction reduced the neuroinflammatory phenomenon within the cervical spinal 
cord preventing the MN death at the early stage of the disease. 
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The results obtained in this project are summarised in the table below 
RATIO MCP1 Vs EMPTY 
Tissue  Parameter C57SOD1G93A 129SvSOD1G93A 
 14 weeks 20weeks 17 weeks 
TA muscle MCP1 +182 +180 +11 
 Wasting -0.5 nc nc 
AChRγ -2 nc -2.5  
NCAM nc nc nc 
CD68+ cells (IHC) +2 nc +1.8 
CD8+ cells (mRNA) nc  nc +13 
CD4+ cells (mRNA) nc nc +7.8 
FoxP3+ cells (mRNA) +5.4 nc +4.8 
TNFα -2 nc +2.3 
gp91PHOX / -1.6 +0.7 
IGF1 -0.5 -2.8 -2.4 
Arginase1 +2 nc nc 
Pax7 nc nc nc 
MyoG +2.2 nc nc 
MyoD +1.5 / / 
Neutrophils  -4.3 / / 
SIRT1 +1.5 / / 
% SDH+ muscle fibres -1.1 / / 
% Pax7+/MyoD- cells  -0.1 / / 
% Pax7+/MyoD+ cells nc / / 
% Pax7-/MyoD+ cells +5 / / 
Centralized myonuclei +1.7 / / 
Sciatic Nerve MCP1 nc nc +1.7 
 CD68+ cells (mRNA) nc -1.3 nc 
CD8+ cells (mRNA) nc nc +2.2 
TNFα nc -1.5 nc 
NF200 / +2.3 nc 
β importin / nc nc 
p75NTR nc +1.5 nc 
MBP / +3 nc 
Lumbar SC MCP1 +1.7 nc nc 
 MN nr +1.4 +1.7 nc 
GFAP nc nc nc 
Iba1 nc nc nc 
CD68 (mRNA) / nc nc 
Arginase1 +2.8 nc nc 
gp91PHOX nc nc nc 
IL1β nc -1.7 nc 
IL4 +2.1 / / 




RATIO MCP1 Vs EMPTY 
Tissue  Parameter C57SOD1G93A 129SvSOD1G93A 
 14 weeks 20weeks 17 weeks 
TB muscle MCP1 +12 +7.5 +40 
 Wasting -7.7 -1.3 nc 
AChRγ nc -2 +2 
NCAM nc -2 nc 
CD68+macrophages (IHC) +2.3 +1.3 / 
CD8+ cells (mRNA) +3.8 nc / 
CD4+ cells (mRNA) nc nc / 
FoxP3+ cells (mRNA) nc nc / 
TNFα +2.7 nc / 
IGF1 +1.5 nc / 
Arginase1 nc +3.2 / 
% Pax7+/MyoD- cells  nc -1.1 / 
% Pax7+/MyoD+ cells nc nc / 
% Pax7-/MyoD+ cells nc +1.8 / 
Cervical SC MCP1 +2.8 nc / 
 MN nr nc nc / 
GFAP nc nc / 
Iba1 nc nc / 
Arginase1 +1.7 nc / 
gp91PHOX nc nc / 
IL4 nc nc / 
IL1β nc nc / 
Table 13: Summary of the results obtained in this project (nc, no change; /, not analysed). 
TA muscle_ The significant MCP1 upregulation recorded in the TA muscle of 14 weeks-old 
C57 SOD1G93A mice protected the damaged organ from the denervation atrophy 
anticipating the peripheral immune response. The activation of the inflammatory 
response in conjunction with the appearance of the first degenerative events allowed its 
correct management, sustaining the phenotypic switch of the infiltrated leucocytes 
toward the M2 pro-regenerative phenotype and the eventual activation of the myogenic 
programme. However, the strength of the MCP1-mediated boosting of the immune 
response was not sufficient to protect the skeletal muscle until the symptomatic stage of 
the disease. Nevertheless, the M2 polarisation of the inflammatory milieu was still 
detectable in the hid paw muscles of 20 weeks-old C57 SOD1G93A mice. 
Conversely, the significant MCP1 upregulation recorded in the TA muscle of 129Sv 
SOD1G93A mice translated in a delayed activation of the immune response that 
exacerbated the inflammatory phenomenon within the peripheral compartment. 




Sciatic Nerve_ The data collected in the 129Sv SOD1G93A mice confirmed that the delayed 
activation of the inflammatory response is not enough to protect motor axons from 
degeneration. Conversely, C57 SOD1G93A mice's better capability to manage the 
inflammatory response (boosted by MCP1) translated into PNS preservation until the 
advanced disease stage. Notably, our data confirmed the previous evidence (Chiu et al. 
2009; Kano et al. 2012) indicating that the sciatic nerve of ALS mice is not damaged 
enough to require the activation of the inflammatory response at the pre-symptomatic 
stage of the disease. 
Lumbar SC_ The data collected showed that the novel immune unrelated capability of 
MCP1 was able to extend the so-called stable phase of the neuroinflammatory 
phenomenon in C57 SOD1G93A mice thus preserving MNs from the degeneration until the 
advanced disease stage. However, the neuroprotective effect mediated by MCP1 was no 
detectable in the CNS of 129Sv SOD1G93A mice. 
TB muscle_ The early MCP1 induction within a body compartment belatedly affected by 
the ALS degenerative phenomenon allowed the prompt activation of the inflammatory 
response and its correct management (M1 -> M2 phenotypic switch) resulting in the TB 
muscle preservation until the symptomatic stage. Conversely, the scAAV9_MCP1 injection 
did not preserve the forepaw muscle of 129Sv SOD1G93A mice at the symptomatic disease 
stage. 
Cervical SC_ The data collected confirmed the ability of MCP1 at extending the initial M2-
polarised phase of the neuroinflammatory response in the CNS of ALS mice, albeit without 
protecting cervical MNs significantly. Surprisingly, the neuroprotective effect of MCP1 
was lost at the advanced stage of the disease.
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GENERAL DISCUSSION and CONCLUSIONS 
In this study, we examined the involvement of the MCP1-mediated axis in governing the speed of 
the disease progression of two ALS models characterised by remarkable differences in the clinical 
phenotype.  
Our observations revealed that the induction of MCP1 in the motor unit of slow progressing 
SOD1G93A mice ameliorated the clinical phenotype anticipating the recruitment and phenotypic 
switch of leucocytes within the peripheral compartment, hence sustaining the myogenic 
programme and nerve regeneration. Conversely, in fast progressing SOD1G93A mice, the treatment 
exacerbated the inflammatory response resulting in the worsening of the motor ability. Besides, we 
found that the characterisation of the immune response fingerprint in the skeletal muscle of ALS 
patients might be a prognostic adjunct useful for a precise stratification in clinical practice.  
Intriguingly, our data showed a role for this chemokine in the modulation of the neuroinflammation 
in the CNS of SOD1G93A, with the overall effect of preventing MNs degeneration in the slow 
progressing but not fast progressing ALS mice. 
We recently reported a different activation of MCP1 within MN soma and peripheral compartment 
of the two SOD1G93A models (Nardo et al. 2013; Nardo et al., 2016b). Notably, our studies revealed 
that, despite the same extent of MN loss during disease progression (Marino et al., 2015), fast 
progressing mice showed earlier muscle denervation and motor axon deterioration that correlates 
with a reduced immune cells (i.e. macrophages and T lymphocytes) infiltration in the peripheral 
compartment compared with slow progressing ALS mice (Nardo et al., 2016b; Vallarola et al., 2018). 
We speculated that this defective immune response underpinned the higher peripheral 
degeneration and the faster disease progression of 129Sv SOD1G93A. 
This evidence put MCP1, and the eventual peripheral immune cell recruitment, forward as a 
discriminating factor of the different speed in the disease progression recorded in the two ALS 
models.  
Several lines of evidence indicate a pivotal role of the MCP1-mediated axis in orchestrating the 
nerve (Stratton et al., 2020; Tofaris et al., 2002; Kwon et al., 2015) and muscle (Shireman et al., 




2007; Lu et al., 2011a; Martinez et al., 2010) regeneration upon damage. Moreover, a pleiotropic 
neuroprotective activity of the chemokine has been recorded within the injured CNS (Locatelli et 
al., 2012; Papa et al., 2018). 
With this study, the therapeutic potential of the chemokine has been assessed in the two ALS 
models through the injection of a self-complementary AdenoAssociated Virus serotype 9 
engineered with the murine sequence of the MCP1 gene (scAAV9_MCP1).  
Our data revealed that a single injection of the scAAV9_MCP1 in the hind limb and forelimb skeletal 
muscles of pre-symptomatic (8 weeks-old) 129Sv and C57 SOD1G93A mice was sufficient to transduce 
the upper and lower motor units in ALS mice. Notably, the experimental protocol herein applied 
demonstrated its efficiency at inducing the chemokine several weeks after the scAAV9_MCP1 
injection (until the symptomatic disease stage: 17 weeks, 129Sv SOD1G93A; 20 weeks, C57 SOD1G93A). 
An equipped immune response within the peripheral compartment is fundamental to counteract 
the ALS progression in SOD1G93A mice 
The data obtained by the experimental work detailed in this Thesis indicate that, upon 
scAAV9_MCP1 injection, the chemokine was upregulated with the same extent in the tibialis 
anterior (TA) muscle of the two strains of SOD1G93A mice. However, this translated in the 
amelioration of the clinical phenotype in the slow progressing but not fast progressing ALS mice. 
The opposite effect recorded arguably stemmed from a different immune environment developed 
by the two ALS models within the peripheral compartment upon the scAAV9_MCP1 injection. 
Indeed, we previously demonstrated that 129Sv SOD1G93A mice are less prone than C57 SOD1G93A 
mice at activating an efficient immune response within the peripheral compartment at the disease 
onset (Nardo et al., 2016b; Vallarola et al., 2018). The data collected at the symptomatic stage of 
the disease endorsed our findings, showing that the immune responsiveness of C57 SOD1G93A mice 
was finely regulated and, unexpectedly, not further increased by MCP1 induction. Conversely, 
129Sv SOD1G93A mice required an exogenous boosting (i.e. MCP1 induction) to elicit the peripheral 
immune response within the damaged muscle.  




The better ability of slow progressing ALS mice in triggering an earlier immune response allowed to 
properly exploit the chemokine induction hastening the macrophages and lymphocytes 
recruitment within muscles in the early disease stage, as demonstrated by the data collected six 
weeks after the scAAV9_MCP1 injection. The activation of the immune response in conjunction 
with the emergence of the first muscle degenerative events proved to be crucial to allow the 
phenotypic switch (M1->M2) of the recruited macrophages thus creating a permissive milieu for 
tissue regeneration (Yang and Hu 2018; Howard et al., 2020; Musarò 2014). Notwithstanding the 
hindlimb skeletal muscles were significantly damaged at the symptomatic stage, the last glimpse of 
the protective effect exerted by the early MCP1-mediated immune response was still detectable. 
Indeed, at 20 weeks, the cytoarchitecture and the myelin wrapping around motor axons were 
maintained in the scAAV9_MCP1 treated mice. Notably, the PNS preservation recorded upon MCP1 
induction might be coupled to the capability of the chemokine at promoting the axonal outgrowth 
(Locatelli et al., 2012), which is not mediated by its chemotactic power. Regardless, the PNS 
protection lighted the recruitment of the immune cells, resulting in the reduced toxic inflammation 
within the sciatic nerve of the treated mice compared with the control group.  
Based on these findings, we could surmise that the activation of the peripheral immune response 
early in the disease course delayed and attenuated the dying-back degenerative phenomenon in 
the slow progressing ALS mice (Dadon-Nachum et al., 2011; Kano, 2012). However, our data do not 
provide any hint to understand the worsening of the clinical phenotype found in 129Sv SOD1G93A 
mice upon MCP1 induction. The different clinical outcome recorded in the fast progressing mice 
could be ascribed to a strain-related deficit in the activation or management (i.e. M1->M2 
phenotypic switch) of the immune response (White et al., 2002; Piirsalu et al., 2020). Based on our 
findings, we could speculate that this deficiency is exacerbated upon MCP1 boosting through the 
induction of a persistent inflammatory milieu within the periphery of 129Sv SOD1G93A mice, which 
significantly hampers tissue regeneration (Büttner et al., 2018; Forcina et al., 2020). 
 




The temporal activation of the immune response as a discriminating factor for the successful 
regeneration of the peripheral compartment in SOD1G93A mice 
The analysis of the effect of the scAAV9_MCP1 injection in the slow progressing mice demonstrated 
the value of a prompt immune response in slowing down the degeneration of the peripheral 
compartment and thus the speed of disease progression.  
The data collected at 14 weeks demonstrated that the MCP1-mediated early increase in leucocytes 
recruitment and phenotypic switch significantly delayed the TA muscle degeneration promoting 
and sustaining the myogenic programme (Yang and Hu 2018; Howard et al., 2020; Musarò 2014; 
Chazaud 2020). The importance of this anticipated immune response in the C57 SOD1G93A treated 
mice was detectable even at the symptomatic disease stage when the M2 polarisation of the 
inflammatory milieu was maintained, and a partial effect on the preservation of neuromuscular 
junctions innervation was observed. Moreover, the early protection of the skeletal muscles coupled 
to the intrinsic capability of MCP1 at preserving the axons (Locatelli et al., 2012) might have limited 
the dying-back degeneration of the neuromuscular system in ALS mice. Indeed, the Schwann cell-
mediated response was significantly activated, and the cytoarchitecture and the myelin 
ensheathment maintained in the sciatic nerve during the disease progression. 
The protective effect exerted by the early immune response in preserving the skeletal muscle from 
degeneration was even more pronounced at the TB muscle level. In line with the delayed 
involvement of the forelimbs in the SOD1G93A mice pathology (Bruijn et al., 1997; Schäfer and 
Hermans 2011; Bendotti and Carrì 2004), at 14 weeks the TB muscle exhibited ~20% of muscle 
wasting compared with the ~40% of the TA muscle. The early induction of MCP1 forced and 
sustained the immune response in conjunction with the hinted damage of the forepaws muscle. 
Indeed, higher macrophages and lymphocytes infiltration was recorded in the treated mice 
compared with the control group, resulting in the almost complete preservation of the TB muscle 
from the denervation atrophy at 14 weeks.  
Intriguingly, the MCP1-mediated early leucocytes recruitment was pivotal in promoting the correct 
management of the immune response, as demonstrated by the M2 fingerprint of macrophages and 




the decreased inflammatory response recorded in the forepaw muscle at 20 weeks. Therefore, the 
permissive environment established resulted in the significant preservation of the TB muscle, which 
might be the leading responsible for the ameliorated motor ability recorded in the treated mice at 
20 weeks in light of the negligible contribution of the hind limbs in the advanced disease stage 
(Nardo et al., 2018).  
Remarkably, our data strongly support the hypothesis that the delayed immune response is a 
pathological feature of both ALS strains, as demonstrated by the emptiness of the immune-
mediated regenerative mechanisms physiologically activated by C57 SOD1G93A mice. Indeed, our 
analysis showed that at 14 weeks (i.e. ~2 weeks before the motor onset) the TA muscle is 
significantly affected by the disease, as demonstrated by the marked atrophy and denervation. 
Unlike the rapid kinetics of leucocytes recruitment, which is pivotal to rescue skeletal muscle upon 
acute injury (Yang and Hu 2018), ALS mice have just launched their inflammatory response, as 
demonstrated by the significant infiltration of neutrophils but not macrophages or lymphocytes.  
Altogether this evidence suggests that mSOD1 mice have a poorly responsive immune system, 
which is unable to promptly activate an effective wound healing process in the peripheral 
compartments. Accordingly, the delayed immune response within significantly compromised body 
compartments remarkably affected the phenotypic switch of the recruited immune cells. The end-
game is a chronic inflammation which is detrimental to the process of tissue healing (Nathan and 
Ding 2010). Our observations might mirror previous evidence by Kunis et al. (2015), who showed 
that SOD1G93A mice are immunocompromised and that the enhancing of the leucocytes trafficking 
within CNS resulting in the amelioration of the disease course. 
The phenotypic switch of the infiltrated macrophages is pivotal to protect the skeletal muscles of 
ALS patients from the degeneration 
The preliminary data obtained from the analysis of the muscle biopsies collected from fast and slow 
progressing ALS patients corroborated our preclinical observations, confirming a crucial role for the 
immune response in governing the degeneration of the peripheral compartment in the disease. 




Due to the delay in the ALS diagnosis, especially in patients with the spinal onset (Richards et al., 
2020), the data obtained mirror a full-blown disease stage, at which, as previously shown in the two 
mSOD1 models herein examined, the activation of MCP1 signalling and the extent of infiltrated 
immune cells seems to be irrelevant to the speed of the disease progression. Indeed, we did not 
find any correlation between the ΔFS and the muscular activation of the MCP1 pathway or the 
extent of Iba1+ monocytes infiltration. 
Nevertheless, the evidence we have obtained highlight the relevance of the inflammatory 
fingerprint acquired by the recruited immune cells in preventing the skeletal muscle degeneration. 
Indeed, the M1 and M2 polarization of the infiltrated macrophages was recorded in the muscle of 
fast and slow progressing ALS patients, respectively. These observations demonstrate the relevance 
of the phenotypic switch of recruited macrophages in mediating the protection of the skeletal 
muscle in ALS.  
The easy accessibility in the collection of the muscle bioptic samples paves the way for a more in-
depth characterisation of the immune muscle profile, even longitudinally in the ALS course. This 
might be an attractive tool to shed light on the involvement of the peripheral immune response in 
governing the speed of the disease progression. Moreover, the characterisation of the muscle 
profile early in the disease might confirm the evidence of the two SOD1G93A strains, hence putting 
the peripheral immune signatures forward as a prognostic biomarker in ALS. It will be therefore 
essential to look at a more systemic profile of immunoregulation in ALS, which would be more 
accessible in the clinical setting and could mirror the changes thus far identified within the affected 
muscle. 
A Novel immune-unrelated pleiotropic role of MCP1 in the CNS of the SOD1G93A mice 
The data herein collected confirmed the previous evidence demonstrating that, besides its well-
known toxic inflammatory role (Semple et al., 2010b; Madrigal and Caso 2014), MCP1 possesses an 
indirect (modulating the recruited immune cells inflammatory phenotype) (Matsubara et al., 2015; 
Kwon et al., 2015; Niemi et al., 2016) and direct (reducing excitotoxicity and promoting axonal 
outgrowth) (Locatelli et al., 2012; Papa et al., 2018) neuroprotective role in the CNS. 




Our observations demonstrate that the specific induction of MCP1 within the MN perikaryon is 
effective at reducing the neuroinflammatory phenomenon in SOD1G93A mice. Notably, the 
protective role was not related to the chemotactic activity of MCP1, since considerable 
observations have demonstrated that the haematogenous monocytes required an exogenous 
boosting to enter in the CNS of SOD1G93A mice (Kunis et al., 2015; Chiu et al., 2009; Chiot et al., 
2020), but rather to its ability to modulate astroglial activation and hence the polarization of the 
neuroinflammatory milieu (Quinones et al., 2008; Kalehua et al., 2004; Semple et al., 2010a). 
Intriguingly, the data collected in the comparative study of the two SOD1G93A strains showed that 
the treatment was effective at preventing the MNs degeneration in slow progressing but not fast 
progressing ALS mice. This disparity in neuroprotective effect might have been influenced by the 
different modulation of the chemokine basally recorded in the two ALS models during disease 
progression (Nardo et al., 2013). Indeed, the higher physiological activation of MCP1 in C57 
SOD1G93A mice in addition to the scAAV9-mediated chemokine induction might have exerted an 
additive effect resulting in lumbar MN preservation until the advanced disease stage. Conversely, 
this additive effect was not sufficient to significantly counteract the neurodegenerative 
phenomenon in the fast progressing mice, arguably due to the weak activation of the chemokine 
recorded within the MN of the 129Sv SOD1G93A mice since the early stage of the disease. 
The neuroprotective effect of the scAAV9-mediated induction of MCP1 was also detectable in the 
cervical spinal cord of 14 weeks-old slow progressing ALS mice. Nevertheless, the analysis 
performed at 20 weeks revealed a weak effect of the treatment at modulating the 
neuroinflammation hence resulting in the lack of difference in the cervical MN survival between 
the two experimental groups of C57 SOD1G93A mice. This discrepancy might be linked, as previously 
discussed for the lumbar spinal cord of the two ALS strains, to the different physiological activation 
of the chemokine within MNs. Therefore, we can suppose that, at 14 weeks, the scAAV9-mediated 
chemokine induction was sufficient to exert a beneficial effect arguably thanks to the reduced 
damage of the cervical spinal cord in the early disease stage. Conversely, as the disease progresses, 
the scAAV9-derived MCP1 induction was not sustained by the endogenous activation of the 




chemokine within cervical MNs, thus resulting in the lack of the neuroprotective effect at 20 weeks. 
However, we have not evidence regarding the modulation of MCP1 by cervical MN; therefore, 
further analyses are necessary to verify our hypothesis. 
In conclusion, in this project we shed light on the involvement of the peripheral immune system in 
the ALS course. The evidence herein collected confirm the relevance of the mechanisms involved 
in the wound healing of the peripheral compartment upon an acute injury (e.g. nerve 
crush/transection, i.m. injection of toxins) (Gaudet et al., 2011; Yang and Hu 2018) in the chronic 
degenerative cascade of ALS.  
Our observations suggest that, although potentially protective, the peripheral immune response is 
delayed in ALS mice and hence ineffective to sustain the full recovery of the damaged tissues. 
Intriguingly, our evidence showed that the inflammatory fingerprint acquired by the recruited 
immune cells is pivotal in driving a functional regeneration of the peripheral compartment and thus 
in defining the speed of the ALS progression. In keeping with this, the clinical observations indicate 
that the characterisation of the immune muscle profile might serve as prognostic adjunct useful for 
more precise patients stratification in clinical practice. 
Finally, according to our original observation, we confirmed the protective role of MCP1 in the 
neuromuscular system of ALS mice. Moreover, we demonstrated a novel immune-unrelated 
capability of the chemokine at modulating the inflammatory phenomenon in the CNS, thus 
preserving MNs from degeneration. 
Altogether, these observations nominate the peripheral compartment as a primary target for the 
development of effective therapeutic interventions in ALS capable of significantly slow down the 
disease progression. Moreover, the comprehension of the mechanisms underlying the protective 
role fulfil from MCP1 in the motor unit of mSOD1 mice might provide innovative evidence regarding 
the contribution of the immune response in ALS.  
























ALS is a multisystemic non-cell autonomous disease (Chiot et al. 2019; Moloney et al. 2014). 
However, the contribution of the immune response in governing the ALS progression is still 
debated. Moreover, mounting experimental evidence highlights the different role fulfils from the 
inflammatory response in the CNS compared with the periphery (i.e. nerves and muscles) (Chiu et 
al. 2009; Dibaj et al. 2011). 
In keeping with this, we started from the observation that the higher NMJs denervation and muscle 
degeneration underlying the faster disease progression of 129Sv SOD1G93A mice resulted from the 
faint activation of the peripheral immune response compared with the C57 SOD1G93A mice. This 
evidence highlights the pivotal role of the peripheral compartment in driving the speed of ALS 
progression and the involvement of the inflammatory response as a fundamental mechanism to 
counteract its degeneration. 
Intriguingly, here we identified the delayed immune cells recruitment within the peripheral 
compartment as a pathological feature of mSOD1 mice, which can be exacerbated by the intrinsic 
(background related) immunological profile. Moreover, the data collected upon MCP1 induction, 
corroborated by the human ALS bioptic material examination, demonstrated the importance of the 
activation of a functional peripheral immune response but even harder its correct management (i.e. 
leucocytes phenotypic switch) once triggered. 
Therefore, the characterisation of the inflammatory fingerprint of both circulating and infiltrating 
immune cells might be an attractive tool to correlate the nature and management of the immune 
response with the degeneration/regeneration of the peripheral compartment and, thus, the speed 
of ALS progression. 
Aimed to fill this knowledge gap, we will: 
 characterise the blood levels and the transcriptomic profile of the "classically" (M1) 
and "alternatively" (M2) activated monocyte in fast and slow progressing mSOD1 
mice during the disease progression. Besides, the more relevant molecular 
signature obtained from the pre-clinical analysis will be validated in the peripheral 




blood mononuclear cells (PBMCs) derived from fast and slow progressing ALS 
patients. 
 evaluate the immunological fingerprint of macrophages infiltrated within the 
skeletal muscles of fast and slow progressing mSOD1 mice and ALS patients. 
 characterise the fast and slow progressing mSOD1 mice derived macrophages' 
responsiveness to pro-inflammatory/anti-inflammatory stimuli and their capability 
to influence the satellite cells response.  
This project will be founded by the Italian Ministry of Health (SG2019 - 12371083). 
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